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RNA STABILITY REGULATES DIFFERENTIAL EXPRESSION OF
THE METASTASIS PROTEIN, OSTEOPONTIN, IN HEPATOCEL-
LULAR CANCER
Sirisha Emani, PhD, Jinping Zhang, MD, PhD, Luci Guo, Hongtao Guo,
MD, PhD, Paul C Kuo, MD
Duke Univ Med Ctr, Durham, NC
Introduction. Osteopontin (OPN) is a potential therapeutic target in
hepatocellular cancer (HCC) as it is a critical mediator of metastatic
function. OPN antibody blocks HCC cell invasion in vitro and inhibits
pulmonary metastasis in vivo. However, the molecular mechanisms which
determine expression of OPN in HCC are largely unknown. In this study, we
examine differential OPN expression in HepG2 (high OPN) and Hep3B (low
OPN) HCC cell lines.
Methods. OPN protein was measured with Western blots; Northern blots
determined steady state OPN mRNA levels. Chromatin immunoprecipita-
tion assays (ChIP) for RNA pol2 at the OPN promoter measured transcrip-
tion. Actinomycin D (100 mcM) was used to inhibit transcription. Transient
transfection analysis used the full length human OPN promoter (2.1 kb)
cloned into a luciferase reporter vector. In vitro decay analysis measured
OPN mRNA decay relative to the poly (A) tail. The contribution of OPN 3?-
UTR (400 bp) or 5?-UTR (170 bp) was determined by transient transfection
of luciferase-3?UTR or 5?-UTR-luciferase constructs in pGL3 promoter
vector following excision of the SV40 poly (A) signal; luciferase mRNA
determined differences in RNA degradation. RNA gelshift assays measured
extent and patterns of protein binding to OPN 5?-UTR. (Data are expressed
as mean9SEM; analysis was performed with the Students t test.)
Results. HepG2 OPN protein in cell lysate and medium was 12-fold higher
than Hep3B (pB0.01 for cell lysate and media). Similarly, OPN mRNA was
7-fold greater in HepG2 cells (pB0.01 vs Hep3B). However, transfection of
the OPN promoter demonstrated equivalent luciferase activities in the two
cell lines; the rate of transcription was also equivalent as determined by ChIP.
OPN mRNA half life was 6.390.9 and 1.190.3 hrs in HepG2 and Hep3B,
respectively (pB0.02). RNA stability is regulated by the poly (A) tail, 5?-
UTR or 3?-UTR. In HepG2 and Hep3B, nucleotide sequence of OPN and its
5?-UTR and 3?-UTR were identical between. The poly (A) tails were also
equivalent in length and did not impact OPN mRNA stability. Luciferase
mRNA coupled with OPN-5?-UTR was 6-fold higher in the HepG2 cells
(pB0.01 vs Hep3B); 3?UTR did not alter OPN mRNA expression. RNA
gelshift assays demonstrate differing protein binding patterns to 5ƒ-UTR
between the 2 cell lines.
Conclusion. In HepG2 and Hep3B, different repertoires of RNA binding
proteins targeting OPN 5?-UTR regulate OPN mRNA stability and alter
OPN expression. We conclude that RNA stability is one mechanism which
regulates OPN expression in HCC to convey metastatic function. This has
not been previously described for OPN regulation in any setting.
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ATTENUATED LISTERIA STRAINS DEPLETED OF REGULA-
TORY T CELLS EFFECTIVELY TARGET HEPATIC COLOREC-
TAL METASTASES
Kiyoshi Yoshimura, MD, PhD, Lindsay Sue Laird, None, Kristen Faith
Meckel, None, Drew Mark Pardoll, MD, PhD, Richard David Schulick, MD
Johns Hopkins Medical Institutions, Baltimore, MD
Background and Objectives. The liver represents a major and frequently
sole site of metastases for many types of cancer, particularly gastrointestinal
cancers. Here we demonstrate that administration of multiple doses of an
engineered hepatic targeting Listeria monocytogenes (LM) generates thera-
peutic responses against hepatic metastases. LM treatment of mice bearing
hepatic metastases induced tumor-specific CD8 responses that were en-
hanced by depletion of regulatory T cells either by anti-CD25 or Cytoxan
treatment. Antitumor activity of LM was dependent on the presence of NK
cells but was inhibited by the presence of NKT cells.
Methods. BALB/c mice were challenged with 10e5 CT26 (syngeneic
colorectal cancer cells) in an isolated hepatic metastasis model. Three days
after tumor challenge, the mice were inititiated on a course of intraperitoneal
injections of attenuated strains of LM (at 1/10 of the LD50) for three doses
three days apart. Survival was followed and immune cells were analyzed for
phenotype, activation status, and effector function. Depletions of key subsets
of immune effectors was performed to analyze effect.
Results. LM treatment provided a significant survival advantage which was
greatly enhanced by depletion of CD25 regulatory T cells. (See Figure).
Furthermore depletion of CD8 T cells abrogated the survival advantage of
LM and depletion of CD4 T cells was intermediate in effect.
Conclusions. These results demonstrate the utility of LM in the treatment
of hepatic metastases and further suggest that blockade of regulatory T cells
will enhance anti-tumor activity.
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TREATMENT OF UNRESECTABLE CHOLANGIOCARCINOMA
WITH GEMCITABINE-BASED TRANSCATHETER ARTERIAL
CHEMOEMBOLIZATION (TACE): SINGLE-INSTITUTION EX-
PERIENCE
Niraj Gusani, MD, Fady Balaa, MD, Jennifer Steel, MD, David A Geller,
MD, Wallis Marsh, MD, Brain Carr, MD, PhD, T. Clark Gamblin
UPMC Liver Cancer Center, University of Pittsburgh, Pittsburgh, PA
Background. Survival for patients with unresectable cholangiocarcinoma is
reported to be only 58 months. Systemic chemotherapy has been
disappointing and not shown to significantly improve survival. Transcatheter
arterial chemoembolization (TACE) has been shown to prolong survival in
hepatocellular carcinoma patients but experience with cholangiocarcinoma is
limited. We report our experience with TACE using chemotherapeutic
regimens based on the well-tolerated drug gemcitabine.
Methods. Forty-two patients with unresectable cholangiocarcinoma were
treated with one or more cycles of gemcitabine-based TACE (20012006) at
our institution. Follow-up imaging was performed on all patients after each
TACE procedure. Regimens of TACE included: gemcitabine only (17),
gemcitabine followed by cisplatin (2), gemcitabine followed by oxaliplatin
(5), gemcitabine and cisplatin (15), and gemcitabine and cisplatin followed
by oxaliplatin (3). Actual survival is reported, as 40 of 42 patients have died
from disease (95%).
Results. Patients were 59.4 years of age (range 3687) and a median of 4
treatments (range 111) were administered. 37 patients (88%) had central
cholangiocarcinoma and 5 (12%) had peripheral tumors. Median survival
from time of first treatment was 9.7 months overall. Patients receiving
gemcitabine followed by cisplatin or oxaliplatin had improved survival
(median 16.5 and 11.2 months respectively) when compared to gemcitabine
alone (median 6 months). Patients receiving gemcitabine and cisplatin as a
combination also had improved survival (median 11.3 months) compared to
single agent gemcitabine. Patients who progressed on gemcitabine and
cisplatin and then received oxaliplatin also showed improved survival
(median 14.3 months) compared to gemcitabine only. Neutropenia, throm-
bocytopenia and hyperbilirubinemia were the most common toxicities
observed. Three patients in the entire series exhibited grade 3 thrombocy-
topenia while seven patients had grade 3 and one had grade 4 elevation of
bilirubin levels.
Conclusions. Our report represents the largest series to date regarding
hepatic artery directed therapy for unresectable cholangiocarcinoma and
provides evidence in favor of TACE rather than historically reported
alternatives such as systemic chemotherapy or chemotherapy/RT. Our results
suggest that gemcitabine based TACE is well-tolerated and with seemingly
better survival when given in combination therapy for patients with
unresectable cholangiocarcinoma.
ISSN 1365-182X print/ISSN 1477-2574 online # 2007 Taylor & Francis
DOI: 10.1080/16515320701258846
HPB, 2007; 9: 36110
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PANCREATIC TRANSECTION MARGIN AT THE TIME OF PAN-
CREATICODUODENECTOMY: CLINICAL IMPLICATIONS OF A
POSITIVE MARGIN
Curtis J Wray, MD, Henry F Gomez, MD, Jean Nicholas Vauthey, MD,
Eddie K Abdalla, MD, Jeffrey E Lee, MD, Huamin Wang, MD,PhD,
Douglas B Evans, MD, Peter Wt Pisters
Houston, Center, Cancer Anderson MD Texas of University
Introduction. The pancreatic transection margin (PM) is often submitted
for frozen section when performing pancreaticoduodenectomy for adenocar-
cinoma to allow re-resection if the PM is positive. However, the natural
history of patients with an initially positive PM is not well defined and
therefore, there are no clear guidelines for the performance of a frozen section
or the management of a positive PM.
Methods. The pancreatic cancer database was queried for all patients with
pancreatic adenocarcinoma who underwent pancreaticoduodenectomy. Pa-
tients with cystic neoplasms (including IPMN) were excluded. Pathology and
operative reports were re-reviewed to verify margin status. Patients were
classified based on the status of the PM as: Group 1: negative initial frozen
section; Group 2: negative after re-resection of a positive PM; and Group 3:
positive margin.
Results. PD was performed on 383 patients with PA from 1990 to 2005, 14
patients were excluded due to follow-up less than 1 year (n6), post-
operative death (n4) or incomplete records (n4). Of the remaining 369
patients, the PM was negative on intraoperative frozen section in 309 (84%),
positive in 45 (12%) and margin assessment was not performed in 15 (4%).
Of the 309 Group 1 patients, permanent pathology review confirmed a
negative PM in 308, and 1 was changed to a positive margin. All 45 patients
with a positive intraoperative margin underwent re-resection; 40 (89%) were
successfully re-resected to a negative PM (Group 2) and re-resection was
unsuccessful in achieving clear margins in 5 (11%). Other margins of
resection were positive in 7 (18%) of the 40 Grp 2 patients and in 1 (20%) of
the 5 Grp 3 patients. Median survival was 24.2 months for the 309 Grp 1
patients, 23.8 months for 40 Grp 2 patients, and 17.5 months for 5 Grp 3
patients.
Conclusions. Patients who undergo successful re-resection of an initially
positive PM have a survival similar to patients that had a negative PM on
initial frozen section. These findings support the practice of intraoperative
frozen section assessment of the PM and re-resecting additional pancreatic
parenchyma if the initial margin is positive.
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SIGNIFICANCE OF THE ANTI-INFLAMMATORY FACTOR HE-
MEOXGENASE-1 (HO-1) FOR THE FUNCTION OF TUMOR
INFILTRATING MACROPHAGES IN HUMAN HEPATOCELLU-
LAR CARCINOMA
Christoph Benckert, MD, Armin Thelen, MD, Thorsten Cramer, MD,
Anotonino Spinelli, MD, Peter Neuhaus, MD, Sven Jonas, MD, Charite´
Campus Virchow Klinikum, Universita¨tsmedizin Berlin, 13353 Berlin,
Germany
Introduction. The infiltration of various tumours with macrophages as
indicated by tumor associated macrophage density (TAMd) is associated with
a higher rate of metastasis and a poor prognosis. The underlying mechanisms
are widely unknown. Hemoygenase-1 (HO-1) is expressed in macrophages
and acts predominantly anti-inflammatory and anti-oxidative. The signifi-
cance of HO-1 for the migration of macrophages in human hepatocellular
carcinoma (HCC) and the accumulation in surrounding tumor tissue has not
been investigated so far.
Methods. TAMd was determined by using macrophage specific ant-CD68
antibody and counting immunostained macrophages analogous to the
determination of the microvessel density as shown by Weidner. HO-1 was
immunostained with a monoclonal antibody. In vitro expression and
regulation of HO-1 was measured by western blot and real time PCR in
the human monocyte cell line THP-1. Migration was analysed in THP-1 cells
in Boyden chamber invasion assays.
Results. Determination of TAMd showed a correlation between low TAMd
an better survival in HCC patients (p50,05). In vivo Expression of HO-1
was determined in 30/70 human HCCs over tumor associated macrophages
and correlated with a better survival (p50,05). In vitro HO-1 protein and
RNA could not be detected in THP-1 cells under normal conditions.
Stimulation by oxidative stress lead to a highly significant stimulation of the
HO-1 RNA and protein expression (150-fold). Induction of the HO-1
activity by haemin resulted in a significant decrease of the migration of THP-
1 cells. Otherwise, inhibition of the HO-1 activity by Sn-protoporphyrin
resulted in a significantly higher migration rate of THP-1 cells.
Discussion. Our results show that TAMd is associated with poorer survival
in human HCC and HO-1 expression leads to a survival benefit. For the first
time we could demonstrate the exclusive expression of HO-1 in human HCC
tissues by macrophages and/or kupfer cells and confirm data shown by other
groups in animal HCC models. Inhibition of the migration of macrophages
by HO-1 activation adverts to a central role of HO-1 for the accumulation of
macrophages in human HCC. Further studies should investigate whether
HO-1 inhibition may reduce HCC tumour growth.
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C-REACTIVE PROTEIN AS A PREDICTOR OF PROGNOSIS
FOLLOWING CURATIVE RESECTION FOR COLORECTAL LI-
VER METASTASES
Vincent Kh Wong, Hassan Z Malik, MD, Zaed Hamady, Ahmed Al-
mukhtar, Dhanny Gomez, K Rajendra Prasad, Giles J Toogood, Peter A
Lodge, MD
St. James’s University Hospital, Leeds, United Kingdom
Aim of Study. To analyze the impact of an elevated C-reactive protein
(CRP) on outcome following curative resection for colorectal liver metas-
tases.
Method. Retrospective analysis of a prospectively gathered dataset. 170
patients with CRP measurements taken immediately prior to the surgery were
included in this study. Patients were followed up at specialist clinics with
regular blood tests, including tumor markers carcinoembryonic antigen
(CEA) and CA19-9, and liver function tests. In addition, regular chest and
abdominal computerized tomography were performed. Patients were fol-
lowed up a minimum period of 1 year post liver resection at the time of study
(range 15 years; median 28 months). The data examined included patient
demographics; liver resection histology; pre-hepatectomy CEA and CA19-9
tumor marker; pre-hepatectomy CRP; post-operative morbidity/mortality
results as well as recurrence and survival figures. A CRP value above 10 mg/l
was taken as elevated.
Results. Pre-operative CRP was elevated (10 mg/l) in 54 (31.8%)
patients. The median survival of patients with an elevated CRP was 19
months (95% CI 7.531.2 months) compared to 42.8 months (95% CI
33.252.5 months) for those with a normal CRP, p0.0044. The results of a
multivariable analysis of the predictors of survival showed that an elevated
CRP(p0.032) as well as primary ‘‘T’’ stage(p0.019) both predicted for
poorer overall survival.
Conclusions. This study showed that an elevated CRP level, measured
before surgery, is present in a significant proportion of patients with CLM.
This is found to predict for a poor survival outcome in patients who had liver
resection performed. The inflammatory response, as reflected by CRP, is the
only factor that can be modulated pre-operatively in these patients and this
may lead to the use of novel therapies among this group of patients in the
future.
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LONG-TERM OUTCOMES FOLLOWING LIVER TRANSPLANTA-
TION FOR HEPATIC HEMANGIOENDOTHELIOMA: THE UNOS
EXPERIENCE FROM 1987 TO 2005
Joel A Rodriguez, Natasha S. Becker, MD, Neal R. Barshes, MD, Christine
A. O’mahony, MD, Thomas A. Aloia, MD, John A. Goss, MD
Baylor College of Medicine, Houston, TX
Introduction. Hepatic hemangioendothelioma is a vascular neoplasm with
intermediate malignant potential that commonly afflicts pediatric and young
adult patients. Outcomes following liver transplantation, which is currently
reserved for patients with unresectable liver involvement, have only been
reported as small, single-institution experiences. The purpose of this study
was to evaluate patient and graft survivals following liver transplantation in a
large, multi-institutional cohort of patients with hepatic hemangioendothe-
lioma (HEH).
Methods. Using the United Network for Organ Sharing (UNOS) database,
we identified 105 patients with a diagnosis of HEH who underwent 117
transplants between 1987 and 2005. Demographic information including
age, race, and gender were recorded, and 1-year and 5-year patient and graft
survivals were calculated using Kaplan-Meier survival curves. Analyses were
further stratified by the cause of death.
Results. Of the 105 transplanted patients, 71 patients (68%) were female, 77
patients (73%) were Caucasian, and the median age was 36 years (range: 0
70 years). The 30-day post-transplant mortality rate was 1.7%. At a median
follow-up interval of 742 days (range: 05,497 days), 1-year and 5-year graft
Abstracts 37
survivals were 71.6% and 54.9%, respectively. Calculated 1-year and 5-year
overall survivals were 80.1% and 62.3%, respectively, with 31 actual 5-year
survivors. (See figure below.) Nine patients (8.6%) required re-transplanta-
tion, including 2 patients who received a third graft. Of the 39 patients who
died during follow-up, 14 patients (36.9%) died of recurrent disease.
Conclusions. Analysis of the UNOS dataset indicates that survivals
following transplantation for hepatic hemangioendothelioma (5-yr OS:
62.3%) are favorable, particularly in comparison to the survivals associated
with transplantation for other hepatic malignancies. Given the propensity for
recurrence following resection, these data support consideration of liver
transplantation for all patients with this disease.
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METABOLIC CHANGES IN THE PIG LIVER DURING WARM
ISCHEMIA AND REPERFUSION MEASURED BY MICRODIALY-
SIS
Anne-sofie Kannerup, MD, Peter Funch-jensen, MD, PhD, Henning
Gronbaek, MD, PhD, Rasmus Langelund, MD, Frank Viborg Mortensen,
MD, PhD
Aarhus University hospital, A˚rhus C, Dk-8000, Denmark
Background and aims. Portal triad clamping by the Pringle manoeuvre
(PM) during liver surgery can cause ischemia-reperfusion (I/R) injury. The
aim of the present study was to monitor metabolic changes in the four lobes
by microdialysis before, during and after warm ischemia in the pig liver.
Material and Methods. Eight landrace pigs (body weight 60 kilos)
underwent laparotomy followed by ischemia by the PM. Four microdialysis
catheters were placed in the liver, one in each lobe. A reference catheter was
placed in a peripheral muscle. Microdialysis samples were collected at
intervals of 30 minutes starting two hours before one hour of total ischemia
followed by three hours of reperfusion. Glucose, lactate, pyruvate and
glycerol concentrations in the liver were measured by microdialysis and
blood samples from a peripheral vein were drawn for determination of
standard liver parameters.
Results. During the first two hours of normal liver perfusion (baseline),
glucose, lactate, glycerol and pyruvate remained stable. Immediately after
initiating total ischemia lactate and glycerol levels increased significantly (PB
0.05), while an insignificant increase was observed for glucose and pyruvate.
Lactate levels decreased 30 minutes after reperfusion and did not reached
baseline levels. Glycerol levels started to decrease immediately after reperfu-
sion and continued to decrease for the rest of the experiment but did not
return to initial values. Glucose levels started to decrease at the start of
reperfusion and normalized at the end of reperfusion. From the time of
ischemia pyruvate showed a slight increase which lasted for the rest of the
experiment. The lactate-pyruvate ratio increased significantly after initiating
ischemia (PB0.05) and decreased immediately after reperfusion. An insig-
nificant increase in standard liver parameters was seen after ischemia/
reperfusion. The metabolic changes where comparable and similar between
the four liver lobes.
Conclusions. During and after warm ischemia there were profound
metabolic changes in the pig liver measured by microdialysis and there
were no difference the four liver lobes in between. This indicates that one
catheter for microdialysis will be sufficient for monitoring metabolic changes
in the whole of the liver during warm ischemia and reperfusion induced by
the PM.
9
SYNTHETIC TACE INHIBITOR Y-41654 IMPROVES HEPATIC
ISCHEMIA REPERFUSION INJURY
Ari J Cohen, MD, George Loss, MD, PhD, Zhenya Tang, MD, PhD
Ochsner Clinic Foundation, New Orleans, LA
Aim. Our previous study has demonstrated that hepatic TACE expression is
increased in a pattern similar to the pro-inflammatory cytokine TNF-a and
IL-6 expression following ischemia /reperfusion injury to the liver. This
implies that TACE plays an important role in liver ischemia-reperfusion
injury (TIMP-3 ameliorates hepatic ischemia/reperfusion injury through inhibition
of tumor necrosis factor-alpha-converting enzyme activity in rats. Transplantation
2006, in press ). In this study, we applied a synthetic TACE inhibitor Y-41654
to our hepatic ischemia-reperfusion injury rat model and found that Y-41654
improves hepatic ischemia-reperfusion injury.
Methods. Male Wistar rats received an i.v. injection of Y-41654 at a dosage
of 12 mg/Kg body weight (experimental group, n8) or saline (control
group, n8) at a speed of 1 ml/hour. One hour later, the animals underwent
30 minutes of partial warm ischemia followed by 6 hours of reperfusion.
Hepatic TACE and TNF-a were assessed by RT-PCR. Serum TNF-a was
measured by ELISA. Liver function (ALT level) was tested.
Results. Serum TNF-a levels (92.5916.34 vs 106.1698.1 pg/ml, pB0.05)
and ALT levels (1900.839212.88 vs 2153.969153.65 units/L, pB0.05)
were significantly reduced in Y-41654 treated group than control group, but
hepatic levels of TACE and TNF-a mRNA were unchanged with Y-41654
treatment.
Conclusion. Synthetic TACE inhibitor Y-41654 may improves hepatic
ischemia-reperfusion injuries presented as reduction of ALT levels and
depression of circulating levels of TNF-a, demonstrating that TACE
inhibition may have an important role in preventing liver ischemia/reperfu-
sion injuries. Besides TACE inhibition, Y-41654 may also have effects on
some other biomarkers such as MMPs and warrants further study.
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GENDER DIFFERENCES INFLUENCE NFkB-DEPENDENT RE-
SPONSES TO HEPATIC ISCHEMIA-REPERFUSION
Jane M Liaw, MD, Travis J Pagliara, None, Krista A Csontos, None,
Sucharita Das, MS, Sabarinathan Ramachandran, PhD, Thalachallour
Mohanakumar, PhD, William C Chapman, MD
Washington University, St Louis, MO
Introduction. Gender differences influence responses to hepatic injury
including ischemia-reperfusion (I/R) and alcoholic liver disease. Estrogen is
thought to protect the liver through activation of eNOS, improving hepatic
circulation. However, mechanisms of hepatic injury and protection are not
fully understood.
Methods. Male and female transgenic 5?-HIV-LTR-Luciferase (HLL) mice
underwent 35% hepatic cryoablation using a recirculating liquid nitrogen
probe to simulate liver ischemia. Control mice underwent exploratory
laparotomy. Mice were sacrificed 4 hours post-reperfusion, with blood and
organs collected for NF kB analysis and cytokine profiling. Separate male and
female HLLs were given a single intraperitoneal injection (250 mg) of LPS
endotoxin, and sacrificed 3 hours following injection. NF kB activation was
measured by a standard luciferase reporter assay using liver protein
homogenates. Serum cytokines were measured using standard luminex
techniques. Total RNA was isolated by Trizol extraction, reverse transcribed,
32P-labelled, and hybridized to GEArray Q microarrays containing cDNA
sequences of genes mediating inflammation, pro- and anti-apoptosis.
Results. At four hours post-reperfusion, NF kB was significantly activated in
male versus female mice, p0.006. In LPS injected males, NF kB was again
significantly elevated versus females, p0.008. This differential activation
was associated with an increase in serum cytokines TNF-a (10069239 vs
7299181 pg/mL) and IL-1b (231961 vs 178940 pg/mL), although results
did not reach significance. There was a significant decrease in serum KC
(11497944 vs 126459567 pg/mL) and MIG (6489106 vs 15319246 pg/
mL), p50.05 in males versus females.
Conclusions. Male mice undergoing hepatic cryoablation ischemia-reperfu-
sion injury show significantly increased NF kB activation and differential
expression of inflammatory cytokines associated with increased morbidity/
mortality, compared to female counterparts. Similar patterns were observed
with endotoxin challenge. Gender differences can thus significantly influence
NF kB dependent hepatic injury. Identification of pathways to which females
appear resistant to hepatic injury will result in the identification of normal
targets to ameliorate I/R mediated injury.
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A PROLONGED GRAFT COLD ISCHAEMIA TIME IS SIGNIFI-
CANTLY ASSOCIATED WITH INCREASED RECIPIENT MOR-
TALITY IN LIVER TRANSPLANT RECIPIENTS
Martin W Drage, MD, MBBS, Yumin Li, MBBS, Raaj Praseedom, MBBS
University of Cambridge, Cambridge, United Kingdom
Introduction. The shortage of donor livers and the increasing need for liver
transplantation has led to the use of more marginal donors. The aim of this
study is to analyze the impact of various donor and recipient factors on
outcome following cadaveric liver transplantation.
Method. The analysis included all liver transplants performed over a five
year period at Addenbrooke’s Hospital, University of Cambridge, UK. A
selection of donor and recipient variables were identified and assimilated
38 Abstracts
from the Addenbrookes transplant donor database, recipient database and
the United Kingdom Transplant (UKT) database. Missing data were
obtained directly from the case notes. Univariate, multivariate and survival
analyses were performed (SPSS v12.0, Inc. Chicago).
Results. A total of 373 liver transplants were carried out in 346 patients
consecutively during this period. The overall graft failure and recipient
mortality rates were 20.64% (77/373) and 14.16% (49/346) respectively. A
cold ischaemia time of greater than 16 hours was significantly associated with
increased recipient mortality using univariate analysis. Cox’s regression
analysis revealed that a cold ischaemia time of greater than 16 hours and a
secondary warm ischaemia time of greater than 1 hour were significantly
related to poor patient survival. A significantly poorer overall patient survival
on Kaplan-Meier analysis was shown using donor livers with a cold ischaemia
time of greater than 16 hours.
Conclusion. A cold ischaemia time of more than 16 hours and a secondary
warm ischaemia time of more than 1 hour are associated with reduced patient
survival. These factors are therefore important and must be considered when
using livers from marginal donors.
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OUTCOMES OF LIVER ALLOGRAFTS THAT HAVE EXPERI-
ENCED SURGICAL OR TRAUMATIC INJURY
John Renz, MD, PhD, James Guarrera, MD, Ben Samstein, MD, Dominique
Jan, MD, Sarah Bellemare, MD, Milan Kinkhabwala, MD, Jean Emond, MD
Columbia University, New York, NY
Introduction. Donor allograft injury from trauma or surgical error is a
frequent occurrence that can result in organ refusal and potential loss of an
opportunity for transplantation.
Purpose. To evaluate outcomes of liver allografts that had experienced either
traumatic or surgically-induced injury and underwent subsequent repair and
transplantation.
Methods. Retrospective analysis of 329 liver allografts transplanted between
07/03 and 10/06. This included 289 allografts from adult donors (age 
18yrs) and 40 allografts from pediatric donors (ages: 1 mo17 yrs). Donor
injuries were categorized as vascular (transection of an hepatic artery) or
parenchymal (avulsion, Grade II laceration). All injuries were recognized
and repaired as a back-table procedure prior to implantation. Vascular
injuries were primarily repaired utilizing microsurgical techniques (7-0
polypropylene, interrupted) from the remnant gastroduodenal or splenic
artery origin. Parenchymal injury was repaired utilizing oxidized-cellulose
matrix with or without a surgical sealent. Patient and graft survival, and the
occurence of a complication associated with the repair (vascular: stenosis/
thrombosis, parenchymal: hemorrhage) were analyzed.
Results. Vascular injuries were encountered in 8 allografts (2%). Injuries
occurred in 5 pediatric and 4 adult allografts. All vascular injuries were
inadvertent transection of a replaced right hepatic artery with no available or
insufficient remnant. Parenchymal injuries occurred in 6 adult allografts
(2%). Long-term Doppler interrogation revealed 7 of 8 repaired injuries
patent at 30days with thrombosis of 1 repair leading to elevated liver
function tests and subsequent biliary ischemic injury. Return to the operating
room for hemorrhage secondary to parenchymal repair was required in 1
recipient. No allograft was not transplanted as a result of an injury.
Conclusion. Back-table repair of vascular and parenchymal injuries from
trauma or surgical error yield outcomes that support their utilization.
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ARE LACERATED LIVERS TRANSPLANTABLE?  A CASE RE-
PORT WITH REVIEW OF THE LITERATURE
Hamidreza Fonouni, MD, Arianeb Mehrabi, MD, PhD, Bruno Schmied,
MD, PhD, Peter Kienle, MD, PhD, Ju¨rgen Weitz, MD, PhD, Markus W
Bu¨chler, MD, PhD, Jan Schmidt, MD, PhD
University of Heidelberg, Heidelberg, Germany
To reduce the gap between organ demand and supply transplant centers
defined extended donor criteria to use more marginal donors. Using
traumatized liver for liver transplantation (LTx) can in part decrease this
disparity. Our aim is to present a successful case of LTx using a high grade
traumatized liver as well as a review of the literature for reported cases which
have shown a promising outcome. For LTx, we used a traumatized liver from
a 19 years old brain dead patient suffering from a simultaneous liver and
spleen injury. The liver had a grade IV laceration on the right lobe without
vascular disruption and a grade II laceration on the left lobe, which were
managed by digital compression, sealing of the lacerations by sealants with
consecutive stitching and perihepatic packing following the splenectomy. The
liver and kidneys were preserved using HTK. The liver was transplanted to a
49 years old male with a hepatitis C induced liver cirrhosis accompanying
HCC (cold ischemia time: 4.5h). The 2-month follow up was uneventful with
a normal liver function test. All published LTx cases using traumatized livers
(n17) were analyzed emphasizing the graft and patient survival. The mean
donors and recipients age were 24 and 57 years, respectively. The severity of
liver injury varied from subcapsular hematoma to deep ruptures leading to
liver resection in 4 cases. No hepatic vascular avulsion was reported. About 2/
3 of reported lacerations were on right lobe. The intraoperative hemostatic
managements were digital compression, electrocautery and perihepatic
packing. Mean post-LTx follow-up period was 7.5 months (626). The
reported complications were primary non-function (18%) or poor-function
(one case), liver abscess (one case), and hematoma (one case). For all
reported cases, the 6-month grafts and patients survival rates were 71% and
88%, respectively. With meticulous managements and intact major hepatic
vasculatures, traumatized livers can be used for successful LTx. Using this
option allows transplant surgeons to expand the donor pool. Due to the
complexity of the management of the traumatized livers the harvesting should
be done by experienced liver surgeons. Moreover, because of the vulnerability
of these organs to develop primary non- or poor-function they should be
classified as marginal organs and offered to HCC or elderly patients. Finally
for better analyzing and defining a guideline, it is mandatory to start
multicentric collaborations to gather and analyze the data of all performed
LTx cases using traumatized livers with emphasizing the longterm outcome
and quality of life of these patients.
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DONOR AGE AFFECTS IMMEDIATE BUT NOT LONGTERM
SURVIVAL FOLLOWING LIVER TRANSPLANTATION
Markus Selzner, MD, Nazia Selzner, MD, PhD, George Therapondas, MD,
Stuart Mccluskey, MD, Ian Mcgilvray, MD, PhD
Toronto General Hospital, Toronto, ON, Canada
Organ shortage has resulted in an increased use of elderly donors (60
years) for liver transplantation (OLT). The aim of this study is to re-examine,
in a modern era of transplantation, the effect of donor age on outcomes
following OLT. In addition, we compared the effect of old donor livers on
outcomes following transplantation between young and old recipients.
Methods. Data was collected in a prospective clinical database on 479
patients receiving cadaveric liver transplantation between January 1998 and
October 2005. Donor and recipient age were analyzed as continuous and
categorical variables. Univariate and multivariate regression analysis were
performed investigating donor and recipient age, cold and warm ischemia
time, recipient gender, hepatitis B & C infection, year of transplantation,
MELD score, and acute vs chronic liver failure. Postoperative outcomes were
assessed by length of hospital stay, postoperative AST, ALT, creatinin, INR,
bilirubin, alk phos, complication score, graft failure, and patient survival.
Results. As expected, cold and warm ischemic times were significantly
associated with postoperative AST and ALT levels, and postoperative
creatinine was predicted by the MELD score and warm ischemia time.
When the influence of donor and recipient age was examined, we found that
an increased donor age was associated in univariate analysis with the max
postoperative, AST, ALT, bilirubin, and INR. This association held true in
multivariate analysis for AST, ALT, and bilirubin. Recipient age was
associated in univariate analysis only with increased max ALT, an association
that did not persist upon multivariate regression analysis. Combining older
donor livers with young (540 years) or old (]60 years) recipients resulted in
identical peri-operative outcomes. Graft and patient survival as well as the
overall complication score were identical between patients receiving livers
from old or young donors. Combining old donors and old recipients did not
result in worsened long-term survival.
Conclusion. The use of old donor livers for liver transplantation is
associated with increased indices of reperfusion injury in the immediate
postoperative period. However, recipient survival is not affected by the age of
the donor, and the age of the recipient receiving the older donor liver does not
affect short or long-term results. This study provides evidence for the safety
of using older liver grafts.
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PLASMAPHERESIS IN SEVERE COAGULOPATHY AND SEVERE
GRAFT DYSFUNCTION IN LIVER TRANSPLANTATION: IS IT
WORTH THE RISK?
Robert L Shapiro, John W Mcgillicuddy, MD, Zachary P Evans, Kenneth D
Chavin, MD, PhD
Medical University of South Carolina, Charleston, SC
The use of plasmapheresis in the setting of liver transplantation (OLTx)
remains controversial. The goal of our study was to evaluate our single center
experience using plasmapheresis in the setting of severe pre-operative
coagulopathy and post-operative severe graft dysfunction (SGD). We have
begun to retrospectively review all OLTx’s performed in our center, and from
06/99 through 10/01, 22 of 178 total transplant patients received plasma-
pheresis pre- and/or post-operatively. Data collection included donor and
recipient demographics, PT/PTT/INR, factor V, percent steatosis, serum
transaminases, MELD scores both before transplant and before intervention,
rates of retransplantation, and graft and patient survival. SGD encompassed
both delayed graft function and primary nonfunction (PNF) and was defined
by peak AST greater than 1000 IU/L, within seven days post-operatively,
along with clinical determination of poor liver function. Twenty-two patients
(12.3%) received plasmapheresis: 3 for severe coagulopathy pre-operatively,
and 19 for SGD. Patients who received pre-operative plasmapheresis saw a
significant decrease in INR values from 3.3391.04 to 1.7490.57 (p0.03)
and 100% patient and graft survival at one year. Eight of the 19 patients with
SGD were retransplanted because of PNF, and one-year survival for the
patients with SGD was 45.5% and 37.5% with and without retransplantation
respectively. There were no statistically significant differences in patient and
donor demographics, ischemia time, MELD scores, or peak serum AST and
ALT values between patients experiencing graft survival and failure. Sepsis
was the cause of death in almost all patients who expired regardless of
recovery of graft function. Our experience suggests a beneficial role of
plasmapheresis in the treatment of pre-operative coagulopathy, but not for
the treatment of patients experiencing SGD after liver transplantation.
Though plasmapheresis shows some temporary benefit in the setting of
SGD, the apparent predisposition to sepsis that it imparts on patients
warrants caution in its use.
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ISLET ISOLATION FROM NON-HEART BEATING DONOR AND
EVALUATION OF DONOR FACTORS TO AFFECT ISOLATION
RESULTS
Michihiro Maruyama, MD, PhD, Takashi Kenmochi, MD, PhD, Kenichi
Saigo, MD, PhD, Naotake Akutsu, MD, PhD
Chiba-east National Hospital, Chiba, Japan
Background. Because of recent progression in islet transplantation this
therapy has become one of the most important therapies for patients with
type 1 diabetes mellitus. However the shortage of cadaveric donor is an
obstacle preventing widespread application of islet transplantation. An
application of marginal donor is necessary. Pancreatic graft from brain
dead donor is generally applied to pancreatic transplantation prior to islet
isolation in Japan. Grafts from non-heart beating donor (NHBD) are mainly
used for islet isolation. We have experienced islet isolation from 18 NHBDs
and evaluate which donor factors affect islet isolation from NHBDs.
Methods. In only two cases, life support was withdrawn, and in the other
cases death was declared after cardiac asystole without life support with-
drawn. The period from death declaration to organ perfusion was defined as
warm ischemia time (WIT). Pancreata were harvested after removal of both
sides of kidneys. University of Wisconsin Solution or two-layer method was
used for preservation and transportation of pancreata. Islets were isolated
using the automated two-step digestion method we had originally developed
by the same isolation team.
Results. Overall; Donor age was averaged 40.0 year old (range, 1069).
WIT was averaged 11.2 min (230), and cold ischemic time (CIT) was
averaged 316 min (211540). Total islets number after purification was
145,124 IE (38,560491,040). The purity after purification was averaged
40.6% (1080). Islets from 3 out of 18 cases were transplanted immediately.
Influence of donor variance; Only long CIT affected the recovery of islets
statistically. Islet yield of up to 300 minutes of CIT group were 219,1769
153,435 (mean9SD) and that of over 300 minutes group were 93,2889
60,698 (pB0.05). The episode of cardiac arrest, hypoxia as cause of death,
long (over 240 minutes) anuria before death and no use of two-layer method
were tended to affect isolation results.
Conclusions. The result of isolation of islets from NHBD was varied with
the donor condition. However in some cases, functioning isles were
successfully isolated and were successfully transplanted to type 1 diabetes
patient. NHBD may be a good source for islet transplantation. However it is
necessary to improve the technique of islet isolation from NHBD.
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COMPOSITE TUMOR OF THE AMPULLA OF VATER: SIGNET-
RING CELL AND NEUROENDOCRINE CARCINOMA  A CASE
REPORT
Kunmoo Choi, MD, PhD, Daiwoon Eom, MD
Univ. of Ulsan, Gang Neung Asan Medical Center, Dept. of Surgery,
Gangneung, Republic of Korea; Univ. of Ulsan, Gang Neung Asan Medical
Center, Dept. of Pathology, Gangneung, Republic of Korea
Most tumors affecting Vater’s ampulla are ordinary adenocarcinoma and
other histological variants or mixed forms are less frequent, even rare. We
encountered a rare case of composite signet-ring cell carcinoma and well
differentiated neuroendocrine carcinoma of the ampulla of Vater in a 72-year-
old Korean man with postprandial abdominal discomfort and jaundice for
two weeks. Computed tomography and endoscopic retrograde cholangio-
pancreatography (ERCP) revealed about 2 cm protruding mass with abrupt
narrowing of distal common bile duct. Pancreaticoduodenectomy was
performed. An ill-defined nodular 2 cm sized mass in the ampulla of Vater
invaded the entire duodenal wall and pancreatic parenchyma with duct
dilatation of remaining common bile duct and pancreatic duct. Two out of
twenty regional lymph nodes were metastatic. Histopathologically, the tumor
was composed of mucinous adenocarcinoma with predominant signet-ring
cell components (80%) and well differentiated neuroendocrine carcinoma
(20%). Intimately intermingled or transitional areas between both elements
as well as amphicrine tumor cells with dual differentiation were also present.
By immunohistochemistry, the adenocarcinoma with signet-ring cells was
positive for CK7 and CEA and neuroendocrine carcinoma was diffusely
positive for CK7, synaptophysin, chromogranin but negative for insulin and
CEA. Of the two metastatic peripancreatic nodes, one was neuroendocrine
carcinoma and the other was adenocarcinoma. The patient is alive and
disease-free 13months since surgery.
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INTRAHEPATIC PAPILLARY CHOLANGIOCARCINOMA: A
RARE CHOLANGIOCARCINOMA WITH A MORE FAVORABLE
PROGNOSIS
Christopher D Anderson, MD, Majella Doyle, MD, William C Chapman,
MD, Jeffrey A Lowell, MD
Section of Abdominal Transplantation, Washington University in St. Louis,
St Louis, MO
Introduction. Intrahepatic papillary tumors are the most rare form of
cholangiocarcinoma. Some studies suggest that this tumor has a more
favorable biology and better survival than other types of cholangiocarcinoma;
however, there are limited data on outcomes following intrahepatic papillary
tumors. Here we report a case and review the available literature on
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intrahepatic papillary cholangiocarcinoma (IPC). Case: A 57 year old female
with right upper quadrant pain underwent an ultrasound revealing left
intrahepatic ductal dilatation with a normal extrahepatic biliary tree. Her
bilirubin and transaminases were normal, but she had an elevated CA 19-9
(278). A cholangiogram revealed a left hepatic duct stricture. A subsequent
CT angiogram revealed biliary dilatation of segment 2 and 3 with no obvious
mass and normal hepatic vasculature. She underwent a left hepatectomy and
pathology revealed an intraductal papillary cholangiocarcinoma with negative
margins.
Methods. The clinical and pathologic features of our case were reported.
The English language literature was searched for IPC. Articles which
reported papillary pathology, intrahepatic location of tumor, patient age
and sex, and therapy provided were selected. Available clinical data were
collected from these articles.
Results. Twelve articles meeting the stated criteria were located. Cumula-
tively, there were 194 patients with average age of 59.8912 years. There was
a predominance of female patients (112 female, 73 male) and left lobe tumors
(126 left vs 31 right). Resection was carried out in 183 patients with a
negative margin reported in 155. Cumulative perioperative mortality was
6.6%. Cumulative survival was incompletely reported, but averaged 37.6
months with the vast majority remaining alive with no evidence of disease at
last followup.
Conclusions. IPC is a rare form of cholangiocarcinoma. It should be
suspected when unilobar or segmental biliary dilation is discovered. The
majority of the reported cases occur during the 6th and 7th decade of life with
a female predominance. Margin negative resection offers long term survival
and this tumor may have a more favorable prognosis than other histological
types of intrahepatic cholangiocarcinoma.
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SYNCHRONIC CANCER OF THE BILIARY TRACT: CASE RE-
PORT AND REVIEW OF THE LITERATURE
Ne´stor A Go´mez, Jero´nimo J Gaibor, Jorge L Mejillo´n, Jorge A Zapatier,
Paola E Vargas
Department of Surgery, Medicine School, University of Guayaquil and
Institute of Digestive Diseases ‘‘Esperanza Foundation’’, Guayaquil, Ecua-
dor; Institute of Digestive Diseases ‘‘Esperanza Foundation’’, Guayaquil,
Ecuador
Introduction. The association of two or more cancerous lesions (synchron-
ism, double cancer) limited to biliary tract is uncommon. The literature
reports twelve cases. Adenocarcinoma of gallbladder associated to cholan-
giocarcinoma is a rare presentation of a double cancer.
Case Report. A 69 years old male patient was seen in admission for
presenting jaundice, choluria and weight loss with an evolution of 6 months.
He did not present abdominal pain. In addition, he presented pruritus and
fever. Physical examination showed generalized jaundice and non painful
hepatomegaly. The laboratory tests were all normal, except for a marked
elevation of total bilirrubin: 27.19 (N: 0.90), CEA: 2.5 ng/ml, Ca 199: 38
U/ml, Ca 125: 30 U/ml, AFP: 10 ng/ml. The preoperative ultrasonography
showed dilatation of the intra and extrahepatic biliary tree, and cholelithiasis.
Cholangioresonance (MRC) confirmed dilatation of ducts due to obstruction
of the biliary tract in its distal segment. Cholecystectomy was practiced plus
choledocoduodenostomy. The pathological study reported adenocarcinoma
of gallbladder and adenocarcinoma of choledocus. The post surgical
evolution was remarkable and received the medical discharge one week later.
The patient died five months after the operation.
Discussion. Single world-wide literature reports twelve cases of double
cancer of gallbladder and biliary ducts, associated mainly to ducts anomalies
of the pancreatic-biliary system. The symptomatology is silent and can be
confused with other pathologies. The visualization by ultrasonography of
expanded intrahepatic or extrahepatic tract demands the complementation of
its study with cholangioresonance (MRC) and endoscopic cholangiography
(ERCP) mainly and others diagnostic tests if they are considered necessary.
Mortality by this type of tumors continues elevated.
References.
1. Kubicka S. Cholangiocellular and gallbladder carcinoma. Z Gastroenterol
2004; 42(5):397 402.
2. Takayashiki T, et al. Double cancer of gallbladder and bile duct associated
with anomalous junction of the pancreatobiliary ductal system. Hepatogas-
troenterology 2002; 49(43):109 12.
3. Daines W, et al. Gallbladder and biliary tract carcinoma: A comprehensive
update, Part 2. Oncology (Huntingt) 2004; 18(8):1049 59.
4. Anderson CD, Pinson CW, Berlin J, et al. Diagnosis and treatment of
cholangiocarcinoma. Oncologist 2004; 9(1):43 57.
5. Cormier J, Vauthey JN. Biliary Tract Cancer. Current Opinion in
Gastroenterology 2000; 16:43743.
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SURGERY FOR ADVANCED KLATSKIN’S TUMOR WITH VASCU-
LAR INVOLVEMENT
Huang Ching Wen, MD, Chen Hong-Yaw, MD, Ker Chen-Guo, PhD,
FACS, Juan Chung-Chou, PhD
Yuan’s General Hospital, Kaohsiung, Taiwan
Purpose. Klatskin’s tumor today is still a challenge for hepatobiliary
surgeon, especially for those advanced cases with extensive bile duct and
vascular invasion. Complete resection of tumor is the only way for long-term
survival.
Materials and methods. We report one case of advanced Klatskin’s tumor
with main portal vein and extended bile duct involvement. Extended right
lobectomy (RightS1S4a), portal vein resection and hepatico-jejunostomy
were performed. The main portal vein was resected 2 cm in length. Left and
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main portal veins were reconstructed. Portal vein thrombosis was found
during operation and thrombectomy was done immediately. Ductal plasty
was performed for making S4 and S23 bile ducts to one hole to simplify
hepatico-jejunostomy.
Results. The post-operative course was eventful. This patient stayed in the
ICU for a long time due to CO2 retention caused by COPD. Color Doppler
sonographies were performed 3 and 10 days after operation. The recon-
structed PV blood flow was good. The cholangiography performed two weeks
after operation showed good hepatico-jejunostomy anastomosis. Bile leakage
was noted from liver stump. The pathology showed tumor-free resection and
no lymph node metastasis. This patient was discharged fifty-one days after
operation.
Conclusion. Advanced Klatskin’s tumor is a tough work to overcome.
Sufficient pre-operative management (such as PTCD, PTPE) and excellent
operation technique can increase the tumor-free resection rate.
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RECURRENCE-FREE SURVIVAL AND PATTERN OF RECUR-
RENCE FOLLOWING RESECTION OF HILAR CHOLANGIOCAR-
CINOMA
Fumito Ito, MD, PhD, Robert Rettammel, None, Mark Bean, None, David
M Mahvi, MD, Layton F Rikkers, MD, Sharon M Weber, MD
University of Wisconsin, Madison, WI
Background. Hilar cholangiocarcinoma is a rare tumor with a poor
prognosis. We sought to evaluate recurrence pattern and prognostic factors
for recurrence-free survival in surgically resected hilar cholangiocarcinoma.
Methods. From 1985 to 2006, patients with hilar cholangiocarcinoma
referred to a tertiary surgical clinic were evaluated. Demographic data, tumor
characteristics, and outcome were analyzed retrospectively.
Results. Thirty-eight patients underwent resection, which included excision
of the extrahepatic biliary system and porta-hepatis lymphadenectomy, with
(n20) or without (n18) hepatic lobectomy. The 30-day operative
morbidity and mortality was 32% and 0%. Overall three-year survival was
47%. The median recurrence-free survival was 31 months, with a median
time to recurrence of 19 months. Factors predictive of improved disease-free
survival on univariate analyses included negative histological margins,
concomitant hepatic lobectomy, lack of nodal disease, and an earlier tumor
stage (pB0.05). On multivariate analysis the only significant favorable
prognostic factor was lack of nodal disease (p0.02). Of the 20 patients
with recurrent disease, the site of first recurrence was porta hepatis lymph
nodes (n6, 30%), liver (n4, 20%), peritoneal deposits (n3, 10%), lung
(n1, 5%), and multifocal recurrence (n6, 25%).
Conclusions. Hilar cholangiocarcinoma is an aggressive tumor with a high
likelihood for recurrence. Because it is possible to decrease the risk of
recurrence by performing concomitant hepatic lobectomy and obtaining a
negative margin, aggressive resection including hepatectomy should be the
standard treatment. Improvements in adjuvant therapy are essential to
improving outcome in patients with hilar cholangiocarcinoma.
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A CASE OF COMBINED RESECTION FOR SYNCHRONOUS
PRIMARY CARCINOMAS OF GALLBLADDER AND DUODE-
NUM
Chol Kyoon Cho, MD, PhD, Hyun Jong Kim, MD, PhD, Yang Seok Koh,
MD, FRCP, Soon Ju Jeong, MD, Jung Chul Kim, MD, PhD, Young Hoi
Hur, MD, Chang Hwan Park, MD, PhD, Wan Sik Lee, MD, PhD, Sung Kyu
Choi, MD, PhD, Jong Sun Rew, MD, PhD, Sei Jong Kim, MD, PhD, Yong
Yeon Jeong, MD, PhD, Sang Soo Shin, MD, Jae Hyuk Lee, MD, PhD,
Young Eun Joo, MD, PhD
Chonnam National University Medical School, Gwangju, Republic of Korea
Purpose. The incidence of multiple primary malignant tumor ranged from
0.7% to 11% in the literatures. In digestive system, vrious organs are the site
of multiple primary cancer (MPC). The major sites are large intestine,
stomach and liver, and others are esophagus, pancreas, small bowel and
gallbladder (GB). MPC may be synchronous or metachronous depending on
the interval between their diagnosis. To the best of our knowledge, the
resected case of synchronous primary carcinomas developed in GB and
duodenum has been reported very rarely.
Methods. We present a patient who underwent a operation for synchronous
primary carcinomas of GB and duodenum. A 51 year-old-female was
admitted for postprandial abdominal discomfort. CT scan and MRI of
abdomen showed 32 cm sized heterogenously enhancing mass in GB and
3.72.7 cm sized hetrogenously enhancing mass in duodenal 2nd portion.
The laboratory findings including tumor markers were non-specific. Elective
operation was done under the impression of combined GB cancer and
duodenal 2nd portion cancer. In operative findings, there were 32.5 cm
sized mass in GB and 54 cm sized duodenal mass with near complete
luminal obstruction 3 cm distal from pyloric ring. Radical cholecystectomy
with wedge resection of liver bed and Whipple’s operation was performed.
Results. In microscopic examination, GB mass was well differentiated
adenocarcinoma and duodenal mas was moderately differentiated adenocar-
cinoma, and one lymphnode(lymphnode along common hepatic artery)
among 18 dissected lymphnodes was invaded by tumor cells. In immuno-
histochemical study, GB mass shows CK7(), c-erbB2(3), Topoisomerase
II(, B10%), p53(, B5%), E-cadherin(3), Ki-67(, 50%), CK20()
and duodenal mass shows CK7(), c-erbB2(2), Topoisomerase II(,
70%), p53(), E-cadherin(2), Ki-67(, 50%), CK20(). The micro-
scopic and immunohistochemical findings showed that the GB mass and
duodenal mass were synchronous primary carcinomas. The patient had
recovered uneventfully and is well alived without evidence of recurrence in
20-month-follow up evaluation.
Conclusions. We report a case of combined curative resection for
synchronous primary carcinomas of gallbladder and duodenum.
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PRIMARY NON-HODGKIN’S LYMPHOMA OF THE GALLBLAD-
DER
Siddharth K Bhende, Burt Cagir
Guthrie/RPH, Sayre, PA
Primary non-Hodgkin’s lymphoma of the gallbladder is a very rare location of
extranodal non-Hodgkin’s lymphomas. More common than primary lym-
phoma of the gallbladder is secondary involvement with adjacent lymph
nodes in patients with known malignant lymphoma. A search through the
literature demonstrates only 12 cases of reported primary non-Hodgkin’s
lymphoma of the gallbladder. The origin of gallbladder lymphoma is
controversial as lymphoid tissue in normal gallbladder mucosa is sparse.
Cholelithiasis usually causes chronic cholecystitis leading to infiltration of the
gallbladder mucosa with lymphocytes. A method for preoperative diagnosis
has not been established. All cases have been diagnosed after surgery by
pathologic examination. Most patients present with signs and symptoms
indicating biliary disease. The majority of cases are found incidentally in
cholecystectomy specimens performed because of cholecystitis or cholelithia-
sis. We present a patient without a history of lymphoma who presented with
clinical and radiographic signs of cholecystitis. An open cholecystectomy was
performed and final pathology demonstrated primary non-Hodgkin’s lym-
phoma (Diffuse Large B-cell lymphoma).
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A SINGLE-CENTER EXPERIENCE ON THE SURGICAL TREAT-
MENT OF THE GALLBLADDER CARCINOMA
Yoshikazu Toyoki, MD, PhD, Kenichi Hakamada, MD, PhD, Shunji
Narumi, MD, PhD, Mutsuo Sasaki, MD, PhD
Hirosaki University School of Medicine, Hirosaki, Japan
Aim. To optimize surgical treatment of the gallbladder carcinoma, we
analysed prognostic factors of these cancer patients based on a single center
experience.
Methods. The records of 64 patients with the primary gallbladder cancer
between October, 1994 and December, 2004 at our department were
reviewed retrospectively. Fifty-nine patients of them were performed Surgery
in this sample. Data were collected by chart review including review of
surgical records, pathological specimens and clinical information.
Results. Eight of the patients with surgery were performed only bypass
operation. The overall 3, 5-year survival rate of the patients performed
resection (51 patients) was 43.8% and 38.9%. Thirty-three patients of the
patients with resection were performed macroscopic curative resection. The
3, 5-year survival rate of patients with curative resection was accomplished
was 62.7% and 55.7%. No metastatic lymph node status and no biliary
invasion were predictors of favorable outcome (pB0.05). For the invasion of
the liver cases, the prognosis of patients treated with anatomical liver
resection (segment 5 and of the lower part of segment 4) was better than
that of patients performed extended cholecystectomy under the condition of
curative resection (pB0.05). In the patients with regional lymph node
metastasis, the prognosis of patients performed radical lymphadenectomy
was better than that of patients not performed radical lymphadenectomy (pB
0.05).
Conclusions. Our data suggested that lymph node metastasis and biliary
invasion were prognostic predictors and patients with gallbladder carcinoma
with directly invaded the liver should be performed radical resection
including the anatomic resection of the liver segment 5 and of the lower
part of segment 4 with radical lymphadenectomy.
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INCIDENTALLY DETECTED T3/T4 CARCINOMA OF GALL
BLADDER: THE RACE AGAINST TIME AND DISEASE TIDE
Nihar R Dash, MS, Pawan Kumar, MS, Sujoy Pal, MS, Peush Sahni, MD,
Tushar Kanti Chattopadhyay, MS
AIIMS, New Delhi, India, New Delhi, India
Recent literature review on carcinoma of gall bladder (CaGB) suggest that
incidental CaGB with T3 or T4 tumor status could also be considered for
extended sugeries.We looked into our data retrospectively. During a 20 year
period 335 cases of CaGB were operated in the department of GI surgery and
liver transplant in the All India Institute of medical Sciences, Delhi, India. 20
of them were incidental. 11 of them had T3 and one had T4 adenocarci-
noma.The mean age of the 12 patients was 46.3 years. Two of them were
males. Five were following laparoscopic cholecystectomy. 9 of the 12
presented after 2 months (13,9,7,6,4,3,3,3,2.5 months respectively) of
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primary surgery.3 of them presented with recurrence at scar site. All 9 cases
had disseminated disease at second surgery. Some form of palliative resection
or bypass was done in 5 cases. 4 had laparotomy and closure. One patient
died on 16th post operative day due to cholangitis. 6 cases died within 2 to
6months. Two were lost to follow-up. 3 of the 12 cases presented within 1 to
2 months of primary surgery. Extended cholecystectomy (ECCX) was
possible in one case. However the resected specimen did not show any
tumor on histopathology. He had no evidence of recurrence at one year
follow-up. The second case underwent ECCX with resection of adjacent
colonic segment and pylorus. She survived for 6 months. The third patient
had disseminated disease. She died after 3 months. Seven of the 20 cases of
incidental CaGB presented with T2 disease. Six of them presented within 19
days to 2 months. All 6 underwent ECCX with R0 resections. One patient
who presented after 1 year had dissemination. One case of T1 disease had
extended ECCX after 2 months of primary syrgery. She presented after 30
months with local recurrence and obstructive jaundice .Only a segment III
bypass could be possible. Our data suggest that the prognosis of patients
presenting with incidentally detected T3 or T4 disease is dismal, especially if
they present after 2 months. Further studies are required on the surgical
outcome in this subgroup of patients presenting at the earliest. That would
possibly answer, whether the disease tide has too less time to be with in the
reach of the surgeon.
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SURGICAL TREATMENT OF GALLBLADDER CANCER: A PO-
PULATION BASED ANALYSIS
Natalie G Coburn, MD, MPH, Kouros Moozar, MD, Jensen C. C. Tan,
MD, Calvin Law, MD, MPH
University of Toronto, Toronto, ON, Canada
Introduction. The primary modality of cure for gallbladder cancer, an
uncommon but aggressive neoplasm, remains surgical resection. Multiple
single institutional studies have reported that a more aggressive surgical
approach results in better survival. A population-based analysis was
performed to study the access to and outcomes following radical resection
for gallbladder cancer.
Methods. From 19882002, all patients (ages 18 years and greater) with
gallbladder cancer were identified from the Surveillance, Epidemiology, and
End Results (SEER) registry. Patients identified initially with metastatic
disease or diagnosed by autopsy or death certificate only were eliminated.
Results. 3,684 patients were identified. Median age of the population was
71.8 years and 72% of patients were female. Surgical treatments included:
15.1%, no surgical intervention; 4.1%, exploratory surgery without resection;
74.6%, simple cholecystectomy; and 6.2%, radical resection. Depth of
invasion included: 7.2% T1a; 13.4% T1b; 21.9% T2; 47.4% T3; 10.1%
localized NOS. For all patients, survival was not improved with radical
resection. However, on subgroup analysis, there was improved survival with
radical surgery for T2 tumors only (p0.0495). Survival analysis of T1a and
T1b was limited due to small numbers. In patients with T3 tumors, there was
no survival benefit in patients undergoing radical resection compared to
cholecystectomy (p0.7746). Only 4.8% of patients with T2 tumors
underwent radical resection. The proportion of patients undergoing radical
resection varied by SEER region (range 4.19.7%). Other predictors for
receiving a radical resection included younger age, T3 tumor, and moder-
ately-well differentiated tumors.
Conclusion. The benefits of radical resection in T3 tumors that are seen in
single institution studies do not seem to be translated to population-based
outcomes. However, relatively few patients appear to be selected for radical
resection and these criteria cannot be assessed using SEER data. Further
detailed studies on the outcomes of gallbladder cancer need to be conducted,
including criteria for resection and access to radical resection, where
appropriate.
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EFFECTIVENESS OF THE INTRA-ARTERIAL INFUSION CHE-
MOTHERAPY FOR THE LIVER METASTASIS OF THE RECUR-
RENCE OF LOWER BILE DUCT CANCER
Hideaki Andoh, MD, PhD, Yoshio Kobayashi, MD, Yuich Tanaka, MD,
Manabu Onuki, MD, Koji Fukuda, MD
Nakadori General Hospital, Akita, Japan
Introduction. This study shows the effect of the intra-arterial infusion
chemotherapy for the liver metastasis of recurrent bile duct cancer.
Patients. Nine patients were treated with the intra-hepatic-arterial infusion
chemotherapy for the recurrence of the liver metastasis. Pancreatoduode-
nectomy were performed for all patient with lower bile duct cancer.
Method. The catheter was guided to the common hepatic artery or splenic
artery with partial embolization to the splenic artery. The 5-FU was
administered 500 mg/day for 7 days conteniously. MMC 10 mg once at the
first day. After then, 5-FU 500 mg administrated once a week. Second line
chemotherapy was low dose CDDP (10 mg/w; a.i.) every week.
Results. No side effect was occurred in all patients. Average duration period
between surgery and liver metastasis was 355 days (0533 days). Total mean
5-FU dosage for chemotherapy was 14.8g/case (725.5g/case).In effect, CR
was two case, PR two cases, NC two case and PD three cases. Response ratio
was 44%, and median survival time was 330 days. In seven cases, liver
metastasis was controlled with chemotherapy. One case was died for liver
metastasis but other eight cases were died for distant metastasis such as brain
or lung metastasis.
Conclusion. For the liver metastasis of lower bile duct cancer, intra-arterial
infusion chemotherapy was effective without side effect nor high invasive
treatment. But it was not effective and could not protect the distant
metastasis.
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USEFULLNESS OF GEMCITABINE COMBINED WITH 5-FLUOR-
OURACIL AND CISPLATIN (GFP) IN PATIENTS FOR AD-
VANCED BILIARY TRACT CANCER
Kozo Yoshikawa, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Tomoharu
Yoshizumi, Mitsuo Shimada
Department of Surgery, Tokushima, Japan; University of Tokushima,
Tokushima, Japan
Background. Advanced biliary tract cancers have poor prognosis and
chemotherapy has been shown to have little impact. To date, effective
chemotherapy regimens for this carcinoma have not been established. The
effectiveness of CDDP with 5FU therapy is established in several digestive
cancers. Furthermore the effectiveness of gemcitabine for billiary tract cancer
is indicated recently. Therefore we hypothesized CDDP with 5FU combined
with gemcitabine (GFP) therapy is effective, we induced this therapy for
biliary tract cancers from 2004. The aim of the present study is conducted to
clarify the effectiveness of GFP chemotherapy for advanced biliary tract
cancer.
Patients and methods. Twenty-seven patients of unresectable cholangio-
carcinoma, eleven patients of unresectable gallbladder cancer were enrolled.
Of these, five patients of cholangiocarcinoma and six patients of gallbladder
cancer with no prior chemotherapy were treated with a 4-week cycle GFP
chemotherapy consisting of gemcitabine at 1000 mg/m2 on days 1,8,15, and
22, and of 5-FU at 250 mg/m2 and CDDP at 3 mg/m2 on days 1 to 5, 8 to 12,
15 to 19 and 22 to 26.
Result. In six cases with gallbladder cancer, three patients demonstrated
partial response (PR) with an additional two patients having stable diseases
(SD), as assessed by RECIST. Clinical benefit rate and response rate were
83% and 50% individually. The median survival time was 8.7 months. In
efficacy case, multiple liver metastasises could be reduced after GFP
chemotherapy, we could do radical operation. In five cases with cholangio-
carcinoma cases, one patient demonstrated PR with an additional three
patients having SD, as assessed by RECIST. Clinical benefit rate and
response rate were 80% and 20% individually. The median overall survival
time was 10 months. Although response rate was lower than gallbladder
cases, survival time prolonged. In efficacy case, Tumor which replace almost
liver was reduced after 4 course GFP chemotherapy. Over all survival rates
improved significantly compared with cases before induction of GFP
chemotherapy in both biliary tract cancers (PB0.05).
Conclusion. This GFP chemotherapy has promising antitumor activity in
patients with advanced biliary tract cancers. This regimen needs to be
evaluated in large numbers of patients.
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THE DEVELOPMENT OF A SWINE MODEL OF SECONDARY
LIVER TUMORS FROM A GENETICALLY INDUCED SWINE
FIBROBLASTS CELL LINE
Rime Abbas, MD, Ann Robinson, Stacy Adam, PhD, Mike Mcgee, MD,
Julian Kim, MD, PhD, Christopher M Counter, PhD, Juan R Sanabria, MD
University Hospitals  Case Medical Center  Case WR University,
Cleveland, OH; Duke University, Durham, NC
Swine models of secondary liver tumors may demonstrate to be an ideal
model to study the efficacy of surgical and ablative treatment options
available for liver tumors. The purpose of the present studies was to develop
a secondary liver tumor in a large animal model. Fibroblasts from swine were
isolated from ear lobule; cells then were transfected with amphotrophic
retroviruses encoded with human genetic (hTERT, p5300, cyclinD-1,
CDK4R24C, MycT58A, RASG12V) material. Transformed cell lines were
inoculated into swine under tacrolimus based immunosuppression (n4).
Isolates from first pass were cultured and then inoculated as a second pass
into 1) nude immunodeficient mice (n5), 2) immune intact wild mice (n
2) and, 3) porcine animals without immunosuppression (n2). Tumor
growth was evident in 75% of immunosuppressed swines. One animal die
with diarrhea and failure to thrive before the completion of experiment
(3 weeks). Growth of tumors was slow in two animals while in one animal
tumor was larger with a peak growth of 42 mm at three weeks. All growths
showed to be malignant on histology. Cell morphology changed from initial
cell line as compared with cell isolates after first pass. Tumor growth was
evident in 100% of the nude immunodeficient mice with a peak size of
22 mm (1795 mm, Mean9SD) at the time of sacrifice (3 weeks). Tumor
growth was evident in all wild mice with a peak size of 8.9 mm at the end of
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the third week. Tumor growth in swine was characterized for slow growth
with a peak size of 8 mm at three weeks. Characterization of new mutations in
cell lines after first pass is the matter of current studies. Further changes may
produce a more rapid growth of genetically induced tumorogenic cells in the
immune-intact swine.
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DENDRITIC CELLS GENERATION FROM PERIPHERAL BLOOD
MONONUCLEAR CELLS OBTAINED FROM JAUNDICED PA-
TIENTS WITH PANCREATIC ADENOCARCINOMA
Andre S Matheus, Mariza Treglia, Jose Jukemura, MD, PhD, Jose Eduardo
M. Da Cunha, MD, PhD, Marcel C. C. Machado, MD, PhD, Jose Alexandre
M. Barbuto, MD, PhD
University of Sao Paulo, Sao Paulo, Brazil
Pancreatic adenocarcinoma (PAde) is an aggressive malignancy with poor
prognosis, urging for improved or new therapeutic strategies. Dendritic cells
(DC)-based vaccination is one of such promising approaches. DC are the
most potent antigen-presenting cells and central to the induction and
maintenance of an immune response. However, in cancer patients DC
generation and function may be deficient, imposing an obstacle to the success
of their use. Here, we describe the in vitro generation of DC from peripheral
blood mononuclear cells (PBMC) obtained from jaundiced patients with
PAde and, also, the effect of jaundiced plasma (JP) in the phenomenon.
PBMC were separated from blood obtained from 10 patients and 10 healthy
controls over a density gradient. Adherent cells were cultured with GM-CSF
and IL-4 (50 ng/mL) for 7 days. On the 5th day, TNF-Alpha (50 ng/mL) was
added for DC activation. Cultures were performed in 10% JP or normal
plasma (NP). Non-adherent cells were harvested at day 7, labeled with
FITC- or PE-conjugated monoclonal antibodies against CD86, CD80,
CD1a, CD11c, CD14, HLA-DR and analyzed by flow cytometry. Patient
cells, cultured in 10% JP, compared to healthy donor cells, cultured in 10%
NP, had a significantly (pB0.05) lower expression of CD11c, CD80, CD86
and HLA-DR. It is noteworthy that cells generated from patients PBMC did
not express CD11c, while 60% of those derived from healthy donor cells did
so. The presence of JP in healthy donor cells cultures caused a significant
decrease in the percentage of HLA-DR(66%89%), CD11c(43%
60%) and CD86 cells (43%66%). Finally, when patients PBMC were
cultured in NP, a significant increase in HLA-DR (87%75%) and a
tendency (p0.06) to increase in CD86 (43%30%) expression occurred.
These data indicate a significant alteration in the patients PBMC ability to
differentiate into DC in vitro , a phenomenon that seems to depend both on
soluble factors present in plasma and on the cells, themselves.
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TOLERANCE TO A TUMOR ASSOCIATED ANTIGEN IS DEPEN-
DENT UPON THE SITE OF EXPRESSION AND ANTIGEN LOAD
Diego Avella, MD, Luis Garcia, MD, Eric Kimchi, MD, Kevin Staveley- O’
Carroll, MD, PhD
Penn State University, Hershey, PA
Introduction. Although hepatoma (HCC) is a leading cause of cancer
mortality worldwide, the immune response to this virally-induced tumor has
been largely unexplored. Evidence from liver transplant results and elsewhere
has suggested that the liver is a tolerogenic organ. To evaluate this possibility,
we challenged mice with tumor cells that bear a transforming viral antigen.
Such cells have been shown not to grow in an immunocompetent host when
injected subcutaneously or intraperitoneally. Hypothesizing that tumors that
seed the liver directly might avoid immunologic destruction, we injected
varying doses by intrasplenic and intravenous routes into syngeneic im-
munocompetent hosts and compared the growth kinetics.
Methods. C57BL/6 3 month old mice were innoculated with different
amounts of tumor cells by intrasplenic injection. The tumor cells used were
derived from liver tumors from MTD2 mice. MTD2 mice are syngeneic to
C57BL/6 mice and spontaneously develop T antigen (Tag)-expressing
hepatomas resulting from transgenic expression of the Tag of the SV40
virus. We have grown these tumor cells in culture and demonstrated Tag and
MHC class I expression by flow cytometry. C57BL/6 mice were divided into
3 different groups according to the number of cells injected intrasplenically: 5
million (5 mice), 1 million (5 mice) and 1/2million (3 mice). Tumor cell
growth was evaluated microscopically 30 days after injection. In a separate
experiment comparing intrasplenic versus intravenous routes of injection, 1/2
million cells were injected into the tail vein (5 mice) and intrasplenically (4
mice). Growth in the liver and lung was evaluated grossly at 120 days after
the innoculation.
Results. The groups inoculated with 5 million and 1 million cells
intrasplenically did not show growth at anytime. Similarly, the group injected
IV showed no growth 4 months post injection. Interestingly, the group
injected intrasplenically with 1/2 million cells did grow tumors. In these mice,
30 days after intrasplenic injection, H & E staining showed multiple tumor
foci (3 of 3 mice). Immunohistochemistry staining was used to confirm Tag
expression. 120 days after injection the same group developed hepatocellular
cancer evident macroscopically and with H & E staining (2 of 4 mice).
Overall 5 of 7 mice that recieved 1/2 million cells intrasplenically developed
HCC; none of the other groups developed HCC (pB0.01).
Conclusion. The liver has a critical role inducing tolerance to tumor cells,
but may also induce an effective immune response depending on the antigen
load. To clarify liver specific immunogenicity of tumor antigen, future
experiments will explore the Tag-specific immune response in each group.
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FIBROBLASTS PROMOTE PANCREATIC CANCER CELL
GROWTH IN VITRO
Qiang Dai, PhD, Matthew A. Firpo, PhD, Jill D. Coursen, MS, Sean J.
Mulvihill, MD
University of Utah, Salt Lake City, UT
Desmoplasia is a common histological finding in ductal pancreatic adeno-
carcinoma and fibroblasts, the main cellular constituent of tumor stroma,
may create a context that promotes tumor progression. The tumor micro-
environment is known to effect tumor cell invasion, metastasis, and drug
sensitivity. Juxtatumoral stroma has different gene expression from panstro-
mal cells suggesting that direct communication between tumor cells and
stromal fibroblasts is important for these effects. However, measurements of
tumor growth are difficult in the context of mixed cell types. We developed a
contacting co-culture system consisting of red fluorescent protein (RFP)-
tagged AsPC-1 pancreatic cancer cells and T31 human fibroblasts that allows
direct evaluation of tumor cell growth in a mixed cell culture. In this system,
we assessed the dose response of fibroblasts on RFP-AsPC-1 pancreatic
cancer cell proliferation (Table). Relative proliferation was determined as the
ratio of the mean fluorescence intensity at day 3 divided by the initial mean
fluorescence intensity at day 0. The presence of fibroblasts in co-culture
conferred a significant growth advantage on RFP-AsPC-1 cells. The effect
was fibroblast dose dependent with the highest dose (1:1 ratio) yielding a
34% increase in tumor cell growth relative to controls. Our results suggest
that direct mesenchymal-epithelial cell interaction within the tumor micro-
environment can contribute to tumor cell proliferation.
Proliferation of Pancreatic Cancer Cells in Fibroblast Co-culture
RFP-AsPC-1/Fibroblast Ratio
Relative Fluorescence
(Day3/Day0)9SEM
0 2.9690.62
20:1 3.1990.59*
10:1 3.2990.52**
5:1 3.4690.51**
2:1 3.6890.43**
1:1 3.9690.55**
*P0.05, vs. RFP-AsPC-1 cells only, **PB0.01 vs. RFP-AsPC-1 cells only,
n15/group, 3 replicates.
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THALIDOMIDE TREATMENT OF DEVELOPING HEPATOCEL-
LULAR CARCINOMA: AN IN-VIVO STUDY IN RAT
Jeng Kuo-Shyang, MD, Kuo-Ming Chang, MD
Mackay Memorial Hospital, Taipei, Taiwan
Objective. This animal study was to investigate the effect and possible
mechanisms of thalidomide therapy for developing HCC.
Materials and methods. Adult male LEW/SsN rats were separated into
three groups of 50 each, group A the control, groups B and C given
diethylnitrosamine (DEN), 5 mg/kg/day for 18 weeks. In addition, Group-C
received an intraperitoneal injection of thalidomide, 2.5 mg/kg/day for the
following six weeks. Ten in each group were sacrificed at the 6th, 12th, 18th,
20th and 24th weeks. The body weight of the rat, presence/absence of liver
tumors, and the number of organs involved with HCC were determined at
each stage of observation. Further, at the 24th week, we compared vascular
endothelial growth factor (VEGF) mRNA, methionine aminopeptidase-2
(MetAp-2) mRNA, Bcl-2 mRNA, telomerase mRNA, and telomerase activity
within the liver of Group-A and within HCC from Group-B and C.
Results. No HCC developed deriving from Group A, but tumors were
present for some Group-B and -C by the 18th week. At the 20th and 24th
weeks, the median liver tumor weight for individuals from Group B was,
0.64g (0.580.70 g) and 0.79g (0.700.90g; P0.04), and corresponding
weight for Group C was 0.38g (0.350.42g) and 0.41g (0.350.47 g; P
0.67). The liver weights for Group-C was significantly lower than that for
Group-B (PB0.001, 0.001). The metastasis score (number of organ systems
involved) were two (20%) and three (80%) at the 20th week, and three
(100%) at the 24th week for Group-B rats, and one (80%) and two (20%) at
the 20th week and one (70%) and two (30%) at the 24th week for Group-C
individuals, significant inter-group (B and C) difference (PB0.001, and PB
0.001). The levels of MetAP-2 mRNA within the liver of Group-B and -C
rats were significantly greater than the corresponding values for Group-A rats
(P0.000 and P0.001), although no significant difference between
Group-B and Group-C. The level of Bcl-2 mRNA within test animals’ livers
for both Group-B and Group-C individuals was significantly greater than the
corresponding Group-A value (PB0.001 and PB0.001), whilst no such
difference was noted for the comparison between Group B and Group C.
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Group-B’s and Group-C’s liver telomerase mRNA levels were not signifi-
cantly different.
Conclusion. Thalidomide effectively but not completely, inhibits both HCC
growth and metastasis formation, when administered to rats during the satge
of HCC development. VEGF mRNA may play an essential role in
thalidomide-induced inhibition. Changes to hepatic Bcl-2 mRNA level,
telomerase mRNA level and telomerase activity, but not Met AP-2 mRNA
level, might also make a significant contribution.
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IS IT EFFECTIVE TO TREAT HEPATOCELLULAR CARCINOMA
IN RATS BY TMPYP4?
Jeng Kuo-Shyang, MD, Kuo-Ming Chang, MD
Mackay Memorial Hospital, Taipei, Taiwan
Backgroud. This animal study to investigate the effect and possible
mechanisms of telomerase inhibition therapy on HCC in the rat.
Methods. Adult male LEW/SsN rats were divided into 3 groups of 50
animals each. Group A was the control group. Groups B and C were given
diethylnitrosamine, 5 mg/kg/day. In addition, Group C rats received an
intraperitoneal injection of TMPyP4 (tetra N-methyl-4-pyridyl-porphyrin
chloride), 0.3 mg/kg/day for 14 days. Ten animals in each group were
sacrificed 6, 12, 18, 20 and 24 weeks to evaluate for development of HCC
and metastasis. The weight of the rat, the liver, liver tumors, and number of
organs involved by HCC were measured at each stage. We compared Bcl-2
mRNA, telomerase mRNA, and telomerase activity at 24 weeks in the liver
tissue of group A rats and tumor tissue of HCC from group B and C rats.
Results and Conclusion. No HCC developed in group A, but tumors were
present in group B and C rats by the 18th week. At the 20th and the 24th
weeks, the changes of body weight increased without significance. However,
the median liver weight in group B was 0.62g (range: 0.55 0.72 g) and 0.81g
(range: 0.680.94 g) (P0.04), and that in group C was 0.34 g (range:
0.300.42 g) and 0.39g (range: 0.310.49 g) (P0.43). The group C rats’
liver weight was significantly lower than that of group B rats both times (P
0.012 and 0.007). At the same times, the median metastasis score (number of
organ system involved) was 3 (range: 23) and 3 (23) in group B, and 1
(12) and 1 (12) in group C, a significant difference between the groups
(P0.008 and 0.003). Group B’s Bcl-2 mRNA was significantly higher than
group A’s (P0.025), while group C’s was lower than group B’s, although
not significantly so (P0.530). Group B’s telomerase mRNA was signifi-
cantly higher than group A’s (P0.033), but group C’s was significantly
lower than group B’s (P0.018). The same intergroup relationship was also
true for telomerase activity (P0.001 and 0.037). TMPyP4 effectively
inhibits both liver tumor progression and metastasis in rats ‘‘in vivo’’. A
possible mechanism is TMPyP4-induces inhibition of telomerase and
telomere which plays an essential role in HCC cell proliferation and
progression.
35
GENETIC EXPRESSION PROFILE OF SIGNAL TRANSDUCTION
(ST) PATHWAYS IN W-3 FATTY ACID TREATED PANCREATIC
CANCER CELLS
Anthony Razzak, Justin Hering, MD, Trish Babcock, MS, Joseph Espat, MD
UIC, Chicago, IL
This study profiles the effects of n-3 FA, gemcitabine (GEM) and a
combination treatment of n-3 FA and GEM on 18 human ST pathways to
further the global analysis of n-3 FA treated pancreatic cancer cells.
Methods. MIA PaCa-2 cells were treated with DMEM (control), 100 mm n-
3FA emulsion (95 mm EPA and 78 mm DHA), 100 mm GEM and a
combination treatment of 100 mm n-3 FA emulsion and 100 mm GEM for
12 hours at 378C and 5% CO2. Homogenized cell contents were transferred
to Qiagen RNeasy columns, washed and RNA was eluted;spectrophotometry
and gel electrophoresis confirmed the quality of material. Microarray analysis
used a 60-mer oligonucleotide array (113 genes,18 human ST pathways,
Superarray). Data was analyzed with minimal value background subtraction
and normalized with an interquartile normalization technique. Spots were
considered absent if signal intensity was less than 1.5 the average intensity
of the lower 75th percentile of all non-bleeding spots. Significance was
determined as a 1.5-fold difference in expression compared to control,
DMEM.
Table 1. Significant Differential Expression Profile for Each Treatment.
100 mm n-3 FA 100 mm GEM Combination Treatment
Gene symbol Pathway(s) Fold change Gene symbol Pathway(s) Fold change Gene symbol Pathway(s) Fold change
WSB1 Hedgehog 2.161 FOXA2** Hedgehog 13.066 CYP19A1 CREB 2.337
IL2RA Calcium/PKC 1.959 CDKN1A Androgen
TGFB
p53
1.867 CDKN1A TGFB
p53
Androgen
2.093
TFRC Calcium/PKC 1.760 TNFRSF10B p53 1.840 CDKN2A** TGFB 2.045
TNFRSF10B p53 1.759 CDK2 Androgen 1.640 CDKN2B** TGFB 2.022
TMEPAI Androgen 1.548 STRA6 Retinoic Acid 0.658 TP53 Stress 1.620
CTSD Retinoic Acid
Estrogen
0.663 MYC Wnt
PI3K/AKT
Stress
Calcium/PKC
0.657 IL2 NFKB
NFAT
Calcium/PKC
1.594
EGRI PLC
Mitogenic
CREB
0.651 CDKN1B TGFB 0.651 FN1" PI3/AKT 1.593
FOS Calcium/PKC
PLC
Mitogenic
CREB
Stress
0.630 GYS1 Insulin 0.605 IRF1 Jak-STAT 1.591
BCL2L1 Jak/Src 0.614 NAB2 Mitogenic 0.529 CDKN1B TGFB 0.659
BRCA1 Estrogen 0.574 FOS Calcium/PKC
PLC
Mitogenic
CREB
Stress
0.502 BIRC5 Wnt 0.618
STRA6 Retinoic Acid 0.415 EGRI PLC
Mitogenic
CREB
0.489 NFKBIA NFKB 0.577
KEY: PKCProtein Kinase C
PLCPhospholipase C
FOS Calcium/PKC
PLC
Mitogenic
CREB
Stress
0.520
TMEPAI Androgen 0.506
STRA6 Retinoic Acid 0.438
*Fold Change was calculated relative to cells treated with DMEM for 12 hours (control). Significance was defined as a 1.5-fold change in expression relative to
control after minimum value background subtraction. **Gene in control treatment considered absent (less than 1.5 average intensity of lower 75th percentile
of non-bleeding spots).
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Results. n-3 FA had significant differential expression in 11 genes (Table 1).
Of these, 7 genes were differentially expressed in only n-3 FA treatment:
IL2RA, TFRC, TMEPAI, WSB1, BCL2L1, BRCA1 and CTSD. GEM
treatment had 11 genes differentially expressed, representing 13 pathways
(Table 1). Of these, 5 genes were differentially expressed in only GEM
treatment: CDK2, FOXA2, GYS1, MYC and NAB2. Combination treat-
ment had differential expression in 14 genes, representing 14 pathways (Table
1). Of these, 10 are differentially expressed in only combination treatment:
CDKN2A, CDKN2B, CYP19A1, FN1, IL2, IRF1, TP53, BIRC5,
NFKBIA and TMEPAI. TMEPAI was found up-regulated in n-3 FA and
down regulated in combination treatment and is considered unique to each
treatment because its regulation was different for each.
Conclusion. The anti-neoplastic effects associated with n-3 FA are
associated with differentially expressed genes or combinations of genes not
present and/or differentially expressed in the genetic profile of GEM; for
which there is poor evidence of anti-neoplastic activity. The pathways and
genes highlighted herein will serve as a template for future pathway-focused
studies for n-3 FA and combination strategies to examine genetic-level
mechanisms that may potentially increase pancreatic cancer cell chemosensi-
tization.
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TUMOR GENETICS AND SIGNALING RESPONSE TO GEMCI-
TABINE CORRELATE WITH TREATMENT EFFECT OF GEMCI-
TABINE-BASED MOLECULAR TARGETING STRATEGIES
Bryan K Holcomb, MD, Michele Yip-Schneider, PhD, Jennifer Dixon, MD,
Jason Kennard, MD, Julie Mahomed, Eric Wiebke, MD, Judith Sebolt-
Leopold, PhD, C.max Schmidt, MD, PhD
Indiana University School of Medicine, Indianapolis, IN; Pfizer Pharmaceu-
ticals, Ann Arbor, MI
Introduction. Pancreatic cancer is a deadly cancer with 5-year survival rates
of B5%. Gemcitabine is standard chemotherapy but has minimal efficacy.
Molecular targeting of critical signaling pathways in combination with
gemcitabine may improve responses. Pancreatic cancers may have differential
responses according to their molecular genetics and signaling response to
treatment.
Purpose. To determine if pancreatic cancer cells with different genetic
profiles will respond differently to various molecular-targeted agents.
Methods. PANC-1, PaCa-2, and BxPC-3 cells were treated with curcumin
(0.525mM), LY294002 (550mM), or PD325901 (0.11mM) alone or in
combination with gemcitabine (0.00510mM). Proliferation was measured
with cell counts. Enzyme activity was measured with Western, EMSA and
ELISA.
Results. All cells had concentration-dependent decreased proliferation with
each agent. BxPC-3 was sensitive to low doses of each agent, but gemcitabine
or PD325901 were most effective agents for Kras-mutated PANC-1 or PaCa-
2. All cells decreased NF-kB activity with curcumin (24hr) and MEK activity
with PD325901 (24hr). Pi3Kinase activity decreased early (3hr) but
rebounded to (PaCa-2) or above (Panc-1,BxPC-3) basal in LY294002-
treated cells (24hr). Combination of molecular-targeted agents with gemci-
tabine resulted in at least additive effects on inhibition of proliferation in all
cells. For PANC-1, curcumingemcitabine was nearly synergistic. Corre-
spondingly, PANC-1 demonstrated an increase in gemcitabine-induced NF-
kB activity. For PaCa-2, LY294002gemcitabine was synergistic. Corre-
spondingly, long term(24hr) PaCa-2 Pi3Kinase activity was not induced by
LY294002. Finally, gemcitabinePD325901 was only effective in Kras-
wildtype BxPC-3. Correspondingly, BxPC-3 demonstrated the greatest
increase in gemcitabine-induced MEK activity.
Conclusions. These results demonstrate differences in treatment effects,
which correlate with tumor genetics and signaling response to treatment.
Genetic and signaling profiles of each tumor may be necessary to determine
an optimal treatment strategy for pancreatic cancer.
Table 1: Drug effect on pancreatic cancer cell growth alone or in combination
with gemcitabine
Gemcitabine PD325901 LY294002 Curcumin
Panc-1 IC-50 0.02 0.75 35 17
Panc-1 combination
with gemcitabine
LA A HA
PaCa-2 IC-50 0.01 0.1 10 8
PaCa-2 combination
with gemcitabine
LA S A
BxPC-3 IC-50 0.005 0.4 15 1
BxPC-3 combination
with gemcitabine
HA A A
Concentrations are micromolar. Ssynergism, HAhighly additive, A
additive, LAweakly additive.
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A NOVEL CONDITIONALLY REPLICATIVE ADENOVIRUS GENE
THERAPY TARGETING OVEREXPRESSION OF CHEMOKINE
RECEPTOR CXCR4 IN A PANCREATIC CANCER CELL LINE
Neal Holm, MD, Kerry W. Byrnes, MD, Bradford Siegele, MS, Benjamin Li,
MD, Yoshi Odaka, PhD, Michael Mathis, PhD, Quyen Chu, MD
LSU Health Sciences Center, Shreveport, LA
Background. Overexpression of the chemokine receptor CXCR4 has been
demonstrated in a variety of solid tumors including pancreatic cancer, and is
believed to play a pivotal role in cancer metastasis by facilitation of cell
migration. In vitro and animal studies designed to block CXCR4 have
reduced tumor cell migration and abrogated metastatic development. Use of
a conditionally replicating adenovirus (CRAD) gene therapy may represent a
useful modality to exploit CXCR4 overexpression. CRADs utilize the
expression of a gene product specific to cancer cells as a promoter for
production of cytotoxic gene products. In this study, we investigated the in
vitro activity of a CRAD based gene therapy targeting CXCR4 against the
human pancreatic cancer cell line CRL-1918.
Methods. CXCR4 overexpression was assessed by western blot analysis. The
pancreatic cancer cell line was cultured and divided into three groups. Each
group was treated with a different adenovirus vector. Group 1, the negative
control, was infected with a non-replicative adenovirus expressing green
fluorescent protein. Group 2, the positive control group, was treated with a
CRAD containing no upstream promoter. Group 3 utilized a CRAD with a
CXCR4 promoter. Each group was infected with a logarithmic cell to
adenovirus ratio beginning at 1:1 and ending at 1:10,000. Crystal-violet
staining was used to assess cell viability.
Results. Western blot analysis confirmed overexpression of CXCR4 in this
human pancreatic cell line. Marked cell cytotoxicity was noted in Group 3.
This group achieved 100% cell death at an infection ratio of 1:100 and
1:1000. There was no appreciable cytotoxicity noted in the negative control
group.
Conclusion. The human pancreatic cell line CRL-1918 was found to
overexpress CXCR4. By targeting CXCR4, conditionally replicating adeno-
virus therapy was able to successfully achieve E1A-mediated cytotoxicity at
concentration similar to positive controls. CXCR4 targeted CRAD gene
therapy demonstrates in vitro efficacy against the human pancreatic cell line
CRL-1918. This novel CRAD may serve as a tumor-specific target for the
treatment of pancreatic cancer.
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PEPTIDE YY (PYY) AND INOSITOL HEXAPHOSPHATE (IP6):
EVALUATION OF NATURAL AND NOVEL COMPOUNDS FOR
THE TREATMENT OF PANCREATIC CANCER
Brian Mcmillan, Dale Riggs, Barbara J Jackson, David W Mcfadden, MD
West Virginia University, Morgantown, WV
Background. We have reported that both PYYand IP6 inhibit cell growth in
the PANC1 pancreatic cancer cell line in vitro when applied as single and
combined therapies. To confirm the additive effects of combined therapy with
PYY and IP6, we evaluated their effects in regards to cellular proliferation,
apoptotic activity and VEGF production in both the PANC1 and MIAPACA
cell lines.
Materials and methods. The MIAPACA and PANC-1 human pancreatic
cancer cell lines were cultured using standard techniques and treated with
IP6 (0.8mM/well), PYY (500pMol/ml) and the combination of the two. Cell
viability was measured by MTT at 24, 48 and 72 hours. VEGF production
was measured in the cell supernatants by ELISA. Apoptosis was evaluated by
Annexin V-FITC and results calculated using FACS analysis. Statistical
analysis was performed by ANOVA.
Results. Significant reductions (pB0.01) in cellular proliferation were
observed with IP6 in both cell lines at 24, 48, and 72 hours (Range 12.7
75.3%). The combination of PYY and IP6 displayed additive effects on
cellular proliferation when compared to that of each alone in both cell lines
tested at 48 hours. In MIAPACA cells, IP6 decreased cell proliferation by
40.6% and PYY by 14.1%; however when combined, the response increased
to 63.7%. The anti-proliferative response was increased to 46.5% by
combined treatment in the PANC1 cells; compared to 25.9% with IP6 and
9.6% with PYY alone. No changes in apoptotic or necrotic activity were
observed in either cell line tested with PYY, IP6 or when combined. IP6
reduced VEGF by 37.2% in the PANC1 cells (p0.04) and by 68.3% in
MIAPACA cells compared to control (pB0.001).
Conclusions. These findings support that combination therapy with IP6 and
PYY has the potential to become an effective adjunct for pancreatic cancer
treatment. The reduction in VEGF in both cell lines suggests that IP6 may
act as an anti-angiogenic agent. Further in vivo and human studies are
planned to evaluate the safety and clinical utility of these agents in patients
with pancreatic cancer.
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SYNERGISTIC EFFECT OF SIMULTANEOUS 5-LOX AND COX-2
INHIBITION ON PANCREAS CANCER CELL GROWTH IN VITRO
Jill D. Coursen, MS, Tracy M. Covey, None, Kornelia Edes, MS, Kenneth
M. Boucher, PhD, Matthew A. Firpo, PhD, Frank A. Fitzpatrick, PhD, Sean
J. Mulvihill, MD
University of Utah, Salt Lake City, UT
Inflammatory mediators produced by arachidonic acid (AA) metabolism via
the COX-2 and 5-LOX pathways are thought to play a role in the
development of cancer. The use of non-steroidal anti-inflammatory drugs
(NSAIDs), including COX-2 inhibitors, has been consistently associated
with reduced risk in multiple cancers. In pancreatic cancer, however, the
association of NSAID use and cancer risk is not clearly defined. Pancreatic
cancers frequently over-express both COX-2 and 5-LOX. Specific inhibition
of COX-2 alone may result in a shift of AA towards the 5-LOX pathway
leading to increased production of proinflammatory leukotrienes. We
examined the effect of the COX-2 inhibitor, NS-398, and the 5-LOX
inhibitor, zileuton, on the growth of human pancreatic cancer cell lines,
BxPC-3 and AsPC-1. Proliferation was monitored over 72 hours of exposure
to the drugs individually or in combination. For combination treatments,
minimally effective doses that individually produced 1020% inhibition in
each cell line were selected. Potential synergy between drugs, defined as
greater than additive growth effects, were tested in a linear mixed effects
model fit using a restricted maximum likelihood procedure. In BxPC-3 cells,
which express both COX-2 and 5-LOX, individual drugs inhibited prolifera-
tion by 15.9% for NS-398 (100 microM) and 12.2% for zileuton (250
microM). When the drugs were combined, statistically significant synergy
was seen with inhibition increased to 63.7% (p0.0025). In AsPC-1 cells,
which express 5-LOX but are negative for COX-2 expression, proliferation
was inhibited by 10.8% for NS-398 (25 microM) and 19.9% for zileuton
(31.25 microM) individually. Inhibition was unaffected by the combination
treatment yielding only a 19% growth inhibition (p0.4966). These data
suggest that in tumor cells over-expressing both enzymes, dual inhibition with
COX-2 and 5-LOX inhibitors may prove more effective at reducing tumor
growth. These results could have important implications for developing
personalized therapy based on COX-2 and 5-LOX tumor status.
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INHIBITION OF PANCREATIC CANCER CELL PROLIFERATION
BY A COMBINATION TREATMENT STRATEGY EMPLOYING N-3
FATTY ACIDS AND GEMCITABINE
Justin Hering, MD, Anthony Razzak, Sean Garrean, MD, Babcock Tricia,
Jose Trevino, MD, Ws Helton, MD, N Espat, MD
UIC, Chicago, IL
Gemcitabine (GEM) is the standard treatment for pancreatic cancer.
Pancreatic cancer has been demonstrated to have significant chemoresistance
to GEM attributable to increased NF-kB activation. Several models have
demonstrated that n-3 fatty acids (n-3FA) can significantly decrease
proliferation of several pancreatic cell lines and in MIA Paca2 cells this
decrease has been demonstrated to occur through G2/M arrest leading to
increased apoptosis. These experiments were designed to evaluate combina-
tion n-3FA with GEM as inhibitors of proliferation and evaluate the potential
to overcome the known chemoresistance. In this study, the effects of n-3FA
alone and in combination with GEM on proliferation in 4 distinct in-vitro
models are examined.
Methods. MIA PaCa2 & L3.6 (GEM sensitive[S]) and BXPC3 & Panc1
(GEM resistance [R]) pancreatic CA cell lines were treated with 100 mM of
n-3FA or GEM alone or in combination for 24 and 48 hrs; (n-6 FA were used
as control). Non-lipid control used media alone, for a percent of control
calculation. Proliferation was measured by WST-1 assay. Experiments were
run in triplicate and statistics were done by Chi2 analysis, significance at pB
0.05* (Table ).
Results. n-3FA were found to significantly reduce cellular proliferation as
compared to n-6FA and GEM treated cells at 24&48hr time points. GEM
combined with 100 mM n-3FA was not demonstrated to be any more
effective at inhibiting proliferation than n-3 FA treatment alone except in the
highly sensitive L3.6. n-3FA/GEM did significantly decrease proliferation
compared to n-6FA/GEM. However, n-6FA/GEM treatment was statistically
decreased compared to n-6FA treatment alone in all groups except L3.6.
Conclusion. Based on the individual cell line, underlying GEM R or S;
differential n-3FA effects were observed. For GEM resistant cell lines, n-3 FA
with GEM contributed to increased cell death versus control. In addition, the
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more GEM resistant a cell type was the greater the observed effects of n-3
FA/GEM. These observations have interesting implications for future
treatment design.
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MORTALITY RATES FOR PANCREATICODUODENECTOMY
(WHIPPLE’S PROCEDURE) IN A MEDIUM VOLUME, PUBLIC
FUNDED SYSTEM
Jeremy Lipschitz, MD
Department of Surgery, Health Sciences Centre, University of Manitoba,
Winnipeg, MB, Canada
Background. There is general agreement that regionalization of low volume,
high risk surgical procedures such as a Whipple’s procedure results in lower
mortality rates and may improve survival. The Winnipeg Regional Health
Authority audited Whipple’s procedures performed at the 6 regional hospitals
from 19992001. 34 cases had Whipple’s at 3 hospitals. The Health Sciences
Center (HSC) performed half the cases with a 0% mortality, and the other 2
hospitals had a 6% mortality (NS). Following this audit, all Whipples
procedures in the region are performed at HSC. This paper evaluates
whether this medium volume, public funded, tertiary care institution with a
feeding population of 1.2 million meets the designated standards of
performance for Canada, and those published in the United States.
Method. A retrospective review of Whipple’s procedures at one hospital
(HSC) was undertaken from January 1994 to December 2000. A prospective
audit was institued in 2001, and is ongoing. The database was examined to
establish volume of procedures and mortality rates.
Results. A total of 100 pancreaticoduodenectomies were performed from
1994Oct 2006. Annual hospital volumes increased after consolidation of
services at one site (table1). The in hospital mortality was 1%, and the 30 day
mortality was 2%. The in hospital death apparently occurred from
hemorrhage after reinstitution of long term anticoagulation. The other death
occurred in a patient with long standing cardiac disease who presented to
another emergency room in cardiogenic or septic shock one week after
discharge.
Conclusion. The mortality rate for a Whipple’s procedure at the Health
Sciences Centre in Winnipeg is below that reported in Ontario, and compares
favorably with that reported from higher volume institutions in the United
States. Current volumes are adequate to maintain a regional hepatobiliary
service, avoiding the need to transport patients over 1000 miles to the nearest
larger Canadian center.
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THE OUTCOME OF SURGICAL MANAGEMENT OF PANCREA-
TIC AND NON PANCREATIC PERIAMPULLARY TUMORS
Madhava Pai, Paolo Limongelli, Andrew Healey, Stamp Gordon, Nagy
Habib, Robin Williamson, Long Jiao
Hammersmith Hospital, Imperial College, London, United Kingdom
Background & Aims. Surgery remains the curative option for patients with
either pancreatic or periampullary tumors. The outcome of surgical manage-
ment of patients with these tumors by evaluating the prognostic factors
influencing survival and recurrence is reported here.
Methods. The current study examines the outcome of surgical therapy either
with curative or palliative intention in patients with pancreatic and non
pancreatic periampullary tumors. One hundred and forty patients with these
tumors underwent surgery from January 1990 to December 2004. Survival
and disease-free survival were evaluated. Univariate and multivariate analyses
were performed to determine factors affecting survival and recurrence.
Results. The overall median survival time was 6 months after by-pass
operations (n28) and 20 months after resection (n112). In patients who
underwent resection, the 5 year actuarial survival rate was 14.2% whereas the
5 year disease-free survival rate was 9.8%. Among these patients pancreatic
adenocarcinoma accounted for 55% of resections, with a median survival of
17 months and an actuarial 5 year survival of 6% whereas patients with non
pancreatic periampullary adenocarcinoma had median survival of 31 months
and an actuarial 5 year survival of 24%. In the former subgroup, multivariate
analysis identified an advanced UICC stage (p .01) as a significant
predictor of shorter disease-free survival. However, in the latter subgroup
postoperative sepsis (p .008) and the presence of four or more lymph nodes
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were found to be associated with worse survival rates (p .009) whereas a
poor tumor differentiation (p .03) was found to be significantly related to
shorter disease-free survival.
Conclusions. Patients who had non pancreatic periampullary tumors had a
better prognosis and survival than those with pancreatic tumor. Factors
influencing survival and recurrence included stage of disease, number of
lymph nodes, postoperative sepsis, and tumor grading.
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FEASIBILITY AND SAFETY OF PANCREATICODUDENECTOMY
(THE WHIPPLE PROCEDURE) IN A HIGH VOLUME COMMU-
NITY HOSPITAL
Roozbeh Rassadi, MD, Allison Vo, RN, Dhiresh Rohan Jeyarajah, MD
Dallas Methodist Medical Center, Dallas, TX
Purpose. The purpose of current study is to evaluate whether pancreatico-
dudenectomy (PD) can be safely performed in a high volume community
center with results comparable to a high volume university setting.
Method. Retrospective review of 45 consecutive pancreaticodudenectomies
performed by a single surgeon in a community center over 13 months.
Morbidity, mortality, final pathology, margin and lymph node status were
analyzed.
Results. five PDs were performed for benign preoperative diagnoses. There
was one postoperative death (2.2%). There were 18 periampullary cancers,
12 intrapapillary mucinous neoplasms (IPMN), 4 benign adenoma of
ampulla or duodenum, 1 neuroendocrine tumor, one solid pseudopapillary
tumor and 2 cystadenoma/cystadenocarcinoma. 8 patient had a positive
margin (17.7%) and 14 patient had a positive nodal status (31.1%).
Conclusion. Volume-outcome relation has been reported previously and
regionalization of PD has resulted mostly in academic settings. Here we
report the safety and feasibility of performing PD in a high volume
community center with outcomes comparable to high academic centers.
We propose that such a center can be safely assigned as a regional center for
PDs. The experience of the surgeon and familiarity of hospital team members
with the disease process play a key role in achieving these outcomes.
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SAFETY OF PANCREATIC RESECTION IN THE ELDERLY
Tsuneo Tanaka, MD, PhD, Naoki Kagawa, MD, PhD, Yasuhiro Matsugu,
MD, PhD, Hideki Nakahara, MD, PhD
Hiroshima Prefectural Hospital, Hiroshima, Japan
Aim. In recent years, pancreatic resection has come to be indicated mainly in
the elderly. However, risk increases with age, therefore, indication of the
operation as well as pre- and post-operative management are important. The
safety of pancreatectomy was investigated retrospectively in elderly patients
over 75 years in this department.
Materials and methods. From May 1996 and December 2005, 243
patients underwent pancreatic resection. The operative procedure was
pancreaticoduodenectomy (PD) in 180 cases and distal pancreatectomy
(DP) in 63 cases, and combined resection of portal vein was performed 36
cases. The subjects were divided into two groups by the aged 75 and above
(aged group, n41, 77.13.2 yr) and the aged 74 and below (control, n
202, 61.28.8 yr). Fifteen preoperative factors and 4 operative factors were
compared between these two groups.
Results. Postoperative complications were seen in 86 cases (35.4%), and
death during hospital stay occurred in 10 cases (4.1%). In the term of 15
preoperative factors, the incidence of cardiovascular failure and urea level
were significantly higher in the aged group than in the control. In the 4
operative factors, the operative time was significantly lower in the aged group
than in the control. There were no difference between the groups for post-
operative complication (16/41, 70/202) and hospital death (2/41, 8/202).
Conclusion. Pancreatic resection can be performed safely even in elderly
patients.
Results
Aged group
(Over 75 yrs)
Control
(Less than
74 yrs)
P
value Significance
Jaundice (yes) 17/41 (41%) 78/202 (39%) 0.733 ()
Respiratory
failure (yes)
5/41 (12%) 11/202 (5%) 0.213 ()
Cardiovascular
failure (yes)
12/41 (29%) 18/202 (9%) B0.001 **
Diabetes mellitus
(yes)
10/41 (24%) 54/202 (27%) 0.756 ()
Prothrombin time
(%)
92.612.9 92.816.0 0.949 ()
Cholinesterase
(U/ml)
24483 26270 0.137 ()
Urea (mg/dl) 15.05.5 13.34.6 0.032 *
Blood loss (ml) 660451 870708 0.069 ()
Operation time
(min)
398102 451118 0.007 **
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COMMUNITY HOSPITAL OUTCOMES OF WHIPPLE PROCE-
DURE  FOR REGIONALIZATION OF CARE
Pascal R Fuchshuber, MD, PhD, FACS, R Kwan, MD, C K Chang, MD
Kaiser Permanente Medical Center, Walnut Creek, CA; Department of
Surgery, UCSF-East Bay, Oakland, CA
Because the outcome of Pancreaticoduodenectomy (PD) has been shown to
depend on surgeon and hospital volume we have examined our results for PD
at a regional nonprofit HMO Medical Center that is part of a regional
network of hospitals. The study focus is operative and oncologic outcome. A
detailed analysis of the PD volume at all other network hospitals was
performed. All PD cases from 1999 to 2006 were retrospectively reviewed.
On average 13 PD were performed per year. The Kaplan Meier method was
used for survival analysis. Of 92 patients undergoing PD, 25 had benign
neoplasm’s or non-AdenoCA malignancies. 67 patients with AdenoCa (AC)
of the pancreas or the ampulla were entered in the survival analysis. The
majority of patients had stage 2B. The rate of positive margins was 6%.
Adjuvant therapy was given to 71% of Head AC and 20% of Ampler AC
patients. For the whole series 30 day hospital mortality was 3%, major
morbidity was 15%, average LOS was 11 days, and mean operating time and
blood loss was 4 hrs and 450 ml respectively. Mortality occurred only after
PV or SMV resection with reconstruction. Mean overall survival was 35
months for head AC and 82 months for ampullary AC. Liver metastases were
the major cause of death. The resection rate for all patients explored for AC
of the pancreas was 74%. Median survival in unresected patients was 10
months. Our results show that PD can be performed safely in a high volume
managed care community hospital with outcomes equivalent to those
published in modern series. Analysis at all other network hospitals shows a
great disparity in PD volume. Only 2 network hospitals fulfill ‘‘high volume’’
criteria. This underscores the value of regionalization for high risk, low
volume cancer surgery and supports the creation of a limited number of
regional subspecialty centers for pancreato-biliary disease within an HMO
hospital network.
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OUTCOME FOLLOWING RESECTION FOR PANCREATIC CAN-
CER BASED ON SURGEON EXPERIENCE: THE LONG AND
SHORT OF IT
Emmanuel E Zervos, MD, Nasreen A Vohra, MD, John E. Mullinax,
Alexander S. Rosemurgy, MD
University of South Florida College of Medicine, Tampa, Fl 33612, FL
Introduction. The Medicare database has proven invaluable in correlating
hospital and surgeon volume with short term outcome following major
abdominal surgery. Long term outcome (i.e. survival) is more difficult to
ascertain due to inherent limitations of this database but is arguably the most
important of all outcome variables in patients with cancer. Herein we report
short and long term outcomes following pancreaticoduodenectomy for
adenocarcinoma performed by low and high volume surgeons at the same
institution.
Methods. A pancreatic cancer database begun in 2001 consisting of over 400
patients was queried to identify patients more than 48 months from
undergoing pancreaticoduodenectomy for adenocarcinoma by low (B7/
year) and high (7/year) volume surgeons. Kaplan-Meier survival curves
were generated for each group and compared using the log rank test. Short
term outcomes were tabulated for low and high volume surgeons and
compared using the student’s t-test. Data are presented as mean9standard
deviation.
Results. Patients operated on by low and high volume surgeons were similar
in terms of age, gender and disease stage on final pathologic exam but
inexperienced surgeons operated on patients with significantly higher
comorbidities. Adjuvant chemoradiation therapy was applied with similar
frequency for each group. Surgeon experience significantly impacted most
intraoperative variables such as blood loss, operative time and transfusion
requirement while length of stay, complications and short and long term
survival were not impacted. (Table).
Outcome following resection for pancreatic cancer based on surgeon
experience
Surgeon experience Low (n13) High (n38) p value
Length of Stay (days) 13.295.18 15.3910.25 n.s.
Estimated Blood Loss (ml) 1323.191036.54 562.29312.81 0.0029
Operative Time (hrs) 7.991.23 5.091.03 B0.0001
Intraoperative Transfusion
(units)
2.492.87 0.390.69 0.0017
Postoperative Transfusion
(units)
1.293.05 1.494.48 n.s.
Major complications (%) 46.2 36.8 n.s.
30 day mortality (%) 7.7 5.3 n.s.
Comorbidities per patient 2.592.40 1.291.05 0.0318
Overall Survival (months) 12.199.42 16.1912.53 n.s.
Data presented as mean9SD, (n.s.p value not statistically significant).
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Conclusions. Surgeon experience, while critical in determining periopera-
tive factors does not impact long term outcome following pancreaticoduo-
denectomy for cancer. This observation may reflect the futility of surgical
management for pancreatic cancer, patient selection or the requisite low
number of patients necessary to define inexperienced surgeons for such
comparisons.
47
PANCREATIC CANCER SCREENING PROGRAM: TRANSCUTA-
NEOUS ULTRASOUND, MAGNETIC RESONANCE IMAGING,
AND PSYCHOSOCIAL MEASURES
Heidi Rothenmund, MS, Stephanie Wilson, MD, Masoom Haider, MD,
Saumea Thayalan, Kara Semotiuk, MS, Spring Holter, MS, Poala Ardiles,
Aletta Poll, MS, Steven Narod, MD, Susan Armel, MS, Anne Summers,
MD, David Hogg, MD, Kate Butler, MS, Mary Jane Esplen, PhD, Steven
Gallinger, MD
Mount Sinai Hospital, Toronto, ON, Canada; University Health Network,
Toronto, ON, Canada; Women’s College Hospital, Toronto, ON, Canada;
Toronto Sunnybrook Regional Cancer Centre, Toronto, ON, Canada;
University of Toronto, Toronto, ON, Canada
The poor prognosis associated with pancreatic adenocarcinoma is primarily
due to late detection. Currently, there are no clinical screening guidelines
available for this cancer, particularly for individuals who are at higher risk. We
implemented a pancreatic cancer screening protocol including annual
transcutaneous abdominal ultrasound, magnetic resonance imaging (MRI),
and blood collection (for future biomarker studies) for individuals at
increased risk for this disease. Participants were also asked to complete
pre- and post-test psychosocial questionnaires to measure pancreatic cancer
worry, pancreatic cancer specific anxiety, perceived risk, and satisfaction with
the screening/genetic counselling program. To date, 176 participants have
been enrolled since 2003, with 57 subjects having undergone at least three
sets of screening studies. The majority of participants are individuals with
familial pancreatic cancer (56.8%), BRCA2 carriers (29.5%), and p16
carriers (5.7%). Thirty three (18.8%) individuals have required further
investigation based on ultrasound or MRI findings. No cases of pancreatic
adenocarcinoma have been identified. Incidental findings include a 3.5 cm
neuroendocrine tumour of the pancreas in an individual with familial
pancreatic cancer (FPC); a suspected intraductal papillary mucinous
neoplasm (IPMN) in another FPC case; and a gastrointestinal stromal
tumour (GIST) of the stomach in a p16 carrier. Following screening/
counselling, the FPC group had reductions in perceived risk for pancreatic
cancer while levels of cancer-related worry and anxiety for both the FPC and
BRCA2 groups remained stable from pre to post counselling. Overall
satisfaction with the screening/counselling program has been high. Recruit-
ment and surveillance will continue for at least 5 years for each subject.
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TREATMENT OF PANCREATIC CANCER IN A SINGLE PAYER
NETWORK
CK Chang, MD, JS Choi, MD, RC Liu, MD, SK Liu, MD, T Rolle, MD,
PR Fuchshuber, MD, PhD
Kaiser Permanente, Walnut Creek, CA
Background. The incidence of pancreatic continues to increase. It remains
the 4th leading causes of cancer death in the United States. The purpose of
this study was to characterize multimodality treatment of pancreatic cancer
over several decades. We analyzed the records of 4640 patients diagnosed
with adenocarcinoma of pancreas during this study period.
Methods. A retrospective review was undertaken to identify patients with
adenocarcinoma of pancreas treated at all the Northern California Kaiser
Permanente facilities. The large cohort of patients included all stages of
disease. All patients received their treatment between January 1970 and
January 2006. Univariate and multivariate analyses of predictive factors were
evaluated with the log-rank test and Cox regression. In addition chi-square
test of relevant clinicopathologic factors determined which factors were
predictive of overall survival (OS).
Results. Mean age was 68 years (range 13102). Mean follow-up was 9
months (range 1292) and 52% were male. By univariate and multivariate
analysis age, sex, stage, surgery, chemotherapy and radiation were predictive
of OS (pB.05). The strongest determinate of survival was surgery. Surgery
patients had an OS of 42 months versus 8 months in those patients who did
not undergo any surgical intervention. Chemotherapy and radiation both
increase survival by 4 months and 7 months, respectively (pB.05). However
OS did not changes through the various decades (p.05).
Conclusion. Despite the various advances in technology and chemother-
apeutic agents in the past several decades pancreatic cancer remains lethal.
Complete surgical resection continues to be the strongest predictor of
survival.
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PRACTICE VARIATION AND OUTCOMES OF PANCREATICO-
DUODENECTOMY: A POPULATION-BASED STUDY
Anand Govindarajan, MD, Jensen C. C. Tan, MD, Natalie G. Coburn, MD,
MPH, Calvin H. L. Law, MD, MPH
University of Toronto, Toronto, ON, Canada
Although surgical resection is the only curative modality for pancreatic
cancer, there is ongoing debate on how the technique and extent of surgery
impacts outcomes. This population-based study examines variations in
current surgical practice and outcomes in this group of patients. All patients
1885 years old diagnosed with non-metastatic adenocarcinoma of the
pancreatic head from 19982003 were identified from the Surveillance,
Epidemiology and End Results (SEER) registry. Tumors with extension to
organs other than the duodenum were excluded. Patients were stratified by
the extent of organ resection and lymphadenectomy. Logistic regression was
used to elucidate independent factors associated with the type of surgery.
Early mortality and cancer-specific mortality were derived from Kaplan-
Meier methods and Cox models. A total of 3467 patients were identified, of
whom 1607 had surgery. Subtotal pancreatectomy (SP) was performed in
1428 patients (89%), total pancreatectomy (TP) in 124 (7.7%) and extended
pancreaticoduodenectomy in 55 (3.4%). Among patients who had SP,
pylorus-preserving pancreaticoduodenectomy (PPPD) was performed in
118 patients (8.3%), standard Whipple (SW) in 1225 (85.8%) and the
extent of gastric resection was unspecified in 85(6.0%). There were no
significant differences in age, sex, race, tumor size or extent, nodal status or
use of radiotherapy between patients who received PPPD, SW or TP. There
was marked regional variation in the rates of TP (range 015%, pB.001)
and PPPD (range 035.7%, pB.001). TP was associated with a significantly
higher 30- and 60-day mortality (HR at 30 and 60 days: 2.2), but long term
survival did not differ significantly between TP, PPPD and SW (p.44).
Although the extent of organ resection was not associated with differences in
lymphadenectomy, significant regional variation was found with rates of
extended lymphadenectomy ranging from 0% to 9.8% across SEER regions
(p.02) and the mean number of LN retrieved ranging from 7.7 to 13.5
(pB.001). Importantly, increased LN retrieval independently resulted in
improved long term survival (p.0001). In this large, population-based
study, we found marked regional variation in the surgical treatment of
adenocarcinoma of the pancreatic head. Significant variation in extent of
organ resection was found but there were no associated differences in number
of LN retrieved or long term outcomes. However, extent of lymphadenect-
omy was found to have significant regional variation and was associated with
long term outcomes. Future improvements in surgical therapy for adeno-
carcinoma of the pancreatic head may be best focused on performance of
adequate lymphadenectomy.
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OUTCOME OF DISTAL PANCREATECTOMY FOR PANCREATIC
ADENOCARCINOMA
Brian K Goh, Yu-Meng Tan, MBBS, Peng-Chung Cheow, MBBS, Yaw-Fui
Chung, MBBS, Pierce K. H. Chow, PhD, Wai-Keong Wong, MBBS,
London Lucien Ooi, MD
Singapore General Hospital, Singapore, Singapore
Introduction. Due to the late presentation, adenocarcinoma of the distal
pancreas is often irresectable. However in recent times, investigators are
reporting increasing numbers of patients undergoing distal pancreatectomy
(DP) for adenocarcinoma of the pancreas of which a significant proportion
would require an extended resection. The aims of this study were to
determine the outcome of patients undergoing DP for adenocarcinoma of
the pancreas and to compare extended (portal vein or adjacent organ
resection) versus standard resection. The secondary aims were to determine
factors correlating with survival for ductal adenocarcinoma and to compare
the outcome of DP for ductal carcinoma versus malignant mucin-producing
neoplasms.
Methods. Retrospective review of 29 consecutive patients who underwent
DP for an adenocarcinoma over 15 years.
Results. Twenty-one patients underwent DP for ductal adenocarcinoma, 5
for malignant intraductal papillary mucinous neoplasm and 3 for mucinous
cystadenocarcinoma. Seven patients required an extended resection. An
extended resection was associated with a longer operating time compared to a
standard resection [280 (150355) vs 160 (75250 min, P.004] but there
was no significant difference in terms of surgical morbidity or mortality,
blood transfusions, length of hospitalization, positive margins or long-term
survival. For ductal adenocarcinoma, age 65 yrs, platelet countB200109
and lymph node involvement correlated with survival on univariate analysis.
A mucin-producing cystic neoplasm was less likely to have an elevated CA
19-9, less likely to demonstrate perineural involvement, more likely to have a
well-differentiated cancer and had a longer median disease-specific survival
[42 (3144) vs 14 (1216) months, P.002] compared to ductal
adenocarcinoma. Four patients (50%) with a mucin-producing cystic
neoplasm were actual 3-year survivors compared to 3 (14%) with ductal
adenocarcinoma.
Conclusions. Extended DP can be performed safely with similar long and
short-term outcomes compared with standard resection. Age, platelet count
and lymph node involvement are predictors of survival in ductal adenocarci-
noma. Patients with malignant mucin-producing neoplasms have markedly
improved long-term survival compared to ductal adenocarcinoma.
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TRENDS IN THE EPIDEMIOLOGY AND TREATMENT OF PAN-
CREATIC CANCER
Anthony Chan, Ajith Siriwardena, Irvin Modlin, Mark Kidd
HPB Research Group, Manchester, United Kingdom; Gastric Pathobiology
Research Group, New Haven, CT
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Introduction. Cancer of the pancreas usually develops insidiously and
presents late resulting in poor prognosis.
Methods and Materials. We evaluate pancreatic cancers identified over a
12-year period (19922003) using the Surveillance, Epidemiology and End
Results (SEER) Program of the National Cancer Institute (NCI). SEER*Stat
2.6.4 software was used to search the SEER 13 registry for our analysis.
Results. Our analysis included 44,941 cases of pancreatic cancer. The
majority (49.6%) occurred in the head of the pancreas, and the tail (9.3%)
and body (7.5%). Histology was mainly adenocarcinomas (58.8%) and
carcinomas (23.7%). Endocrinomas made up 1.1% and carcinoid tumours
1.5%. Adenocarcinoma was the prevalent at all sites except the islets of
Langerhans where endocrinomas (66.1%) and carcinoids (23.7%) were the
most prevalent.
The incidence (I) of pancreatic cancer in 2003 is 10.9 per 100,000 and has
not changed significantly in the past 12 years (Percentage Change, PC
3.13; Annual Percentage Change, APC0.11; P0.37). Adenocarcino-
mas (I6.34; PC5.83; APC0.11; P0.63) and cystadenocarcino-
mas (I0.09; PC31.59; APC0.24; P0.91) have not changed in
incidence. Carcinomas (I2.15; PC27.15; APC3.27; PB0.05)
and endocrinomas (I0.1; PC39.65; APC3.42; PB0.05) are
declining whereas duct carcinomas (I0.8; PC94.86; APC7.09;
PB0.05) and carcinoid tumours (I0.22; PC185.1; APC9.44; PB
0.05) are on the increase.
The majority of pancreatic cancers diagnosed have distant (49.6%), regional
(24.2%) or localised (7.4%) spread; 0.2% are in situ. The observed 5-year
survival rates are better in situ (75.3%) and with localised spread (14.2%)
compared with regional (6.4%) and distant spread (1.6%). Most (62.6%)
have unknown histological staging, or are poorly (16.6%) or moderately
(14.2%) differentiated. The majority of pancreatic tumours (31.4%) are
diagnosed with distant spread and unknown histological grade (5-yr
survival1.8%). In 1992, 83.7% were offered no surgery other than biopsy
and explorative surgery, and this hasn’t changed significantly over the 12
years analysed (200383.3%). Prognosis following surgery has improved
over the last 12 years, where the 5-year survival rate in 19982003 is
20.06%, compared to 19921997 where it is just 16.27%. Without surgery,
the 5-year survival for 19921997 and 19982003 is just 1.62% and 1.65%
respectively.
Discussion. Pancreatic cancer remains a disease of poor prognosis. Its
incidence remains the same over the past 12 years and the failure to diagnose
it early has meant most patients are not offered surgery. The same proportion
receives surgery but the prognosis has improved only slightly.
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THE NATURAL HISTORY OF RESECTED PANCREATIC CAN-
CER WITHOUT ADJUVANT TREATMENT
Emmanuel Zervos, MD, Sam Al-saadi, MD, Jonathan Hernandez, MD,
Desiree Villadolid, MPH, Amy Collins, Jennifer Cooper, Rachel Gillman,
Nasreen Vohra, MD, Alexander Rosemurgy, MD
University of South Florida And Tampa General Hospital, Tampa, FL
Introduction. A recently completed prospective double-blinded placebo-
controlled adjuvant therapy trial provides a unique opportunity to study and
establish the natural history of resected pancreatic cancer. Five years after
completion of this trial, we report survival outcomes and patterns of
recurrence in patients undergoing resection for pancreatic cancer without
adjuvant therapy until disease recurrence.
Methods. Records of patients randomized to receive placebo in a double-
blinded placebo-controlled adjuvant therapy trial were reviewed noting
tumor-related factors (AJCC stage, nodal and margin status, CA 19-9,
Karnofsky Performance Score (KPS) at baseline and recurrence) and
patterns of recurrence prior to initiation of salvage chemoradiotherapy.
Multiple regression analysis was utilized to determine which factors impacted
disease-free and overall survival. Recurrence categories were classified as:
liver only, local, distant, multiple, or ‘‘clinical’’ (defined by absence of
radiological recurrence in the presence of unexplained weight loss, intractable
pain, jaundice or ascites). Follow up was 100% at 60 months.
Results. 98 patients receiving placebo as adjuvant therapy until disease
progression were identified. Patients with negative margins (67%) experi-
enced longer (21 mo914.4) overall survival than those with positive margins
(33%) (15 mo913.7, p0.02 Log-rank test) and longer disease-free survival
(16 mo914.4 vs. 10 mo911.7, p0.01 Log-rank test). Multiple regression
analysis documented that only stage significantly correlated with disease-free
survival (p0.01) while only KPS at recurrence significantly predicted
overall survival (pB0.05). Patterns of recurrence and their impact on survival
are noted (Table):
Site of Recurrence
Disease Free
Survival
(months)
Overall
Survival
(months)
p-Value
Compared
to Clinical
Recurrence
Multiple (n13) 799.7 8910.0 B0.0001
Distant (n9) 795.7 1098.3 B0.0001
Liver only (n22) 899.9 13912.0 0.0001
Local (n20) 10911.2 13910.4 0.0002
Clinical (n34) 24915.1 29914.8 N/A
Conclusions. Stage at the time of resection and performance status at the
time of recurrence are the best predictors of survival following resections of
curative intent for pancreatic adenocarcinoma. Anatomical evidence of
recurrent disease leads to particularly short survival. Patients surviving
longest before succumbing to recurrent cancer had initially no identifiable
anatomic site of recurrence and died after a prolonged interval of systemic
manifestations of recurrent pancreatic cancer.
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ACCURACY OF 3 DIMENSIONAL LIVER IMAGES RECON-
STRUCTED FROM CT SCANS USING COMPUTER SOFTWARE:
PROSPECTIVE NON-RANDOMISED STUDY
Osama M Damrah, Paul Tait, Long Jiao, Nagy Habib, Ruben Canelo
Hammersmith Hospital-Imperial College London, London, United King-
dom
Introduction. The ability to construct a 3D model of the liver and its
structures before hepatic resection could be useful in determining the extent
and nature of resection. Accurate assessment of Liver and tumour volume
dictates functional liver volume and predicts postoperative liver failure in
patients undergoing resection.
Methods. A prospective non-randomized study was conducted on patients
scheduled for liver resection following discussion at multi-disciplinary meet-
ing. 3D models were constructed from CT images using computer software.
From these 3D models, total LV, functional LV, and tumor volume were
calculated.The resected Liver volume was also calculated and was compared
to the resected liver weight.
Results. A total of 37 patients of mean age 63 (3178), and male to female
ratio 2:1 were scheduled for liver resection, mean height was (162.49
9.08 cm) and mean weight was (73.87912.39). Of these patients; 28 had
Colorectal Metastasis, 5 had Hepatocellular Carcinoma, 3 had cholangio-
carcinoma, and 1 presented with metastatic leiomyosarcoma of the round
ligament. Pre-operatively; 9 patients went for volume enhancing emboliza-
tion, 2 had a non-resectional approach, and 1 patient was subjected to further
imaging due to proximity of the tumour to the vessels. 8 patients underwent
right hemihepatectomy, 5 underwent extended right hemihepatectomy, 3 had
extended left hemihepatectomy, 5 were operated using Habib resection, 4
had right trisectionectomy, and 1 had left medial sectionectomy, 1 had
trisegmenectomy, 4 patients were managed by local resection, 1 by central
resection, 2 by wedge resection, and atypical resection was used in 3 patients.
Postoperative blood tests showed mean bilirubin level (17.3923.9), Albumin
(35.194.32), PT (11.0691.18), and serum creatinine level (86.4915.22).
Incidence of postoperative liver failure was 0%. The mean total liver volume
calculated based on 3D-CT model was (15659404 ml), mean functional
liver volume was (14049358 ml), and mean tumour volume was (1049
142 ml). computer prediction of resected LV using 3D reconstructed CT
images correlated well with resected liver weight, mean of resected liver
volumes predicted was (578.469307 ml) and the mean specimens weights
was (415.69200.68 g) (P0.05).
Conclusion. 3D-CT reconstructed images can accurately predict resected
liver volume and future liver remnant volume during liver resection surgeries.
It aids the decision on the need for pre-operative portal vein embolization to
induce liver hypertrophy.
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TRANS-ARTERIAL CHEMOEMBOLIZATION FOR HEPATOCEL-
LULAR CARCINOMA  INSTITUTIONAL EXPERIENCE
Osama M Damrah, Madhav Pai, Paul Tait, Nagy Habib, Ruben Canelo,
Long Jiao
Hammersmith Hospital-Imperial College London, London, United King-
dom
Introduction. Lipiodol chemoembolization is a widely used method of
treatment for patients with unresectable hepatocellular carcinoma (HCC),
but its efficacy remains debated. The aim of this study was to assess the
outcome of trans-arterial chemoembolisation (TACE) in the management of
unresectable hepatocellular carcinoma.
Methods. Between January 2002 and May 2006, patients with unresectable
hepatocellular carcinoma who had lipidol chemoembolization (lipido plus
doxorubicin) were reviewed. Both patient, and tumour characteristics, results
of chemoembolization including complications and survival were collected
for analysis.
Results. A total of 28 patients received 61 TACE procedures with a mean
number of treatment of 2 per patient. Tumours were large and multifocal,
Okuda score was II and III in 50% of patients. Twenty patients had a repeat
TACE (71%), 4 three times (14%) and one five times respectively (4%). All
patients tolerated the procedure well. Post TACE, one patient developed liver
abscess which was treated with percutaneous drainage and one patient
developed acute renal failure treated with dialysis. Mild abdominal pain and
fever were common and occurred in 40% of the patients. The mean follow-up
time was 17 months (range, 156 months). Seven patients die of tumour
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progression (25%), one of of acute gastrointestinal haemorrhage from
varices.(3.6%) Partial Response achieved in 50% of the patients. The 3-
year survival was 68%.
Conclusion. TACE is an effective therapeutic option for cirrhotic patients
with unresectable HCC.
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LIVER RESECTION FOR HEPATOCELLULAR CARCINOMA IN
CIRRHOTIC PATIENTS  HOW DYSFUNCTIONING LIVER IS
NOT BENEFICIAL?
Cheng Chung Wu, MD, Shao Bin Cheng, MD, Yee Ji Jan, MD, Dah Cherng
Yeh, MD
Taichung Veterans General Hospital, Taichung, Taiwan
Purpose. The risk of liver resection for hepatocellular carcinoma (HCC) in
cirrhotic patients was higher than in non-cirrhotic patients. The risk will be
higher in those with poor liver function. Moreover, liver cirrhosis was
considered as a pre-cancerous state, even 100% 5-year recurrent rate after
HCC resection in cirrhotic patients has been reported. Liver transplantation
is another option in cirrhotic patients with HCC meeting Milan criteria, but
insufficient cadaver donor or inappropriate living donor remains problematic.
Methods. A retrospective review of 816 cirrhotic patients with HCC who
underwent a curative liver resection from 1990 to 2004 was made. All HCC
patients who were admitted for liver resection required liver images, liver
function test and indocyanine-green (ICG) clearance test. The extent of liver
resection was based on the tumor extension and ICG 15-min retention rate
(ICG). According to ICG 15 value, these patients were divided into 3 groups,
group 1: 563 patients, whose ICG was B20%, group 2: 175 patient, whose
ICG R15 was between 2029.9%, and group 3: 59 patients whose ICG R15
was ]30% and B50%. The patient background, early and long term results
after liver resection were compared among the groups.
Results. Because of different patient selection criteria among the groups, the
tumor size was significantly larger, the extent of liver resection was
significantly greater, and tumor stage (TNM staging) was significantly
more advanced in group1. Liver tumor of group 3 was smaller then the
other two groups. The extent of liver resection was significantly. The blood
transfusion rate, postoperative morbidity and mortality were comparable
among the 3 groups. The 6 year-disease free and actuarial survival rates of the
3 groups were 43.6%, 35.9%, 41.3% (p0.4652) and 45.9%, 38.9%, and
42.5% (p0.3637), respectively.
Conclusion. Under careful patient selection, cirrhotic patients whose ICG
R15B50% will be beneficial for HCC resection. Liver transplantation may
be indicated in patients with poorer dysfunctioning liver. ICG50% and
tumor condition meeting Milan criteria.
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A PERIOPERATIVE COMPLICATION-FREE COURSE WITHOUT
A HIGH SERUM HYALURONATE LEVEL ENSURES PRO-
LONGED DISEASE-FREE SURVIVAL AND OVERALL SURVIVAL
AFTER HEPATECTOMY FOR HEPATOCELLULAR CARCINOMA
Toru Mizuguchi, MD, PhD, Tadashi Katsuramaki, MD, PhD, Minoru
Nagayama, MD, PhD, Makoto Meguro, MD, PhD, Toshihiko Nishidate,
MD, PhD, Takayuki Nobuoka, MD, Yasutoshi Kimura, MD, PhD, Koji
Yamaguchi, MD, PhD, Tomohisa Furuhata, MD, PhD, Koichi Hirata, MD,
PhD
Sapporo Medical University, Sapporo, Japan
Background. Assessment of liver functions before hepatectomy is important
to avoid complications after the operation. However, it is not clear that a
history of perioperative complications is associated with the long-term
prognosis. Therefore, we prospectively surveyed patients who received
hepatectomy in our institute with and without perioperative complications.
Methods. Between January 2001 and December 2005, 100 hepatocellular
carcinoma patients who underwent initial hepatectomy were enrolled. The
complication group (GI) consisted of 32 patients, including four patients who
died during the hospital stay. The non-complication group (GII) consisted of
68 patients who were discharged without any adverse events. The times to
recurrence and death were recorded after hepatectomy for as long as possible.
Factors determining disease-free survival and overall survival were assessed
by univariate and multivariate analyses using the Kaplan-Meier method with
comparisons by the log-rank test and Cox proportional hazards regression
model, respectively.
Results. Among clinical laboratory data, the ICGR15 and serum hyalur-
onate (HA) level in GI were significantly higher than in GII. Furthermore,
values for operative variables such as operative time, bleeding and blood
transfusion in GI were significantly higher than in GII. On follow-up, 18
patients in GI and 16 patients in GII died of either liver failure or cancer
recurrence. The log-rank test revealed that the overall survival rate in GII was
significantly longer than in GI, although there was no significant difference in
disease-free survival. Multivariate analysis showed that HA in GII was the
only independent factor to predict long-term survival. Therefore, we divided
GII into two groups. In the high HA group (n24) the HA level was 150 mg/
dl or more. In the low HA group (n44) it was less than 150 mg/dl. The log-
lank test results for three-year overall survival and disease-free survival rates
in the low HA group showed that they were significantly longer than in the
high HA group (87.3% vs. 42.2%: pB0.001 and 45.1% vs. 16.4%: pB
0.001, respectively).
Conclusions. Perioperative complications could be a predictive factor for
overall survival. Even in patients without complications, a low HA level could
predict both long-term disease-free survival and overall survival in hepato-
cellular carcinoma patients who received initial hepatectomy.
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PROGNOSTIC SIGNIFICANCE OF P53, BETA-CATENIN, AND
ALPHA-FETOPROTEIN EXPRESSION IN PATIENTS WITH SUR-
GICALLY RESECTED HEPATOCELLULAR CARCINOMA
Ana L Gleisner, MD, Michael Torbenson, MD, Timothy M Pawlik, MD,
MPH, Lia R Assumpcao, MD, Michael A Choti, MD, MBA
Johns Hopkins Hospital, Baltimore, MD
Several molecular pathways have been implicated in the carcinogenesis of
hepatocellular carcinoma (HCC), marked by key mutations in the b-catenin
or p53 gene, as well as aberrant expression of alpha-fetoprotein (AFP). The
purpose of this study was to determine the prognostic value of immunohis-
tochemical determination of these molecular markers in sequential sections
from patients with resected HCC. Thirty informative patients with complete
(R0) liver resection were evaluated. Univariate and multivariate analyses were
performed using clinical, pathologic and molecular expression parameters.
35% of tumors were positive for AFP, 22% for p53, and 16% for b-catenin,
with 13% positive for more than one molecular marker. Follow-up informa-
tion was collected to determine survival and the prognostic value of each
parameter. On univariate analysis, AFP was associated with worse prognosis,
while beta-catenin was associated with better prognosis. p53 expression had
no independent association with prognosis. When both beta-catenin and AFP
were included in a multivariate model (table, along with nuclear differentia-
tion), the estimated prognostic information remained nearly the same,
although the expression of beta-catenin was no longer significant. When
nuclear grade, beta-catenin and AFP were combined in a prognostic score,
patients with favorable prognosis had 3- and 5-year survival rates of 91% and
78% respectively, compared with 42% and 17% in patients with two or more
unfavorable factors (pB0.001). In conclusion, utilization of histologic grade
combined with assessment of b-catenin and AFP immunohistochemical
expression has independent prognostic significance. Determination of these
biomarkers may permit more accurate prediction of survival after resection of
HCC.
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SURGICAL TREATMENT OF HEPATOCELLULAR CARCINOMA:
WHICH FACTORS PREDICT RECURRENCE?
Carlo M Contreras, MD, Jake Behrens, None, Clifford S Cho, MD, Robert
Rettammel, MS, Mahvi M David, MD, Rikkers F Layton, MD, Weber M
Sharon, MD
University of Wisconsin Hospital & Clinics, Madison, WI
Background. Effective treatment of hepatocellular carcinoma (HCC)
remains a challenge despite multimodality therapies. We sought to evaluate
predictors and patterns of recurrence in patients undergoing surgical
treatment of HCC with resection and/or ablation.
95,0% CI for Exp (B) 95,0% CI for Exp (B)
Sig. Crude HR Lower Upper Sig. Corrected HR Lower Upper
Nuclear Differentiation
Well 1.00 1.00
Moderate .073 3.34 0.89 12.50 .119 2.94 0.75 11.47
Poor .041 6.65 1.08 41.08 .040 7.29 1.09 48.67
b-Catenin Expression .149 0.40 0.11 1.39 .353 0.53 0.14 2.00
AFP Expression .007 3.82 1.43 10.21 .085 3.33 0.84 13.15
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Methods. Patients with HCC treated with surgical resection or ablation from
19902006 were identified from a prospective hepatobiliary database and
hospital records. Demographic data, clinicopathological characteristics, and
outcome were analyzed.
Results. All patients treated with surgical exploration with curative intent
were identified. This included 66 patients undergoing hepatic resection and
20 ablation; 13 patients who eventually underwent transplantation were
excluded from our long-term analysis. The 30-day mortality was 7% (5/73),
and the overall 5-year survival was 37%. The median disease-free survival was
20 months with a median time to recurrence of 10 months. Preoperative
factors predictive of improved disease-free survival include: absence of
positive margins (p0.006), AFP valueB100 ng/mL (p0.04), and low
Model for End-Stage Liver Disease (MELD) score (p0.03). On multi-
variate analysis, only increasing AFP value and positive margins predicted
recurrence. Notably, none of the following factors were found to be
statistically significant predictors of disease-free survival: tumor number or
size of largest initial lesion, vascular invasion, tumor grade, or hepatitis status.
The sites of first recurrence included liver (76%), distant (50%), or both
(21%). Patients initially undergoing ablation versus resection were equally
likely to develop a recurrence. Following recurrence, the median survival was
37 months; 26% of these patients were treated with resection or ablation,
while 41% received medical treatment. None of the following parameters
predicted increased survival after recurrence: site or number of recurrent
lesions, or type of treatment rendered after recurrence.
Conclusions. Treatment of patients with hepatocellular carcinoma remains
a challenging problem. Careful consideration of both tumor characteristics
and preoperative liver function as reflected by the MELD score are important
in predicting recurrence after initial operation. The site of first recurrence is
the liver in the majority of patients; thus, novel adjuvant treatment regimens
should focus on this regional recurrence pattern.
59
RESULTS OF TREATMENT IN 245 MEXICAN PATIENTS WITH
HEPATOCELLULAR CARCINOMA
Ricardo Joaquin Mondrago´n-sa´nchez 80, MD, PhD, Ofelia Arias-arias 2005,
Elvira Go´mez-go´mez 2003, MD, Rodrigo Jasso-barranco 2006, MD, Alicia
Ivette Lo´pez-estrada 2006, Brenda Elena Aguilar-a´lvarez 2006, MD
Issemym, Toluca, Mexico
Background. The incidence of hepatocellular carcinoma HCC in Mexico is
1.4% with increasing tendency, it is diagnosed at late clinical stages with poor
treatment alternatives.
Aim. To detect risk factors for HCC and its opportune management based
on an observational analysis of 245 patients with HCC in Mexico.
Patients/Methods. Retrospective review from 245 patients with HCC
performed at the Instituto Nacional de Cancerologia and Centro Me´dico
ISSEMyM from January 1990 to September 2006. Data analyzed from
clinical records includes epidemiological data, presentation forms, treatment
and survival.
Results. One hundred twenty six males 51%, 119 females 49%. Mean age:
59 years old (range 1290), mean time at the beginning of symptoms was 4
months, most common presentation was stage II. Clinical manifestations:
abdominal pain 83.1%, weight loss 58%, liver enlargement 45% and anorexia
29.9%. Alpha-fetoprotein (AFP) was found 400 ng/dL in 97 patients
39.5%. Diagnosis performed with computed tomography (CT) in 202
patients 82.4%, ultrasonography (USG) in 172 patients 70.2%, and
magnetic resonance images (MRI) in 19 patients 7.7%. One hundred and
thirty one 54.1% had liver cirrhosis, 58 (23.7%) hepatitis C (HCV), 33
(13.5%) alcohol abuse history, 13 (5.3%) hepatitis B (HBV), and ten patients
(4%) with not determinated cause. Sixty seven patients 27% only had biopsy
and 49 received chemotherapy and radiotherapy 20%, liver resection (LR)
was performed in 26 cases 11%, 25 patients 10% received tamoxifen-
talidomida (TMX-TLD), 22 were not treated 9%, 18 patients 7% received
Tamoxifen (TMX), 18 patients 7% received percutaneous ethanol injection
(PEI), radiofrequency ablation (RFA) in 16 cases 6%, two cases 0.8% were
submitted to LR and TMX-TLD and one case 0.4% received RFA-TMX-
TLD and liver transplant (LT). Median survival for LR was 20.4 months, for
RFA was 10 months, for PEI was 8 months, for chemotherapy and
radiotherapy was 4.1 months, for LR-TMX-TLD was 3.6 months, for those
who did not receive treatment was 2.5 months, for TMX-TLD was 2.3
months, for RFA-TMX-TLD was 1.5 months, for TMX was 1 month and
for the case of LTRFA-TMX-TLD was 10 months of survival.
Conclusions. HCC is usually diagnosed at late clinical stages therefore the
alternatives of management are far away from success. Bad prognosis factors
are age B55 years, AFP 400 ng/ml, HCV, tumor size 5 cm, vascular
invasion, and poor differentiation. LR is the best option for earlier stages.
RFA and PEI are also excellent alternatives for those not elective for
resection. For unresectable lesions TMX-TLD is the best option in our cases.
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FLUORINE-18-FDG-PET COULD BE AN EFFECTIVE SURVEIL-
LANCE MODALITY FOR DETECTION OF DISTANT METASTA-
SIS IN HEPOTOCELLULAR CARCINOMA
Kazuaki Nakanishi, MD, PhD, Toshiya Kamiyama, MD, PhD, Takahito
Nakagawa, MD, PhD, Hideki Yokoo, MD, PhD, Satoru Todo, MD, PhD
Hokkaido Univ, Sapporo, Japan
Aim. To evaluate the role of FGD-PET in the surveillance of hepotocellular
carcinoma after surgery, we compared the sensitivity and specificity of FGD-
PET with that of the ordinary follow-up system.
Method. From November 1999 to December 2003, the total number of
seventy-five post-operative HCC patients (44 cases were received hepatect-
omy and 31 were living-donor liver transplantation cases.) received FGD-
PET at the Hokkaido University Hospital and were included in this study.
Patients usually underwent serial measurement of tumor markers, US, CT
and/or MRI scans every 3 months. ‘‘Post-operative Recurrence’’ was
determined, when the positive sign for recurrence were detected by two or
more different these modalities.
Result. Thirty-seven cases and total 47 recurrence sites were diagnosed as
‘‘post-operative recurrence’’ by the ordinary follow-up system. Twenty-six
cases of 28 FDG-PET-positive cases, post-operative recurrence was con-
formed by ordinary follow-up study, and remained two cases were diagnosed
pancreatic cancer by additional examination. Thirty-six of 47 negative cases
had no post-operative recurrence. The sensitivity of FDG-PET was 41.0,
66.7, 100, 100%, and specificity was 100, 98.4, 100, 100% in intrahepatic,
lung, lymph node, adrenal gland respectively.
Conclusion. FDG-PET was not always useful in HCC surveillance after
surgery, because conventional modalities were enough to detect recurrence,
but in extrahepatic lesions, FDG-PET could be useful for detection of
metastatic lesions. FDG-PETalso had an additional effect to find unexpected
malignancies.
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RESULTS OF YTTRIUM-90 MICROSPHERE TREATMENT IN
THE MANAGEMENT OF UNRESECTABLE LIVER CANCER
Osama M Damrah, Hapreet Wasan, Nagy A Habib, Ruben Canelo, Long R
Jiao
Hammersmith Hospital, London, United Kingdom
Introduction. Selective internal radiation therapy (SIRT) is emerging as a
new therapeutic modality in recent years for management of non-resectable
hepatic metastases. Our initial experience in clinical application of this
treatment is reported here.
Material and methods. From November 2004, patients whose liver tumour
was no longer amenable for any conventional treatment with either
chemotherapy or surgery were considered for yttrium-90 microspheres
treatment after discussion at our multidisciplinary meeting. None of the
patients had extrahepatic disease. A pre treatment planning was carried out
with visceral angiography and technetium-99m macroaggregated albumin
(MAA) for assessment of both tumour volume and extrahepatic shunting in
addition to a baseline PET and CT scan respectively. Two weeks later, a
second visceral angiography was performed to deliver the calculated dosage
of microsphere into the arterial system supplying the tumour. Patients were
then followed up with repeat PET and CT scans of abdomen at 6 weeks, and
3 monthly thereafter.
Result. A total of 19 patients with a mean age of 59 years received yttrium-
microspheres treatment, consisting of cholangiocarcinoma (n3) and liver
metastases from colorectal carcinoma (n10), pancreas (n2), GIST (n
1), breast (n1), squamous cell carcinoma of anus (n1) and adenocarci-
noma of an unknown primary (n1) respectively. The average dosage of
microspheres delivered was 1.990.3 GBq. Injection of microspheres had no
immediate effect on either clinical haematology or liver function tests. At
follow up, 17% of patients showed a radiological response of a reduction in
the size of tumour measured on CT scan at 3 months and 33% of a decreased
PET activity on PET scan at 6 weeks. For patients with colorectal liver
metastases, there was no significant reduction in CEA level (1279115 vs
759.72, p0.39). Four patients died at follow up of pancreatic (n1) and
colorectal primaries (n3). Others remained alive with a stable disease. The
total cost of this procedure was £11,000/patient.
Conclusion. Microspheres treatment should be considered as a last option
for patients with liver cancer. Its use should be balanced against its cost/
effectiveness.
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Y-90 RESIN MICROSPHERE SELECTIVE INTERNAL RADIATION
TREATMENT IN PRIMARY AND METASTATIC LIVER CANCER:
OBJECTIVE RESPONSE AND THERAPEUTIC RATIO ANALYSIS
Seza A Gulec, MD, Geraldine Mesoloras, MS, Howard Wiarda, MD,
Kenneth Pennington, MD, Daniel Bruetman, MD, James Wheeler, MD,
PhD, Richard Hostetter, MD, Douglas Schwartzentruber, MD
Center for Cancer Care at Goshen Health System, Goshen, IN
Introduction. Yttrium-90 (Y-90) microsphere therapy via hepatic arterial
administration is emerging as a mainstream treatment modality in the
management of patients with primary and metastatic liver cancer. The
selective nature of microsphere distribution allows the delivery of high doses
of radiation to tumors while keeping the exposure of the un-involved liver at a
minimum.
Methods. Treatment records and follow-up data on 37 patients (21 M, 16 F,
and ages 4486) with primary and metastatic liver cancer who underwent a
selective internal radiation treatment (SIRT) with Y-90 resin microspheres
(SIR-SpheresTM Sirtex Medical, Lake Forest, IL) were retrospectively
reviewed. Liver and tumor radiation doses were determined using the
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medical internal radiation dosimetry (MIRD) technique. Liver toxicity was
assessed clinically and by liver function tests. Response to treatment was
evaluated by tumor markers and PET-CT in all patients.
Results. Of the 37 patients, 10 had primary liver cancer (8 hepatocellular
carcinoma (HCC), 2 cholangiocarcinoma (CC)), and 27 had metastatic liver
tumors (16 colorectal cancer, 5 neuroendocrine tumors, 2 breast cancer, 1
endometrial cancer, 1 lung cancer, 1 gastric, 1 GIST). Tumor volumes
ranged from 10.0 cc to 1,187.3 cc (mean: 300.2). 9 patients (24%) were
treated for down-staging/bridge to surgery. 28 patients (76%) were treated in
a salvage setting. 8 patients with CRCLM received SIRT concomitantly with
first or second line chemotherapy (6 FOLFOX-6, 2 FOLFIRI). Median
follow-up was 17 weeks (2 to 82 week). 31 patients had at least had a 4-week
response-to-therapy assessment. Mean administered activity was 1.9 GBq
(0.7 to 3.2 GBq). Liver absorbed doses ranged from 5.2 Gy to 173.9 Gy
(mean: 40.4 Gy). Tumor absorbed doses ranged from 45.6 Gy to 699.3 Gy
(mean: 221.2 Gy). An objective tumor response was seen in 21/31 (68%). 5/8
CRC patients who received chemo-SIRT had complete, 3/8 had more than
75% FDG-PET response at 4 weeks. There were two complete responses in
HCC/CC patient group who were treated in a segmental fashion. None of the
patients had clinical radiation hepatitis or therapy-induced liver failure.
Conclusions. SIRT with Y-90 microspheres is an effective cytoreduction
modality with a relatively wide margin of safety. Complete objective tumor
responses are possible with appropriate patient selection, conjunctive
interventions, and treatment planning. The response rate and scale were
markedly better in those who were treated front-line with chemo-SIRT
combination.
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IDENTIFICATION OF NOVEL SINGLE NUCLEOTIDE POLY-
MORPHISM IN THE PROMOTER REGION OF HUMAN ALPHA-
FETOPROTEIN (AFP) GENE IN HEPATOCELLULAR CARCI-
NOMA (HCC)
George G Chen, PhD, Rocky Lk Ho, John Wong, Kit Fai Lee, Paul Bs Lai
The Chinese University of Hong Kong, Hong Kong, Hong Kong
Variations of serum AFP levels found in patients with HCC and HCC cell
lines are likely due to the differential activity of enhancer/silencer elements
that control AFP expression. To understand the potential mechanism
underlying the differential expression of AFP, we have examined the sequence
of the AFP promoter in HCC. Three novel SNPs in the promoter region of
the human AFP gene, which have not been previously reported, were found
at positions 330, 401 and 692 in relation to the transcriptional start
site. The level of serum AFP was significantly higher in HCC patients with
the CT genotype of 330 SNP or the CG genotype of the 401 SNP. The
genotype of CG in 692 SNP was also associated with a significant elevated
level of serum AFP, and further this genotype appeared to be associated with
the high risk of HCC development. Bioinformatics analysis revealed that 401
SNP and 692 SNP were located at the positions of known binding sites for
the transcription factors, HNF1 and the RNA pol III TFIII, which have a
role in the production of AFP and the growth of tumors. Therefore, our study
suggests that the polymorphism identified in the promoter region of the
human AFP gene may be pathologically significant in HCC.
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ONCOLYTIC MUTANT HERPES VIRUS KILLS HEPATOMA
CELLS THROUGH A MITOGEN ACTIVATED PROTEIN KINASE
(MAPK)-DEPENDENT PATHWAY
Taejin J Song, Prasad S Adusumilli, MD, Yuman Fong, MD
Ansan Hospital, Korea University Medical Center, Ansan, Republic of
Korea; Memorial Sloan-Kettering Cancer Center, New York, NY
Introduction. Mutant herpes simplex type 1 (HSV) oncolytic viruses are a
promising anticancer therapy. The cellular determinants of oncolytic HSV
therapy are not completely elucidated. The MAPK signal transduction
pathway is important for cellular proliferation and apoptosis, both important
factors for viral proliferation. We seek to determine if MAPK pathways,
specifically MAPK/extracellular-regulated kinase kinase (MEK) inhibitors,
mediate viral proliferation.
Methods. The human hepatoma cell line PLC5 was infected with the
oncolytic HSV G207, at MOI (multiplicity of infection; number of viral
particles per cell) of 0.1. The MEK inhibitor U0126 (30 micromolar) or
control was added to each well simultaneously. Cytotoxicity was assessed by
LDH release assay and viral growth by viral plaque assay on sensitive Vero
cells.
Results. PLC5 cells exhibited less cell death in the combination G207/
U0126 group compared to virus alone. Viral growth was lower in the
combination groups. Nine days after treatment, G207 alone yielded 70% cell
kill compared to 21% in the combination G207/U0126 group (pB0.01). The
MEK inhibitor decreased viral proliferation from 27 fold increase in virus
alone group to 1.3 fold in the U0126 treated cells (pB0.01).
Conclusion. The MAPK pathway is involved in both viral proliferation and
tumor cell kill. Though MAPK inhibition is a potentially useful therapy for
hepatoma, they should not be used in combination with oncolytic viral
therapy. In fact, MAPK inhibitors could potentially be used as treatment for
unchecked viral proliferation during oncolytic therapy.
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LIVER, PANCREAS AND BILIARY SURGERY, WHAT IS THE
RIGHT FELLOWSHIP FOR THE RIGHT TRAINING?
Roozbeh Rassadi, MD, Richard M. Dickerman, MD, Ernest L. Dunn, MD,
Dhiresh Rohan Jeyarajah, MD
Dallas Methodist Medical Center, Dallas, TX
Purpose. To determine if a non-transplant, non-surgical oncology fellowship
can appropriately train the general surgery resident in organ specific diseases
of upper gastrointestinal tract, based on a personal experience.
Background. General surgery residency training has undergone significant
changes over the last few years including reduced work hours. Subsequently,
exposure to cases in each field of surgery has reduced especially in HPB
(hepatobiliary) and upper gastrointestinal (GI) surgery. This will, in turn,
motivate more residents to pursue further training in a fellowship training
program.
Method. Based on a personal experience we propose a surgical training
model in benign as well as malignant diseases of upper gastrointestinal tract.
This fellowship will be focused on organ specific approach to disease
processes.
Results. Over the first 3.5 months of a hepatobiliary/upper GI fellowship
training program in a relatively high volume community center case logs of
the fellow are as follows: 15 pancreaticodudenectomy, 8 other pancreatic
procedures (including total and distal pancreatectomy), 10 esophageal, 8
complex biliary, 6 liver and 12 other major foregut procedures. Many of the
procedures were approached laparoscopically when possible including distal
pancreatectomy and esophagectomy. During a year of fellowship there would
also be a block in transplant service and a dedicated hepatobiliary GI rotation
performing endoscopic retrograde cholangiopancreaticography (ERCPs) and
Endoscopic ultrasound (EUS). There are also weekly multidisciplinary
conferences with oncology and non oncology services. Also, the fellowship
is designed so that there are no deleterious effects on general surgery
residency program.
Conclusion. Based on a personal experience, we propose that an organ
specific fellowship program in both benign and malignant diseases of upper
gastrointestinal tract provides a practical and focused training in this surgical
field. This model is a non-transplant, non surgical oncology fellowship aiming
to train the general surgery resident in all aspects of HPB/upper GI disease
processes.
66
OUTCOMES OF HEPATOBILIARY SURGERY IN A COMMUNITY
HOSPITAL
Austin Spitzer, MD, CK Chang, MD, Pascal R Fuchshuber
UCSF-East Bay, Oakland, Ca 94602, CA; Kaiser Med. Center, Walnut
Creek, CA
This is a retrospective analysis of open and laparoscopic hepato-biliary
surgeries performed at the Walnut Creek Kaiser Medical Center. We started
performing hepato-biliary surgery in 1999. In 2003 we established a
multimodality clinic for hepato-biliary surgery to serve as a regional referral
center for the network of Northern California Kaiser Medical Centers. A
total of 168 hepato-biliary cases were performed at our institution since 1999,
of which 51 were for primary liver cancer, 96 for metastatic liver cancer and
21 for benign disease. The majority consisted of 77 metastatic colorectal
cancer (CRC) and 40 hepatomas. Clinical data including length of stay,
blood loss and transfusion requirements, stage, adjuvant chemotherapy rates,
recurrence rate and morbidity were analyzed. Overall 90 day surgical
mortality was 0%. Mean survival was 28 months for hepatomas, 34 months
for gallbladder/bile duct cancers, 36 months for CRC and 55 months for
other cancer metastases. Radiofrequency ablation (RFA) was used in 51% of
CRC metastases, 50% of hepatomas, 60% of other cancer metastases and
14% of benign lesions. RFA was not used in biliary cancer cases. One half of
the RFA were performed by laparoscopy. Open hepatectomies included 48
segmentectomies, 30 lobectomies, and five extended lobectomies. In 3 cases
preoperative portal vein embolization was used. This analysis demonstrates
that with appropriate interventional radiology, gastroenterology and medical
oncology support hepato-biliary surgery can be performed safely and with
appropriate surgical and oncologic outcomes in a community hospital setting.
67
OUTCOMES IN PATIENTS UNDERGOING HEPATIC RESEC-
TION IN THE CALGARY HEALTH REGION BEFORE AND
AFTER THE CREATION OF A REGIONAL HPB PROGRAM
Elijah Dixon, MD, Andrew Mckay, MD, Paul Renfrew, MD, Oliver Bathe,
MD, Francis Sutherland, MD
University of Calgary, Calgary, AB, Canada
Introduction. There has been a profusion of information published in
support of the relationship between outcomes(improved) with increasing
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volume of procedures performed for certain complex surgical procedures.
The Calgary Health Region provides care to the residents of Calgary, Alberta
(pop. 1 million), as well as a large portion of the southern half of the province
of Alberta, Canada. Very few studies have examined what effect at a
population level the creation of a regional program (multidisciplinary HPB)
has had on outcomes.
Methods. Using administration discharge data from all hospitals in the
Calgary Health Region, we reviewed all hepatic resections performed.
Hepatic resections were identified using procedure codes for hepatic
resection (ICD  9 prior to April 2002, and ICD  10 and CCI after April
2002). All patient encounters from 1990 to 2004 were identified. The
creation of a multidisciplinary HPB program occurred in 2002/3.
Results. From January 1990 to December 2004 there were a total of 421
hepatic resections performed. The average was 55 (95% CI, 19 91). The
majority of the hepatic resections were performed for metastatic disease,
hepatocellular carcinoma, and miscellaneous diseases (Figure 1). Fifty-five
percent of the patients were male. Comorbidity of the patients as measured
by the Charlson score did not change significantly over time. The average
length of stay was 14.5 days (median is 10, 1183 range). Overall there were
25 deaths, for a mortality of 6%. Figure 2 illustrates the annual change in
volume of hepatic resections along with the annual mortality rates.
Conclusions. The creation of a multidisciplinary hepatobiliary and pan-
creatic surgery program has resulted in both increasing volumes of hepatic
resections, and concomitantly improved outcomes (mortality).
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LAPAROSCOPIC HEPATIC CYST MARSUPIALIZATION: A RE-
VIEW OF OUR INSTITUTIONAL EXPERIENCE
Siddhartha Rath, MD, Jeremy Timmer, MD, Kevin Neal Boykin, MD, Gazi
B Zibari, MD
Louisiana State Health Sciences Center in Shreveport, Shreveport, LA
Introduction. In an era of increased use of computed tomography for work-
up of abdominal pain, the incidence of hepatic cysts is increasing. While most
of these cysts are incidental findings and asymptomatic, in some patients,
these cysts become relatively large and manifest as a painful abdominal mass
with obstructive symptoms due to compression of adjacent viscera. Previous
studies have demonstrated cyst resection to have a lower recurrence rate than
cyst aspiration, though patients must be subjected to the morbidity associated
with an open procedure. We reviewed our institution’s experience of both
laparoscopic hepatic cystectomy and open cystectomy, comparing recurrence
rates and complications.
Methods. We performed a retrospective review of patents that underwent
hepatic cyst excision with marsupialization at two institutions. Radiographic
studies and indications for operation were reviewed and complications were
noted, including conversion to an open procedure. Statistical analysis was
performed using Chi-square.
Results. During 19982005, 17 patients underwent treatment for hepatic
cysts. Age range was 4383 with a mean of 60 years. Cyst size ranged from
522 cm with a mean size of 11.5 cm. The most common presenting
symptoms were pain (13/17 [76%]) and nausea/vomiting (7/17 [41%]).
Twelve patients underwent laparoscopic hepatic cystectomy with cyst
marsupialization, five underwent an open procedure, and one had percuta-
neous aspiration. There was an overall cyst recurrence rate of 12% (2/17);
one of these was in the patient who had undergone a previous percutaneous
aspiration and the second was in a patient who had a laparoscopic procedure
(1/12, [8%]). None of the patients who underwent open procedure had a
recurrence. Overall complication rate was 24% (4/17); three were in patients
who underwent open resection (3/5, [60%]) (2 MI, 1 bile leak requiring IR
guided drain placement), and the fourth was a bile leak in a patient who had
undergone laparoscopic resection (1/12, [8%]). There was no significant
difference in recurrence between the laparoscopic and open procedures.
More complications occurred in the patients that underwent an open
procedure and this was statistically significant (P0.02).
Discussion. From these data, we conclude that laparoscopic hepatic cyst
resection with cyst marsupialization is as effective as open cyst resection in
preventing recurrence and also and results in fewer complications.
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SURGICAL TREATMENT OF HYDATID LIVER DISEASE
Alexander R Karamarkovic, MD, PhD
University Center for Emergency Surgery, School of Medicine University of
Belgrade, Belgrade, Serbia and Montenegro
Background. Surgery remains the main treatment modality of hydatid liver
disease. There still debate about the best approach, conservative surgery
(marsupialization, drainage, partial cystectomy) has opposed to radical
surgery in which the cyst is totally removed including the pericyst by total
pericystectomy or partial hepatectomy.
Aim. This study aims to show that radical surgery resection of the hepatic
hydatid cysts is a safe and effective technique.
Patients and Methods. A series of 49 consecutive patients operated on for
liver hydatid disease between January 2001 and December 2005 was
analyzed. The most common compliant were pain (62%), hepatomegaly
and abdominal mass (39%). Diagnostic assessment was obtained with
serology (ELISA) and radiology (US and CT scan). Surgery comprised
conservative methods like partial cystopericystectomy with intracavitary
placed drainage and omentoplasty of residual cavity (21 pt.), and radical
surgical methods like total cystopericystectomy (5 pts.) and liver resection
(segmentectomy, lobectomy, hemihepatectomy) (23 pts.).
Results. In the entire series, morbidity was 19% of which 28% was seen with
conservative surgery and 11% with radical methods (pB0.05). Biliary fistula
was more frequent complication in both groups: 15.9% vs. 4.2% (pB0.01) in
patients that underwent conservative methods and radical methods, respec-
tively. There was no operative and postoperative mortality in our studied
group. Long-term follow-up showed that hydatid disease relapsed frequently
in patients who underwent conservative treatment than in those who
underwent radical surgical approach: 4 pts. Vs. 0 pts.
Conclusion. According to our results, radical surgery of the hydatid liver
disease represents the method of choice over others such as partial
pericystectomy.
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RESECTION OF HEPATIC ADENOMA IN PATIENTS WITH GLY-
COGEN STORAGE DISEASE TYPE IA
Srinevas K Reddy, MD, Dev M. Desai, MD, PhD, Priya S. Kishnani, MD,
Bryan M. Clary, MD
Duke University Medical Center, Durham, NC
Introduction. Hepatic adenomas occur in 5075% of adults with glycogen
storage disease type Ia (GSD Ia). Because better metabolic control has
enabled long-term survival, the incidence of malignant adenoma transforma-
tion is increasing. While limited organ availability makes hepatic resection an
attractive option for dominant adenomas, the metabolic dysfunction,
hepatomegaly, and renal insufficiency common in GSD Ia patients raises
doubts about the safety of resection. The objective of this retrospective study
is to assess the safety of hepatic adenoma resection in GSD Ia patients.
Methods. Clincopathologic, peri-operative, and long-term data were re-
viewed from patients who underwent hepatic adenoma resection from one
center. Peri-operative management of GSD Ia patients included aggressive
treatment of metabolic acidosis, dextrose infusions, and vigilant blood
glucose control. Comparisons were made with Fisher’s exact and Mann-
Whitney tests; survival was estimated with Kaplan-Meier analysis.
Results. From 19982006, 37 patients underwent resection of hepatic
adenomas. Seven (19%) had GSD Ia. Three of seven (43%) with GSD Ia and
16/30 (53%) without GSD Ia underwent major hepatectomy (]3 segments),
pNS. The number of resected adenomas was higher among GSD Ia
patients (median 3 vs. 1, p0.01), with no difference in size of largest
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resected adenoma (median 8 cm for both groups). One GSD Ia patient had
post-operative mortality. GSD Ia patients were more likely to have major
post-operative complications (5/7, 71% vs. 6/30, 20%, p0.02). Complica-
tions among GSD Ia patients included liver failure (2), multisystem organ
failure (2), fascial dehiscence (1), intra-abdominal abscess (1), bleeding from
the liver resection bed requiring re-operation (2), and unstable blood glucose
levels with persistent lactic acidosis (2). Six of seven patients recovered from
resection with no additional long-term morbidity. One patient had HCC and
died of disseminated disease three months after resection. All GSD Ia
patients with benign disease had adenoma progression after resection;
median time to progression was 23 months (range 19 71 months). Of five
living patients, three have undergone successful liver transplantation 77, 32,
and 23 months after resection and one is being evaluated for transplantation
20 months after partial hepatectomy.
Conclusion. Despite frequent post-operative morbidity, partial hepatectomy
is feasible in GSD Ia patients. Given uncertainties on timing of liver
transplantation, waning enthusiasm for adult live-donation, and lack of
priority for cadaveric grafts, resection can be considered for GSD Ia patients
with large adenomas or those with associated symptoms.
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INDICATION AND LONG-TERM OUTCOME OF TREATMENT
FOR FOCAL NODULAR HYPERPLASIA
Glenn K Bonney, Dhanwant Gomez, Ahmad Al-mukhtar, Giles Toogood,
J.peter Lodge, K. Rajendra Prasad
St James’ University Hospital, Leeds, United Kingdom; St James’ University
Hospital, Leeds LS9 7TF, United Kingdom
Background. Unlike malignant liver tumours, the indications for hepatic
resection for benign disease are not as well defined. This is particularly true
for FNH, where the indications for surgery include progressive disease,
increasing pain and lesions where malignancy can not be excluded. Here we
summarise a single-centre experience of the diagnosis and management of
Focal Nodular Hyperplasia.
Methods. Using a prospectively collected database, a retrospective analysis
of consecutive patients who were managed at our centre for Focal Nodular
Hyperplasia between January 1997 and Dec 2006 was performed.
Results. The cohort was divided into two groups; surgically (n15) and
conservatively managed (n37) patients. There was no correlation between
tumour size and no. of lesions with oral contraceptive use (p0.07 and 0.90
respectively) and pregnancy (0.45 AND 0.60 respectively). However, tumour
size (p0.006) and no of lesions (p0.02) were associated with the
occurrence of pain in these patients. Pain was the commonest symptom of
patients (13/15) who were managed surgically. All patients underwent
radiological imaging prior to diagnosis. The sensitivities of Ultrasound, CT
scanning and MRI scanning at characterising these lesions were 30%, 70%
and 87% respectively. The surgical procedures performed on these patients
include 3 trisegmentectomies, 3 lobecomies and 8 segmentectomies. On
histopathological analysis other neoplasms were found incidentally with the
FNH lesions. These included adenomas (n5) and HCC (n1). There
were no post-operative deaths and three post-operative complications that
were successfully managed non-operatively. With a median follow-up of 22
months in the surgically treated group, two patients have developed
recurrence of FNH, one with minor symptoms of pain. 5 patients in the
conservatively managed group continue to complain of atypical pain and are
currently under investigations for this prior to consideration of resection.
Conclusion. FNH is a benign lesion of the liver that can cause pain that is
associated with the increase in size and number of the lesions. Surgical
resection is usually performed in persistent pain and for suspicious lesions on
radiological investigations. In this series, there has been no mortality directly
due to the surgical procedure and a modest morbidity, justifying surgical
resections in selected patients.
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SPONTANEOUS RUPTURE AND HEMORRHAGE OF FOCAL
NODULAR HYPERPLASIA: A CASE REPORT AND REVIEW OF
LITERATURE
Kerry Rodgers, MD, Rajan Chahal, MD, Randall S Zuckerman, MD
The Mary Imogene Bassett Hospital, Cooperstown, NY
A 50 year-old female presented to an outside emergency room for evaluation
of abdominal pain. She was a healthy without significant medical history
other than several back surgeries and hypertension. Emergency room
evaluation included a CT scan showing fluid within her abdomen. The
patient was felt to have an acute abdomen and was taken urgently to the
operating room and was found to have a large volume hemoperitoneum. The
source of the bleeding was felt to be a right-sided liver lesion. The bleeding
was controlled with packing and cautery and biopsies of the lesion were
performed. Original biopsies showed areas of dysplastic hepatocytes with
inflammatory changes. Postoperatively the patient did well. She was referred
for evaluation of her liver mass. This was visible on computerized
tomography. All tumor markers were negative. The patient was allowed to
recover from her original surgery but ultimately had operative resection of
this liver lesion. Preoperatively she was presumed to have an adenoma or
HCC. A partial hepatectomy of segment 7 was performed without
complication. The final pathology was returned as focal nodular hyperplasia.
Focal nodular hyperplasia is a lesion most commonly found in women of
child-bearing age and is associated with use of oral contraceptive pills. It has
been classified as a benign, highly vascularized pseudotumor with a low risk
of complications. In the surgical literature, FNH is very rarely described to
have hemorrhagic complications. Due to this fact, as well as the benign
nature of the lesion, the literature supports non-operative management of
FNH unless the lesion is significantly growing, or causing progressively
worsening symptoms. In the patient that is managed expectantly, the provider
must be aware of this rare but potentially lethal complication.
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SPONTANEOUS HEPATIC RUPTURE
Wai Gin Lee, MBBS, Jonathan Koea, MD
Auckland District Health Board, Auckland, New Zealand
Purpose. Spontaneous hepatic rupture is a rare condition with multiple
reported aetiologies. Many case reports and series are published in the
literature, however, a comprehensive review of this condition has not
previously been undertaken. The aim of the study was therefore to review
the literature with emphasis on the incidence of each respective aetiology and
risk factors for rupture.
Method. A systematic review of the English literature from 1966 to 2005 was
performed using an Ovid Medline search. Keywords included ‘‘sponta-
neous’’, ‘‘hepatic’’ and ‘‘rupture’’. All papers were cross-referenced yielding
242 papers. Exclusion criteria included a history of traumatic rupture and
contained intra-hepatic or sub-capsular haematomas. Series of patients were
checked to ensure that they had not been previously reported.
Results. Spontaneous hepatic rupture occurs more commonly in non-
European countries like Taiwan, China and Japan. The overall incidence of
rupture over the 40 year study period was 49.28 per year (n1971). The
most common cause of rupture was hepatocellular carcinoma (HCC)
followed by pregnancy related conditions. Ninety seven and a half percent
of paediatric ruptures were secondary to neoplasms with the exception of a
rupture following organophosphate poisoning. Miscellaneous conditions
included polyarteritis nodosa, amyloidosis and an amoebic liver abscess.
These conditions generally disrupt the vascular integrity of the liver, or soften
liver parenchyma thus predisposing to rupture. Risk factors for rupture
include tumor hypervascularity, tumor size and location, the use of steroid
hormones and clotting diathesis. Risk factors specific to pregnancy include
multiparity, age and the stage of pregnancy. Pre-eclampsia is also a common
risk factor for rupture.
Conclusions. Spontaneous hepatic rupture is a rare and catastrophic
condition with significant morbidity and mortality. There are various under-
lying aetiologies including HCC, which was the most common by far,
followed by pregnancy. In children, almost all ruptures were related to
neoplasms. Risk factors for rupture universally included the size or severity of
the lesion, the location of the tumour in the liver and associated coagulo-
pathy.
Incidence of Spontaneous Hepatic Rupture by Aetiology
Condition n
Incidence
(per
population)
Reported
Incidence
of Rupture
(per year)
Hepatocellular Carcinoma (HCC) 1694 150/100 000 42.35
Pregnancy 76 66/1000 1.90
Hepatic Adenoma 71 3/100 000 1.78
Metastases 26 Variable 0.65
Paediatric 40 1/1 000 000 100
Miscellaneous 64 Variable 1.60
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A NEW TECHNIQUE FOR A SUCCESSFUL MANAGEMENT OF
SUPRAHEPATIC COMPLETE CAVAL TRANSECTION
Ignazio R. Marino, MD, Fabrizio Di Francesco, MD, Cataldo Doria, MD,
PhD, Salvatore Gruttadauria, MD, Augusto Lauro, MD, Victor L. Scott
Division of Transplantation, Department of Surgery, Jefferson Medical
College, Philadelphia, PA; IsMeTT, Palermo, Italy; Centro Trapianti di
Fegato e Multiorgano, University of Bologna, Bologna, Italy; Department of
Anesthesiology, Maricopa Medical Center, Phoenix, AZ
A vena cava injury should be always suspected if a retroperitoneal hematoma
is present. Exploring the hematoma blindly is a life threatening technical
error. In fact, it is mandatory to clearly visualize the injury, and to keep blood
loss to a minimum to prevent hemorrhagic shock and to avoid irreversible
coagulopathy, acidosis, hypothermia, multi-organ failure and death. Various
operative strategies have been used to decrease the mortality rate such as
atriocaval surgical shunting, vascular clamping, hepatic resection and
perihepatic packing.
Patient and Method. A 17-year-old female, involved in a high-speed
motorcycle crash, was taken to a local hospital where multiple, actively
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bleeding lacerations of the spleen and of the right lobe of the liver were found.
A splenectomy was performed and silk stitches were placed between the liver
and the diaphragm to provide a tamponade effect. Possibly, the sutures had
created a watertight compartment able to tamponade the bleeding and to
support the systemic venous return and filling pressure. Hemostasis was
unsuccessful and after packing, the patient was transported to our operating
room by helicopter. After removing the packing when mobilization of the
right lobe was attempted the blood pressure dropped to a critical level. For
this reason, an injury of the suprahepatic inferior vena cava was suspected. It
was then decided to attempt a direct approach to the juxta-diaphragmatic
segment of the inferior vena cava by placing the patient on an atrial-caval
venous-venous bypass. A complete suprahepatic inferior vena cava (IVC)
transaction was demonstrated and the IVC was reconstructed performing an
end-to-end anastomosis with 30 polypropylene running suture, using the
same technique as in orthotopic liver transplantation.
Results. The patient, in spite of her fixed mydriasis at the time of the surgery,
woke up 8 hours after it and on postoperative day 25, an angiogram of the
IVC demonstrated no leak and no IVC stenosis. On postoperative day 28 the
patient was discharged and after 4 years is in excellent health with normal
liver function.
Conclusions. A new technique of caval-atrial venous-venous bypass is
proposed. This technique allows, by working in a bloodless field, anatomical
control and a direct approach of the traumatic injury of the most inaccessible
portion of the inferior vena cava, which historically has always led to a 100%
mortality rate.
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INTRAHEPATIC PORTAL VENOUS VARIATIONS: DEMONSTRA-
TIONS BY 64-CHANNEL MULTIDETECTOR CT
Dong-eun Park, MD, PhD, Kwon-mook Chae, MD, PhD
Wonkwang University Colledge of Medicine, Ikan, Korea, Republic of Korea
Purpose. We assessed the prevalence and types of intrahepatic portal venous
variations by 64-MDCT.
Methods. In 101 patients without vascular invasion or distortion, 3-
dimensional images of portal vein were gained and studied prospectively to
identify portal venous variations.
Results. Of the 101 patients examined, 82 (82%) had classical pattern,
8(8%) had trifucation, 10 (10%) had a right anterior sectional branch arising
from left portal vein and 1(1%) had a right portal vein arising from left
umbilical portion. The branching pattern of right portal vein was showed
eight different patterns. Sixty patients (60%) had a right anterior sectional
branch feeding upper portion of segment 7,5 and 8 and a right posterior
sectional branch feeding lower portion of segment 7 and 6. Ten (10%) had a
right anterior sectional branch feeding segment 5,7,8 and a right posterior
sectional branch supplying only segment 6. Another small portions of
variations were a right anterior branch supplying segment 7,8 and a right
posterior branch feeding segment 5,6,7.
Conclusion. Sectionectomy or segmentectomy of right liver using Glisson’s
approach will be inaccurate because of many variations of portal vein.
Therefore, the branching pattern of portal vein will be elucidated before
hepatectomy.
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EXTRAHEPATIC PORTAL VEIN ANEURYSM  REPORT OF SIX
CASES AND REVIEW OF LITERATURE
T. Clark Gamblin, MD, Sung Cho, MD, Alan Tsung, MD, Fady Balaa, MD,
David A Geller, MD, Paulo Fontes, MD, Wallis Marsh, MD
UPMC Liver Cancer Center, University of Pittsburgh, Pittsburgh, PA
Introduction. Extrahepatic portal vein aneurysm is a rare condition. We
report six cases of extrahepatic portal vein aneurysm, of which four were
treated surgically. Review of literature was performed to clarify the natural
history, management and outcomes.
Method. Records of patients with extrahepatic portal vein aneurysm greater
than two centimeters in diameter were reviewed (1998 to 2006). There were
5 females, and median age was 66.5 (3077). CT scan was utilized for
diagnosis in all cases. The median diameter of the aneurysm was 4.7
centimeters (2.76.0). The aneurysm was located at the confluence of SMV
and splenic vein in 3 cases, at the main portal vein in two cases, and at the
extrahepatic left portal vein in one case. Indications for surgery included
choledocholithiasis with biliary pancreatitis, compression of the duodenum
and common bile duct by the aneurysm, radiologically nonspecific peripan-
creatic mass, and end stage liver disease.
Result. Three patients underwent aneurysm resection and one patient had
an orthotropic liver transplant due to advanced cirrhosis and an associated
portal vein aneurysm. Two patients were managed conservatively with
observation. The median follow-up from the time of first presentation and
from surgery was 41.5 months (9180 months) and 4 months (173)
respectively. Five patients are alive without symptoms attributable to the
extrahepatic portal vein aneurysm and demonstrate portal vein patency on
surveillance ultrasonography. One patient died two months following liver
transplantation. There was no case of aneurysm rupture. One patient had
intramural thrombus at presentation that resolved on a subsequent CT scan.
Conclusion. This is the largest case series of patients with extrahepatic
portal vein aneurysm who were surgically treated. It provides evidence that
symptomatic aneurysms can be safely resected with acceptable patency.
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EPIDURAL USE IS ASSOCIATED WITH INCREASED RISK OF
BLOOD TRANSFUSION FOLLOWING HEPATIC RESECTION
Andrew Page, MD, Bradley Rostad, None, Keith Delman, MD, Charles
Staley, MD, William Wood, MD, David Kooby, MD
Emory University, Atlanta, GA
Purpose. We examined the influence of epidural pain management on
perioperative outcome for hepatic resection with respect to transfusions,
complications, and length of hospital stay.
Methods. Perioperative outcome of patients undergoing partial hepatectomy
from 2000 to 2004 was analyzed according to route of perioperative pain
management: epidural (EPI) vs. intravenous (IV). Patient factors: age, body
mass index (BMI), ASA classification, and cancer diagnosis and operative
factors: time (OP time), blood loss, use of low CVP anesthesia, extent of
resection, and route of pain management use were analyzed for associations
with blood transfusions, morbidity, and length of stay (LOS). Univariate
(Fisher’s exact) and multivariate (binomial logistic regression) analyses were
performed for those patients who received 52 units, as blood transfusion
may potentially be avoided in this group.
Results. 295 patients were identified. Major resections (]3 Couinaud
segments) were performed in 171 (58%), median LOS was 9 days (range 2
57), and analgesia was delivered by EPI in 200 (67.8%) patients. Complica-
tions were observed in 93 (31.5%) patients. 113 (38.3%) received blood, and
72 (24.4% of all, or 63.7% of transfused patients) received 52 units.
Excluding patients who received 2 units, 56 of 172 (32.6%) EPI patients
vs. 16 of 82 (19.5%) IV patients received blood (p0.03, Chi square),
despite having similar operative blood loss (7449488 cc (EPI) vs. 8729530
cc (IV), pNS, Student’s T test). Factors associated with receiving any
blood transfusion on univariate analysis were age 65, ASA2, OP time 
300 min., blood loss 1L, and EPI use. By multivariate analysis, using the
variables approaching significance on univariate analysis, all 5 factors
maintained independent association with perioperative blood transfusion
(EPI use, p0.04, RR2.1, 95% CI1.024.50). Complication rate and
LOS, however, were not statistically tied to route of pain management.
Conclusions. In comparison to intravenous pain control, epidural pain
management was associated with a greater likelihood of perioperative blood
transfusion, despite similar operative blood loss. The only adjustable variable
associated with transfusion practices was EPI use. EPI anesthesia should not
be routine in patients undergoing partial hepatectomy.
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COMPARISON OF INTRAOPERATIVE BLOOD SALVAGE VER-
SUS CONVENTIONAL METHODS TO LOWER CENTRAL VE-
NOUS PRESSURE IN PATIENTS UNDERGOING LIVER
RESECTION FOR PRIMARY AND SECONDARY HEPATIC MA-
LIGNANCIES
Cheng Chu, None, Sarah Bodin, MD, Gregory Pomper, MD, Thomas
Mccoy, MS, Perry Shen, MD
Wake Forest School of Medicine, Winston-salem, NC
Introduction. Hepatic resection for primary and secondary malignancies of
the liver has become safer partly due to less perioperative blood loss. Low
central venous pressure (CVP) during surgery has been shown to decrease
back bleeding from hepatic veins during parenchymal transaction. The
optimal method to achieve low CVP has not been determined.
Methods. One hundred ten patients who underwent hepatic resection
between 2000 and 2006 were retrospectively examined. Patients who had
intraoperative blood salvage (IOBS) to help achieve low CVP with autologous
transfusion after the resection was finished, were compared to patients who
had low CVP achieved with either fluid restriction or pharmacologic agents
alone. Patients were matched according to number of segments resected,
histology of cancer, and liver function rating (03 severity range). Statistical
analyses took into account the matched pairs using Wilcoxon signed-rank or
Sign tests.
Results. Ten patients who underwent IOBS were successfully matched to 10
patients achieving low CVP by other methods. Matched pairs were similar in
age, gender, and race. All patients in both groups had a liver function rating
of ‘‘0’’, while 1 patient in the IOBS group had cirrhosis. The median volume
of blood withdrawn in the IOBS group was 500 cc (range, 250500). Median
CVP achieved during parenchymal transaction was 5.75 mmHG (range, 3
12) for the IOBS group and 5.25 mmHG (range, 49) for the non-IOBS
group. The mean number of segments resected in both the IOBS and non-
IOBS group was 2 (range, 14) with an average vascular inflow occlusion
time of 25 minutes (range, 1060). The median operative time was 380.5
minutes (range, 214695) and 350 minutes (range, 173720) for the IOBS
and non-IOBS group, respectively. The mean operative blood loss was
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766.7 cc (range, 1003000) in the IOBS compared to 541.7 cc (range, 125
1050) in the non-IOBS group (p.406). The mean perioperative transfusion
(PRBCFFP) was 0.8 units (range, 06) in the IOBS group versus 0.5 units
(range, 04) in the non-IOBS group (p0.907). Using a complication rating
scale of 05, the IOBS and non-IOBS group had a mean rating of 1.3 (sd
1.70) and 0.89 (sd1.36), respectively (p.800). There was no post-
operative mortality in either group.
Conclusion. There was not a significant difference in perioperative clinical
outcomes using IOBS versus other methods to achieve low CVP. Until
further research proves otherwise, low CVP for hepatic resection can be
achieved using various methods with equal effectiveness.
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CURRENT PRACTICE OF US HEPATIC SURGEONS  RESULTS
OF A SURVEY OF SURGICAL TECHNIQUE
Majella Doyle, MD, Marcus C Tan, MD, Christopher D Anderson, MD,
Steven M Strasberg, MD, William G Hawkins, MD, William C Chapman,
MD, David C Linehan, MD
Washington University School of Medicine, St Louis, MO
Introduction. Despite the plethora of equipment available to surgeons for
parenchymal transection during liver resection, the optimal technique
remains undefined. Whether the method of transection affects the incidence
of complications such as biliary fistiula is difficult to determine because of low
overall rates and use of multiple techniques. The aim of the study was to
examine the techniques employed by US hepatic surgeons performing major
hepatic resections.
Methods. A questionnaire was sent to all 440 active members of the AHBPA
via mail. Details of each surgeon’s preference for methods of liver
parenchymal transection in both normal and cirrhotic livers, as well as
anatomical and non anatomical resection were requested. Use of drains,
hemostatic agents and methods (if any), to check for bile leak from the cut
surface of the liver was queried. Details of the surgeon volume and perceived
complication rates for all types of liver resection, liver transplants and living
donor resection were also requested.
Results. 149 responses were returned (34% response rate). 10 of these were
from AHBPA members who do not practice hepatic surgery and were not
included in the analysis. 139 responses were analyzed. 39 respondents were
transplant surgeons also performing hepatic resections and 31 had living
donor surgery experience. The most popular technique among non-trans-
plant surgeons was fracture with clips/sutures or the Cavitron Ultrasonic
Surgical Aspirator (CUSA). The ligasure and gyrus were the least utilized.
Transplant surgeons however, use the waterjet dissector and linear staplers
more commonly than non-transplant surgeons (pB0.005). Sealants were
used selectively by 55%, always by 30% and never by 15% of surgeons and
the most popular ones were Avitine, Surgicel and Tisseal. 51% of surgeons
always use drains for anatomical resection and 19% for non-anatomic
resections. Perceived biliary fistula rate was 5%. Endoscopic intervention
was performed most commonly for persistent fistula, while acute surgical
intervention was reserved only for uncontrolled sepsis.
Conclusions. Optimal parenchymal transection technique is not known.
Despite the availability of many technologically advanced instruments, use of
the simple fracture and ligate method still predominates. It is unknown
whether transection methods affect complication rates or outcome.
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FACTORS PREDICTING OUTCOMES FOLLOWING HEPATIC
RESECTION IN LIVERS WITH ABNORMAL PARENCHYMA
Glenn K Bonney, Dhanwant Gomez, Alistair Young, Kirubakaran Ranga-
nathan, Giles Toogood, Peter Lodge, K. Rajendra Prasad
St James’ University Hospital, Leeds, United Kingdom; St James’ University
Hospital, Leeds LS9 7TF, United Kingdom
Background. Liver resection in patient with steatosis, fibrosis and cirrhosis
is associated with a high morbidity and mortality rate. Belghiti et al described
the ‘‘5050’’ criteria in predicting outcome following liver resections. Such
criteria will help in post-operative management, allocation of scarce Intensive
Care resources and prognostication of disease.
Methods. Using a prospectively collected database, a retrospective analysis
of consecutive patients who underwent liver resection surgery with under-
lying liver pathology of steatosis and fibrosis between 1999 and 2005 were
studied. The impact of preoperative liver and kidney function, American
Society Anaesthesiologists (ASA) grade, Model of End Stage Liver Disease
(MELD) score, extent of resection, day 5 Bilirubin, day 5 Prothrombin Time
(PT) and ‘‘5050 criteria’’ (day 5 Bilirubin 50 mmol/l and day 5 PT
B50%) on morbidity and mortality was analysed.
Results. 236 patients underwent liver resection surgery for colorectal
metastases (n198) and Hepatocellular Carcinoma (n38) with abnormal
liver parenchyma of steatosis (n203) and fibrosis (n33). The median
patient age was 65 years (range: 3086) with 44% of patients classed as ASA
grade 1, 41% ASA grade 2, 15% ASA grade 3 and median MELD of 5.2.
The median hospital stay was 8 days (range: 362), Intensive Care was
required in 35 (14.8%) of patients. On multivariate analysis, ASA grade, Day
5 PTB50% and ‘‘5050 criteria independently predicted the need for
Intensive Care (p0.04, B0.001 and 0.017 respectively). The post-
operative complication and mortality rate was 46.2% and 3.8% respectively.
PTB50% on day 5 was the only independent predictor of morbidity and
mortality on multivariate analysis.
Conclusion. ASA status and ‘‘5050’’ criteria predicted ICU stay but not
mortality in liver resection surgery on livers with abnormal parenchyma. Only
PT B50% on day 5 predicts ICU stay, morbidity and mortality. In this
cohort, adding Bilirubin of 50 mmol/l at day 5 to to this PT result did not
contribute to predicting surgical outcome.
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THE RISK OF GAS EMBOLISM DURING LAPAROSCOPIC LIVER
RESECTION IS RELATED TO PARENCHYMAL TRANSECTION
TECHNIQUE
Gerry N. Polyhronopoulos, MD, Liane S. Feldman, MD, Anthony L.
Mccluney, MD, Jean Buithieu, MD, John B. Martinie, MD, Peter Metrakos,
Gerald M. Fried, MD
McGill University Health Centre, Montreal, PQ, Canada
The risk of gas embolism during laparoscopic liver resection has been
previously shown. However, whether parenchymal transection technique
affects the risk of gas embolism has not been previously studied. The purpose
of this study was to evaluate whether staple transection of the liver reduced
the risk of gas embolism compared to thermal energy techniques in a porcine
model.
Methods. Fifteen female pigs underwent laparoscopic left lateral hepatect-
omy. For transection technique, pigs were randomized into 3 groups:
Ultrasonic Coagulation Shears (UCS) (n5), Electrothermal Bipolar Vessel
Sealer (EBVS) (n5), or Endostapler (n5). CO2 pneumoperitoneum was
established at 12 mm Hg, and a transesophageal echo (TEE) probe was
positioned to detect gas emboli. A reviewer blinded to the transection
technique measured the frequency, duration, and grade of gas emboli events.
Grade of gas emboli ranged from 0 (no emboli) to 4 (total vessel opacification
with emboli). Blood loss was measured with a laparoscopic suction device,
and operative time was measured from the start of liver marking for
transection to the completion of resection. Proper TEE sampling was
confirmed at the end of each case. Data are presented as median [IQR]
and were compared using the Kruskal-Wallis Test. A p-value of B0.05 was
considered statistically significant.
Results. Proper TEE sampling was confirmed in 14/15 pigs. Gas emboli
occurred in 5/5 cases with the UCS, 4/4 cases with the EBVS, and in 4/5
cases with the Endostapler. However, there was a significant difference
between groups for grade of gas emboli, operative time, and blood loss
favoring the Endostapler (Table).
Conclusions. Gas emboli occurred during laparoscopic left lateral hepa-
tectomy with all transection techniques used in this study. However, the
endostapler device was associated with the lowest grade and duration of gas
emboli events, as well as the shortest operative time and least operative blood
loss.
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A COMPARISON OF STAPLED TRANSECTION VERSUS LIGA-
SURE IN LAPAROSCOPIC LIVER RESECTION
Reza Saidi, MD, Ahmed Ahad, MD, Rossini Escobar, I Nalbantoglu, MD,
Volkan Adsay, MD, Michael J Jacobs
Providence Hospital and Medical Centers, Southfield, MI; Detroit Medical
Center, Detroit, MI
Background. Advancements in technology have allowed laparoscopic
surgery to expand into advanced procedures such as liver resection; however,
the transection method is debatable. This study was designed to evaluate the
UCS EBVS Endostapler P-Value
Grade of gas emboli 4 [2.54] 3 [2.253.75] 1 [0.52.5] 0.040
Frequency of gas emboli events 3 [29] 4.5 [1.755.75] 3 [15.5] 0.491
Duration of gas emboli events (seconds) 388 [149659] 163.5 [81.5439] 11 [1196] 0.110
Operative time (minutes) 25 [2248] 52 [33.571.5] 22 [19.524] 0.018
Operative Blood loss (mL) 120 [100150] 70 [32.5100 50 [27.585] 0.021
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feasibility and outcome of laparoscopic liver resection comparing the
Ligasure device versus endomechanical stapling devices for parenchymal
transection in a swine model.
Methods. Laparoscopic left hepatectomy was performed in 2 groups (n5
in each group) comparing the stapler device with the Ligasure device. The
cut surfaces of the liver were evaluated for bleeding and biliary leakage at the
time of the operation and one week later. The animals were euthanized one
week after the operation to determine hemorrhage, bile leakage, and to allow
for histological evaluation of the liver. Serum liver enzymes were checked
before, after, and one week postoperatively.
Results. No evidence of biliary leakage or hemorrhage was noted at the time
of the operation and one week later for both groups. There was a trend
toward an increase in blood loss in the stapled group compared to Ligasure
(40916.4 cc vs. 1793.7 cc, p0.05). There was also a trend toward shorter
transection time in the stapled group compared to the ligasure group (159
4.1 min vs. 21.895.3, p0.05). The instrument cost was significantly higher
in the stapled group (7209110 vs. 400950; pB0.05). There was no
difference in serial liver enzymes and liver histopathology in either group.
Conclusions. The Ligasure device and endomechanical stapler can be safely
and effectively used for parenchymal transection during laparoscopic liver
resection. However, using endomechanical staplers is associated with an
increase in cost.
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LESSONS LEARNED FROM 130 LAPAROSCOPIC LIVER RESEC-
TIONS
Nicholas O’rourke, Les Nathanson, Ian Martin, George Fielding, George
Hopkins
Royal brisbane hospital, Auchenflower, Australia
Laparoscopic liver resection is steadily increasing worldwide. This paper
examines the first 130 lap liver resections performed at our institution.
Patient selection and surgical technique have evolved considerably over 10
years. 128 patients (2 had successful iterative resections). 91 female, mean
age 51(2186). Operations: 19 rights, 5 lefts, 61 left laterals, 29 segmentals
and 26 subsegmental resections. Six operations were hand assisted. Conver-
sions of 10% are not considered failure. Most were for blood loss(mean
400 mls in whole group, 250mls in nonconverted cases; range 02500 mls).
Mortality of 1 liver failure after left lateral in cirrhotic. Bile leak rate of 4%;
overall morbidity of 11% Over the first 8 years, most patients had benign
conditions. Over the last 2 years 26 of 45 resections were for malignancy.
‘Chemonaive’ livers are preferred and this is influencing our adjuvant therapy
decisions. Positive margins appear more common in subsegmental resections.
Laparoscopic ultrasound is essential and Ligasure, harmonic shears and
linear staplers are used for parenchymal resection. As experience grows more
challenging cases are attempted with an accepted rise in conversion rates,
either to hand assist or full laparotomy. Video of current techniques and
problems will be demonstrated.
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MESOHEPATECTOMY AS A SAFE ALTERNATIVE TO EX-
TENDED HEMIHEPATECTOMY IN CENTRAL LIVER TUMORS
Zh. A. Mood, MD, A. Mehrabi, MD, PhD, N. Roshanaei, MD, J. Weitz,
MD, PhD, M. W. Buechler, MD, PhD, J. Schmidt, MD, PhD
University of Heidelberg, Heidelberg, Germany
Despite significant improvement of perioperative management in extended
right and left hemihepatectomy, as the curative option for treatment of
central liver tumors, the high morbidity and mortality rate is still an
important obstacle. Mesohepatectomy, as a sectoral but not a segment-
oriented resection, preserves up to 35% more functional liver tissue than
either extended left or right hepatectomy. However, mesohepatectomy has
not been generally applied, which might be partially due to the difficulty of
this procedure as a complex resection method. The aim of this study is to
present our experience using mesohepatectomy for central liver tumors. At
our department, thirty nine consecutive patients (m/f27/12) with centrally
located liver tumors underwent mesohepatectomy. The peri- and post-
operative data were prospectively evaluated and analyzed regarding the
morbidity and mortality rate. The mean age of the patients was 63.9 years.
The indication of mesohepatectomy was liver metastasis (n19), HCC (n
8), gallbladder carcinoma (n5), cholangiocellular carcinoma (n3), and
others (n4). Mean operative time was 239 min (range: 65480 min) and
mean intra-operative blood loss was 1285 ml (range: 1505000 ml). For the
moment, mean intra-operative RBC and FFPs transfusion was 3.9 units
(range: 012 unit) and 4.5 units (range: 014 unit), respectively. Mean
postoperative hospitalization was 17.4 days (range: 6104 days). Post-
operative surgical complications were seen in 11 patients (28.2%) including;
intra-abdominal abscess, bilioma or bile leakage, hemorrhage and hematoma,
peritonitis due to intestinal perforation, and wound infection. Two patients
(5.1%) died in the early postoperative phase. The causes of death were portal
vein bleeding with severe coagulopathy due to liver failure in one patient and
septic multiorgan failure in the another one. Compared to the traditional
extended liver resection the mesohepatectomy accompanies with a clearly
smaller parenchymal loss. Although it is a technically difficult operation and
requires special attention to prevent surgical complications it is justified in
selected patients, with centrally located tumors, as a safe alternative to
extended liver resection. However, further prospective multicentric investiga-
tion about advantages and disadvantages of this technique is demanding.
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PROLIFERATIVE ACTIVITY OF LIVER TUMOURS FOLLOWING
EMBOLIZATION OF THE PORTAL VEIN
Osama M Damrah, Nagy Habib, Long Jiao
Hammersmith Hospital-Imperial College London, London, United King-
dom
Introduction. Although Portal Vein Embolization (PVE) proved to be
effective in extending the indications for liver resection in patients previously
considered with non-resectable liver tumours, the effects of this procedure on
tumor growth remain controversial.
Methods. 12 patients with liver tumours of mean age 63 year and male to
female ratio 4:3, underwent preoperative PVE between 2001 and 2006 (PVE
group). Of these patients 8 had Colorectal Liver Metastasis, 1 had
Neuroendocrine Tumour, 1 had metastatic GIST, and 1 had GB carcinoma.
9 patients who underwent major hepatic resection without PVE served as
control (non-PVE group) 4 of which had Colorectal metastasis, 1 had
Hepatocellular Carcinoma, and, 1 had Cholangiocarcinoma, 1 had Neu-
roendocrine Tumour, 1 had metastatic GIST, and 1 had Pancreatic cancer.
The resected livers were examined using immunhistochemical staining of
tumour cells. Cell proliferation was determined by over or under-expression
of Ki-67, Vascular Endothelial Growth Factor (VEGF), Hepatocyte Growth
Factor (HGF), Hypoxia Induced Factor (HIF), CAIX and CD34.
Results. Ki67 was overexpressed in 50% of patients who underwent PVE
and in 42.9% of patients who did not have PVE (pB0.05). Again VEGF was
overexpressed in the PVE group (63.6%) (pB0.05). No significant over-
expression difference was noted in the other markers (HIF, CAIX and
CD34). Correlation with clinical findings and radiological progression was
made.
Conclusion. We conclude that PVE increases tumor proliferation and
overgrowth. Although PVE is effective in extending indications for surgery,
this potential effect on tumour growth should be taken into consideration.
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MORBIDITY AND MORTALITY FOLLOWING MULTI-VISCERAL
RESECTIONS IN COMPLEX HEPATIC AND PANCREATIC SUR-
GERY
Andrew Mckay, MD, Oliver F. Bathe, MD, Francis R. Sutherland, MD,
Elijah Dixon, MD
University of Calgary, Calgary, AB, Canada
Introduction. Complex multi-visceral resections in major hepatic and
pancreatic surgery are relatively infrequent, and evidence regarding the
Pathologies of Patients Undergoing Multivisceral Resection According to Primary Operation Performed
Pathology
Number of
Patients (N)
Liver Resections
Performed (n)
Pancreaticoduodenectomies
Performed (n)
Distal
Pancreatectomies
Performed (n)
Total
Gastrectomies
Performed (n)
Neuroendocrine Tumor 5 2 1 2
Pancreatic Adenocarcinoma 3 1 2
Gastric Adenocarcinoma 3 3
Sarcoma* 4 1 2 1
Colorectal Adenocarcinoma 2 2
Renal Cell Carcinoma 2 2
Inflammatory Mass Mimicking Cholangiocarcinoma 2 2
Gall Bladder Carcinoma 1 1
Melanoma 1 1
* Includes 1 GIST, and 1 sarcoma of bile duct.
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associated morbidity and mortality is scant. The purpose of this paper was to
describe the outcomes following such aggressive surgical treatment.
Methods. A retrospective review of the outcomes following multi-organ
resection in the setting of major liver or pancreatic resection was conducted
form 2002 until July 2006. The primary outcome measures analyzed were
postoperative morbidity and mortality. Secondary outcomes were recurrence
rates and survival.
Results. 23 patients underwent multivisceral resections in that time period.
There were 13 males and 10 females, with a mean age of 62.2 years. The
various pathologies and the principle operations performed are listed in Table
1. A median of 4 organs were resected (range 2 to 6). Median operating time
was 398 minutes (range 191 to 683) and median blood loss was 1500 ml
(range 300 to 5000). Ten patients received a peri-operative blood transfusion,
with a median of 2 units transfused. Median length of stay was 23 days (range
7 to 60). Three patients (13%) were admitted to ICU for a median of 3.5
days. There was one operative mortality (4.3%) in a patient who underwent a
pancreaticoduodenectomy, right trisegmentectomy, and bile duct resection
for what was thought to be a cholangiocarcinoma, but proved to be a bile duct
sarcoma. In the remaining patients, minor and major morbidity occurred in 6
(27%) and 8 (36%) patients, respectively. One patient suffered a leak from a
biliary anastomosis after a pancreaticoduodenectomy and two patients
suffered pancreatic fistulas following distal pancreatectomies. After a median
follow-up of 5.7 months (range 1.2 to 46.3), 5 patients (23%) suffered
disease recurrences, and 5 have died. Median disease-free and overall
survivals have not been reached.
Conclusions. The morbidity following such multivisceral resections is
significant. However, with careful patient selection, acceptable results may
be achieved. The requirement to remove multiple organs should not be a
contraindication to tumor resection in complex hepatobiliary and pancreatic
surgery.
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LIVER AUTOTRANSPLANTATION ACCORDING TO A ‘‘MODI-
FIED ORTHOTOPIC PIGGY-BACK’’ TECHNIQUE
L. Roveda*§, U. Prati*§, A. Puzziello*§#, G. Vescio*§#, B. DiVenere8, D.
Timurian8, J. Bakeine8, A. Zonta, Laura Roveda, MD
Cancer Institute, University of Magna Graecia, Germaneto, Catanzaro, Italy
We performed OLT in the treatment of diffused liver mets from colorectal
cancer by Boron Neutron Capture Therapy (BNCT) in 2 patients; the
method includes neutron irradiation of ex situ liver inside a nuclear reactor.
Reconnection of the liver after BNCT resulted to be rather difficult, total
ECC set up was required, the VC reconstruction was performed by the
interposition of a dacron prothesis, required a long time and several post
perative complications were registered. To simplify the procedure and to
shorten the operating time as well as the time of total ECC we propose a
modified orthotopic piggy back technique for OLT. The method was
developed in the swine model (25 kg). After hepatectomy the VC flow was
preserved by interposing a goretex prothesis by 2 end to end anastomosis.
The vascular reconnection of the liver was then performed by a side to side
VC prothesis anastomosis with lateral clamping of the prothesis so that
the VC flow was uninterrupted also during the reconnection. The mean time
for VC reconstruction was 54 (98) min. and the mean time for side to side
VC prothesis anastomosis was 13 (94) min. In our previous experiences
the main difficulty in the reimplant of the liver was represented by the
reconstruction of suprahepatic VC and the interposition of a prothesis
(Ø 20 mm) was required in the reconstruction of infrahepatic VC; on the
whole 3 end to end sutures were performed and the mean time of total ECC,
was 5.30 hrs including portal vein reconstruction (15 min.). The time
required to treat the liver in the nuclear reactor was 45 minutes. In the
postoperative period we registered not inconsiderable morbidity. The
modified piggy back technique that we propose could shorten the times of
liver reconnection and of total ECC as VC reconstruction by interposition of
a prothesis could be carried out during the anhepatic phase, when the liver is
away for neutron irradiation, then the VC flow could be immediately
restored. Nonetheless, this is not a reason to completely forget a veno venous
bypass, to avoid the inevitable congestion of the splanchnic system in
situations without poorly developed porto systemic collateral circulation.
Finally to perform a side to side VC prothesis anastomosis by lateral clamping
of VC is obviously easier and faster than to perform end to end anastomoses
with the liver in situ. All this should decrease the risk of afterbleeding and
owing to the reduced time of total ECC, furthermore potential haemody-
namic disruption and circulatory instability should be reduced.
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TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE)
FOR BREAST CANCER LIVER METASTASIS: SINGLE INSTITU-
TION EXPERIENCE
Sung Cho, MD, Fady K Balaa, MD, Jennifer Steel, PhD, Brian Carr, MD,
PhD, T. Clark Gamblin, MD
UPMC Liver Cancer Center, University of Pittsburgh, Pittsburgh, PA
Introduction. More than half of patients with breast cancer develop liver
metastasis in their lifetime. Recent data suggests hepatic resection may
prolong survival in carefully selected patients. Currently there is a paucity of
data on the role of TACE as a locoregional therapy for hepatic metastasis.
Method. From a prospectively established database ten patients treated with
TACE for liver metastasis from breast primary were reviewed (1998 2006).
Median age was 46.5 (29 to 60). Nine patients had multiple bilobar liver
metastases and one had a single large right lobe lesion. The liver was the only
site of metastasis in five patients. The remaining five patients also had bony
metastasis, which were treated with external beam radiation. Adriamycin was
chosen as the TACE agent for 6, cisplatin for 3 and oxaliplatin for one
adriamycin-failure patient. TACE agents were chosen based on prior
systemic therapy administered. Median number of TACE cycles was 3 (1
to 5).
Result. Median time interval from the primary breast cancer to diagnosis of
liver metastasis was 16 months (0 to 95). Surveillance CT scans showed that
liver metastasis progressed in 6 patients, regressed in 2 patients and stabilized
in 2 patients. Tumor markers (CA15.3 or CA125) decreased in 5 patients
during TACE therapy. Median time interval from diagnosis of liver metastasis
to death (n7) or last follow-up (n3) was 24 months (1 to 65). 6 patients
developed new or progressive extrahepatic metastasis during TACE therapy.
Toxicity of TACE included: 7 patients with post-embolization syndrome
(mild nausea, vomiting or abdominal pain) and 3 patients needed neupogen
for transient neutropenia. One patient died of upper GI bleeding and hepatic
failure.
Conclusion. Hepatic artery directed therapy offers a feasible locoregional
palliative therapy which is generally well tolerated. This is the largest case
series of patients with metastatic breast cancer to the liver who were treated
with chemoembolization. TACE for metastatic breast cancer may aid in
controlling progression of hepatic metastasis, however prognosis of patients is
generally poor.
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LIVER HYDATID CYST: LAPAROSCOPIC TREATMENT
Martı´n Palavecino, MD, Mariano Bregante, MD, Diego Ferna´ndez, MD,
Vı´ctor Im, MD, Eduardo De Santiban˜es, Juan Pekolj, MD
Hospital Italiano, Buenos Aires, Argentina
Background. Hydatidosis is an endemic disease in South America. The gold
standard treatment for the liver hydatid cyst is surgery. The classical
approach was laparotomy. In the last 10 years, minimally invasive techniques
emerged as alternative treatments. The laparoscopic approach still remains
controversial and with few cases reported in literature.
Objetive. To show the laparoscopic resection of a hepatic hydatid cyst.
Methods. Sixty-five year-old male patient, referred to our Unit with a
hepatic cystic mass in segment IV. CT Scan showed a cystic image with
internal septums. Serology (Arc 5) was positive. Previous the surgery, the
patient received pharmacological treament with albendazol.
Results. Previous to the resection, the cyst was evacuated with a fine needle
aspiration. A laparoscopic cystectomy was performed. For the transection, we
used monopolar electrocautery. A cholecystectomy was associated due to
gallbladder lithiasis. The patient was discharged at day 2 without post-
operative complications.
Conclusions. Laparoscopic treatment for liver hydatid cysts is feasible in
selective cases and in high volume centers. It provides the benefits of
minimally invasive approach.
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SMALL DIAMETER PROSTHETIC H-GRAFT PORTACAVAL
SHUNT
Alexander Rosemurgy II, MD, Sam Al-saadi, MD, Desiree Villadolid, MPH,
Rachel Gillman, Emily Kraemer, Sarah Cowgill, MD
University of South Florida and Tampa General Hospital, Tampa, FL
The small diameter prosthetic H-graft portacaval shunt decompresses the
portal system directly and provides partial portal decompression. This video
presents our technique of small diameter prosthetic H-graft portacaval shunt.
The operation is undertaken through a transverse abdominal incision. A
limited Kocher maneuver is used to expose the inferior vena cava and
ultimately the portal vein. About 50% of the circumference of the inferior
vena cava needs to be freed, and, similarly, about 70% of the circumference of
the portal vein needs to be freed to undertake shunting. An 8 mm PTEF graft
is utilized. The graft is 3 cm from toe-to-toe, and 1.5 cm from heel-to-heel,
with the bevels cut at 908 to each other to accommodate the orientation of the
portal vein to the inferior vena cava. The cava-graft anastamosis is completed
first, followed by the portal vein-graft anastamosis. Pressures in the portal
system and the inferior vena cava are measured before and after shunting.
Shunting should lead to a decrease in the portal vein pressure of
10 mmHg, a decrease in the portal vein-inferior vena cava pressure
gradient of 10 mmHg, a gradient of B10 mmHg between the portal vein
and the inferior vena cava, and a thrill in the inferior cava just cephalad to the
cava-graft anastamosis. Outcomes after small diameter H-graft portacaval
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shunt promote its application. Small diameter prosthetic H-graft portacaval
shunts optimally palliate portal hypertension, prevent variceal rehemorrhage,
and promote long-term survival.
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VIDEO: BLOODLESS OPEN RIGHT HEPATIC LOBECTOMY
FOR METASTATIC COLORECTAL CANCER WITH THE STAPLE
TECHNIQUE
Allan Tsung, MD, Fady K Balaa, MD, T. Clark Gamblin, MD, David A
Geller, MD
UPMC Liver Cancer Center, University of Pittsburgh, Pittsburgh, PA
Purpose. A 5-minute video will be presented showing a rapid technique for
open right hepatic lobectomy (hemihepatectomy) for metastatic colon cancer
facilitated by linear stapling devices.
Results. After liver mobilization and ligation of the short hepatic veins from
the IVC, the right hepatic vein is divided with endoGIA stapler. The right
hepatic artery is doubly ligated. The right portal vein, and right hilar plate
with right hepatic duct(s) are sequentially divided with the endoGIA stapler.
Intra-operative U/S is then used to delineate the transection plane for
clearance of the tumor margin and identification of the crossing middle
hepatic vein branches. The liver parenchymal slice is then accomplished
under Pringle inflow occlusion using a one-handed crushing endoGIA
stapler. The entire right lobe parenchymal slice takes 34 minutes, and
EBL is typically B100 ml. For this case, pathology showed a solitary 4 cm
tumor adjacent to the right portal vein. Margins were negative. The patient is
NED 2 yrs after the resection. We have performed more than 200
hemihepatectomies with this technique. Overall transfusion rate is 5%,
and bile leak rate is B2%.
Conclusion. Use of endovascular staplers for vascular and parenchymal
transection in major hepatic resection is a safe and rapid technique.
92
HEPATIC METASTECTOMY USING A FOUR-PRONG RADIO-
FREQUENCY COAGULATION DEVICE (HABIB 4X, RITA MED-
ICAL)
Byrne Lee, MD, Lawrence D. Wagman, MD
City of Hope National Medical Center, Duarte, CA
Background. Advances in surgical technique and perioperative care have
reduced mortality from liver resection over recent years. A significant focus
has been on the reduction of blood loss during parenchymal division.
Intraoperative hemorrhage during parenchymal transection and need for
transfusion remain a predictor of perioperative morbidity.
Methods. The video details a segmental resection of segments 3 and 4. The
patient is a 30-year-old female with a history of adenoid cystic carcinoma of
the left lacrimal gland. She was treated by an orbital resection and adjuvant
radiation. She was found to have liver-only metastases two years after
treatment of her primary. From August 2005 to October 2006, 29 patients
with hepatic lesions underwent resection using a four-prong radiofrequency
(RF) device. The use of bipolar RF energy and multiple prongs rapidly
creates a zone of necrosis within the liver substance approximately 1 cm wide
and nearly as deep as the needles are placed. Intraoperative ultrasound was
performed to delineate the tumor location and assess for other lesions. The
selected line of transection is thermoablated using the device. The parench-
yma is then cut using a scalpel or parenchymal fracture (clamp or finger
fracture). Surgical clips are selectively used to ensure vessel and bile duct
ligation.
Results. No drains were used. There were 5 right hepatic lobectomies, 4 left
hepatic lobectomies, and 20 segmental resections. A synchronous colonic
resection was performed on three patients having segmentectomies. Mean
operative blood loss was 354 ml (Range1001500). Mean procedural time
was 244 minutes (Range97557). Average LOS was 8 days (Range4
18). The duration of the case presented was 153 minutes. The estimated
blood loss was 100 ml. The largest tumor size was 13 cm. She was discharged
on postoperative day 6.
Conclusions. Use of the four-prong radiofrequency dissecting device for
liver resection is safe. This novel device offers a new tool for near bloodless
hepatic parenchymal transection.
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EN BLOC RESECTION OF THE LEFT COLON, DISTAL PAN-
CREAS, SPLEEN AND SIMULTANEOUS RIGHT HEPATECTOMY
FOR METASTATIC COLON CARCINOMA BY THE LAPAR-
SCOPIC APPROACH
Chandrakanth Are, Simonetta Iacovitti, MD, Guiseppe Mustacciouli, MD,
Francesco M Crafa, MD
Ospedale Madre Guiseppina Vannini, Rome, Italy
Introduction. The preferred treatment approach for patients presenting
with colon carcinoma and hepatic metastasis (Stage IV) is induction
chemotherapy. In the presence of impending symptoms an immediate
operative intervention is warranted to address the primary. In a select group
of patients, it is sometimes possible to resect the hepatic tumours also
simultaneously. The ability to perform this via the laparoscopic approach may
facilitate recovery. We present a case of en bloc resection of left colon, distal
pancreas, spleen and simultaneous right hepatectomy for metastatic colon
carcinoma by the laparoscopic approach.
Material. A 57 year old male patient that presented with abdominal pain,
anorexia and weight loss. Colonoscopy revealed an apple-core at the splenic
flexure which on biopsy revealed adenocarcinoma. A CT scan and MRI scan
of the abdomen showed a lesion of the splenic flexure involving the distal
pancreas and spleen in addition to a metastatic lesion involving segment VI,
VII and VIII of the liver. Due to the obstructive nature of the lesion and the
inability to place a colonic stent, it was decided to proceed with operative
intervention.
Result. The patient underwent en bloc left hemicolectomy, distal pancrea-
tectomy, splenectomy and simultaneous right hepatectomy via the laparo-
scopic approach. The splenic flexure carcinoma was initially approached with
en bloc resection of the left colon, distal pancreas and spleen, following which
an stapled anastomosis was performed between the transverse colon and the
distal sigmoid colon. A right hepatectomy was performed with extra-hepatic
division of the hepatic artery and portal vein. The bile duct and the right
hepatic vein were encountered during parenchymal transaction and divided.
The estimated blood loss was 500 ml (100 ml for colectomy and 400 ml for
hepatectomy) and the operative time was 330 minutes. (120 minutes for
colectomy and 210 minutes for hepatectomy) Histo-pathology revealed T3
N0 (of 25 nodes) M1 (stage IV) colon carcinoma with negative margins for
the colon (4.5 cms) and the liver (2 cms). Post operatively, the patient
developed a bile leak which was managed conservatively. The patient
tolerated diet on the 5th and was discharged home on the 20th post operative
day respectively.
Conclusion. We present a case of en bloc resection of left colon, distal
pancreas, spleen and simultaneous right hepatectomy via the laparoscopic
approach
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LAPAROSCOPIC HEPATIC AND DIAPHRAGMATIC RESECTION
FOR THE TREATMENT OF AN OVARIAN TUMOR IMPLANT
Diego Ferna´ndez, MD, Martı´n Palavecino, MD, Christian Bertona, MD,
Mariano Bregante, MD, Rodrigo Sa´nchez Claria´, MD, Oscar Mazza, MD,
Eduardo De Santiban˜es, MS, Juan Pekolj, MD
Hospital Italiano, Buenos Aires, Argentina
Background. Laparoscopic resection is a possibility for the treatment of an
ovarian cancer implant. There are few publications describing this approach.
Objective. to show a laparoscopic resection of a hepatic and diaphragmatic
ovarian cancer implant.
Population. A 64 year-old patient with a bilateral oophorectomy, hyster-
ectomy and omentectomy because of an ovarian cancer. During the follow-
up, the patient presented an increasing level of tumoral markers and appeared
a hepatic nodule in segment VII.
Methods. The patient was placed in left lateral position. Four trocars were
needed (10 mm, 5 mm3). There was no carcinomatosis. There was a
hepatic nodule, compromising the adjacent diaphragm. The invaded
diaphragm was resected with endo-scissor and pneumothorax was created.
The diaphragmatic orifice was closed with separated stitches, without pleural
drainage. The hepatic parenchyma was resected with monopolar electro-
cautery. The implant was packed and removed through the umbilical access.
Results. The patient was discharged at day 2, without postoperative
complications. In the 6th month follow-up there are no evidences of tumoral
recurrence.
Conclusions. Hepatic lesions with limited diaphragmatic extension can be
safely resected by laparoscopic approach, in selected cases.
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RIGHT HEPATECTOMY WITH CHOLECYSTECTOMY FOR ME-
TASTATIC COLORECTAL CANCER
Alexander Rosemurgy II, MD, Mallika Tarkas, Ashley Thomas, Desiree
Villadolid, MPH, Donald Thometz, Sharona Ross, MD, Sarah M Cowgill,
MD
University of South Florida and Tampa General Hospital, Tampa, FL
This operation typifies an optimal approach for hepatic resection for
metastatic cancer to the liver. Hepatectomy begins with an incision that
allows for adequate exposure. An upper abdominal transverse incision was
utilized and extended to the xiphoid process after documenting no metastatic
cancer beyond the liver. The liver was mobilized and the retro-hepatic vena
cava was exposed with numerous branches between the liver and the inferior
vena cava being divided. The inflow to the right side of the liver was
controlled. The right hepatic duct was identified, doubly ligated, and divided.
After demarcation, the dissection was carried into the left side of the liver to
obtain an adequate margin about the lesion in Segment 5. During the
dissection through the parenchyma of the liver, the right branch of the portal
vein was divided near the porta hepatis. The right hepatic vein was clamped,
divided, and sutured. The incision was closed after omentum was placed over
the cut edge of the liver. The wound was closed with monofilament suture
and the skin was approximated with paper strips. Hepatic function remained
intact with minimal blood loss. Hepatectomy can be undertaken without
notable difficulty and with wide exposure.
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VIDEO: LAPAROSCOPIC LEFT HEPATIC LOBECTOMY FOR 12
CM HCC
Fady K Balaa, MD, T Clark Gamblin, MD, David A Geller, MD
UPMC Liver Cancer Center, University of Pittsburgh, Pittsburgh, PA
Purpose. A 8-minute video will be presented showing laparoscopic left
hepatic lobectomy (Left Hemihepatectomy) for a large 12 cm HCC arising in
a non-cirrhotic liver.
Results. A low midline handport is placed along with 3 LUQ (212 mm, 1
5 mm) and 1 RUQ (12 mm) trocars. After dividing omental adhesions, the
round, falciform, and left triangular ligaments are divided. The left hepatic
vein is exposed. The left hepatic artery is divided. The left portal vein is
dissected and clamped with an intra-corporeal bulldog. Laparoscopic liver U/
S delineates the transection plane through segment 4, and confirms contra-
lateral inflow through the right portal vein. The liver parenchyma is divided
with combination of harmonic scalpel, tissuelink, and endoGIA vascular
staplers. The left hepatic vein is divided flush with the IVC using a stapler.
The left portal vein is divided last with the stapler. The left hepatic lobe is
removed intact through the handport incision. The margins were widely
negative, and pathology showed a large HCC. EBL was 125 ml, and blood
transfusion was not required. The patient was discharged home on the 2nd
postoperative day.
Conclusion. Laparoscopic liver resection is safe and technically feasible,
even in the setting of anatomic hepatic lobectomy for malignancy. It requires
training in both MIS skills and open hepatic surgery.
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MIRIZZI’S SYNDROME: LAPAROSCOPIC TREATMENT
Martı´n Palavecino, MD, Mariano Bregante, MD, Victoria Ardiles, MD,
Diego Ferna´ndez, MD, Eduardo De Santiban˜es, Juan Pekolj, MD, PhD
Hospital Italiano, Buenos Aires, Argentina
Background. Mirizi’s Syndrome is a rare complication of a long standing
cholelithiasis. Many surgical approaches of varing complexity have been
advocated for treatment. Minimally invasive surgery has been used for many
other procedures and it could be feasible to resolve different types of this
syndrome.
Objetive. to show two Mirizzi’s Syndrome type II cases resolved by
laparoscopic approach.
Population and Methods. Case one is a female 73 year-old patient with
abdominal pain and jaundice; Ultrasound showed a cholecystitis with a
gallstone impacted at the infundibulum and intrahepatic duct dilatation.
Case 2 is a male 82 year-old with abdominal pain and jaundice; the CT scan
and MRI showed gallbladder dilatation with a gallstone and intrahepatic duct
dilatation.
Results. Both patients were approached by laparoscopy, first case was
resolved doing a subtotal cholecistectomy and laparoscopic closure; second
case II was resolved performing a laparoscopic hepaticojejunostomy; Both
patients were discharged at 3 and 4 day respectively without postoperative
complications.
Conclusion. Mirizzi’s syndrome sometimes can be anticipated on the basis
of preoperative staging, and often is diagnosed or confirmed during the
procedure. Subtotal cholecystectomy and simple closure with secure in-
traperitoneal drain appears to be a safe option for these patients, also a
hepaticojejunostomy could be performed when the closure is not safe because
the local conditions.
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INTRAHEPATIC SEGMENT III HEPATICOJEJUNOSTOMY FOR
BILIARY OBSTRUCTION AFTER RIGHT HEPATECTOMY
Richard A Mackey, MD, Conrad H Simpfendorfer, MD, J. Michael
Henderson, MD
Cleveland Clinic Foundation, Cleveland, OH
Extrahepatic duct obstruction requires decompression by surgical bypass or
biliary stenting to relieve jaundice, pruritus and prevent secondary biliary
cirrhosis. Unresectable hilar obstruction lead to a modification in biliary
bypass procedures for palliation. Left sided, intra-hepatic segment III
hepaticojejunostomy has been described for malignant obstruction. We
report a case of an intra-hepatic segment III hepaticojejunostomy for
obstructive jaundice following right hepatic lobectomy for metastatic colon
carcinoma. A benign post-operative stricture developed 6 months following
lobectomy. Following a prior failed attempt at an extrahepatic hilar
reconstruction, the patient had long term decompression with a percutaneous
transhepatic catheter. Re-exploration and a successful segment III hepatico-
jejunostomy, through the umbilical fissure, was performed. The patients
post-operative course was unremarkable. Segment III hepaticojejunostomy
can provide adequate internal biliary decompression and effectively palliate
selected patients with an unapproachable hilus.
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LAPAROSCOPIC TREATMENT OF CHOLEDOCHAL CYST
Sergio E Bustos (Maac), MD, Jorge Nefa (Maac), MD, Pablo Omelanczuk,
MD, Walther Minatti (Maac), Mario Masrur, MD, Mariana Debe´, MD
Italian Hospital of Mendoza, Mendoza, Argentina
Purpose. To present our experience with the technical aspects of the
laparoscopic resection of a type Ic Choledochal-Cyst.
Methods. 22 years-old woman complaining of abdominal pain. Abdominal
ultrasound, Computerized Axial Tomography and Cholangio Magnetic
Resonance were performed showing the presence of a choledochal cyst.
Exploratory laparoscopy was performed and the cyst was identified. The
presence of a Todani type-Ic Cyst was confirmed by cholangiography. The
hepatic duct and the neck of the cyst were isolated from the portal vein. A
cholangioscopy of the cyst was performed. The hepatic duct was transected
and the cyst removed. A Roux-en-Y anastomosis was performed. The
jejunojejunostomy was completed in an open fashion extending the umbilical
port incision. The hepatojejunostomy was performed laparoscopically.
Results. Operative time was 210 minutes and the hospital stay 5 days. No
complications were observed.
Conclusion. Type-Ic Choledochal-cyst can be treated by laparoscopy in a
safe manner as in open surgery.
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LAPAROSCOPIC BILIODIGESTIVE ANASTOMOSIS
Mariano Bregante, MD, Martı´n Palavecino, MD, Diego Ferna´ndez, MD,
Rodrigo Sa´nchez Claria´, MD, Eduardo De Santiban˜es, Juan Pekolj, MD
Hospital Italiano, Buenos Aires, Argentina
Background. Bilio-enteric anastomosis have historically been performed
using an open technique. We describe here a single experience with this
procedure using laparoscopic techniques in 3 consecutive patients.
Materials and methods. During a 2 year period between july 2002 and july
2004, the authors attempted 3 bilio-enteric reconstruction by a total
laparoscopic approach. Indications included benign primary intrahepatic
lithiasis in one patient, benign stricture in one patient with a previous open
choledochoduodenostomy and one patient with choledochal cyst. Operations
performed included choledochoduodenostomy, hepaticojejunostomy and
choledochal cyst excision with hepaticojejunostomy and extraabdominal
Roux-en-Y anastomosis.
Results. The mean operation time was 180 minutes (r 140 310). There was
no intraoperative complications and no major complications associated with
anastomosis leakage or obstruction. No operative or post-operative transfu-
sion was required. Oral food intake was started within 2 days and tolerated
well, the average length of hospital stay was 5 days. Median follow up was 15
months, all patients are symptom free with no signs of stricture or recurrent
biliary obstruction.
Conclusion. Total laparoscopic biliary reconstruction is feasible for a select
group of patients, but requires advanced laparoscopic skills, including
intracorporeal suturing. It must be attempted only in centers well versed in
advanced laparoscopic surgery.
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ORGAN-PRESERVING PANCREATIC HEAD RESECTION IN
CHRONIC PANCREATITIS
Gyula Farkas, MD, PhD, La´szlo´ Leindler, MD, Gyula Farkas Jr., MD
Department of Surgery, Faculty of Medicine, University of Szeged, Szeged,
Hungary
Introduction. Twenty to thirty per cent of patients with chronic pancreatitis
(CP) develop enlargement of the head of the pancreas in consequence of
inflammatory alterations, which leads to complications such as obstruction of
the pancreatic duct, common bile duct stenosis and duodenal compression. A
safe procedure has been developed for organ-preserving pancreatic head
resection.
Patients and Methods. The surgical procedure consists in a wide local
resection of the inflammatory tumour in the region of the pancreatic head,
without division and cutting of the pancreas over the portal vein. Recon-
struction, with drainage of the secretion from the remaining pancreas into the
intestinal tract, takes place through a jejunal Roux-en-Y loop applied one-
layer Vicryl† suture. In icteric cases or in patients with stenosis of the
common bile duct, prepapillary bile duct anastomosis is also performed with
the jejunal loop.
Results. This procedure was performed in 142 patients with no mortality.
The mean operative time was 150 min (range 120 to 180). In the
postoperative period, only one reoperation was required in consequence of
anastomosis bleeding, another gastrointestinal bleeding was treated conser-
vatively and one patient had pneumonia. The duration of hospitalisation
ranged between 7 and 12 days, with a median of 8.5 days. In the median
follow-up period of 4.0 years (range 3 months to 7 years), 90% of the patients
became complaint-free, and the weight increased by a mean of 11.3 kg (range
428).
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Conclusion. This organ-preserving pancreatic head resection is a safe and
effective procedure for definitive control of the complications following the
inflammatory alterations of CP and should be regarded as a recommended
procedure in the treatment of CP.
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BILIARY PERITONITIS: LAPAROSCOPIC TREATMENT
Diego Ferna´ndez, MD, Martı´n Palavecino, MD, Mariano Bregante, MD,
Rodrigo Sa´nchez Claria´, MD, Eduardo De Santiban˜es, Juan Pekolj, MD
Hospital Italiano, Buenos Aires, Argentina
Background. Biliary peritonitis is one of the troublesome complications
after laparoscopic biliary surgery. Relaparoscopy allows drainage of bile
collection and direct control of the site of leakage in selected situations.
Objetives. To show 4 cases of biliary peritonitis treated by laparoscopic
approach.
Methods. We present 4 patients with biliary peritonitis: Case 1: Patient
referred to our Unit with a bile duct injury after a laparoscopic cholecys-
tectomy. Case 2: Patient with abdominal pain in the postoperative time after a
laparoscopic cholecystectomy. The laparoscopy demonstrated the migration
of the Endoloop. Case 3: Patient with abdominal pain after the removal of a
T-Tube. The exploration showed a biliary peritonitis secondary to a leakage
in the T-Tube fistula. Case 4: Patient with pain after a needlescopic
cholecystectomy. The laparoscopy demonstrated a leakage from an aberrant
biliary duct in the gallbladder bed.
Results. All patients were solved with relaparoscopy without postoperative
complications. Mean operative time was 75 minutes (r: 55120). Mean
length of stay after relaparoscopy was 3 days (r: 17). Case 1: We performed
a drainage of the peritonitis. Case 2: After a cholangiogram demonstrating
the absence of associated bile duct injuries, a new Endoloop was placed. Case
3: A cholangiogram trough the T-Tube fistula showed no leakage in the
common bile duct. The fistula was sutured. Case 4: After a normal
cholangiogram, the aberrant duct was sutured.
Conclusions. Relaparoscopy is useful in the management of biliary
peritonitis. Minimally invasive technique can be applied to these complica-
tions safely and effectively in selected cases and performed by experienced
surgeons.
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LAPAROSCOPIC DISTAL PANCREATECTOMY AND SPLENECT-
OMY FOR INSULINOMA
Maki Yamamoto, MD, Michael S Hayashi, MD, Blanding U Jones, MD,
Peter Lin, MD, Kaylene Anne Barrera, John G Lee, MD, Thang D Nguyen,
MD, Ninh Nguyen, MD, David K Imagawa, MD, PhD
UC Irvine Medical Center, Orange, CA
Minimally invasive surgery is becoming more widespread in its usage for
cases that had previously been treated with open procedures. Prior to the
advent of laparoscopy, pancreatic neoplasms were treated with laparotomy.
Currently, laparoscopic distal pancreatectomy (LDP) has only been pub-
lished in small series of patients. In this video, we show our technique with
this relatively new procedure. To date we have performed 20 LDP. In our
series of patients, LDP with or without splenectomy has been shown to be
feasible with minimum morbidity.
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COMPLEX BILE DUCT INJURY TREATMENT WITH A RIGHT
HEPATECTOMY AND HEPATICOJEJUNOSTOMY
Eduardo De Santiban˜es, MD, PhD, Martı´n Palavecino, MD, Diego
Ferna´ndez, MD, Mariano Bregante, MD, Juan Pekolj, MD, PhD
Hospital Italiano, Buenos Aires, Argentina
Background. Laparoscopic cholecystectomy is the treatment of choice
for symptomatic gallstones. This approach is associated with a higher
incidence of biliary injuries. Complex injuries could lead to major hepatic
resections.
Objetive. To show a case of a complex bile duct injury that required right
hepatectomy.
Population and Methods. A 59 year-old female patient referred to our Unit
with an E5 (in Strasberg Classification) bile duct injury. The laparoscopic
cholecystectomy was carried out 6 months before. The patient developed
colangitis and was successfully managed with ERCP and a stent was placed in
the biliary tract. The patient was admitted to our Hospital for elective
surgery. A CT Scan showed a right lobe atrophy, MRI showed a E5 Strasbeg
BDI and angiography showed an associated right hepatic artery injury. The
surgery was done without complications.
Results. We performed right hepatectomy, due to the atrophy of this lobe.
We used an ultrasonic dissector for transection. The biliary reconstruction
was made with a Roux-en-Y hepaticojejunostomy. The patient developed
right pleural effusion that required a percutaneous drainage and she was
discharged at day 14 postoperative.
Conclusions. In selected cases, a major hepatectomy is needed to treat
complex bile duct injuries. These cases must be treated in HPB centers by a
trained team.
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SYSTEMATIC APPRAISAL OF BIOCHEMICAL MARKERS FOR
ASSESSMENT OF DISEASE SEVERITY IN ACUTE PANCREATI-
TIS: GUIDANCE FOR EVIDENCE-BASED PRACTICE IN 2007
Benoy I Babu, MBBS, Ajith K Siriwardena, MD
HPB Unit, Dept of Surgery, Manchester Royal Infirmary, Manchester,
United Kingdom
Introduction. Early detection of patients with severe acute pancreatitis is
pertinent as it allows treatment to be delivered in an appropriate ‘‘high-
dependency’’ environment with invasive monitoring. Although a host of
biochemical markers have been evaluated as markers of severity there are no
current selection guidelines. This study undertakes a structured, systematic
appraisal of the available evidence in an attempt to identify optimal markers.
Methods. A 56-year search from1950 to 2006 on EMBASE and MEDLINE
using keywords ‘‘acute pancreatitis, markers and severity’’ was performed.
Articles were excluded if they were: experimental data, non-english medium,
case reports, reviews or letters to produce a total of 384 studies. Further
restriction to report markers which were prospectively analysed and where
there was evidence from more than one study resulted in a reduction to 82
publications reporting 5390 patients. Data for sensitivity, specificity and
ROC curve (where available) are presented.
Results.
Conclusion. Interpretation of these data must accept that data-pooling for
systematic review has inherent limitations in sensitivity of analysis. Although
the findings favour urinary trypsinogen and serum elastase, there is strong
support for the continued use of admission haematocrit and C-reactive
protein at 48hours as widely available and inexpensive markers of severity
with results that translate readily across health-care systems.
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THE LOGISTIC ORGAN DYSFUNCTION SCORE-MODIFIED
ATLANTA CATEGORIZATION PERMITS PRECISE PROGNOS-
TICATION AND ALLOCATION OF SEVERITY IN ACUTE PAN-
CREATITIS
Srinivasan Balachandra, MBBS, James M Mason, PhD, Anil Bagul, MBBS,
Ajith K Siriwardena
HPB Unit, Dept of Surgery, Manchester Royal Infirmary, Manchester,
United Kingdom; School for Health, University of Durham, Stockton-on-
tees, United Kingdom
Introduction. The 1992 Atlanta consensus conference defined two cate-
gories of acute pancreatitis  severe and mild  according to the presence or
absence, respectively, of organ failure (OF). However OF can be transient.
This study tests the hypothesis that application of a contemporary, well-
validated organ dysfunction scoring system such as the Logistic Organ
Dysfunction Score (LODS) will provide greater precision in categorization.
Marker
Number of
studies
Number of
patients
ROC for
severity Median
Median sensitivity
(%) (range)
Median Specificity
(%) (range)
Serum Amyloid A 5 300 0.65 76 (6777) 69 (6970)
CAPAP 6 140 n/a (6789) (8196)
Procalcitonin 13 478 0.61 94 (92100) 84 (7384)
Hematocrit 5 797 0.73 on
admission
na na
c-reactive protein 37 2130 0.69 78 (693) 83 (993)
Urinary Trypsinogen 11 1147 0.96 93 (9096) 91 (8692)
Serum Elastase 6 496 0.956 92 91
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Methods. A prospective single-centre study was undertaken in a consecutive
series of 181 patients with a clinical diagnosis of acute pancreatitis (AP)
presenting to a University Teaching Hospital from June 2001 through
November 2004. Patients with known chronic pancreatitis and those
transferred for tertiary care were excluded. In addition to demographic
detail, data were collected on critical care occupancy, in-patient stay and in-
hospital mortality. Charts were reviewed at end-of-episode for allocation of
conventional Atlanta category (blind to other scoring). Variables required for
calculation of LODS (omitting hepatic score component) were collected on
admission and at 24 hours. Data were analyzed by receiver operator curves
(ROC). The principal end-points were selected as utility of categorization
system in prediction of in-patient stay and critical care unit occupancy as
these translate across health-care systems. The study was approved by
institutional review board.
Results. For critical care occupancy, the ROC for conventional Atlanta
was 0.62 (95% confidence interval [c.i.] 0.56 0.68). LODS 2 at 24h
as a descriptor of severe disease generated a ROC of 0.63 (95% c.i. 0.51
0.74) which was further improved to ROC 0.75 by modelling cut-offs as
LODS2 at 24h or LODS0 at 48h for selection of severe disease. For in-
patient stay, ROC for conventional Atlanta was 0.69 compared to 0.76 for
LODS-categorized Atlanta.
Conclusion. Calculation of a one-off logistic dysfunction score on the day of
admission in patients with acute pancreatitis permits precise assessment of
prognosis with a cut-off of LODS2 at 24h identifying severe disease.
Calculation of the LODS score on admission in acute pancreatitis should
replace prognostic testing and combines the value of admission predictive
tests with improved disease categorization.
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PANCREATIC PSEUDOCYSTS: IS DELAYED SURGICAL INTER-
VENTION ASSOCIATED WITH ADVERSE OUTCOMES?
Kaori Ito, MD, Michael Abramson, MD, Alexander Perez, MD, Hiromichi
Ito, MD, Amarsanaa Jazag, MD, PhD, Jill Van Der Zee, MD, Edward E
Whang, MD
Department of Surgery, Brigham and Women’s Hospital, Harvard Medical
School, Boston, MA
Background. Non-surgical interventions are increasingly applied for pan-
creatic pseudocysts. We hypothesized that surgical therapy applied after
failure of percutaneous or endoscopic therapies for pseudocysts are asso-
ciated with poorer outcomes than cases in which surgery is the initial
intervention.
Methods. Medical records of all 284 patients diagnosed with pancreatic
pseudocysts at our institution from January 1990 through September 2005
were analyzed. 46 patients underwent surgery as the initial interventional
therapy (group A). Among 162 patients who underwent percutaneous or
endoscopic drainage as the initial intervention, 75 patients required
subsequent surgery after failure of non-surgical intervention (group B).
Results. Groups were comparable in demographic variables and with respect
to location, number, and size of pseudocysts. 42% of group B patients
developed infection within their pseudocysts after their non-surgical inter-
ventions. Compared to group A patients, group B patients had a higher
overall perioperative morbidity rate (44.0% v.s. 72.4%, p0.01), a higher
postoperative readmission rate (24.0% vs. 44.7%, p0.04), and a higher
pseudocyst recurrence rate (16.0% v.s. 35.5%, p0.04). Five (6.7%) group
B patients died in the perioperative period; there were no perioperative deaths
among group A patients.
Conclusion. Delayed surgical intervention for pancreatic pseudocysts are
associated with higher incidences of recurrence, readmission, morbidity and
mortality. The increasing application of non-surgical interventions needs to
be re-evaluated.
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LONG-TERM FOLLOW-UP AFTER ORGAN-PRESERVING PAN-
CREATIC HEAD RESECTION IN PATIENTS WITH CHRONIC
PANCREATITIS
Gyula Farkas, MD, PhD, La´szlo´ Leindler, MD, Attila Paszt, MD, Ma´ria
Daro´czi, MD, Gyula Farkas Jr., MD
Department of Surgery, Faculty of Medicine, University of Szeged, Szeged,
Hungary
Introduction. In chronic pancreatitis (CP), enlargement of the pancreatic
head develops as a result of inflammatory alterations. An organ-preserving
pancreatic head resection (OPPHR) technique has been developed, and this
report is concerned with the results attained with this operation in a 7-year
period.
Patients and Methods. In 135 patients (m: 103, f: 32; mean age: 49.5 yr.),
an organ-preserving procedure was performed. The preoperative morbidity
comprised frequent abdominal pain, a weight loss in all patients, jaundice in
10 patients, and latent and insulin-dependent diabetes mellitus (IDDM) in
16 and 21 patients, respectively. The surgical procedure consists in a wide
excision of the inflammatory tumour in the region of the pancreatic head,
without division and cutting of the pancreas over the portal vein. Recon-
struction, with drainage of the secretion from the remaining pancreas into the
intestinal tract, takes place through a jejunal Roux-en-Y loop. In 10 icteric
cases and in 15 patients with stenosis of the common bile duct, prepapillary
bile duct anastomosis was also performed with the jejunal loop. The quality of
life was measured during the follow-up using our simplified ESPAC Quality-
of-Life Questionnaire (QoL).
Results. Only one reoperation was required in consequence of anastomosis
bleeding, but no mortality was noted in the postoperative period. The
duration of hospitalisation ranged between 7 and 12 days. The mean follow-
up period was 4.1 years (range 0.5 to 7.0). The late mortality rate was 3.7%
(4 and 1 patients died after a cardiovascular attack and accident, respec-
tively). The QoL improved in 88% of the patients. 116 patients became
complaint-free, 14 patients had moderate symptoms and the weight increased
by a median of 11.3 kg (range 428). One or two years after the operation,
bilio-digestive anastomosis was performed in 5 patients because of bile duct
stenosis. No change was noted in the preoperative endocrine function of 125
patients, but 10 patients with latent diabetes mellitus acquired IDDM.
Conclusion. The 7-year experience clearly reveals that this OPPHR
technique is a safe and effective procedure for definitive control of the
complications following the inflammatory alterations of CP and should be
regarded as a recommended procedure in the treatment of CP.
109
SURGICAL TREATMENT OF ALCOHOL-INDUCED CHRONIC
PANCREATITIS: THE CHALLENGES AND PITFALLS
Thomas Schnelldorfer, MD, David B. Adams, MD
Medical University of South Carolina, Charleston, SC
Introduction. Long-term excessive alcohol consumption is the most
common risk factor for development of chronic pancreatitis. Management
of patients with alcohol-induced chronic pancreatitis can differ because of
problems associated with dependency, psychosocial burden, and physical
changes like malnutrition and hepatic insufficiency.
Methods. The records of 171 consecutive patients who underwent lateral
pancreaticojejunostomy (LPJ, n102), pancreaticoduodenectomy (PD, n
38), or distal pancreatectomy (DP, n31) for alcohol-induced chronic
pancreatitis between 1995 and 2003 were retrospectively reviewed and
analyzed. Long-term outcome was assessed by patient survey with a median
follow-up of 5.890.3 years.
Results. According to patient questioning, the prevalence of alcohol
cessation prior to operation was 81%. Co-existing addictions were found
frequently with 78% of patients admitting to tobacco use and 61% of patients
using narcotic analgesics on a regular basis. Forty-one percent of patients
were at least moderately or severely malnourished and 2% had hepatic
insufficiency due to alcohol abuse. Peri-operative morbidity was 20%, 50%,
and 26% after LPJ, PD, and DP respectively with an overall peri-operative
mortality rate of 2%. Average hospital length of stay was 991.3 days. During
hospital stay, patients were treated for early symptoms of alcohol withdrawal
using a standardized protocol. None of the patients developed delirium
tremens. The presence of continued alcohol abuse prior to operation did not
affect peri-operative morbidity (p0.05). Follow-up was available for 95
patients, out of which 37 patients (39%) had died. Out of the remaining 58
patients, 13 (22%) were pain free, 13 (22%) had good pain control, and 32
(55%) had poor pain control. The median weight loss was 292.5 kg. Alcohol
cessation occurred in 91% of patients by the time of follow-up, while relapse
of alcohol use was found in 3% of patients. Continuation of alcohol abuse
after operative intervention did not affect success for pain control at follow-
up (p0.05).
Conclusion. Surgical treatment of alcohol-induced chronic pancreatitis can
be performed with similar morbidity and mortality compared to other forms
of chronic pancreatitis. Alcohol cessation is preferred but not mandated in
order to achieve good operative long-term outcome. Caution needs to be
taken to prevent postoperative alcohol withdrawal. Long-term follow-up with
psychosocial support and management of co-existing addictions is important.
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PREDICTIVE RISK FACTORS FOR DEVELOPMENT OF PAN-
CREATIC FISTULA UTILIZING THE ISGPF CLASSIFICATION
SCHEME
Wande Pratt, Mark Callery, MD, Charles Vollmer, MD
Beth Israel Deaconess Medical Center, Boston, MA
Background. The ISGPF classification scheme has become a useful system
for characterizing the clinical impact of pancreatic fistulae. However, it is
unclear what factors predispose patients to clinically relevant fistulae, and
whether these features are equivalent between proximal and distal resections.
We sought to identify predictive factors for pancreatic fistulae, and to
describe the clinical and economic significance of risk stratification within
this framework.
Methods. 287 consecutive pancreatic resections occurred from 10/01 to 9/
06  209 pancreatoduodenectomies (PD) and 78 distal pancreatectomies
(DP). Pancreatic fistula is defined as either biochemical (amylase-rich
effluent on or after POD 3) or clinically relevant (therapeutic intervention
required) according to ISGPF criteria. Logistic regression analysis was
performed to identify risk factors for pancreatic fistula development. These
features were compared across resection types, and then analyzed to
determine whether additive risk equates to worsening clinical and economic
impact.
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Results. Overall, pancreatic fistula occurred in 86 patients; yet only 42
(14%) were clinically relevant. There are no identifiable risk factors for
biochemical fistulas. For PD, univariate analysis shows that age, diabetes, and
patient acuity (POSSUM) are associated with clinically relevant fistulae, as
are those factors that are also significant by multivariate analysis  small
pancreatic duct size (B3 mm); soft gland texture; ampullary, duodenal,
cystic, or islet cell pathology; and operative blood loss500 ml. An additive
effect is illustrated using these 4 parameters (risk profile) in which clinical and
economic outcomes progressively worsen as the number of risk factors
increases (Table). For DP, increased body mass index is the only significant
variable; overweight patients (25 kg/m2) develop fistulae twice as often
(48% vs. 24% p.028).
Conclusion. For PD, small duct, soft gland texture, ampullary, duodenal,
cystic, or islet cell pathology, and increased operative blood loss are
convincing risk factors for developing clinically relevant fistulae as judged
by ISGPF classification. As risk profile accrues, patients suffer more severe
clinical and economic outcomes. However, predictive factors for proximal
and distal pancreatic resections differ, further demonstrating the inherent
differences in these operations.
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PANCREATIC LEAK RATES AFTER DISTAL PANCREATECT-
OMY USING THE INTERNATIONAL GRADING SYSTEM (ISGPF)
Thien Khai Nguyen, MD, L. William Traverso, MD
Virginia Mason Medical Center, Seattle, WA
Objective. To assess usefulness of the ISGPF and calculate the leak and
clinical severity rates after distal pancreatectomy.
Method. From May 1998 to February 2006, 125 distal pancreatectomies
(DP) were performed by one surgeon. One surgical drain was used, the duct
was ligated, and the stump was fish-mouthed. Cases were divided into 4
groups  No leak, Grade A (chemical leak only, drain amylase 3x upper
limit of normal serum, ]postoperative day 3), Grade B (leak that alters
postoperative management, i.e. percutaneous drainage, prolonged drain use,
prolonged length of stay, readmission), and Grade C (severe clinical sequelae,
i.e. sepsis, ICU, reoperation). We compared the predictability of ISGPF
chemical leak to the Sarr definition (J Am Coll Surg 2003;196:556565,
drain amylase 5x upper limit of normal serum, 30 ml/day, ]post-
operative day 5).
Results. The overall ISGPF leak rate was 36% (45/125)  Grade A26%,
B8%, C2.4%. The ISGPF system missed 2 patients without chemical
leak but were readmitted for symptoms of peripancreatic fluid collections.
The chemical leak criteria had a positive predictive value (PPV) of 23%,
negative predictive value (NPV) 95%, Accuracy 57%. Using the Sarr
definition, PPV was 100%, NPV 89%, Accuracy 90%.
Conclusion. The clinical course after distal pancreatectomy in our patients
was altered in 10% due to pancreatic leak. The NPV using either definition
was similar but the Sarr definition was more accurate, and hence, more useful
at predicting clinical outcomes after distal pancreatectomy.
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EFFECT OF BIOGLUE ON THE INCIDENCE OF PANCREATIC
FISTULA FOLLOWING PANCREAS RESECTION
William E. Fisher, MD, Christy Chai, MD, Sally E. Hodges, Meng-fen Wu,
MS, Susan G. Hilsenbeck, PhD, F. Charles Brunicardi, MD
Baylor College of Medicine, Houston, TX
Background. Despite numerous modifications of surgical technique,
pancreatic fistula remains a serious problem and occurs in about 10% of
patients following pancreas resection. Bioglue is a new sealant that creates a
flexible mechanical seal within minutes independent of the body’s clotting
mechanism.
Hypothesis. Application of Bioglue sealant will reduce the incidence of
pancreatic fistula following pancreas resection.
Methods. A retrospective cohort study was performed with 64 patients
undergoing pancreas resection. Bioglue sealant was applied to the pancreatic
anastomosis (Whipple) or resection margin (distal pancreatectomy) in 32
cases. Factors that could affect the rate of postoperative pancreatic fistula
were recorded. Pancreatic fistula was defined as 50 cc of drain output with
amylase content 3 times normal serum value after postoperative day 10. To
improve the sensitivity of our study, we also examined pancreatic fistula with
a strict definition of any drain output on or after postoperative day 3 with a
high amylase content and graded the fistulas in terms of clinical severity.
Grade A leaks were defined as subclinical. Grade B leaks required some
response such as making the patient N.P.O., T.P.N., octreotide, antibiotics, or
a prolonged hospital stay. Grade C leaks were defined as serious and life
threatening. They were associated with hemorrhage, sepsis, resulted in
deterioration of other organ systems and mandated intensive care. Compar-
isons between the 2 groups were made using the chi-square test or Fisher’s
exact test for categorical variables and by the Wilcoxon rank-sum test for
continuous variables. P-values of 0.05 or less were deemed statistically
significant.
Results. There were no differences between the patients who received
Bioglue and the control cohort in terms of comorbid conditions, tumor
location and stage, texture of the pancreas, size of the pancreatic duct, or
surgical technique. By the common definition, pancreatic fistula occurred in
19.0% (Bioglue) vs. 10.7% (Control). By the strict definition, a subclinical
leak (Grade A) occurred in 37.5% (Bioglue) vs. 50% (Control), and a clinical
leak (Grade B) occurred in 25.0% (Bioglue) vs. 11.5% (Control). There were
no severe (Grade C) leaks. There were no statistically significant differences
in the incidence or severity grades of postoperative pancreatic fistulas
between the two groups. Patients who did experience a pancreatic fistula
were more likely to experience additional complications.
Conclusion. Application of Bioglue sealant does not reduce the incidence of
pancreatic fistula following pancreas resection.
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PANCREATICOBILIARY MALJUNCTION WITH NON-DILATED
BILE DUCT IS AN EXTREME HIGH RISK GROUP OF BILIARY
TRACT CANCERS: ANALYSIS OF A NATION WIDE REGISTRY
OF PANCREATICO-BILIARY MALJUNCTION IN JAPAN
Mitsuo Shimada, MD, Teruyoshi Amagai, MD, Toshihide Imaizumi, MD,
Hiroshi Shimada, MD, Hideo Takamatsu, MD, Akira Toki, MD, Toshinobu
Matsumura, MD, Shuichi Miyakawa, MD, Yuji Morine, MD
Japanese Study group on Pancreaticobiliary Maljunction, The University of
Tokushima, Tokushima, Japan; Committee for Registration of the Japanese
Study group on Pancreaticobiliary Maljunction, Tokushima, Japan
Introduction. Pancreaticobiliary maljunction (PBM) is a congenital anom-
aly which can be defined as a union of the pancreatic and biliary ducts that is
located outside off the duodenal wall. Pancreatic juice regurgitates in the
biliary tract continuously, and this eventually causes the cancer to occur in
the biliary mucosa. Regarding the PBM patients without bile duct (BD)
dilatation, it remains controversial whether or not BD should be removed in
the treatment. We herein investigate characteristics of PBM with non-dilated
BD focusing on coexistence of biliary tract cancers.
Patients and Methods. During 15years (from January 1, 1990 to December
31, 2004), a nationwide survey was conducted and 2,237 patients were
registered as patients with PBM at 141 medical institutions in Japan. Among
them eligible patients (n2,222) were divide into two groups according to
bile duct (BD) dilatation (Dilated BD group: n1712; Non-dilated BD
group: n510). Cpmaparison of clinical variables, especially coexistence of
biliary tract cancers was performed between the two groups.
Clinical and Economic Impact of Risk Factors for Pancreatic Fistula in Pancreaticoduodenectomy
Risk Profile
(# Risk Factors)$
None
N33
1 Risk Factor
N75
2 Risk Factors
N68
3 Risk Factors
N24
4 Risk Factors
N9 p-value
Pancreatic Fistula (%)
Overall 6 (18) 13 (17) 25 (37) 12 (50) 4 (44) .004
Biochemical (Grade A) 5 (15) 7 (9) 12 (18) 3 (13) 1 (11) .692
Clinically Relevant (Grade B/C) 1 (3) 6 (8) 13 (19) 9 (37) 3 (33) B.001
Non-fistula Complications (%) 13 (39) 36 (48) 32 (47) 15 (63) 6 (67) .382
LOS (mean, days) 8.6 9.7 11.3 12.1 15.3 .007
Hospital Costs (mean) $20,429 $23,093 $27,166 $30,882 $39,137 .161
$ Risk factors: (a) small pancreatic ductB3 mm; (b) soft gland texture; (c) ampullary, duodenal, cystic, or islet cell pathology; (d) intraoperative blood loss
500 ml.
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Results. (Tables 1and 2): Characterisitis of PBM patients with non-dilated
CBD are as follows: adult dominant, male dominant, PBM type B dominant,
and higher incidence of biliary tract cancers than those with dilated CBD
(non-dialted CBD 39% vs dilated CBD 11.3%). Incidence of biliary tract
cancers in patients with PBM is extreme high, when compared with
epidemiologic prevalence of biliary tract cancers in Japan (around 0.002%).
Analysis according to time period showed increased incidence of bile duct
cancer instead of gallbladder cacncer.
Conclusions. PBM is an extreme high-risk group of biliary tract cancers.
Furthermore, PBM patients with non-dilated CBD has a higher risk than
those with dilated BD, and has increasing tendency of bile duct cancer.
Surgeons, therefore, should take it into account to perform not only
cholecystectomy but also resect extrahepatic BD with hepatico-jejunostomy.
Table 1. Comparison of clinical variables in PBM
(Non-dilated BD vs. Dilated BD)
Variables
Dilated BD
(n1712)
Non-dilated BD
(n510) p-value
Child : Adult 812:891 56:453 pB0.001
Male : Female 436:1575 143:375 pB0.005
PBM type
A : B : C 981:551:97 153:299:30 pB0.001
Biliary tract cancer
Total 194 (11.3%) 199(39.0%)
GB 123 (7.2%) 167(32.7%) pB0.001
BD 62 (3.6%) 23 (4.5%)
GBBD 9 (0.5%) 9 (1.8%)
Pancreaticobiliary maljunction (PBM): n2237 (data unknown: n15).
GB: gallbladder, BD: bile duct.
BD dilation was defined as diameter of more than 10 mm.
PBM type: according to Ohi’s classification.
Table 2. Comparison according to time period
Dilated BD Non-dilated BD
Biliary tract
cancers
199097
(n1025)
982004
(n687)
199097
(n310)
982004
(n200)
Total 101 (9.8%) 93 (13.5%) 117 (37.7%) 82 (41.0%)
GB 70 (6.8%) 53 (7.7%) 104 (33.5%) 63 (31.5%)
BD 30 (2.9%) 32 (4.6%) 8 (2.6%)* 15 (7.5%)*
GBBD 1 (0.1%) 8 (1.2%) 5 (1.6%) 4 (2.0%)
*: pB0.01.
Prevalence in Japan : GB cancer and BD cancer Male 11.5/100,000
(0.0115%) Female 13.2/100,000 (0.0132%).
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LOSS OF FHIT EXPRESSION IN PANCREATOBILIARY CAN-
CERS
Mark Bloomston, MD, Jeffrey Kneile, MD, Osama Al-saif, MBBS, Peter
Muscarella II, MD, E. Christopher Ellison, MD, Wendy L Frankel, MD
Ohio State University, Columbus, OH
Background. Chromosome 3p is one of the most commonly deleted
chromosomal regions in human tumors. The Fragile Histidine Triad Gene
(FHIT ) is a tumor suppressor gene which encompasses the FRA3B fragile
site. Genomic alterations at the FHIT locus have been described in several
solid tumors, including pancreatic cancer. Little is known, however, regard-
ing FHIT loss in other pancreatobiliary cancers. We sought to determine
FHIT expression patterns in cancers of the pancreas, ampulla of Vater, and
gall bladder and to investigate whether loss of FHIT correlates with tumor
characteristics or survival.
Methods. Tissue microarrays (TMAs) were created in duplicate from
formalin fixed paraffin-embedded resected specimens retrieved from archival
files for pancreatic cancer (N98), gall bladder cancer (N23), ampullary
cancer (N49), normal pancreas (N11), chronic pancreatitis (N35),
and benign gall bladder (N15). Immunohistochemistry for FHIT was
undertaken on all TMAs and compared between malignant and benign
tissue. Staining of at least 5% of cells was considered positive. FHIT
expression was correlated with tumor grade, nodal status, and stage as well as
survival.
Results. FHIT was expressed in all normal pancreas and gall bladder cases
and in 97% of chronic pancreatitis cases. FHIT expression was significantly
reduced in pancreatic cancers (49%) and ampullary cancers (20%) relative to
normal pancreas and chronic pancreatitis (pB0.00001, Fisher’s exact test).
Similarly, FHIT expression was decreased in gall bladder cancers compared
to benign gall bladders (57% vs. 100%, p0.003). FHIT expression was
significantly lower in ampullary cancer compared to pancreatic cancer (20%
vs. 49%, p0.02) and gall bladder cancer (20% vs. 57%, p0.007) and was
similar between pancreatic cancer and gall bladder cancer (p0.64). FHIT
expression did not correlate with the tumor characteristics measured nor was
it predictive of survival.
Conclusions. FHIT expression does not predict tumor progression and
subsequent patient survival. Loss of FHITexpression, however, appears to be
important in the pathogenesis of cancers of the gall bladder, pancreas, and
ampulla, supporting its role as a tumor suppressor in pancreatobiliary
malignancies.
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THE ROLE OF THYMIDYLATE SYNTHASE (TS) AND DIHYDRO-
PYRIMIDINE DEHYDROGENASE (DPD) EXPRESSION IN BILI-
ARY TRACT CARCINOMA
Yuji Morine, MD, PhD, Satoru Imura, MD, PhD, Tetsuya Ikemoto, MD,
PhD, Kotaro Miyake, MD, PhD, Hiroki Mori, MD, Yusuke Arakawa, MD,
Mami Kanamoto, MD, Kozo Yoshikawa, MD, Tomoharu Yoshizumi, MD,
PhD, Mitsuo Shimada, MD, PhD
Department of Surgery, University of Tokushima, Japan, Tokushima, Japan
Introduction. Thymidylate synthase (TS) and dihydropyrimidine dehydro-
genase (DPD) are important enzymes to metabolize 5-fluorouracil and have
been indicated as possible predictive markers for epithelial malignancies.
However no reports have examined the expression of these enzymes in biliary
tract carcinoma. This study was conducted to clarify a role of TS and DPD
gene expressions and a prognostic factor for biliary tract carcinomas
according to TS and DPD gene expressions.
Patients and Methods. Twenty-eight patients with intrahepatic chorangio-
carcinoma (IHCC) and forty-four patients with gallbladder carcinoma
(GBC) who underwent surgical resection were included in this study.
Intratumoral DPD mRNA expressions were examined by using the Danen-
berg tumor profile method consisted of laser microdissection of tumor cells
on FFPE specimens, RNA extraction and cDNA synthesis and quantification
of mRNA expression by real-time PCR. The expression of TS and DPD was
classified into 2 groups according to median values: high and low groups,
individually. The impact of gene expression was evaluated and significant
prognostic factors were determined using the clinicopathological variables
including TS and DPD mRNA expression.
Results. Median values of TS and DPD were 1.15 and 0.88 in IHCC, 2.28
and 1.44 in GBC, individually. In IHCC, DPD expression was higher than
median values of all gastrointestinal malignancies (total number: 1977 cases)
reported from TAIHO pharmaceutical co., LTD. (TS: 1.99, DPD: 0.67).
Furthermore, in GBC, TS and DPD expression were higher than itaˆtTMs
values. In the correlation to clinicopathological variables, difference of
macroscopic type was observed between high and low DPD expression
groups in IHCC, while no correlation was observed between both genes
expression (high and low groups) and any clinicopathological variables in
GBC. Postoperative survival rate in low DPD expression group was
significantly lower than that in high DPD expression group in IHCC.
However, in GBC, there was no significant difference according to expression
of both genes in postoperative survival rate.
Conclusion. In biliary tract carcinoma, the tolerance of 5-FU based
chemotherapy seems to be occurred by high expression of TS and DPD.
Furthermore, DPD mRNA expression in tumor cells is suggested to be a new
prognostic indicator in IHCC.
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INTRAHEPATIC CHOLANGIOCARCINOMAS: TREATMENT
CHARACTERISTICS AND RESULTS
Roderich E Schwarz, MD, PhD, David D. Smith, PhD
UMDNJ-RWJMS, New Brunswick, NJ; City of Hope Cancer Center,
Duarte, CA
Background. Intrahepatic cholangiocarcinoma (ICC) frequently poses
challenges to proper diagnosis and treatment. We investigated prognostic
information and survival outcomes for ICC in U.S. patients.
Methods. A clinical ICC dataset was created from the SEER 19702003
database. Prognostic factors with survival impact, and relationships between
treatment modality and overall survival (OS) were analyzed.
Results. A total of 5397 patients classified with an ICC diagnosis were
identified. The median age was 72 (range: 19102), and 52% of patients
were male. The median primary tumor size was 5.0 cm (0.430). The
disease extent included single lesions (29%), multiple intrahepatic lesions
(15%), and extrahepatic metastatic disease (56%). Two multivariate survival
analyses were conducted, based on the status of clinicopathologic informa-
tion. In the first model including all patients, treatment modality, stage,
grade, age, marital status (all at pB0.0001), vascular invasion (p0.0004),
total LN count (p0.0006), radiation (p0.0012), race (p0.0013), and
gender (p0.03) were prognostic variables. In the second model based only
on individuals with complete pathologic information, disease extent, LN
involvement, age, and local therapy mode remained significant (all at pB
0.0001). Median survival after resection (20 m) exceeded that after ablation
(18) and no or incomplete local treatment (4, pB0.0001). Long-term
survival, while not evaluable after ablation, was only observed after resection
(see graph). Interestingly, the number of negative LNs examined had
significant survival implications, both for N0 (pB0.0001) and N stage
categories (p0.03). Cancer as cause of death differed between anatomic
66 Abstracts
resection (62%), ablation (53%), segmental/wedge resection (75%), incom-
plete resection (92%), and no resection (90%, pB0.0001).
Conclusions. Despite some limitations within the dataset, the importance of
complete local treatment is obvious. Aside from disease extent and stage, the
local treatment mode strongly influences ICC survival. Although the data do
not allow for a specific comparison to transplantation or ablation, complete
anatomic resection of localized disease appears to be linked to best long-term
survival results.
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EVOLVING INCIDENCE AND OUTCOMES FOR CHOLANGIO-
CARCINOMA IN THE U.S.: ANALYSIS OF 7,410 CASES
William E Sumner III, MD, Juan C Gutierrez, MD, Dido Franceschi, MD,
Alan S Livingstone, MD, Leonidas G Koniaris, MD
University of Miami, Miami, FL
Purpose. Analyze the changes in incidence, treatment patterns, and
outcomes in patients with cholangiocarcinoma (CCA).
Methods. Analysis of all CCA reports in the SEER registry from 1973
2003.
Results. Overall, 7410 cases of CCA were identified. The age-adjusted
incidence of CCA increased in from 0.92/100,000 in 1992 to 1.27/100,000 in
2003. Incidence of extra-hepatic biliary CCA increased significantly from
1992 to 2003 (0.14 v. 0.53/100,000, APC 16%), while for liver and intra-
hepatic CCA it did not (0.77 v. 0.69/100,000, APC 1.2%). Median age at
diagnosis was 70, with a slight male predominance (53%). Ethnic distribution
was 68% Caucasian, 12% Hispanic, 7% Black, and 13% Asian/Native
American. There were 5220 (70%) intra-hepatic tumors, 2190 (30%) extra-
hepatic tumors, and 10% were Klatskin tumors. Histologically, 18% were
well-differentiated, 39% moderately-differentiated, 40% poorly differen-
tiated, 3% anaplastic, and 5% were combined CCA and hepatocellular
carcinoma. Regarding stage, 1480 (20%) patients presented with localized
tumors, 1775 (24%) with regional, and 1959 (26%) with distant disease.
Since 1997 statistically more patients have presented with local and regional
as opposed to distant disease (pB0.02). In 2406 (32%) patients surgery was
a component of the treatment, and in 1189 (16%) radiation was used. Mean
survival was 13 months with 24%, 12%, and 4%, 1, 2, and 5-year survival,
respectively. Patients with localized tumors doubled their mean (16 v. 35
months) and median (6 v. 12 months, pB.0001) survival with surgery.
Conclusions. The overall incidence and incidence of extra-hepatic CCA has
increased in the United States. Contrary to analysis of previous years, the
incidence of intra-hepatic and liver CCA has not increased. While there has
been little improvement in overall survival, detection while still localized with
prompt surgical intervention remains the best chance for cure.
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GERMLINE APC AND MYH MUTATIONS DO NOT ACCOUNT
FOR A SIGNIFICANT FRACTION OF SPORADIC AMPULLARY
CANCER
George Zogopoulos, MD, PhD, Zane Gallinger, Robin Kim, MD, Ian D.
Mcgilvray, MD, PhD, Alice Wei, MD, Bryce Taylor, MD, Bernard Langer,
MD, Paul Greig, MD, Richard Hart, MD, Runjan Runjan Chetty, MD,
Steven Gallinger, MD
University of Toronto, Toronto, ON, Canada
Adenocarcinoma of the ampulla of Vater is uncommon in the general
population and usually presents after the fifth decade of life. However, in
patients with familial adenomatous polyposis (FAP) or MYH Associated
Polyposis (MAP), ampullary neoplasia presents earlier and is a major cause of
morbidity and mortality. Both FAP and MAP are caused by germline
mutations of tumor suppressor genes, dominantly inherited mutations of
APC in the case of FAP, whereas biallelic recessively inherited MYH
mutations cause MAP. Since individuals with FAP and MAP are at increased
risk for periampullary and ampullary cancer, and since variable expression of
these syndromes is well known, we hypothesized that a fraction of apparently
sporadic ampullary cancer patients may have germline APC or MYH
mutations as a predisposing cause of their malignancy. A retrospective review
of pathology department databases and hepatobiliary/pancreatic surgeon
practices at the University of Toronto identified 61 cases, treated between
August 1994 and August 2005, with a diagnosis of ampullary adenoma or
ampullary cancer. A death clearance was performed by the Ontario Cancer
Registry, and with the approval of the treating surgeon, living subjects were
approached by mail for participation in this study. Screening for germ-line
APC and MYH mutations was performed using the protein truncation test
and denaturing high performance liquid chromatography analysis, respec-
tively. We did not identify truncating germline APC mutations or pathogenic
biallelic MYH mutations in the 33 subjects tested. One subject was found to
have a monoallelic G382R MYH mutation, although this unlikely contrib-
uted to her ampullary cancer, since heterozygous MYH mutations do not
seem to be a strong predisposing factor to colorectal or periampullary
neoplasia. These data suggest that germline APC and MYH mutations are
likely not causative in sporadic ampullary cancer.
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ESTROGEN RECEPTOR a, ESTROGEN RECEPTOR b AND
PROGESTERON RECEPTOR AS A POSSIBLE PROGNOSTIC
FACTOR IN RADICALLY RESECTED PRIMARY GALLBLADDER
CARCINOMA
Dong-Sup Yoon, MD, PhD, Joon Seong Park, MD, Kyung-Sik Kim, MD,
PhD, Jin-Sup Choi, MD, Woo-Jung Lee, MD, Hoon-Sang Chi, MD, PhD
Yonsei University Medical College, Seoul, Republic of Korea
Background. Gallbladder carcinoma is a relatively rare malignancy with an
extremely poor prognosis. The pathologic staging of gallbladder carcinoma is
a key determinant of the patient’s prognosis and the treatment options.
However, we have often encountered patients in whom the course of their
disease differed substantially from what would be predicted based on their
clinical staging, which highlights the needs to consider additional predictive
factors. Gallbladder carcinoma occurs more frequently in women than men,
yet expression of the estrogen receptor (ER) family and progesterone (PR)
have not been studied. We applied an immunohistochemical technique to
examine the expression of ERa, ERb and PR in radically resected gallbladder
carcinoma tissues and then compared their expression status with several
clinicopathological factors.
Methods. We immunohistochemically investigated 30 formalin-fixed, paraf-
fin-embedded specimens of gallbladder adenocarcinoma tissues using ERa,
ERb and PR antibodies. The expression of ERa, ERb and PR were compared
using the Chi-square test. Survival was analyzed using the Kaplan-Meier
method, verified by the Log-Rank test.
Results. The results indicated that adenocarcinoma of gallbladder are both
negative for ERa and PR, irrespective of histologic grade, TNM stage and
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sex. However, twenty-two of 30 cases (73.3%) were confirmed positive for
ERb, which was significantly correlated with poor differentiated tumor grade.
Overall survival rates of ERb-positive and negative patients were 77.3% and
37.5%, respectively (p0.034). In multivariate analysis, only ERb was
statistically significant (p0.033).
Conclusions. Evaluation of ERb expression in gallbladder carcinoma may
be an important factor in identifying a poor prognostic group of gallbladder
carcinoma.
Key Words. gallbladder, carcinoma, estrogen receptor(a), estrogen re-
ceptor(b), progesterone receptor.
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LONG TERM FOLLOW-UP OF MEXICAN PATIENTS WITH
GALLBLADDER CANCER
Ricardo Joaquin Mondrago´n-sanchez 80, MD, PhD, Elvira Go´mez-go´mez
2003, MD, Alicia Ivette Lo´pez-estrada 2006, Ofelia Arias-arias 2005,
Rodrigo Jasso-barranco 2006, MD, Brenda Elena Aguilar-a´lvarez 5006, MD
Issemym, Toluca, Mexico
Background. Gallbladder carcinoma (GC) is a rare neoplasm with a poor
prognosis because of its rapidly tumor growth and early dissemination. At the
time of diagnosis, only 10% of these tumors are candidates for resection.
Aim. To analyze epidemiological and prognostic factors in Mexican patients
with GC.
Patients and Methods. A retrospective review of the clinical files of patients
with gallbladder carcinoma diagnosed and treated in two hospitals in Mexico
between January 1987 and November 2005 was performed. Epidemiologic
data, clinical presentation, forms of diagnosis and treatment were analyzed.
Actuarial survival of these patients was also performed.
Results. 170 patients with diagnosis of gallbladder carcinoma were registered
in this period in both institutions. 149 (87%) patients were women and 21
(12%) were men. The median age at the time of diagnosis was 56 years
(range 19 to 86 years). The most common symptoms were abdominal pain in
161 patients (94%), weight loss in 51 (30%), palpable mass in 44 (25%),
jaundice in 44 (25%), nausea and vomiting in 17 (10%). 78 patients had
abdominal CT Scan, and 48 (28%) had ultrasound. Seven patients (4%)
were diagnosed at stage I, 19 (11%) Stage II, 31 (18%) Stage III, 13 A (7%)
stage III B, 78 (45%) stage IV and 22 (12%) patients were not classified. 110
(64%) were operated, of whom 17 (10%) had a palliative intent, 30 (17%)
radical cholecystectomy and lymphadenectomy, 22 (12%) biopsies of the
lesion only and the rest 40 (23%) were treated with simple cholecystectomy
and 1 (5%) had a radical cholecystectomy, lymphadenectomy and Whipple
procedure. 37 (21%) patients received adjuvant radiotherapy, 10 (6%)
patients received chemotherapy alone, 9 (5%) received chemotherapy plus
radiotherapy. The most common histology type was Adenocarcinoma in 119
(70%) patients. Global survival was 15.1 months (range from 6 days to 117
months). For the patients in stage I the mean survival was 50.3 months
(range from 1 to 99 months), 33.2 months for stage II (range 3 months to 129
months), 21.5 months for stage IIIA (range 1 to 117 months), 5.3 months for
stage IIIB (range 6 days to 24 months), 3.8 months for stage IV (range 15
days to 30 months) and 17.3 months (range 1 to 88 months) for those
patients that were not classified. Patients that were treated were radical
resection had the best survival.
Conclusions. Gallbladder cancer is a rare neoplasm with a poor prognosis.
Radical resection is the better option for patients with stage II and III of the
disease. For more advanced stages none of the treatments used in this study
modified the natural history of the disease.
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DIAGNOSTIC LAPAROSCOPY FOR PATIENTS WITH POTEN-
TIALLY RESECTABLE PANCREATIC ADENOCARCINOMA: IS IT
COST EFFECTIVE IN THE CURRENT ERA?
C. Kristian Enestvedt, MD, Skye C Mayo, MD, MPH, Brian Diggs, PhD,
Tomi Mori, PhD, Donald Austin, MD, MPH, Donald K Shipley, MS, Brett
Sheppard, MD, Kevin G Billingsley, MD
Oregon Health and Science University, Portland, OR; Johns Hopkins
Hospital, Baltimore, MD; Oregon State Cancer Registry, Portland, OR
Introduction. Diagnostic laparoscopy (DL) identifies small-volume liver
and peritoneal disease in a subset of patients with potentially resectable
pancreatic cancer (PAC), sparing them a nonresectional laparotomy. The aim
of this study is to retrospectively assess the cost effectiveness of laparoscopy
using population-based data.
Methods. Data from a state cancer registry was linked with primary medical
record data for years 1996 2003, identifying surgically treated patients with
PAC using ICD-9 diagnosis and CPT procedural codes. Operative notes and
pathology reports were reviewed to determine the role and findings of
laparoscopic exploration. Average hospital and physician charges for lapar-
otomy, biliary bypass, pancreaticoduodenectomy, and DL were determined
by review of billing data from our institution and Medicare data for fiscal-
years 20056. The cost of DL as an adjunct procedure was based on
physician fees, cost per minute of operative time, and equipment charges.
Cost effectiveness was determined by comparing three methods of utilization
of DL: 1) in all patients, 2) selectively, and 3) no utilization.
Results. During this study period surgeons used laparoscopy selectively in a
subset of patients with PAC. Of 298 patients, 86 underwent laparoscopy.
Periampullary tumors were present in 238 patients (79.9%). The prevalence
of unresectable disease was 14.1% diagnosed at either laparotomy or DL.
Metastatic disease or vascular invasion precluded resection. Cost analysis
revealed similar average cost per patient in each of the groups. Selective use
proved to be the least expensive, with $1058 and $2247 saved per patient
versus incorporating DL with all or none of the patients, respectively. The per
patient cost based on DRG coding, physician fees, and the addition of DL is
shown for each method in the accompanying table.
Discussion. The use of DL is not cost-prohibitive. In fact, we found that
selective or routine use of DL in pancreatic cancer was effectively cost neutral
when compared to non-utilization of DL. These data support the liberal use
of DL in potentially resectable PAC in patients for whom there is a high index
of suspicion for metastatic disease.
Average cost per patient for three methods of applying diagnostic laparoscopy
Approach to DL Mean Cost Per Patient ($)
All Patients 94,505
Selective 93,447
Not Used 95,694
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HOW USEFUL ARE CLINICAL, BIOCHEMICAL AND CROSS-
SECTIONAL IMAGING FEATURES IN PREDICTING PREMALIG-
NANT OR MALIGNANT CYSTIC LESIONS OF THE PANCREAS?
Brian K Goh, MBBS, Yu-meng Tan, Choon-hua Thng, MBBS, Peng-chung
Cheow, MBBS, Yaw-fui Chung, MBBS, Pierce K. H. Chow, PhD, Wai-
keong Wong, MBBS, London Lucien Ooi, MD
Singapore General Hospital, Singapore, Singapore
Introduction. Presently, the management of cystic lesions of the pancreas
(CLP) remains controversial as the natural history of pancreatic cystic
neoplasms is not fully understood and the preoperative characterization of
CLP is unreliable and often impossible. The aim of the present study is to
determine if preoperative clinical, biochemical and cross-sectional imaging
features are useful in predicting a potentially malignant or malignant CLP.
Methods. Between 1990 and 2006, 153 consecutive patients underwent
surgical treatment for a suspected pancreatic cystic neoplasm at a single
institution. The patients’ clinical, radiology and pathology reports were
reviewed retrospectively. The predictive effect of clinical, biochemical and
radiologic factors on the malignant potential of a CLP was evaluated with
both univariate and multivariate analysis.
Results. The median age of the patients was 52 years (range, 1482 years)
and there were 101 females. 60 patients had CLP discovered incidentally of
which 63 were benign, 46 potentially malignant and 44 malignant lesions.
The presence of symptoms, elevation of serum carcinoembryonic antigen
(CEA) or carbohydrate antigen 199 levels (CA 19-9), cyst size3 cm and
presence of 1 or more of 3 morphologic features on cross-sectional imaging
such as solid component, peripheral calcification and dilatation of the main
pancreatic duct were predictors of a potentially malignant or malignant CLP
on univariate analysis. On multivariate analysis, elevation of serum CEA or
CA 19-9, cyst size3 cm and the presence of 1 or more of the 3 morphologic
features on cross-sectional imaging were independent predictors. The logistic
regression model had a sensitivity, specificity, positive predictive value and
negative predictive value of 82%, 75%, 82% and 75% in predicting a
potentially malignant or malignant CLP.
Conclusion. Elevation of serum CEA or CA 19-9, cyst size3 cm and the
presence of morphologic features on cross-sectional imaging such as solid
component, peripheral calcification or main pancreatic duct dilatation are
independent predictors of a potentially malignant or malignant CLP. Patients
with a high likelihood of harboring a potentially malignant or malignant
lesion based on this model should undergo resection without further
investigations.
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CHARACTERISTICS OF MALIGNANCY IN INTRADUCTAL PA-
PILLARY MUCINOUS NEOPLASMS
Jayme B. Stokes, MD, Edward B. Stelow, MD, Marc Sarti, MD, Eduard E.
De Lange, MD, Christopher A. Moskaluk, MD, PhD, Reid B. Adams, MD,
Todd W. Bauer, MD
University of Virginia, Charlottesville, VA
Objective. To evaluate the clinical, radiographic, and pathologic features of
resected intraductal papillary mucinous neoplasms (IPMN’s) of the pancreas
at a single institution.
Methods. All patients undergoing pancreatic resection for IPMN between
January 1998 and August 2006 were evaluated. Charts were retrospectively
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reviewed using a set of prospectively defined criteria. Imaging studies (CT
and MRI) were independently, retrospectively reviewed by two blinded
radiologists. Pathology slides were reviewed by a single pathologist. IPMN’s
were categorized pathologically as Benign (Adenoma or Borderline) or
Malignant (Carcinoma In Situ or Invasive) and radiographically as Main
Duct (MD), Side Branch (SB) or Combined (CB). Adverse radiographic
features (mural nodules, papillary projections, or septations) were noted.
Results. Twenty-six pancreatic resections for IPMN were performed. The
median age of patients with malignant and benign disease was 64.9 and 69
years, respectively (pNS). Demographics were similar in both groups. The
presence of two or more symptoms (new/change in diabetes, jaundice,
abdominal pain, weight loss, nausea/vomiting, acute pancreatitis, GI bleed)
was significantly more common in the malignant group (71% vs 25%, pB
0.05). Malignant lesions (n14) were significantly larger than benign lesions
(n12) (10.87 vs. 3.21 cm, pB0.05), were more likely to contain adverse
radiographic features (81.8% vs. 14.3%, pB0.01), and were associated with
greater main pancreatic duct diameter (13.6 vs. 3.77 mm, pB0.05). Benign
IPMN’s were more likely to occur in the tail (71% vs 18%, pB0.05). All
malignant MD/CB lesions were greater than 4.0 cm in size (only one tumor
smaller than 11 cm) and had main duct diameters 6.5 mm. All benign
MD/CB lesions were smaller than 5 cm in size had main duct diametersB
5.5 mm. Two of the malignant SB IPMN’s in this series were less than 2.5 cm
with main duct diameters less than 5 mm, but contained adverse radiographic
features.
Conclusions. Some main duct IPMN’s may not require resection and they
may be distinguishable by lesion, main duct size, and adverse radiographic
features. MRI detection of mural nodules or papillary projections is
important in detecting malignant side branch IPMN’s. Further evaluation
of IPMN’s is needed in order to optimize consensus recommendations for
resection.
Malignant
(n14)
Benign
(n12) p-value
Mean Age 63.85 (99.77) 69 (99.5) NS
Median Age 64.5 69 N/A
% Male 5 (35.7%) 5 (41.67%) NS
Caucasian 13 (92.3%) 12 (100%) NS
Smoking Hx 9 (64.3%) 8 (66.67%) NS
Presence of symptom 12 (85.7%) 9 (75%) NS
Presence of 1 symptom 10 (71.4%) 3 (25%) 0.0236
Hx of DM 4 (28.6%) 4 (33.3%) NS
New/Change in DM 2 (14.3%) 1 (8.3%) NS
Obs. Jaundice 2 (14.3%) 1 (8.3%) NS
Abdominal Pain 10 (71.4%) 5 (41.67%) NS
Wt. Loss 6 (42.9%) 4 (33.3%) NS
Nausea/Vomiting 3 (21.4%) 1 (8.3%) NS
Acute Pancreatitis 2 (14.3%) 2 (16.7%) NS
GI Bleed 0 (0%) 0 (0%) N/A
Fevers/Chills 0 (0%) 1 (8.3%) NS
Extra pancreatic
Malignancy
3 (21.4%) 2 (16.7%) NS
Incidental Finding 4 (28.6%) 4 (33.3%) NS
Size of Lesion (cm) 10.87 (96.59) 3.21 (91.92) 0.006
Main Duct Diameter
(mean)
13.61 (98.97) 3.77 (91.68) 0.0118
Uncinate 27.30% 28.60% NS
Tail 18.10% 71.40% 0.0387
Diffuse 45.50% 14.30% NS
Pts w/ any adverse
radiographic feature
81.80% 14.30% 0.009
Mural Nodules 63.60% 14.30% NS
Papillary projections 18.2% 0% NS
Septations 18.2% 0% NS
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PANCREATIC ADENOCARCINOMA: THE ACTUAL 5YR SURVI-
VORS
Cristina R Ferrone, MD, Peter J Allen, MD, Daniel G Coit, MD, Sun
Chung, MD, Laura Tang, MD, David Klimstra, MD, Murray F Brennan,
MD
Massachusetts General Hospital, Boston, MA; Memorial Sloan Kettering
Cancer Center, New York, NY; New York Hospital, New York, NY
Background. Less than 15% of patients diagnosed with pancreatic
adenocarcinoma will undergo resection. Most reports on patients undergoing
resection report estimated (actuarial) 5-year survival rates. Actual five-year
survival is rarely described, and factors associated with this long-term survival
are not well known.
Methods. Review of a prospectively maintained database of patients under-
going resection for periampullary neoplasms identified 616 patients who
underwent resection for pancreatic adenocarcinoma between 1/19831/
2001. Patient, tumor, and treatment related variables were assessed for their
association with 5yr survival. This includes the 125 yr survivors previously
reported by Conlon et al.
Results. There were 73 patients who survived 5 yrs after resection (73/
616, 12%), and 18 patients who survived 10 yrs (18/352, 5%). Our actual
survival may be lower than published actuarial survival since 6.5% (35/543)
died of another cause and 2.9% (16/543) were lost to follow up. Patient age
(median 67y vs 68y, p0.8), gender (female 56% vs 49%, p0.4), and
tumor location (head 84% vs 85%, p0.3) were not different between those
who survived 5 yrs and those who did not. Early AJCC stage (figure 1, pB
0.001), and the presence of a negative margin (p0.001) were associated
with 5yr survival. Within the sub-group of patients who survived 5 yrs (n
73) median follow-up was 108 mos, with 43 patients (59%) developing
disease recurrence and succumbing to their disease at the time of last follow-
up. No factor (AJCC stage, margin status, tumor differentiation, perineural/
perivascular invasion, or the use of adjuvant therapy) was found to predict
death after the 5th post operative year. In the group of 5 yr survivors tumors
were moderately differentiated in 58% (42/73), perineural invasion in 55%
(40/73), lymphovascular invasion in 19%, positive margins in 9.6% (7/73),
median size of 2.8 cm (0.813 cm), and adjuvant therapy was received by
22% (16/73).
Conclusions. In this group of patients with pancreatic adenocarcinoma
actual 5and 10-year survival rates were 12% and 5%, respectively. Patients
with Stage IA disease (B2 cm, lymph node negative tumors) had an actual
5yr survival of 26%. Early detection and intervention for patients with
pancreatic cancer is crucial.
Figure 1. Percent of patients who survived more than five years.
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ADJUVANT CHEMOTHERAPY IS ASSOCIATED TO GOOD SUR-
VIVAL IN PATIENTS UNDERWENT EXTENDED PANCREATICO-
DUODENECTOMY FOR PANCREATIC CANCER
Calogero Iacono, MD, Maurizio Cantore, Andrea Ruzzenente, MD,
Giuseppe Verlato, Enrico Facci, Tommaso Campagnaro, Andrea Mambrini,
Silvia Pachera, Alfredo Guglielmi
University of Verona, Verona, Italy; Dept of Oncology, Massa Carrara, Italy
Backgrounds. In pancreatic cancer after surgery several types of adjuvant
treatments have been proposed to improve survival. Aims: The present study
aims is to evaluate whether survival is increased in patients undergoing
adjuvant chemotherapy (ADJCT) with respect to patients undergoing
surgery alone. The rational for this treatment is to combine local control of
the disease, achieved by Extended Pancreaticoduodenenctomy (EPD), with
control of distant metastases, achieved by ADJCT.
Patients and Methods. From January 1994 to October 2005, 84 patients
underwent EPD, 54 patients with ductal pancreatic carcinoma were included
in this study. Twenty patients received ADJCT while 34 receive surgery alone.
Fifteen of 20 patients received intra-arterial chemotherapy employng FLEC
regimen (5-fluoruracil 750 mg sqm1, leucovorin 75 mg sqm1, epirubicin
45 mg sqm1, carboplatin 225 mg sqm1 administered every three weeks in
to coeliac axis for three cycles), in 7 cases followed by systemic gemcitabine
(at the dosage of 1 g sqm1 on days 1, 8, 15 every 4 weeks for three months);
five of 20 patients received others type of adjuvant treatments.
Results. The two group were comparable for gender, age, grading, tumor
size, stage, N status, R0 or R1 resection. Median follow up time was 17.5
months. The overall mean and median survival was 43 months and 18
months (range 4144), respectively, with actuarial 1, 3 and 5-year survival
rates of 77.8, 36.4 and 19.3%, respectively. ADJCT was well tolerated, with
only one case of grade 3 nausea/vomiting, one patient had grade 3 anemia
and leukopenia, and two patients had grade 3 thrombocytopenia. Significant
difference in mean survival (50 vs 31 months, pB0.05) and actuarial 5-year
survival rates (50 vs 10%, pB0.05) was seen in those who received ADJCT.
ADJCT significantly influenced distant recurrence rate (60% vs 85%, pB
0.05) but it did not reduced local recurrence rate (35% vs 35%, p0.2).
Conclusions. ADJCT is associated with long-term survival and decreased
distant recurrence rates in patients with pancreatic cancers who have
undergone EPD. Intra-arterial chemotherapy employing FLEC regimen
combined with gemcitabine seem to be the better adjuvant therapy after
surgery.
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NEOADJUVANT CHEMOTHERAPY AND RADIATION FOR PA-
TIENTS WITH LOCALLY UNRESECTABLE PANCREATIC ADE-
NOCARCINOMA: SAFETY, EFFICACY AND SURVIVAL
John D Allendorf, Margaret Lauerman, Aliye Bill, Mary Digiorgi, Nichole
Goetz, Beth Schrope, William Sherman, Robert Fine, John Chabot
Columbia University, New York, NY
Purpose. We evaluated the safety and efficacy of neoadjuvant chemotherapy
and radiation for patients with locally unresectable pancreatic cancer.
Methods. From October 2000 to August 2006, 245 patients with pancreatic
adenocarcinoma underwent surgical exploration at our institution. Of these,
78 patients (32%) had undergone neoadjuvant therapy for initially unresect-
able disease, while the remaining patients (serving as the control group) were
explored at presentation (n167). All neoadjuvant patients received
gemcitabine based chemotherapy, often in conjunction with docetaxel and
capecitabine (81%). 75% of neoadjuvant patients also received preoperative
abdominal radiation (4500 rads).
Results. Neoadjuvant patients were younger than control group patients
(60.8 vs 66.2 years, pB0.002). 76% of neoadjuvant patients were resected
with curative intent as compared to 83% of control patients (NS).
Concomitant vascular resection was required in 76% of neoadjuvant patients,
but only 20% of control patients (pB0.01). Complications were more
frequent in the neoadjuvant group (44.1% vs 30.9%, pB0.05), and mortality
was higher (10.2% vs 2.9%, pB0.03). Among the neoadjuvant patients, all
but one of the deaths were in patients that underwent arterial reconstruction.
Mortality for patients undergoing a standard pancreatectomy was 0.8% in
this series. Of patients resected, negative margins were achieved in 84.7% of
neoadjuvant patients and 72.7% of control group patients (NS). Within the
cohort of neoadjuvant patients, radiation significantly increased the compli-
cation rate (13.3% vs 54.6%, pB0.006), but did not affect median survival
(512 vs 729 days, NS). Using intention to treat analysis, median survival for
neoadjuvant patients (503 days) was higher than control group patients that
were found to be unresectable (192 days, pB0.001) and equivalent to control
group patients that were resected (498 days).
Conclusions. Resection rate, margin rate, and median survival were
equivalent when neoadjuvant patients were compared to patients considered
resectable by traditional criteria, demonstrating efficacy. Surgical resection
following neoadjuvant therapy for patients with locally advanced pancreatic
cancer can be performed with acceptable morbidity and mortality. This
approach extended the boundaries of surgical resection and greatly increased
median survival for the ‘‘inoperable’’ patient.
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MANAGEMENT OF DELAYED ARTERIAL HAEMORRHAGE
AFTER PANCREATICODUODENECTOMY  A META-ANALYSIS
Madhava Pai, Paolo Limongelli, Andrew Healey, Osama Damrah, James
Jackson, Robin Williamson, Long Jiao
Hammersmith Hospital, Imperial College, London, United Kingdom
Background & Aims. Controversy exists regarding the best management of
delayed haemorrhage after pancreaticoduodenectomy. We reviewed exten-
sively the published articles describing this complication and reported our
own series among 180 pancreaticoduodenectomy to examine both the role of
diagnostic and interventional radiology and laparotomy in management of
this serious condition.
Methods. A literature search of all reported cases in the last 15 years on
delayed haemorrhage after pancreaticoduodenectomy together with identifi-
cation and review of cases among 180 pancreaticoduodenectomy from our
unit between 1993 and 2003.For meta-analysis, the end points evaluated
were of operative and functional outcomes and adverse events. A random-
effect model was used for analysis and sensitivity analysis was performed to
examine the bias in patient selection.
Results. One hundred cases of delayed arterial haemorrhage were described
among a total of 2503 pancreaticoduodenectomy (3.9%). Analysis revealed
that recurrent bleeding occurred in 42.2%of patients undergoing laparotomy
in comparison with 23.6% of embolised patients. The mortality rate was
28.8% in laparotomised patients (as compared to 14.6% in radiologically
embolised patients) Four cases of delayed arterial haemorrhage were
identified among 180 pancreaticoduodenectomy performed in our unit
(2.2%). All cases had urgent diagnostic visceral angiography. Two patients
were successfully managed with transcatheter arterial embolisation of
bleeding vessels. But two patients who were operated on died in the
postoperative period from multiorgan failure.
Conclusions. Delayed arterial haemorrhage after pancreaticoduodenectomy
carries significant mortality. Radiological management with transarterial
embolisation would seem to be a better treatment option than laparotomy.
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RESECTION FOR METASTATIC PANCREATIC CARCINOID TU-
MORS IMPROVES SURVIVAL
Jensen C. C. Tan, MD, Anand Govindarajan, MD, Natalie G. Coburn, MD,
Sherif Hanna, MD, Calvin H. L. Law, MD
University of Toronto, Toronto, ON, Canada
Introduction. Surgery is the recommended therapy for carcinoid tumor of
the pancreas, but is often not performed due to advanced disease at
presentation. We examined a population based cancer registry to examine
the rates and impact on survival of pancreatic resection in the setting of
metastatic disease.
Methods. Patients over 18 years with histologically confirmed carcinoid
tumor of the pancreas were identified from the Surveillance, Epidemiology
and End Results (SEER) Program from 1998 to 2003. Overall survival (OS)
was evaluated using Kaplan-Meier and Cox proportional hazards modeling.
Logistic regression was used to determine independent predictors for
pancreatic resection.
Results. A total of 607 patients were identified. Distribution of tumors
within the pancreas were 37% head; 11% body; 22% tail; and 30% not
otherwise specified. At diagnosis, 65% of patients had metastatic, 20%
regional and 15% localized disease. While 64% patients were not treated with
surgery, 2% had a local excision, 14% had a partial pancreatectomy
(including distal pancreatectomy), and 13% had a pancreatoduodenectomy.
In total, 28% of the 215 pancreatic resections were performed in patients
with metastatic disease. Overall, surgical resection was significantly asso-
ciated with an improved OS compared to no resection (5 year OS63%
versus 12% respectively, pB0.0001). In the final model, performance of
surgery was independently associated with improved OS (HR 0.3 [0.2 0.4]).
Decreased OS was associated with age over 60 years (HR 2.0 [1.62.6]) and
black race (HR 2.1 [1.43.0]). Metastatic disease, tumors extending beyond
the pancreas, tumor site and SEER region were not independently associated
with survival. When stratified by metastatic disease, surgery was associated
with a significant improvement in OS in both groups (HR 0.3 [0.20.6] and
0.2 [0.10.4] for metastatic and non-metastatic, respectively). Independent
factors associated with pancreatic resection included lesions in the body (p
0.03), tail (pB0.001), and localized disease only (p0.001). Metastatic
disease (pB0.0001) and age over 60 years (pB0.0001) were associated with
not receiving pancreatic resection. There was no regional or racial variation
associated with the performance of surgery.
Conclusion. This study confirms that many patients with pancreatic
carcinoid tumors present with metastases. It appears that these patients
may benefit from surgical resection, however this is often not performed,
perhaps due to the burden of disease at presentation. Studies must be
conducted to identify patients for whom an aggressive surgical approach is
warranted.
Free Papers
Basic Science
FP-04
4/21/07 10:00 to 12:15 am
Abstract Numbers 129139
129
TUMOR LYSATE-PULSED DENDRITIC CELLS CONFER PRO-
TECTIVE IMMUNITY IN A MURINE PANCREATIC CANCER
MODEL
Nasreen A. Vohra, MD, Shari Pilon-thomas, PhD, James J Mule´, PhD,
Emmanuel E. Zervos, MD
University of South Florida College of Medicine, Tampa, FL; H. Lee Moffitt
Cancer Center, Tampa, FL
Purpose. Use of dendritic cell (DC) based immunotherapy has shown
promise in the treatment of solid tumors by inducing anti-tumor immunity.
PANC02 is a murine pancreatic adenocarcinoma (PCA) that is resistant to
traditional forms of treatment. By using this model of PCA in immunocom-
petent mice, we attempt to study mechanisms that lead to anti-tumor
immunity with the ultimate goal of improving the efficacy of dendritic cell
based vaccines.
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Methods. To measure PANC02 specific killing by CD8 T cells, mice were
vaccinated subcutaneously three times at seven-day intervals with whole
PANC02 tumor lysate- pulsed DC. One week after the final vaccine,
splenocytes were collected, restimulated in vitro for five days, and used as
effector cells in a standard chromium release assay. To measure vaccine
efficacy, mice were immunized three times at seven-day intervals with DC
pulsed with whole PANC02 tumor lysate or PBS. One week after final
vaccination, mice were challenged subcutaneously with 3105 PANC02
cells. To determine the effects of CD8 T cells on tumor rejection, CD8 T
cell depletion was undertaken using a monoclonal antibody one day prior to
tumor challenge and continued through the end of the experiment. Tumor
size measurements were recorded and survival was measured.
Results. Splenocytes isolated from mice vaccinated three times with
PANC02 lysate-pulsed DC demonstrated PANC02 specific killing in a
cytotoxic assay. Negative control cells, GL26 and Yac-1, were not lysed. Mice
receiving tumor lysate-pulsed DC displayed the smallest tumors and the most
delay in tumor growth, CD8 depleted mice had intermediate size tumors and
PBS treated mice grew the largest tumors. Tumor suppression and survival
were significantly enhanced in immunized mice as compared to non-
immunized controls (Figure).
Conclusions. Suppression of tumor growth in vaccinated mice indicates a
tumor specific immune response. CD8 T cells demonstrate tumor specific
cytotoxic activity. The presence of intermediate size tumors in CD8 depleted
mice shows that CD8 T cells are important in inducing anti-tumor
immunity but are not the only effector mechanism.
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LIVER SPECIFIC TOLERANCE TO A TUMOR ASSOCIATED
ANTIGEN
Eric Kimchi, MD, Olivier Rolin, Diego Avella, MD, Luis Garcia, MD, Kevin
Staveley-o’carroll, MD, PhD
Penn State University, Hershey, PA
Introduction. The MTD2 mouse line expresses the oncogenic SV40 T
antigen (Tag) transgene under the major urinary protein (MUP) promoter
effecting the progression of Tag-expressing hepatocellular cancers (HCC).
The 501 mouse strain expresses this oncogenic Tag transgene under the a-
amylase promoter leading to Tag-expressing osteosarcomas. Hypothesizing
that tumor location might lead to differences in antigen presentation that will
induce different CD8 T cell responses, we compared and contrasted the fate
of naı¨ve Tag-specific CD8 T cells after exposure to tumor antigen in these
spontaneous tumor models.
Methods. Naı¨ve, T antigen epitope I-specific CD8 T cells from T-cell-
receptor-transgenic mice (TCR-I cells) were transferred into HCC-bearing
MTD2 mice, osteosarcoma-bearing 501 mice, or syngeneic C57BL/6 mice
that do not express tumor antigen. Six and seven days after transfer, T cells
were isolated from spleens, tumors, and tumor draining lymph nodes.
Fluorescent staining quantified epitope I-specific CD8 T cells, and T-cell
function was assessed through epitope I-specific g-interferon production.
Results. In osteosarcoma-bearing mice, tumor antigen-specific TCR-I cells
underwent a robust, ten-fold, proliferative expansion in spleens and tumor
draining nodes. In addition, these cells acquired effector function as
demonstrated by their ability to produce epitope I-specific g-interferon. In
HCC-bearing mice, tumor antigen-specific CD8 T cells underwent a very
transient, 12 fold expansion and were unable to produce epitope I-specific
g-interferon. Accordingly, tumor antigen-specific cells were found to infiltrate
osteosarcomas but not hepatomas: staining revealed the presence of
significant amounts of TCR-I cells infiltrating the osteosarcomas in 501
mice; however, no site I-specific cells could be detected in the HCC tumors
of MTD2 mice. Assessed by intracellular cytokine staining, approximately
10% of TCR-I isolated from mice with osteosarcomas produced epitope I-
specific g-interferon, a slightly diminished number compared to TCR-I
isolated from spleens and lymph nodes. While the vast majority of CD8 T
cells infiltrating osteosarcomas were tumor antigen specific, there were many
CD8 T cells isolated from HCC tumors with unknown specificity.
Conclusions. The dichotomous fate of naı¨ve, tumor antigen-specific T cells
in the two models points to an important role for tumor location and antigen
presentation at the interface of tolerance and immunity to cancer. Liver
specific tolerance may impose a significant burden to be overcome by
successful vaccine strategies. This model represents a powerful tool for the
assessment of strategies to break this tolerance of HCC antigens.
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ENHANCING GEMCITABINE-MEDIATED EFFECTS AGAINST
EXPERIMENTAL PANCREATIC CANCER VIA TWO ANTIANGIO-
GENIC STRATEGIES
Roderich E Schwarz, MD, PhD, Srivani Konduri, PhD, Niranjan Awasthi,
PhD, Danielle Cafasso, Lauren Caldwell, Margaret A Schwarz, MD
UMDNJ-RWJMS, New Brunswick, NJ
Background. Systemic treatment options against pancreatic ductal adeno-
carcinoma (PDAC) remain sparse. We tested an approach to enhance
gemcitabine (Gem) mediated effects through antiangiogenic therapy.
Methods. Human ASPC PDAC cells were injected into nude mice (1106
per animal s.c., n7 per group), and treatment was initiated at an average
tumor volume of 50 mm3. Anti-VEGF-A bevacizumab (50 mg), and Gem
(100 mg/kg) were injected i.p. twice weekly. Antiendothelial human recom-
binant endothelial monocyte-activating polypeptide II (EMAP-II) was
administered through daily i.p. injections at 80 mg/kg. Group comparisons
were undertaken with ANOVA and Kruskal-Wallis tests.
Results. After 14 days of therapy, net tumor growth showed significant
differences based on treatment group (p0.003). net tumor growth (in
mm3) after EMAP (81, p0.05), Bev (116, pNS), or Gem (115, pNS)
monotherapy showed only mild effects compared to controls (194). Dual
combinations reduced tumor growth more effectively: EB (64, p0.01), EG
(62, p0.008), and BG (59, p0.006). The triple combination EBG
demonstrated the smallest net growth (7, p0.0006). Addition to Gem of
EMAP (p0.05), Bev (p0.04), or of both (EB, p0.0007) resulted in
significantly enhanced benefits. Tolerance of combination therapy, as
measured by weight loss during treatment (in gm, vs. controls), was better
in all combination groups (EB: 0.88, EG: 0.79, BG: 0.52, EBG: 0.83), than
after Gem alone (1.23, p0.0008). Group comparisons of mean microvessel
counts (MVC) per HPF and TUNEL-positive apoptotic index showed
significantly enhanced activities in all treatment groups over controls, but no
further effects in combination. The proliferative index, however, was
significantly reduced only in the EMAP containing groups: Gem vs. EG
(p0.004), Gem vs. BG (pNS), BG vs. EBG (p0.0002). Mechanistic in
vitro studies of EMAP II demonstrated specific binding affinity to alpha5-
beta1 integrin, interference with fibronectin/integrin mediated cell adhesion,
endothelial cell cytotoxicity, and decreased PDAC cell migration.
Conclusions. Both antiangiogenic agents EMAP II and bevacizumab
significantly enhanced the gemcitabine-mediated antitumor effects against a
PDAC in vivo xenograft. As the EMAP and Bev mechanisms appear to be
different, the triple combination therapy was most effective, and offers a
promising direction for clinical PDAC therapy.
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A NOVEL SUICIDE GENE THERAPY REGIMEN TARGETING
THE OVEREXPRESSION OF EUKARYOTIC INITIATION FAC-
TOR 4E IN A PANCREATIC CANCER CELL LINE
Kerry W Byrnes, MD, Neal Holm, MD, Bradford Siegele, MS, Benjamin Li,
MD, Michael Mathis, PhD, Yoshi Odaka, PhD, Quyen Chu, MD
LSU Health Sciences Center, Shreveport, LA
Background. Eukaryotic initiation factor 4E (eIF4E) is a 25 kDa cap-
binding protein involved in the initiation of protein synthesis. A number of
solid tumors have demonstrated overexpression of eIF4E. To exploit this
dysfunction, the 619 base pair 5?UTR of FGF-2 was spliced upstream of the
herpes simplex virus thymidine kinase gene in an adenovirus vector (Ad-
HSV-UTK), with the expectation that the gene product thymidine kinase will
be expressed in cells which overexpress eIF4E, and thus yield these cells
susceptible to ganciclovir. In this study, we investigated the in vitro activity of
this suicide gene therapy regimen against the human pancreatic cancer cell
line (CRL-1918).
Methods. eIF4E overexpression was assessed by Western blot. The
pancreatic cancer cell line (CRL-1918) was cultured and divided into 3
groups. Group one was infected with the Ad-HSV-TK vector (no additional
5? UTR) while group two was infected with the Ad-HSV-UTK vector (with
the additional 5? UTR), the third group (the control arm) was not infected.
24 hours after infection each group was further divided into 5 groups, each
receiving a progressive dose of ganciclovir: group 10, group 210mcg/ml,
group 350 mcg/ml, 4100 mcg/ml, 51000 mcg/ml. Successful infection
of the cell line was determined by Western blot analysis for the gene product
thymidine kinase. Crystal violet staining assessed cell viability.
Results. Western Blot analysis confirmed the overexpression of eIF4E in this
human pancreatic cancer cell line. Successful infection of the cell lines was
demonstrated by measurable expression of the gene product thymidine kinase
by both groups one and two. Marked cytotoxicity was noted in both the Ad-
HSV-TK and Ad-HSV-UTK infected groups with a 100-fold less concentra-
tion of ganciclovir as compared to the control groups, which received
ganciclovir alone.
Conclusion. The human pancreatic cancer cell line (CRL-1918) was found
to overexpress eIF4E. By splicing a 5?UTR upstream of HSV-TK, this
overexpression of eIF4E resulted in the expression of thymidine kinase and
subsequently rendered these cells susceptible to treatment with ganciclovir.
Marked cytotoxicity was evident in the treatment groups, even at a much
lower concentration of ganciclovir. Suicide gene therapy selectively targeting
malignant cells by exploiting the overexpression of eIF4E appears effective
against the CRL-1918 human pancreatic cancer cell line.
133
PROLIFERATIVE BILIARY EPITHELIA ARE THE MAJOR CON-
TRIBUTOR TO HIGH LEVELS OF HEPATIC CD44 EXPRESSED
BY CHOLESTATIC LIVERS
Yao He, MD, PhD, Gordon D Wu, MD, Jan Li, PhD, Tomohito Sadahiro,
MD, PhD, Hui Zhu, MD, PhD, Sangik Noh, MD, Andrew S Klein, MD
Cedars-Sinai Medical Center, Los Angeles, CA
Objective. In previous study we demonstrated in a rat model that cholestatic
livers induced by bile duct ligation (BDL) expressed high levels of CD44.
The current study was carried out to further investigate the cellular source of
CD44 expression.
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Methods. Cholestatic cirrhotic livers were induced in rats by BDL and
compared with sham-operated livers. Total non-parenchymal liver cells
(NPLC) were obtained via a standard procedure consisting sequential liver
perfusion, collagenase digestion and gradient centrifugation. Biliary epithelial
cells (BEC) and hepatic stellate cell (HSC) were isolated by gradient
centrifugation with isotonic Percoll. CD31 hepatic endothelial cells
(HEC) and ED2 Kupffer cells (KC) were isolated though flow cytometric
cell sorting. Expression of CD44 standard (s) and variant (v) isoforms by
different types of NPLC was examined by quantitative real time PCR.
Histological distribution of the cells expressing CD44 proteins was examined
in cryostat sections of the livers with immunofluorescent technique. Deposi-
tion of extracellular hyaluronic acid (HA) was studied by histochemical
staining of the liver sections with a hyaluronan binding protein (HABP).
Results. CD44 mRNA levels in the BDL livers were significantly increased
when compared to sham controls (pB0.001). The levels of CD44 E5 mRNA
expressed by BEC isolated from the cholestatic livers were as high as 20-, 8-
and 6-fold as that expressed by HSC (pB0.01), Kupffer cells (pB0.01) and
HEC (pB0.01), respectively. Immunofluorescent staining of the liver
sections showed increased expression of cell surface CD44 proteins, mainly
by the proliferative biliary epithelial cells. Metamorphic analysis of the liver
sections stained with HABP demonstrated a striking increase in HA synthesis
in the portal triads of the BDL livers when compared with that of sham
operated controls.
Conclusion. In cholestatic livers bile duct proliferation was accompanied by
remarkable upregulation of CD44 expression by the biliary epithelial cells
and an increase in synthesis of extracellular matrix HA in the portal triads.
CD44 species expressed in the cholestatic livers were exclusively variant
isoforms. Though the biological implication of CD44v gene up-regulation on
biliary epithelial cells in the development of cholestatic cirrhosis is unclear,
detection of this CD44 may have a diagnostic value in clinical monitoring of
hepatobiliary diseases.
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DISRUPTION OF TRANSFORMING GROWTH FACTOR-b SIG-
NALING THROUGH b -SPECTRIN ELF LEADS TO EARLY HE-
PATOCARCINOGENESIS THROUGH OVEREXPRESSION OF
CYCLIN D1
Krit Kitisin, MD, Natarajan Ganesan, PhD, Eugene A Volpe, PhD, Sang Soo
Kim, PhD, Varalakshmi Katuri, PhD, Wilma Jogunoori, PhD, Jon Mendel-
son, MS, Bibhutibhushan Mishra, MD, Lopa Mishra, MD, Lynt B Johnson,
MD
Georgetown University, Washington, DC
Recent studies in human hepatocellular carcinoma (HCC) have revealed the
importance of the transforming growth factor-ß (TGF-ß ) signaling pathway
in suppressing tumorigenesis through Smads and adaptor proteins such as
embryonic liver fodrin (ELF). TGF-ß signaling induces antiproliferative
gene responses by inhibiting cell cycle progression in the G1 phase. Our
laboratory has demonstrated that up to 40% of elf/mice (16/40)
spontaneously develop HCC within 15 months. We now demonstrate that
immunohistologic studies of HCC specimens taken from elf/ mice show
increased nuclear cyclin D1 expression, which is a major G1 cell cycle
regulatory protein. To investigate the correlation between TGF-ß inactiva-
tion and hepatocarcinogenesis, we examine the expression of TGF-ß
signaling proteins in four human HCC cell lines, SNU-182, SNU-398,
SNU-449, and SNU-475. ELF expression is significantly reduced in one cell
line, SNU-398, and moderately decreased in SNU-182, SNU-449, and
SNU-475. TGF-ß receptor II (TBRII) expression was significantly reduced
in three cell lines, SNU-182, SNU-398, and SNU-475. Restoration of ELF
results in a moderate decrease in cyclin D1 expression in SNU-182 and
SNU-475 and 8-fold decrease in SNU-398. More importantly, under TGF-ß
stimulation, ectopic expression of ELF together with TBRII demonstrates an
additive decrease in cyclin D1 expression compared to the non-TGF-b
stimulated naı¨ve SNU-398 cell line. The decrease in cyclin D1 is accom-
panied by a decrease in hyperphosphorylated-retinoblastoma (pRb-P)
expression. Restoration of ELF and TBRII in SNU-398 results in an additive
decrease of pRb-P. Further analysis of the role of TGF-ß signaling in human
HCC confirmed reduced ELF expression by immunohistochemical staining
in 7 out of 9 human HCCs (pB0.039). These human HCCs displays
increased nuclear cyclin D1 expression as in the elf/ mouse HCCs.
Furthermore, immunohistochemical analysis also demonstrates abnormal
cytoplasmic localization of TBRII and decreased expression of Smad4 in
HCCs, although the changes do not achieve statistic significance. Thus, we
show for the first time that disruption of TGF-ß signaling by the adaptor
ELF plays an important role in human hepatocarcinogenesis, possibly
through cyclin D1 deregulation. Loss of ELF could serve as a primary event
in hepatocarcinogenesis, further studies on the mechanisms underlying the
inactivation of the TGF-ß signaling pathway could hold promise for new
therapeutic approaches in human HCCs.
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THE EMERGING ROLE OF NK-kB IN HEPATITIS C-ASSO-
CIATED HEPATOCELLULAR TUMORIGENESIS
Amanda Cooper, MD, Jian-min Wu, PhD, Poornima Nakshatri, MS,
Harikrishna Nakshatri, PhD, Mary Maluccio, MD, MPH
Indiana University School of Medicine, Indianapolis, IN
Purpose. With over 4 million Americans infected with hepatitis C, the
number of cases of hepatocellular carcinoma (HCC) continues to rise, with
no significant improval in targeted therapies. The transcription factor nuclear
factor-kB (NF-kB) promotes the production of angiogenic, anti-apoptotic,
and pro-metastatic factors that are involved in carcinogenesis. In addition,
NF-kB has been linked to inflammation-associated cancers. This study
addresses the applicability of NF-kB-targeted therapy in hepatitis C-
associated hepatocellular carcinoma.
Methods. Electrophoretic mobility gel shift assays (EMSA) were used to
evaluate NF-kB DNA binding in vitro . NF-kB activity in two immortalized
cell lines (Hep 3B and HepG2) was compared to normal hepatocytes
(CL48). The clinical relevance of NF-kB was evaluated using Western blot
analysis of NF-kB subunits/heterodimers (p65/p50) in 12 cases of hepato-
cellular carcinoma taken from explanted livers in patients with hepatitis C
undergoing transplantation. NF-kB activity in tumor versus adjacent liver
was also analyzed.
Results. NF-kB was constitutively active in both the immortalized cancer
cell lines and normal hepatocytes. The degree of p65 DNA binding activity
appeared to be highest in Hep 3B cells and lowest in normal hepatocytes
(CL48). NF-kB also appeared to be constitutively active in all HCC patient
samples analyzed, with greater activity noted in the tumor versus adjacent
liver tissue. In addition, the p50 subunit of the NF-kB complex was also
constitutively active in vitro and in vivo compared to expression of its
precursor protein p105. In hepatocellular carcinoma, the precursor inhibitory
protein p105 was negligible compared to the active subunit p50 in all
samples.
Conclusion. Constitutively active NF-kB is apparent in both immortalized
in vitro cell lines and human hepatocellular carcinoma samples. Attempts to
inhibit NF-kB in liver cancer makes clinical sense and warrants further study.
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INCREASED ENDOTOXIN TRANSLOCATION IN OBESITY: A
CAUSE OF STEATOTIC LIVER DAMAGE
Justin D Ellett, Zachary P Evans, Matthew Crumpler, Kenneth D Chavin,
MD, PhD
Medical University of South Carolina, Charleston, SC
In human transplantation, endotoxin (LPS) is thought to be a major
contributing factor to the pathogenesis of ischemia/reperfusion (I/R) injury.
Upon portal occlusion, bowel congestion causes bacterial and endotoxin
translocation and the LPS is introduced into the portal circulation. Upon
LPS exposure and recognition by toll-like receptor 4 (TLR4), there is a large
release of proinflammatory cytokines, including TNF and IL-1b, which cause
inflammation, necrosis, and apoptosis of the hepatocytes. It is well known
that steatotic livers are highly sensitive to the effects of endotoxin as
compared to their lean counterparts post-I/R. Blockade of endotoxin
signaling with a specific monoclonal antibody significantly ameliorates injury
and improves animal survival from 14.4% to 83.3%. Therefore, we propose
the novel hypothesis that differential injury is due to a higher exposure to
endotoxin rather than an increased sensitivity to endotoxin. To test these
hypotheses, we subjected male 10-week-old C57BL/6 (lean) and ob/ob mice
to 15 minutes of total hepatic ischemia and collected portal blood at baseline
(pre-ischemia) and immediately post-reperfusion and measured endotoxin
levels (n5/group). We observed significantly increased portal levels of
endotoxin at baseline in ob/ob animals (0.23190.013 EU/mL vs. 0.2089
0.005 EU/mL in lean, pB0.05). In addition, we saw significantly increased
levels immediately post-reperfusion (0.29790.03 EU/mL in lean vs. 0.3839
0.008 EU/mL, pB0.001). Our prior experience with this model has shown
drastically increased ALT levels and necrosis in the ob/ob animals, correlating
well with the endotoxin bolus. In addition, we have seen no differences in
levels of TLR4 mRNA (0.28890.049 relative density units in lean vs.
0.23390.11 in ob/ob) in these animals. Similarly, CD14 protein levels are
not significantly elevated between lean and ob/ob animals. Due to the
apparent constancy in the receptor complex proteins, we propose the
increased endotoxin translocation in obese animals as a cause of increased
damage in steatotic livers after I/R and transplantation. We hypothesize that
this difference in translocation is caused by an increased permeability in the
intestines of the obese animals. This has extremely important implications in
the clinic. Should human livers behave similarly, this is a possible cause for
liver damage after any abdominal surgery, especially transplantation, as any
manipulation of the bowel or bowel ischemia causes this translocation.
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REMOTE ISCHEMIC PRECONDITIONING MODULATES HEPA-
TIC MICROCIRCULATION THROUGH THE HEMEOXYGENASE
PATHWAY IN A RAT MODEL OF WARM ISCHEMIA REPERFU-
SION INJURY OF THE LIVER
Niteen Tapuria, MS, Sameer Junnarkar, MS, Barry Fuller, PhD, Alexander
M Seifalian, PhD, Brian R Davidson, MD, Neelanjana Dutta, MD
Royal Free Hospital, London, United Kingdom; Kings college Hospital,
London, United Kingdom
Introduction. Liver resection and transplantation surgery involve a period of
ischemia reperfusion injury (IRI) which initiates an inflammatory cascade
resulting in hepatic and remote organ injury. IRI leads to nonfunction or
dysfunction of liver grafts in clinical transplant settings. Davidson’s group
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have shown that remote ischemic preconditioning (RIPC) protects liver
function. However the mechanism of protection has not been studied. This is
the first study to investigate the effect of RIPC upon hepatic microcirculation
by intravital microscopy and to study the role of hemeoxygenase pathways
(HO-1) as a candidate mechanism. Aim-To study the role of HO-1 pathways
in RIPC as the candidate mechanism in the modulation of hepatic
microcirculation in a rat model of hepatic IRI.
Material and methods. The effect of RIPC was studied in a rat model of
ischemia reperfusion injury with 45 minutes of partial liver ischemia (70%)
followed by 3 hours of reperfusion. Five groups of animals namely Sham, IRI,
RIPCIRI, RIPCSham, pyrrolidine dithiocarbamate (PDTC)IRI, Zinc
protoporphyrin (ZNPP)RIPCIRI were studied with six animals in each
group. PDTC is a HO-1 inducer while ZNPP is a HO-1 inhibitor. Hepatic
microcirculation was assessed by studying velocity of blood flow, sinusoidal
perfusion, sinusoidal flow, sinusoidal diameter and neutrophil adhesion.
Apoptosis was assessed by propidium iodide staining under intravital
microscopy. Liver functions were assessed in all groups. Liver histology and
immunohistochemistry for HO-1 expression were also done.
Results. The velocity of blood flow was significantly better in the RIPC
group at the end of three hours of reperfusion compared to IRI group (PB
0.05) but no difference was found between RIPC and Sham. Sinusoidal
perfusion and flow was better in the RIPC group. The number of apoptotic
cells in the RIPC group was significantly less as compared to IRI only (PB
0.05). The PDTC group (HO-1 inducer) showed significantly improved liver
functions compared to IRI and ZNPP groups. ZNPP (HO-1 inhibitor)signi-
ficantly blocked the effects of RIPC on the microcirculation at about two
hours of reperfusion and significantly increased apoptosis strongly suggesting
the role of HO-1 pathways in RIPC mediated amelioration of hepatic IR
injury.
Conclusion. This is the first study by intravital mivroscopy to demonstrate
that RIPC modulates hepatic microcirculation in order to ameliorate IRI and
hemeoxygenase pathways maybe one of the key pathways in the mechanism
of RIPC.
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INCREASED ACTIVATION OF PROAPOPTOTIC GENES IN OLD
VS YOUNG LIVERS FOLLOWING ISCHEMIA AND REPERFU-
SION: A NEW MECHANISM OF INJURY
Markus Selzner, MD, Nazia Selzner, MD, PhD, Limin Chen, PhD, Ivan
Borozan, PhD, Jing Sun, PhD, Ian Mcgilvray, MD, PhD
Toronto General Hospital, Toronto, ON, Canada
Ischemia/reperfusion injury (IRI) is exacerbated in old livers when compared
to young livers. We investigated whether the higher susceptibility of old livers
to ischemic injury is associated with differences at the level of the cellular
molecular response.
Methods. C57BL/6 mice at the age of 6 weeks (young) and 12 months (old)
underwent 60 minutes of hepatic ischemia and 0 min, 1hr and 3hr of
reperfusion. Hepatocyte injury was investigated with ALT levels and degree
of necrosis. Caspase 3 activation was determined after 3hr of reperfusion.
Using a 15K murine cDNA array, we compared gene expression levels after
60 minutes of ischemia and 1hr of reperfusion to sham-operated livers in both
young and old mice (n5 per group). Genes with at least 1.5-fold up- or
down regulation with a p -value of 0.05 were considered of interest. Real-time
PCR was used for verification of array results.
Results. Although comparable indices of liver injury were seen after 60
minutes ischemia and 1 hr of reperfusion, older livers manifested progres-
sively worse injury at later time points. Comparing old to young livers, ALT
after 60 minutes of ischemia and 1hr of reperfusion was 1000 U/L vs 1100 U/
L (p0.1) but 6200 U/L vs 3900 U/L (p0.045) after 3 hours reperfusion.
After 3hr reperfusion older mice had significantly more liver necrosis than
young mice (35% vs 10% p0.03). Applying gene expression analysis to the
earlier time point, there was hepatic up-regulation of pro-apoptotic genes
such as caspase 6, Annexin A3 and TNFR following 60 minutes of ischemia
and 1hr of reperfusion in the younger mice. In contrast, anti-apoptotic genes
such as heat shock protein 25, 86, 105, Bcl2 -associated athanogene 3 and
early growth response 3 were significantly down regulated. Comparing young
and old mice following reperfusion injury, there was a more pronounced up-
regulation of proapototic genes, such as FADD and growth arrest specific 6,
in the older mice, while levels of antiapoptotic genes, such as Bcl-2 and
heatshock protein 70 & 105, were even more reduced in older livers. Caspase
3 activation, as a second endpoint of apoptosis, was significantly increased in
old mice compared to young animals following 3hr of reperfusion.
Conclusion. Ischemia/ reperfusion injury is associated with increased
expression of pro-apoptotic genes, reduced expression of anti-apoptotic
genes, and activation of intracellular mediators of apoptosis. This difference
is more prominent in older than in younger livers, which might explain in part
the decreased tolerance of old livers to reperfusion injury.
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UNCOUPLING PROTEIN-2 PROMOTES HEPATOCYTE DEATH
IN A MODEL OF IN VITRO STEATOSIS AND HEPOXIA/REOX-
YGENATION
Zachary P Evans, William N Toussaint, Justin D Ellett, Kenneth D Chavin,
MD, PhD
Medical University of South Carolina, Charleston, SC
Liver steatosis is associated with severe complications following liver
surgeries, which include periods of ischemia. We have shown that the up
regulation of mitochondrial uncoupling protein-2 (UCP2) correlates with
steatotic liver sensitivity to ischemia/reperfusion. UCP2 is an intermembrane
bound protein, which uncouples the mitochondria from oxidative phosphor-
ylation in the effort to decrease the cell’s exposure to reactive oxygen species
at the expense of efficient ATP production. We propose the hypothesis that
fat induced UCP2 expression sensitizes steatotic hepatocytes to injury
following hypoxia and reoxygenation (H/R). To test this we employed both
WT and UCP2 knockout 8-week old C57BL6 mice (n5/group). Hepato-
cytes were harvested by collagenase perfusion and purified via density
gradient, then plated in control or 6% intralipid (emulsified fatty acids)
supplemented media. After 24 hours, hepatocyte phenotypes were deter-
mined by GCMS and Oil Red O. For all measured fatty acids, significant
increases were observed in the intralipid treated groups over control, and
ORO staining showed significant intracellular fat accumulation. There were
no differences between the WT and UCP2 KO groups. Next, we subjected
the same groups to H/R in the effort to mimic ischemia/reperfusion. After 24-
hour culture, media was replaced with unsupplemented (serum free) media.
Experimental plates were placed in an anaerobic chamber for 4 hours then
removed and allowed 24-hours for reoxygenation. Following reoxygenation,
hepatocytes were harvested and assessed for viability by trypan blue
exclusion. Groups not receiving hypoxia, serving as baseline, displayed the
following percentages of cell death: WT control (9.09.09%), UCP2 KO
control (7.691.9%), WT intralipid (7.89.07%), UCP2 KO intralipid (9.19
2.3%). For the groups receiving H/R, percent cell death was: WT control
(20.093.3%), UCP2 KO control (19.691.8%), WT intralipid (31.69
3.2%), UCP2 KO intralipid (23.792.9%). Cell death for all groups after
hypoxia was significantly higher than baseline. After H/R, death was
significantly different between the WT groups (control vs intralipid) and
for the intralipid groups (WT vs KO) (pB0.05). Although compensatory at
baseline, UCP2 expression in the steatotic hepatocyte promotes death
following the stress of H/R. Down regulation of UCP2 through global
decrease of hepatic steatosis, or targeted down regulation prior to transplan-
tation may enhance hepatocyte function, decreasing the probability of
primary nonfunction. In addition, we have established a model of in vitro
steatosis and H/R in hepatocytes. Both may be useful for other areas of
research.
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ROLE OF PRIMARY RESECTION FOR HCC UNDER THE ERA
OF LIVER TRANSPLANTATION
Toshiya Kamiyama, Kazuaki Nakanishi, MD, PhD, Hirofumi Kamachi, MD,
PhD, Hideki Yokoo, MD, PhD, Munenori Tahara, MD, PhD, Hirofumi Toi,
MD, PhD, Kenichiro Yamashita, MD, PhD, Masahiko Taniguchi, MD, PhD,
Tomomi Suzuki, MD, PhD, Tsuyoshi Shimamura, MD, PhD, Hiroyuki
Furukawa, MD, PhD, Michiaki Matsushita, MD, PhD, Satoru Todo, MD,
PhD
Hokkaido University, Sapporo, Japan
Objective. To evaluate the advantage and disadvantage of hepatic resection
(Hx) for hepatocelluar carcinoma (HCC) when patients with HCC were
classified according to Milan criteria under the era of liver transplantation.
Methods. Between 1990 and 2006, consecutive 501 HCC patients under-
went curative primary Hx, in whom 321 (Group1) met Milan criteria and
180 (Group2) did not. The median follow-up period was 53.6 months
(range, 5184).
Results. In 114 death cases of Group 1, 81 (71.1%) died of tumor
recurrence, 9 (7.9%) of liver failure, 2 (1.8%) of operative complications,
17 (14.9%) of unrelated medical conditions. In 96 death cases of Group 2, 77
(80.2%) died of tumor recurrence, 8 (8.3%) of liver failure, 3 (3.1%) of
operative complications, 7 (7.3%) of unrelated medical conditions, 1 (1.0%)
of unknown. Patients survival (PS) and disease free survival (DFS) of
Group1 were 73.6% and 40.6% at 5years, and 55.8% and 25.0% at 10years.
Of the 145 Group1 patients who recurred, only 60(18.7%) exceeded Milan
criteria. One hundred forty-five (45.2%) had no recurrence to date. PS and
DFS of Group2 were 52.2% and 23.2% at 5years, and 33.7% and 17.4% at
10years. While 116 patients developed recurrence, 39 (21.7%) were within
Milan criteria. Fifty-five (30.6%) had no recurrence to date. ICGR15,
Anatomical resection, and tumor number were significant preoperative
predictors of survival and recurrence for HCC within Milan criteria by
multivariate analysis. Preoperative prognostic scoring system was established
by three risk factors as ICGR1515%, Non anatomical resection, and
multiple tumor. Patients who corresponded to no factor were assigned a score
0, patients with any one factor were a score 1, patients with any two factors
were a score 2, and patients with all three factors were a score 3. While the
selected patients within Milan criteria who had a score 1 or a score 2 were
survived 78.5% and 64.9% at 10 years after hepatectomy, the patients who
had a score had no 5 years-survivors.
Conclusion. After Hx, 18.7% within Milan criteria at the initial hepatect-
omy lost the chance of liver transplantation (LTx). Hx made 30.6% without
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Milan criteria which was not transplantable at the first time alive without
recurrence and 21.7% without MIlan criteria recurrent within Milan criteria
and transplantable, who may be rescued by receiving salvage LTx. Thus, Hx
remains as an important strategy for the treatment of HCC even under an era
of LTx.
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IMPROVED SURVIVAL IN HEPATOCELLULAR CARCINOMA:
RESULTS OF A SINGLE CENTER ANALYSIS OF 501 PATIENTS
David Kooby, MD, Vasili Egnatashvili, MD, Michael Graiser, PhD, Keith
Delman, MD, William Wood, MD, Charles Staley, MD
Emory University, Atlanta, GA
Purpose. Incidence of hepatocellular carcinoma (HCC) is increasing. An
analysis of patients treated at a single center was performed to identify
outcome changes, as management has evolved.
Methods. Three databases (structured query language, tumor registry, and
pathology) were queried for HCC patients treated at our institution from
19902004. Records were reviewed to confirm diagnosis, and to obtain
treatment and outcome data. As criteria for orthotopic liver transplantation
(OLT) were established in 1996, patients treated from 19901996 (group A)
were compared to those treated from 1997 2004 (group B) for outcome
differences. Survival was calculated from date of first visit, to permit
comparison with patients receiving supportive care.
Results. Between 19902004, 501 patients were identified, 172 (34%) in
group A and 329 (66%) in group B. Median age was 60 (range, 1989), 361
(72%) were men and 392 (78%) had cirrhosis. 73 (14%) underwent OLT, 99
(20%) were resected, 135 (27%) had ablative/embolic therapy (A/E), and
194 (39%) had chemotherapy or supportive care (CT/SC). Median survival
for all patients was 10 months, and by therapy: OLT, 82 months; resection,
28 months; A/E, 12 months; and CT/SC, 6 months (pB0.001, Fig. 1). On
multivariate analysis, factors associated with reduced survival were cirrhosis,
vascular invasion, non-surgical therapy, and treatment prior to 1997. By time
interval, survival was better in group B as compared with group A (11 vs. 7
mos, p0.03, Fig. 2). When all OLT patients were excluded from the
analysis, this survival benefit was no longer present (8 vs. 6 mos, p0.17).
This effect was not observed by subtracting any other method of treatment
from the analysis.
Conclusions. HCC referrals to our hospital have increased over time in
keeping with rising rates. Surgery is associated with better outcome. In this
series, treatment post-1996 is associated with improved survival, likely due to
improved criteria for OLT.
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TUMOR SIZE AND MELD SCORE PREDICT MICROVASCULAR
INVASION IN CIRRHOTIC PATIENTS WITH HEPATOCELLULAR
CARCINOMA
Swee H Teh, MD, B C Sheppard, MD, J Schwartz, MD, K G Billingsley,
MD, S Cha, PhD, P S Kamath, MD, S L Orloff, MD, D M Nagorney, MD
Depart of Surgery, Oregon Health Sciences University, Portland, OR; Mayo
Clinic, Rochester, MN
Introduction. Microvascular invasion is a poor prognostic indicator for
hepatocellular carcinoma (HCC) in patients with and without cirrhosis,
regardless of treatment modality. The status of microvascular invasion is
usually unknown prior to surgical intervention. The aim of this study is to
determine whether pre-intervention Model of End Stage Liver Disease
(MELD) score alone and in combination with other tumor characteristics,
can serve as a surrogate marker for tumor microvascular invasion in patients
with cirrhosis undergoing hepatic resection.
Methods. All consecutive patients with cirrhosis that had undergone hepatic
resection for HCC between Jan 1993 to Jan 2005 from Oregon Health &
Science University, Portland VAMC and Mayo Clinic, Rochester were
retrospectively reviewed.
Results. One hundred fourteen cirrhotic patients (27 F: 87 M) with a mean
age of 63 years underwent hepatic resection for HCC. The etiology of
cirrhosis was viral hepatitis B and/or C in 61 (53.5%), alcohol in 21 (18.3%),
cryptogenic in 17 (15%) and other in 15 (13.2%) patients. The mean MELD
score was 9 (range 6 to 17) and tumor size was 5 cm (range 1 to 16 cm).
Microvascular invasion was present in 36 patients (32%) based on resection
specimen histology. Clinical variables that predicted microvascular invasion
were tumor size (0.005), MELD score (0.05), and high AFP (0.04), but not
tumor multifocality. Tumor size of 53 cm, 3.1 to 5 cm and 5.1 to 7 cm
and7.1 cm had the respective incidence of microvascular invasion of 9%,
31%, 47% and 65%. MELD score 59 and ]10 had the respective incidence
of microvascular invasion of 26% and 40%. The incidence of microvascular
invasion when these two predictors were combined is shown in the table 1.
The 1, 3 and 5 year overall survival for patients with and without vascular
invasion was (60% vs. 72%), (30% vs. 51%) and (18% vs. 40%), respectively
(p0.018).
Conclusions. Microvascular invasion reflects the biologic aggressiveness of
HCC in patients with cirrhosis. Objective clinical criteria, based on tumor
size and MELD score, can be used as a guideline to stratify treatment
modalities and to predict outcomes. Patients with cirrhosis who have
tumors5 cm and MELD score ]10 may not benefit from aggressive
hepatic resection and alternate therapy should therefore be considered.
Group A
(n47)
Group B
(n28)
Group C
(n22)
Group D
(n17) p-value
Tumor Size (cm) B5 B5 5 5
MELD Score 59 ]10 59 ]10
Microvascular
Invasion (%)
14% 25% 50% 64% 0.0003
Median Survival
(years)
4.5 2.2 2.4 0.2 B0.0001
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OUTCOMES ANALYSIS FOR 280 PATIENTS WITH CHOLANGIO-
CARCINOMA TREATED WITH LIVER TRANSPLANTATION
OVER AN 18-YEAR PERIOD
Natasha S Becker, MD, Joel Rodriguez, MD, Neal R Barshes, MD, MPH,
Christine O’mahony, MD, John A Goss, MD, Thomas A Aloia, MD
Baylor College of Medicine, Houston, TX
Introduction. Cholangiocarcinoma is an aggressive malignancy associated
with a 5-year survival of less than 15%. Based largely on single institution
data, liver transplantation is now being considered as a primary treatment
option. The purpose of this study was to evaluate a large, multi-institution
experience with liver transplantation for patients with this malignancy.
Methods. The United Network for Organ Sharing (UNOS) database for the
years 19872005 was used to identify 280 patients with cholangiocarcinoma
who underwent a total of 302 liver transplants. Study variables, including age,
race, gender, and date of transplant, were recorded. Survivals were calculated
using Kaplan-Meier curves and compared with log-rank tests.
Results. The study cohort included 63.6% male patients and 86.8%
Caucasian patients with a median age of 48 years (range: 1873 years). 59
of the 280 study patients (21%) carried a primary diagnosis of primary
sclerosing cholangitis. The 30-day post-operative mortality rate was 4.0% (12
patients). At a median follow-up interval of 452 days (range: 06166 days),
the 1 and 5-year patient survivals were 74.1% and 38.4%, respectively, with
49 actual 5-year survivors and 21 actual 10-year survivors. Twenty patients
required re-transplantation, including 2 patients who received a third graft,
yielding 1 and 5-year graft survivals of 68.9% and 35.5%, respectively.
Survival analysis determined that patients transplanted after 1998 (n142)
experienced improved survivals (5-yr OS: 44.6%) compared to patients
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transplanted in the previous era (n138, 5-yr OS: 32.9%)(p0.005). In
addition, recurrent cholangiocarcinoma was associated with a significantly
lower 5-year survival rate (52.4% vs. 17.2%. pB0.001) (Figure 1).
Discussion. Analysis of the UNOS dataset indicates that selected patients
undergoing liver transplantation experience a survival benefit (5-yr OS:
38.4%). Outcomes have improved over time, likely due to advances in
perioperative care and adjuvant therapies. Freedom from recurrence was
found to be a significant factor related to long-term survival, providing
further support for the inclusion of liver transplantation in cholangiocarci-
noma multimodality therapy protocols.
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UTILIZATION OF HTLV POSITIVE DONOR LIVERS FOR
TRANSPLANTATION
James V Guarrera, MD, Barbara Alkofer, MD, Jean C. Emond, MD, John F.
Renz, MD, PhD
Columbia University, New York, NY
Introduction. A positive serologic test for Human T-Cell Lymphotrophic
Virus (HTLV) has been considered a contraindication to organ donation.
Potential complications of HTLV-I viral transmission including tropical
spastic paraparesis (TSP) and adult T cell leukemia. HTLV-II transmission
is associated with more benign symptoms.We hypothesize that there is a high
false positive rate of serologic testing and that underutilization of organs from
HTLV seropositive donors may be inappropriate.
Patients and Methods. This prospective IRBapproved study (IRB-
AAAC1797) was conducted from 11/03 through 08/06 (median follow-up:
8.3mos). 15 deceased donor liver allografts from HTLV positive donors
documented by ELISA were evaluated and 12 OLT performed. All ELISA
positive results were confirmed by Western Blot or Immunoblot analysis
(typically available 710d post-OLT). Predictors of HTLV infection in
donors were assessed including gender, ethnicity, age, cause of death,
serologies, CDC high-risk behavior, country of birth, transfusion and travel
history. Complete recipient demographic and physiologic data were collected
including pre-transplant HTLV serology. Serologic surveillance for viral
infection post-OLT was performed at 1, 3, 6 and12 months.
Results. All recipients were HTLV negative pre-OLT. Seven of 15 HTLV
ELISA positive donors had negative confirmatory testing and 4 donors were
indeterminant by repeat testing. Only 4/15 (26.6%) HTLV ELISA positive
donors were confirmed HTLV positive by Western blot or Immunoblot.
Three were HTLV-II and 1 was HTLV-I positive. Of these, 3 (all HTLV-II
positive) allografts were utilized. One recipient died 8 d post-OLT without
seroconversion.The remaining two patients are both clinically asymptomatic.
One has seroconverted at 1 month and the other remains seronegative 6
months post-OLT.
Conclusions. Utilization of HTLV seropositive donors can increase the
potential organ pool. Confirmatory testing shows that the majority of these
donors are indeterminant or false positive. Even when the donor was a true
positive seroconversion has been inconsistent. Medical need, detailed elective
discussion, informed consent and intensive risk assesment are essential in
determining proper allocation of these grafts.
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LIVER TRANSPLANTATION IN LATIN AMERICA
Eduardo De Santiban˜es, MD, PhD, Martı´n Palavecino, MD, Diego
Ferna´ndez, MD, Victoria Ardiles, MD, Juan Mattera, MD, Juan Pekolj,
MD, PhD, Miguel Ciardullo, MD
Hospital Italiano, Buenos Aires, Argentina
Background. Since liver transplantation became the gold standard treat-
ment of end-stage liver disease, Latin America adopted this procedure. After
the first successful surgery in Brazil (1987), the number of transplants
increased with similar morbidity-mortality rates compared with those
published in international literature.
Objective. To show the Latin American experience in liver transplantation.
Methods. Data was obtained retrospectively from the Transplantation
Society of Latin America and the Caribbean’s database, the National
Registries of each country, Institutional Databases of the principal Trans-
plantation Centers in each country and also contacting Chairmen of the
principal groups. The analysis was performed in the 2000 2005 period
(when possible).
Results. In 12 countries liver transplantation is performed. Brazil, Argen-
tina, Chile, Mexico and Colombia carried out the largest number of
procedures. Despite Brazil has more than 5200 transplants, Argentina
performs more surgeries per habitants. Mean cost of the procedure is
25000 U$ (r 21000 30000). Principal indication in HCV cirrhosis in adult
recipients and fulminant hepatitis (HAV) in pediatric recipients. Organ
shortage determined the use of living related donors. Mean survival rate is
85% at 1 year (r 7791.7).
Conclusions. Despite organ shortage, costs, difficulties of most patients to
arrive to specialized centers, results in liver transplantation in Latin America
are encouraging.
Liver Translantation in Latin America
Country Transplants
Transplantation
Units
Population
(millions)
Transplants/
Million
Habitants
Brazil 5258 62 186 4.5
Argentina 1969 14 37 5.4
Mexico 546 20 97 07
Chile 471 7 15 4.1
Cuba 59 2 10 1.6
Costa
Rica
22 1 4 2.5
Peru 20 1 24 0.2
Venezuela 19 1 23 0.1
Uruguay 13 1 4 1.0
Bolivia 6 1 8 0.3
Ecuador 1 1 12 0
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HOW TO BALANCE THE RISK FOR A LIVING LIVER DONOR 
OR IS DEATH ALWAYS PREVENTABLE?
Burckhardt Ringe, MD, PhD, Humberto Soriano, MD, Ralph Petrucci, MD,
William Meyers, MD
Drexel University College of Medicine, Philadelphia, PA
Expanding the organ pool has become a major goal in transplantation, and
living donation is an essential part of this evolution. Concerns have always
been the safety and risk for the donor, and one of the important questions is
 where are the limits? In a consecutive series of 40 living liver donors we have
analyzed preoperative risk factors, and compared to postoperative complica-
tions, graded by the classification of Dindo (2004). Donor age was 1969
years (median 41 years). Types of surgery were 30 right lobe, 1 left lobe, and
7 left lateral lobe resections; the donor operation was aborted in two cases. In
6/40 donors (15%) no preoperative risk could be identified. The majority had
one (9), two (13), and three or more risk factors (12), including overweight/
obesity in 25 (median BMI of all 40 donors was 26 kg/m2), smoking in 15,
hypercholesterolemia in 9, steatosis hepatis (530%) in 9, history of alcohol
and/or illicite drugs in 8, heterozygous factor V Leiden mutation in 4, s/p
cholecystectomy in 4, and hypothyreosis in 4 cases, respectively. Post-
operative surgical complications occurred in 24/40 (60%) patients. 15 were
grade I (wound infections, pleural effusion, ileus), 3 grade II (venous
thrombosis, duodenal ulcer), 5 grade III a (biliary leakage/stricture,
hematoma), and 5 grade III b (incisional hernia repair). One donor died
57 days after surgery from illicite drug overdose. Preoperative risks correlated
to some extent with postoperative complications: except two, all other 10
patients with wound infection and/or incisional hernia were overweight or
obese. 1/4 donors with factor V Leiden mutation developed deep vein
thrombosis, and one donor died from cocaine use known before surgery. All
III a complications occurred in right lobe donors. On the other hand, only 2/6
patients without risk factors were free of complications, as compared to 14/34
patients with different risk factors before surgery who had no postoperative
complication. Hepatic steatosis did not contribute to an increase of liver
dysfunction after surgery. Ideally, living donors should be completely healthy
without any significant preoperative risk. In our experience, 85% of liver
donors that were accepted and went into surgery had at least one or more risk
factors which may have contributed to postoperative complications to some
degree. Except one, the outcome of our donors has been very good, obviously
justifying our decision to move along. However, more caution seems to be
advocated under certain psychosocial circumstances.
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LAPAROSCOPICALLY-ASSISTED RIGHT LOBE DONOR HEPA-
TECTOMY: RESULTS AND COMPARISON WITH OPEN LOBE
DONOR HEPATECTOMY
Alan J Koffron, MD, Robert Kung, None, Greg Auffenberg, Michael
Abecassis, MD
Northwestern University Medical School, Chicago, IL
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Objectives. Recent technical innovations for laparoscopic hepatectomy have
suggested its potential application to donation of the liver in living donor liver
transplantation (LDLT). However, the technical nuances, efficacy and safety
of such a laparoscopic procedure has yet to be assessed. We describe our
technique and outcomes of laparoscopically assisted donor hepatectomy
(LADH) for adult to adult LDLT.
Methods. Right lobe donor hepatectomy was performed on 20 donors
through our laparoscopically assisted method. Surgical manipulation via 2
ports and a 57 cm subxiphoid incision was used, and parenchymal
transection achieved using saline-enhanced electrosurgery (TissueLink).
Case-controlled contemporaneous living liver donors and recipients, who
donated through the traditional open procedure, were selected as controls.
Results. Laparoscopic assisted right lobe donor hepatectomy was completed
in 20 donors with a mean operative time of 179.9924.0 minutes and a mean
blood loss of 2709130.4 mL; Mean operative time and blood loss for open
liver donors were 307.8964.8 minutes and 483.39299.4 mL. Open
conversion was not required, we experienced no donor biliary complications
in any laparoscopic patients, and laparoscopically-harvested grafts had
comparable function. The length of post-operative hospital stays was 2.29
0.8 days and 4.191.1 days in the laparoscopic and open donors respectively.
Currently, all donors and recipients are healthy and have returned to normal
activities.
Conclusion. We have demonstrated a novel, less invasive method for live-
donor hepatectomy. The procedure resulted in favorable donor outcomes and
successful transplants in the recipients, suggesting its feasibility as an
alternative to the traditional open donor hepatectomy.
TABLE. Comparison between lap-assisted and open procedures: Donors’
Perioperative characteristics
Variable
Lap-Assisted
(n20)
Open
(n24) P value
Pre- and intraoperative variables
Male/Female 8/12 7/17
Age (y, mean9SD) 31.996.5 38.4911.4 NS
BMI (mean9SD) 26.193.5 25.894.0 NS
Operative time
(min, mean9SD)
179924.0 307.8964.8 NS
Blood loss (mL, mean9SD) 2709130.4 483.39299.4 NS
Graft Volume (mL, mean9SD) 948.19156.4 1003.39243.1 NS
Perioperative variables (peaks)
AST (UL1, mean9SD) 295.1966.3 288.849116.3 NS
ALT (UL1, mean9SD) 290.6977.9 236.849125.8 NS
Total Bilirubin
(mg/dL, mean9SD)
2.691.1 3.291.9 NS
AP (mean9SD) 103.7937.3 168.39148.9 NS
Length of hospital stay
(d, mean9SD)
2.290.8 4.191.1 NS
Biliary Leaks 0 2 NS
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VENOUS RECONSTRUCTION IN LIVING-DONOR HEPATECT-
OMY
Atsushi Shimizu, MD, Yoshikazu Yasuda, MD, Masanobu Hyodo, MD,
Taketo Fujiwara, MD, Yasunaru Sakuma, MD, Keisuke Yamashita, MD,
Nobuyuki Hojo, MD, Hideo Chiba, MD, Makoto Ota, MD, Yoshito Nihei,
MD, Hideo Nagai, MD
Jichi Medical School, Tochigi, Japan
With wide spread experiences in living-donor liver transplantation, issues of
venous outflow have been well recognized and are often discussed with regard
to graft function especially using the right lobe. Preservation of the main
middle hepatic vein (MHV) and its tributaries is crucial to avoid outflow
blockage in the anterior sector of the right lobe. To date remnant liver
function in the donor, however, has not been fully addressed assuming that
the donor has adequate liver function and therefore can tolerate the
procedure. In order to maintain remnant liver function and ensure donor
safety, we have reconstructed hepatic veins or inferior vena cava (IVC) during
donor hepatectomy when congestion of the remnant liver is of concern. The
aim of this presentation is to describe our techniques for venous reconstruc-
tion in the donor. From May 2001 to August 2006, 94 adult-to-pediatric
living-donor liver transplantations were successfully performed in our
institution. Donor surgery consisted of 16 extended left lobectomies, 24
left lobectomies and 54 left lateral segmentectomies. Of these, venous
reconstructions were performed in 22 donor hepatectomies including (1)
direct anastmoses of MHV tributaries to IVC in 7 cases and (2) interposition
grafts between MHV branches to IVC in 12 cases, and (3) venous patches
over IVC or MHV in 8 cases. Reconstruction of MHV or its tributaries was
indicated when intraoperative doppler ultrasonography disclosed regurgitated
portal flow in the right anterior sector after clamping. Umbilical vein, ovarian
vein or inferior mesenteric vein were used as autologous vein grafts. With
reconstruction, antegrade portal flow as well as adequate hepatic venous flow
were confirmed in all reconstructed cases. In conclusion, by reconstructing
hepatic veins or IVC, we have successfully maintained the remnant liver
function of the living donor without compromising safety.
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THE EFFECTS OF PHYSICAL QUALITY OF LIFE, TIME, AND
GENDER ON CHANGE IN SYMPTOMS OF ANXIETY AND DE-
PRESSION AFTER LIVER TRANSPLANTATION
Robert T. Russell, MD, Irene D. Feurer, PhD, Panarut Wisawatapnimit,
C. Wright Pinson, MD, MBA
Vanderbilt University Medical Center, Nashville, TN
Introduction. Previous research demonstrated that functional performance
and health-related quality of life (HRQOL) improve following liver trans-
plantation, but the extent to which improvement in symptoms of anxiety and
depression is related to post-transplant physical HRQOL has not been
characterized. The aim of this study was to test the effects of physical
HRQOL, time post transplant, and gender on pre- to post-transplant change
in symptoms of anxiety and depression.
Methods. Longitudinal HRQOL data were prospectively collected at specific
times before and after liver transplantation using the SF-36† Health Survey
(SF-36), Center for Epidemiologic Studies Depression Scale (CES-D), and
Beck Anxiety Inventory (BAI). Within-subject change scores were computed
to represent the longest follow-up for each patient. Multiple regression was
used to test the effects of time post transplant, gender, and post-transplant
SF-36 physical component summary (PCS) scores on change in BAI and
CES-D scores. Baseline scores on outcome measures were modeled to
account for and quantify their expected effects. A complementary model of
change in PCS was also developed. Summary data are reported as mean9
SD.
Results. 107 patients (74% male; 51% HCV; age5498 years) reported
474 survey points over 43 months. Time post-transplant ranged 1 to 39
months (mean998). Patients with the poorest pre-transplant HRQOL
showed the greatest improvement on every model. Change in CES-D and
PCS scores continued with time post transplant. Reduced post-transplant
physical quality of life was associated with less improvement in symptoms of
anxiety (model 1) and depression (model 2). This relationship is also
reflected in model 3, which quantifies the negative effect of post-transplant
anxiety on change in PCS. Gender did not affect these outcomes (table).
Conclusions. Despite improvement on all HRQOL measures, there was less
improvement in symptoms of anxiety and depression in those patients with
reduced physical HRQOL after liver transplantation. Awareness of the
significant relationships between physical and mental quality of life indicators
in both men and women suggests the importance of early recognition and
intervention strategies to promote continued improvement in mental and
physical quality of life following liver transplantation.
Multivariate models of pre- to post-transplant change (D) in mental and
physical HRQOL
Effect/Parameter
(Model 1)
D BAI
(Model 2)
D CES-D
(Model 3)
D PCS
Model outcome a 7911 ** 9912 ** 8911 **
Baseline score 0.85 ** 0.63 ** 0.44 **
Time post txp 0.02 0.22 * 0.26 *
Gender 0.06 0.09 0.05
Post-txp PCS 0.24 ** 0.31 **
Post-txp CES-D 0.04
Post-txp BAI 0.38 *
Model R2 0.71 ** 0.53 ** 0.40 **
Unless noted entries are standardized regression coefficients. aMean
change9SD. R2squared multiple correlation coefficient. * pB0.05, ** p5
0.001.
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IMPACT OF LOCAL THERAPY FOR HEPATOCELLULAR CAR-
CINOMA ON SURVIVAL OUTCOMES IN THE U.S. POPULATION
Roderich E Schwarz, MD, PhD, David D. Smith, PhD
UMDNJ-RWJMS, New Brunswick, NJ; City of Hope Cancer Center,
Duarte, CA
Background. Hepatocellular cancer (HCC) frequently presents with clinical
limitations to resection. We investigated survival outcomes after various local
HCC therapies in U.S. patients.
Methods. A surgical HCC data set was created from the SEER 19702003
database. Prognostic factors with survival impact, and relationships between
local therapy modality and overall survival (OS) were analyzed.
76 Abstracts
Results. Out of a cohort of 46,065 patients with primary hepatobiliary
malignancy, 5,317 individuals with HCC were selected based on complete
data. The median age was 62 (range: 097), and 68% of patients were male.
The median tumor size was 5.2 cm (0.230). There were single lesions
(52%), multiple lesions (28%), and extrahepatic disease (20%). A multi-
variate OS analysis yielded these prognostic variables: tumor size, extra-
hepatic disease extent, grade, gender, age, and local treatment modality (all at
pB0.0001), stage (regional or distant disease, p0.0018), race (p0.0033),
total LN count (p0.0064), and year of diagnosis (p0.0087). Compared
to segmental/wedge resections, other modalities had the following risk ratios
(95% CI): transplantation (LTX) 0.44 (0.38 0.51), anatomic resection 0.89
(0.810.97), ablation 1.13 (1.021.24), no or incomplete local therapy 2.5
(2.342.7). At a median follow up of 12 months (23 for survivors, range: 0
190), the 5-year OS (in %) was 67 for LTX, 38 for resections, 19 for ablation,
and 3 for no local therapy (pB0.0001). Among ablation techniques, 5-year
OS was 26% (RFA), 22% (cryo), 20% (PEI), 20% (fulguration, laser), or 0%
(PDT). 30-day mortality (%) was 6.7 (resection), 3.4 (LTX), 3.0 (ablation),
or 21 (no local therapy, pB0.0001). Cirrhosis and HCC differed as causes of
death between ablation (6.6 and 70.4%), resection (2.9 and 68.7%), and
LTX (7.0 and 37.2%, pB0.0001).
Conclusions. Aside from well-established prognostic parameters, the local
treatment mode strongly influences HCC survival. Superior outcomes after
transplantation and resection are likely biased through confounding patient
selection variables, but both treatment options should be considered primary
therapy choices in the therapeutic evaluation of HCC patients.
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A COMPARATIVE ANALYSIS OF SELECTIVE INTERNAL RA-
DIATION THERAPY (SIRT) AND TRANSCATHETER ARTERIAL
CHEMOEMBOLIZATION (TACE) IN TREATMENT OF UNRE-
SECTABLE HEPATOCELLULAR CARCINOMA
Vasili Egnatashvili, MD, Abbas Chamsuddin, MD, Maksym Yezhelyev, MD,
Keith Delman, MD, Charles Staley, MD, David Kooby, MD
Emory University, Atlanta, GA
Purpose. Regional therapy of unresectable hepatocellular carcinoma (HCC)
with transcatheter arterial chemoembolization (TACE) versus Selective
Internal Radiation Therapy (SIRT) using SIR-Spheres (NSW, Australia)
was evaluated for efficacy and complications.
Methods. A prospective database of SIRT patients (2003present) was
analyzed in comparison to a retrospective cohort treated with TACE (1990
present, mixed agents). All patients had liver-only HCC deemed unresectable
by surgical consultation and received no other therapy. Chi square and
Student’s T tests were used to analyze categorical and continuous variables
respectively. Univariate (UVA; log rank) and multivariate (MVA; Cox
regression) were performed for survival.
Result. 73 patients were treated, of which, 47 (64.4%) received TACE and
26 (35.6%) had SIRT. Average ages were 59.8911.4 vs. 58.6910.5 (p
NS), AFP scores were 72291005 vs. 6809937 (pNS), and MELD scores
were 10.594.2 vs. 9.893.1 (pNS) for TACE and SIRT patients
respectively. VI was present in 12 (26%) TACE and 11 (42%) of SIRT
patients (pNS). At a follow up of 11.5913.9 months (survivors), mean
survival was 7.9911.3 (TACE) and 6.997.7 (SIRT, pNS). On MVA,
including age60, VI positive, MELD10, AFP400 and TACE vs. SIRT,
only VI and AFP were independently associated with poor survival.
Complications of therapy were noted in19 (40%) of TACE and 10 (38%)
of SIRT patients (pNS).
Conclusion. In this study population, TACE and SIRT provided similar
survival and complication profiles. Both methods of regional therapy for
unresectable HCC are appropriate, and the comparison merits prospective
evaluation.
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HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA: A
MULTI-INSTITUTIONAL STUDY OF TREATMENT AND LONG
TERM OUTCOME
Eugene A. Choi, MD, Jan Lerut, MD, Ricardo J. Gonzalez, MD, Steven A.
Curley, MD, Jean N. Vauthey, MD, Peter W. Pisters, MD, Eddie K Abdalla,
MD
University of Texas M. D. Anderson Cancer Center, Houston, TX; Saint-
Luc University Clinics, Universite Catholique de Louvain, 1200 Brussels,
Belgium
Background. Hepatic epithelioid hemangioendothelioma (HEHE) is a rare
malignant neoplasm of vascular origin. The natural history is poorly under-
stood, and treatment recommendations vary widely. HEHE may be an
indolent disease for which disease evolution over time may better direct
selection of treatments, including observation.
Methods. We performed a retrospective review of thirty-four (34) patients
with HEHE who were identified from tumor registries (1989 to 2004) at two
academic centers. Presentation, treatments and outcomes were analyzed.
Results. The median patient age was 42 years (range, 18 to 72 years); 22
(65%) were women and 12 (35%) were men. The most common presenting
symptoms were abdominal pain (50%), fatigue (18%), and weight loss
(15%). Twenty-seven patients presented with diffuse liver disease with (n
13) or without metastatic disease (n14); seven (7) patients presented with
localized liver disease. Treatments included A: surgery (liver resection or
transplantation, 44%), B: non-surgical treatment (systemic or liver-directed
chemotherapy, embolization, or tumor injection, 32%) or C: observation (no
treatment or COX-2 inhibitor, 24%). There was no treatment-related
mortality for surgery or transplantation; 2 of 12 patients in group B died
from complications of treatment. Survivals for Groups A, B and C (mean9
SD) were 1689307, 49938, and 1809422 months, respectively (median
follow-up, 52 months, median survival has not been reached). Among all
patients, overall survival (OS) was not different after surgery vs. all other
therapies (p0.13) or treatment vs. observation (p0.95). In the subgroup
with diffuse liver disease, OS was similar whether patients were treated or
observed (p0.93). Survival was similar in patients with metastatic disease
who were treated or observed (p0.53. figure).
Conclusion. Hepatic resection and transplantation are safe, effective
treatments for HEHE. However, all treatment modalities, including observa-
tion, are associated with long-term survival. Therefore, selection for treat-
ment must be highly individualized and a period of watchful waiting with
delayed intervention might be considered for patients who present with
asymptomatic HEHE.
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BENEFICIAL EFFECT OF ELASPOL (SIVELESTAT SODIUM
HYDRATE) AFTER MAJOR HEPATECTOMY USING INTERMIT-
TENT PRINGLE MANEUVER IN SWINE
Mitsugi Shimoda, Yoshimi Iwasaki, MD, PhD, Tokihiko Sawada, MD, PhD,
Keiichi Kubota, MD, PhD
Dokkyo Univ, School of Med., Mibu, Tochigi, Japan
Objective. Ischemia-reperfusion (I/R) injuryis widely accepted as a sig-
nificant source of morbidity and mortality in the liver surgery. However, the
mechanism of the I/R is still unclear and it is problem how to protect liver
against I/R after major hepatectomy. We investigated the effect of selective
neutrophil elastase inhibitor; Elaspol (ONO-5046) on hepatic I/R injury in a
swine liver resection reperfusion model to evaluate its possible therapeutic
effects on hepatic I/R injury.
Methods. Swines (n12) were divided into two groups (Elaspol group:
Group I and saline group: Group II). A left hemihepatectomy was performed
using IPM (cycles of 15-min ischemia and 5-min reperfusion) in all swines. In
the group I, Elaspol was injected intravenously during operation (10 mg/kg/
hr), in group II, same dose of saline was also injected during operation.
Hemodynamic change and plasma concentrations of aspartate aminotrans-
ferase (AST), lactae dehydrogenase (LDH), lactic acid (LA) and hyaluronic
acid (HA) were measured at each observation period (60, 120, 180 minutes).
Apoptotic findings (TUNEL staining and electron microscope), plasma
tumor necrosis factor-alpha (TNF-alpha) and NO2- /NO3- were evaluated
after hepatectomy for 180 min. We evaluated effect of Elaspol on nitrite
production in LPS and INFIˆ9stimulated in J744 cells.
Results. There were no significant differences in the body weight, blood loss,
resected liver weight, Pringle time and hemodynamic change between the two
groups. In Group I plasma NO2 /NO3 levels, AST and TNF-alpha
levels were significantly reduced after hepatectomy for 180 min (AST;
114.6930.1 vs 223.8954.6 (IU/l); P0.0045, NOx; 9.093.5 vs 27.8911.9
(mmol/l); P0.0098, TNF-alpha; 257.49181.3 vs 830.89496.5 (pg/ml):
P0.041). Apoptotic cells were significantly fewer in the group I than in the
groups II. Elaspol caused significant reductions of nitrate in virto.
Conclusions. Intermittent Pringle maneuver with Elaspol resulted in less
hepatic injury and apoptotic cell death, compared with control. Elaspol with
intermittent hepatic pedicle clamping has a posibility to reduce I/R in clinical
settings.
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EVALUATION OF AN AUTOLOGUOUS FIBRIN SEALANT IN
PATIENTS UNDERGOING LIVER RESECTIONS: A MULTICEN-
TER RANDOMIZED CLINICAL TRIAL
Dido Franceschi, MD, Alan Livingstone, MD, Michael Choti, MD, Ronald
W Busuttil, MD, PhD, Michael D’angelica, MD, Linda S. Sher, MD, Trista
Madsen, RN, BSN, Vijay Kumar, PhD
University of Miami, Miami, FL; Johns Hopkins Hospital, Baltimore, MD;
UCLA, Los Angeles, CA; Memorial Sloan Kettering Cancer Center, New
York, NY; USC, Los Angeles, CA; Thermogenesis, Rancho Cordova, CA
Introduction. The CryoSeal† FS System consists of a medical device (the
CS-1 instrument) and a proprietary plasma processing disposable that work
in concert to rapidly (approximately 60 minutes) prepare both components of
a fibrin sealant (FS), (cryoprecipitate and thrombin), from a single unit of
autologous blood. Exisitng fibrin sealants are derived from pooled human
plasma with bovine additives. Use of such sealants carries recognized risks of
viral contamination, e.g. HBV and HIV, and of immunological reaction to
bovine products. Alternatively, sealants generated from the CryoSeal† FS
System using autologous blood do not carry the same concerns. The primary
objective of this study was to investigate the safety and efficacy of the fibrin
sealant prepared by the CryoSeal† FS System, in terminating bleeding of the
raw liver resection margin following hepatectomy.
Materials and methods. The study compared the use of fibrin sealant
produced by the CryoSeal† System versus a currently approved adjunct to
hemostasis, a collagen absorbable hemostat (Instat, Ethicon, Inc.). The trial
reported here was a randomized clinical study in 153 patients undergoing
elective hepatectomy, and enrolled at 10 study sites. The primary efficacy
endpoint was the time to hemostasis (time between application of the study
product and when hemostasis was obtained). Secondary endpoints included:
success rate of achieving hemostasis within 10 minutes of application of the
product, intraoperative blood loss, use of blood products, and adverse events.
Safety evaluation included a 30-day (93 days) follow-up post surgery.
Results. The median time to reach hemostasis was 3.43 minutes in the FS
group compared to 8.65 minutes in the control group. Percentage of patients
that achieved hemostasis within 10 minutes was 94.0% for the FS group and
60.4% for the control group. This difference was statistically significant (pB
0.001) and satisfied the non-inferiority criterion. The FS also satisfied the
superiority criterion (pB0.001). The groups were not different in regards to
operative blood loss, operative time, postoperative hospital stay or complica-
tions.
Conclusions. The results of this trial demonstrate that the autologous Fibrin
Sealant produced by the CryoSeal† FS System is safe, effective, well
tolerated, and superior to the collagen absorbable standard of care in this
patient population and indication.
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GUIDELINES FOR POWER AND TIME VARIABLES FOR MICRO-
WAVE ABLATION IN A PORCINE LIVER
William W. Hope, MD, Thomas M. Schmelzer, MD, William L. Newcomb,
MD, Jessica J. Heath, Amy L. Lincourt, PhD, H. James Norton, PhD, B.
Todd Heniford, MD, David A Iannitti, MD
Carolinas Medical Center, Charlotte, NC
Microwave ablation is an emerging thermal ablation technique for primary
and metastatic liver tumors. The purpose of our study was to evaluate two
variables, power and time, and their influence on diameter in microwave
ablations in a porcine liver. We propose guidelines and recommend optimal
time and power variables for use. Microwave ablations using a 3.7 cm active
tip antenna and VivaWaveTM Microwave Ablation System (Valleylab,
Boulder, Co, USA) were performed in-vivo in a porcine liver. Independent
variables were power (20,30,40,45,50,60 watts) and time (2,4,6,8,10,15,20
minutes). The outcome variable was diameter of ablations measured in
millimeters. Ten ablations were performed for each power and time period.
Livers were procured following ablations and the ablation zones were
measured. Representative samples were sectioned and examined for histol-
ogy, nicotinamide adenine dinucleotide (NADH) and hematoxylin and eosin
(H&E) staining. Based on NADH staining, inner ablation diameter was used
representing the minimum ablation diameter correlating with uniform cell
death by coagulation necrosis. Analyses of Variance (ANOVA) was performed
followed by Tukey tests when appropriate. A p-value of B0.05 was
considered statistically significant. Our study consisted of 420 total ablations.
The outcome variable, ablation diameter, was affected significantly by time,
power, and time/power interaction (pB0.0001). For each time point, a 1-way
ANOVA revealed an overall significant difference in ablation size X wattage
(pB0.0001). Tukey tests revealed that at each time point, ablation sizes at
45, 50, and 60 watts were not significantly different. Once it was determined
that 45 watts was optimal, a 1-way ANOVA was performed and revealed an
overall significant difference in ablation sizes for time points at 45 watts (pB
0.0001). Tukey tests revealed that at 45 watts, ablation sizes at 10, 15, and 20
minutes were not statistically different. Our study shows that time, power,
and time/power interaction have a significant effect on diameter in microwave
ablations. We propose guidelines for diameters based on different time and
power variables and recommend usage at 45 watts for 10 minutes to achieve
optimal diameters at the shortest time period and lowest wattage.
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RIGHT HEPATIC TRISECTIONECTOMY  ANALYSIS OF A
SINGLE CENTRE EXPERIENCE OF TWO HUNDRED AND SE-
VENTY FIVE CASES
Karim J Halazun, Ahmed Al-mukhtar, Amer Aldoori, Hassan Malik, Moh’d
Abu Al-hilal, Magdy S Attia, Shahid Farid, K Rajendra Prasad, Giles J
Toogood, J Peter A Lodge
St. James’ University Hospital, Leeds UK, Leeds, United Kingdom
Objective. To assess the use of right trisectionectomy for treatment of
malignant and benign hepatic disease in a single centre. Summary Back-
ground Data: Right trisectionectomy is considered one of the most aggressive
liver resections and is traditionally associated with poor outcome. No large
studies exist which assess the long term outcome of this type of resection.
This study therefore represents the largest study worldwide and provides the
longest follow up for patients undergoing such resections.
Methods. Retrospective analysis of a prospectively gathered dataset. Patient
population included 275 patients.
Results. Of the 275 patients, 14 had resections prior to auxillary liver
transplantation and were excluded. 91% of patients had resections for
malignant disease. One, three, five and ten year survivals were 74%, 54%,
43% and 36% respectively. Overall morbidity was 41%, and post operative
mortality was 8%. Survivals for individual tumour types were acceptable,
with 5 year survivals for colorectal metastasis and cholangiocarcinoma (the
most common malignancies) being 38% and 32% respectively. Multivariate
analysis disclosed the amount of intraoperative blood transfusion to be the
sole independent predictor for the development of morbidity. Age, pre-
operative bilirubin levels and the development of post operative renal failure
were found to be independent predictors of long term survival.
Conclusion. Right trisectionectomy can safely be used in patients with
aggressive malignant liver disease and provides good long term survival in
such patients. Caution must be taken when considering patients above 70
years of age for such resections.
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RIGHT PORTAL VEIN LIGATION IS AS EFFICIENT AS PORTAL
VEIN EMBOLIZATION TO INDUCE HYPERTROPHY OF THE
LEFT LIVER REMNANT
Beatrice Aussilhou, MD, Mickael Lesurtel, MD, Safi Dokmak, MD, Reza
Kianmanesh, MD, Olivier Farges, MD, PhD, Alain Sauvanet, MD, Annie
Sibert, MD, Vale´rie Vilgrain, MD, Jacques Belghiti, MD
Beaujon Hospital, Clichy, France
Background and Aim. Right Portal Vein (PV) obstruction induces
hypertrophy of the future left liver remnant. Right Portal Vein Ligation
(PVL), which is supposed to result in an incomplete and transient occlusion,
has been considered to be less efficient than right Portal Vein Embolization
(PVE) before a right hepatectomy. The aim of this study was to compare PVL
and PVE before right hepatectomy in terms of efficacy for induction of left
liver hypertrophy.
Methods. Between 1998 and 2003, 35 patients with liver metastases
underwent a right portal branch obstruction before ‘‘high risk’’ right
hepatectomy because of a future remnant liver volume less than 30% of
the total liver volume or because of a postchemotherapy liver parenchyma.
PVE was performed percutaneously in 18 patients, while 17 patients
underwent a PVL during a first stage laparotomy for resection of the primary
tumor (n10) and/or resection of left liver metastases (n16).
Results. Right portal vein occlusion was complete in all the cases in both
groups except for one patient in group PVE. Interval time between portal
vein occlusion and liver resection was similar in both groups (793 weeks
after PVE vs. 893 weeks after PVL, p0.6) There was no complication
following PVE and postoperative hospital stay was 291 days. In group PVL,
6 patients had postoperative complications which were related to primary
tumor resection and postoperative hospital stay was 1396 days. The left liver
volume increased from 5099222 ml to 6419220 ml after PVE (pB0.001),
and from 4779179 ml to 6389192 ml after PVL (pB0.001). After PV
occlusion, the increase of the left liver volume was not significantly different
between the two groups (35938% after PVE vs. 38926% after PVL, p
0.7). After PVE, 6 patients were not eligible for right hepatectomy because of
insufficient hypertrophy of the left liver (n2) or tumor progression (n4).
After PVL, 3 patients were not eligible for resection because of tumor
progression (n2) or death (n1). Prior to resection, CT-scan showed a
portal cavernoma in 3 patients of each group. Technical difficulties during
surgical procedure were similar in both groups according to duration of
procedure (6.491 hours vs. 6.791 hours, p0.7) and transfusion rates
(33% vs. 28%, p0.7) after PVE and PVL, respectively. Pathologic
examination showed an amount of tumor necrosis of 47929% in group
PVE and 43943% in group PVL (p0.6).
Conclusion. Right PVL and PVE result in a comparable hypertrophy of the
left liver. During the first laparotomy of a two-step liver resection, PVL can be
efficiently and safely performed.
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THE CHALLENGES OF RESIDENT TRAINING IN COMPLEX
HEPATIC, PANCREATIC, AND BILIARY PROCEDURES
Thomas S Helling, MD, Anjay K Khandelwal, MD
Conemaugh Memorial Medical Center, Johnstown, PA
Operations on the liver and pancreas have fallen within the domain of the
general surgeon and have been part of general surgery training. The more
complex procedures involving these structures are limited in number in most
general surgery residencies and do not afford an opportunity for vast
experience. Moreover, fellowship programs in hepato-bilio-pancreatic
(HPB) surgery, and the development of laparoscopic techniques have further
limited the familiarity of general surgery residents with these areas. It was our
hypothesis that the majority of training programs offers few complex HPB
procedures as training opportunities. We accessed, through the Residency
Review Committee of the Accreditation Council for Graduate Medical
Education, the National Resident Report of operative logs submitted by
general surgery residents at the completion of their training. The number of
operations on the gallbladder, bile ducts, pancreas and liver were examined
over the past 16 years (there were missing data for 3 years). Results were
expressed as mean9SD and mode. From 252279 programs participated.
The results for cholecystectomy (laparoscopic and open), pancreatectomy
(whipple and distal), major liver resection, and common bile duct exploration
(CBDE) (open) are depicted. While the exposure to laparoscopic cholecys-
tectomy seems robust, experience with other hepatic, biliary, and pancreactic
surgery, even open cholecystectomy, is meager. For liver resection, the range
was (SD)924. For pancreas resection the range was (SD)914. The
mean mode (most frequently performed number) for liver resection was 0.5
(either 0 or 1), for pancreatic resections, less than 1.0 (either 0 or 1).Most
residents perform only 24 of these cases during their general surgery
residency. CBDE, as a means of providing familiarity with the extra-hepatic
biliary tree, has steadily decreased in favor of other methods to treat
choledocholithiasis. It is doubtful this experience in HPB surgery engenders
confidence in finishing residents. Although there is pressure to develop
centers of excellence in HPB surgery, attention should be focused on
augmenting training in HPB surgery for general surgery residents perhaps
through a combination of programmatic initiatives, ex vivo experiences, and
mini-fellowships.
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UMBILICAL HERNIA REPAIR IN THE PRESENCE OF CIRRHO-
SIS AND ASCITES: RESULTS OF A SURVEY AND A REVIEW OF
THE LITERATURE
Andrew Mckay, MD, Oliver F. Bathe, MD, Elijah Dixon, MD, Francis R.
Sutherland, MD
University of Calgary, Calgary, AB, Canada
Introduction. Umbilical hernias are common in cirrhotics, yet their
management poses several challenges. The purpose of this study was to
extensively review the available literature, plus conduct a survey to gather
additional consensus evidence from experts in the field.
Methods. An extensive review of the literature since 1980 was performed. In
addition, a survey was electronically distributed to 40 Canadian surgeons
with a special interest in HPB.
Results. 19 surgeons (45%) responded. Table 1 shows the scenarios where
the respondents felt surgery was indicated. For asymptomatic hernias, all
would operate in Child’s A cirrhosis, but not in more advanced disease.
These results seem to reflect the respondents’ higher estimates of morbidity
and mortality with more advanced liver disease. Their averaged estimates of
mortality were 3.8%, 13.2% and 28.9% for class A, B, and C cirrhosis,
respectively. However, recent literature demonstrates much lower morbidity
and mortality than in the past. Of 135 patients reported in the literature since
1980, there were only 4 operative mortalities (2.7%) and the morbidity
averaged 21%. Many now recommend early elective repair. Half of
respondents would use prosthetic mesh, even in emergent situations with
Child’s B or C cirrhosis. The results of the 3 studies identified that examined
the influence of uncontrolled ascites on hernia recurrence rates show that
failure to control ascites appears to be strongly predictive of hernia recurrence
(RR 8.5; 95% CI 2.7 to 26.9) (see Figure 1). This is consistent with the
survey results where 69% of respondents would add a concomitant surgical
procedure to control ascites, with most opting for a peritoneal drain until
adequate healing is judged to have occurred.
Conclusions. Mortality and morbidity are much less than historically
reported, and consideration should be given to early repair. The presence
of ascites influences recurrence rates. Concomitant surgical procedures
to control ascites should be considered when medical treatment is not
enough.
Proportion of respondents offering repair of umbilical hernia according to
different scenarios
Child’s
A*
Child’s
B*
Child’s
C*
Respondent
Total
Asymptomatic Hernia 100% (8) 0% (0) 0% (0) 8
Incarcerated Hernia 79% (11) 86% (12) 86% (12) 14
Ruptured Hernia
(leaking ascites)
88% (14) 88% (14) 94% (15) 16
Impending Rupture
(e.g. skin breakdown)
88% (14) 88% (14) 69% (11) 16
Total Respondents 16
* Values represent percentage of respondents, with number of respondents in
brackets.
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Figure 1. Meta-analysis for influence of uncontrolled ascites on hemia
recurrence rates.
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SURGICAL TREATMENT OF PRIMARY HEPATIC MALIGNANCY
IN THE UNITED STATES
Joshua S Hill, MD, James T. Mcphee, MD, Giles F. Whalen, MD, Mary E
Sullivan, MS, Frederick A Anderson, PhD, Jennifer F Tseng, MD
University of Massachusetts, Worcester, MA
Introduction. Over the past decades, the morbidity and mortality of hepatic
resection has decreased. The purpose of the current study was to determine
whether hepatic operations for primary liver cancer are increasing, and
determine the underlying causal factors for any observed change.
Methods. All patient-discharges with a diagnosis of primary hepatic
malignancy (ICD-9 code 155.0) were identified from the Nationwide
Inpatient Sample (NIS 19982004). Surgical procedures were categorized
as either enucleation/ablation of lesions, partial hepatectomy, or total
hepatectomy/transplantation. Categorical data were analyzed by Chi Square
tests. Mortality was examined using logistic regression with adjustments for
patient demographics and comorbidities.
Results. 77,033 patients were identified with a discharge diagnosis of
primary hepatic cancer. Between 1998 and 2004, there was a yearly increase
in the number of patients with hepatic malignancy (6,861 to 15,556, PB
0.0001). 11,337 patients underwent operative therapy with an increase in
yearly volume (796 to 2,668). 34.4% of operative patients were female;
56.7% were white. Mean age was 61.9 years. Enucleation and/or ablation
were performed in 36.6%, wedge resection in 30.9%, lobectomy in 31.0%
and total hepatectomy/transplant in 1.5%; respective mortality rates were
4.0%, 6.2%, 10.6% and 14.5%. Over 7-years, the percentage of patients
undergoing enucleation/ablation increased 10-fold, wedge resection and
lobectomy both increased moderately and transplantation rates remained
stable (PB0.0001 for trend). In-hospital mortality was 6.9% for operative
cases. Hospital operative volume, liver and renal failure were inversely
correlated with mortality (all univariate analyses PB0.05). An increasing
percentage of patients were treated at high-volume centers in 20032004
versus 1998, which was associated with a concurrent trend toward reduction
in national mortality.
Conclusions. Using the NIS 19982004, we have demonstrated that
admissions for primary hepatic cancers are increasing, and that operations
for these malignancies are increasing at an even faster rate. The cause of this
increase in operative treatment is likely multi-factorial. An important factor
may be the emergence of less-invasive techniques such as enucleation and
ablation, which is supported by our data showing that these increased 10-
fold. The overall mortality in patients undergoing surgery was 6.9%, which
compares favorably to historic reports. As perioperative mortality continues
to improve, an increasing number of patients with primary hepatic cancer
may be referred for and benefit from operative treatment.
161
A SYSTEMATIC REVIEW ON THE EFFICACY OF REPEAT
HEPATECTOMY FOR RECURRENT LIVER METASTASES
FROM COLORECTAL CARCINOMA
Junyang Sim, Tristan Yan, Rui Niu, David Morris
St. George Hospital, Sydney, Australia
Background. Despite the lack of level 1 evidence, hepatectomy has been
considered the standard of care for liver metastases from colorectal
carcinoma. Liver recurrence after hepatectomy is common and associated
with a reduced survival if not treated aggressively. Many treatment centers
advocate the use of repeat hepatectomy and have claimed that not only is it
safe, but also it has similar survival results to initial hepatectomy. The
purposes of this study were to critically appraise the quantity and quality of
current clinical evidence and demonstrate the efficacy of repeat hepatectomy
for colorectal liver metastases (CRLM).
Methods. Electronic literature searches in six databases were performed to
identify all published peer-review medical articles on repeat hepatectomy for
CRLM. The reference lists of all retrieved articles were manually reviewed for
further identification of potentially relevant studies. Original studies using
repeat hepatectomy for recurrent CRLM with a curative intent were searched
for inclusion. All studies selected were human trials, published in English
language. The two investigators then independently appraised each included
article, using the recommended guidelines from the National Health Service
Center for Reviews and Dissemination case series quality assessment criteria.
Clinical effectiveness was synthesized through a narrative review with full
tabulation of results of all included studies.
Results. Thirty-six original studies were identified allowing 1261 patients to
be included. All studies were classified as observational studies without
control groups (level 4 evidence). Seventeen studies had more than 20
patients, including 4 relatively large series (n100). Their median follow-up
since repeat hepatectomy ranged from 19 to 59 months. Their median
survival after repeat hepatectomy ranged from 23 to 56 months, with 1-, 2-,
3- and 5-year survival rates vary from 77100%, 3789%, 2768% and 13
49%, respectively. The disease-free interval after repeat hepatectomy was 9 to
35 months. The perioperative morbidity ranges from 1130% and mortality
varies from 05%. Intra-abdominal abscess and bile leak rates were 023%
and 110%, respectively. The mean blood loss ranged from 450 to 928 cc.
The median hospital stay varied from 8 to 26 days.
Conclusions. Repeat hepatectomy achieves similar survival results to that
after initial hepatectomy. It is associated with moderate morbidity and
mortality in the reported series. Although the level of evidence is low, the
current literature suggests that repeat hepatectomy is efficacious in treating
selected patients with liver recurrence from colorectal carcinoma.
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FACTORS INFLUENCING PERIOPERATIVE BLOOD TRANSFU-
SIONS IN PATIENTS UNDERGOING MAJOR HPB PROCEDURES
Varun Verma, None, Roderich E Schwarz, MD, PhD
UMDNJ-RWJMS, New Brunswick, NJ
Background. Patients undergoing major HPB resections are at risk for
blood loss and transfusion (TF) requirements. Boosting preoperative
hemoglobin levels with synthetic erythropoietin (EPO) offers the rationale
to reduce TF needs and TF related morbidity. To assess such feasibility, we
critically reviewed TF utilization in a HPB practice experience.
Methods. Information of perioperative PRBC TFs was collected prospec-
tively over a 5-year period in a single surgeon academic practice. Outcome
measures of interest were TF needs, amount of PRBC units required,
postoperative morbidity, and length of stay (LOS). Perioperative clinical and
laboratory parameters were tested for TF impact.
Results. Out of 344 patients who underwent a major operation, 231 were
HPB procedures (67%). The median age was 63 (range: 2688), and 55%
were female. HPB cases included pancreatic (n130, 56%), hepatobiliary
(n89, 39%), and other combined operations with a HPB component (n
12, 5%). Median estimated blood loss (EBL, in cc) was 400 (pancreatic: 400,
hepatobiliary: 400, other: 375, pNS). PRBC TFs were given in 50 cases
(22%), at a median of 2 units (116). TF frequency was 23% for pancreatic,
16% for hepatobiliary, and 50% for other resections (p0.02). Preoperative
TFs were given to 5 patients (10% of all TFs), and 11 individuals received
blood postoperatively (22% of TFs). Significant univariate TF associations
were found for ASA class, gender, emergency cases, palliative intent,
procedure type, R category, blood loss, OR length, and the following
preoperative serum laboratory parameters: Hgb, WBC, albumin, calcium,
Na, CO2, Cr, and INR. Significant TF associations on multivariate analysis
were only demonstrated for Hgb (pB0.0001, OR 0.37, 95% CI 0.260.52)
and intraoperative EBL (pB0.0001, OR 1.004, CI 1.003 1.006). TFs
(versus no TFs) were significantly linked to major complications (28 vs. 13%,
p0.01) and increased LOS (median 9 vs. 7 days, p0.0003), but not lethal
events (6% vs. 2.2%, pNS). A potential benefit for preoperative EPO to
realistically avoid TFs (nonemergent case, HgbB12, no preoperative TF
need, B4 PRBCs given) could be derived for only 30 patients (13% of the
231 major operations, or 12% of all patients for whom a major procedure had
been planned preoperatively).
Conclusions. The results show the relatively low TF rate of 22% for patients
who undergo major HPB resections. Aside from preoperative blood counts,
few parameters are able to identify subgroups at high risk for TFs. The data
from this experience would not support routine preoperative EPO adminis-
tration to reduce perioperative TF need, as the cohort with predictable EPO
benefit would only comprise 12% of patients potentially at risk.
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MORBIDITY, MORTALITY AND RISK FACTORS IN DISTAL AND
SUBTOTAL PANCREATIC RESECTIONS FOR PANCREATIC
NEOPLASIA: AN ANALYSIS OF THE NATIONAL SURGICAL
QUALITY IMPROVEMENT PROGRAM
H H Jackson, MD, T L Schifftner, S F Khuri, MD, W F Henderson, PhD, L
Neumayer, MD, S J Mulvihill, MD, R E Glasgow, MD
University of Utah, Salt Lake City, UT; Colorado VAMC, Aurora, CO; West
Roxbury VAMC, West Roxbury, MA
Background. Distal and subtotal pancreatic resections are technically
challenging surgical procedures. Outcomes for this procedure have been
limited to small, single institution series. This study aims to describe the
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30-day morbidity and mortality and to define risk factors utilizing multi-
institutional data.
Methods. The National Surgical Quality Improvement Program prospec-
tively collected data for distal and subtotal pancreatectomy (CPT 48140)
during fiscal years 2002 2004 using trained nurse reviewers and standar-
dized event definitions. Patients were included for review if ICD9 codes
indicated pancreatic neoplasia. Demographics, pre-operative medical condi-
tions and laboratory data, intra-operative variables and outcomes were
reviewed. Stepwise logistic regression was used to construct models
predictive of 30-day post-operative morbidity and mortality.
Results. Patients were gathered from 43 Veterans Affairs Medical Centers
and 14 private sector hospitals. 227 patients were identified with a mean age
of 60 years and male preponderance (56%). Major contributing co-
morbidities were: smoking (23%), alcohol use (4%), diabetes (18%),
pulmonary disease (10% dyspnea and 7% COPD), weight loss (11%) and
disseminated cancer (7%). Neoadjuvant therapy was given to 2.6% of
patients. Common laboratory abnormalities included decreased hematocrit
and albumin and elevated alkaline phosphatase, SGOT, and creatinine.
Wounds were classified as clean in 39% and clean contaminated in 61%.
Mean operative time was 4 hours and on average less than 1 unit of blood
(0.691.6) was transfused. 3.5% of patients returned to the operating room
for complications. The mean post-operative length of stay was 11.297.3
days. 30-day morbidity was 21% overall. Most complications were respiratory
events (8%) with pneumonia (4%) and failure to wean from the ventilator
(2%) being most prevalent. Urinary tract (7%) and wound (6%) infections
were also common. No independent variables were identified as statistically
significant predictors of 30-day morbidity in the logistic regression analysis
because the c index was 0.56. 30-day mortality rate was 1.3% (3 of 227).
Conclusion. Distal and subtotal pancreatic resections are associated with a
high rate of morbidity and low mortality. While medical co-morbidities are
common, no specific factor can be identified that is predictive of patient
morbidity and mortality. Improved strategies to prevent wound, urinary, and
pulmonary infection would be useful in this population.
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POPULATION BASED STUDY OF MANAGEMENT OF PAN-
CREATIC ADENOCARCINOMA
S M Ashamalla, A Eppel, H Rothenmund, R Bromberg, D R Urbach, M J
Moore, M Cotterchio, S Gallinger
Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON,
Canada
The majority of pancreatic adenocarcinoma (PA) is metastatic at presentation
with survival of less than six months. Due to this short mean survival after
diagnosis, enrolling PA patients in prospective population-based epidemio-
logical studies is a challenge. To help overcome this obstacle, the Pathology
Information Management System (PIMS), relying upon electronic pathology
reporting (E-path), was installed in all labs in the province of Ontario,
Canada, to provide rapid case ascertainment based on pathologic diagnosis.
The purpose of this study is to use our prospective, population-based registry
of PA to describe the management of PA in the province of Ontario. Of 852
eligible patients contacted based on pathological diagnosis of PA from 2003
to 2006, 35% (301) enrolled in the study, 24% (203) were deceased at first
contact, 27% (232) refused participation and 14% (116) are being worked up
or were lost to follow-up. Medical records were obtained for all responders.
Non-responders were older (67 vs. 64 yrs, pB0.001), more likely to have
received treatment in non-academic centers (53% vs. 35%, pB0.0001) and
were less likely to have undergone any operative management of their disease
in compared to responders (21% vs. 43%, pB0.0001). Of the responders,
the frequency of potentially curative resection was greater in patients less than
70 years of age (46% vs. 35%, pB0.0001). Of those undergoing any
potentially curative operation, (n148), 87% (129) had successful resec-
tional surgery while 13% (19) were found to have unresectable and/or
metastatic disease and resection was aborted. Within the curative resection
group, 26% (34) were conducted in non-academic centers of whom 32%
(11) had positive margins. Of the 74% (95) resections performed in an
academic center, 24% (23) had positive margins (non-academic vs academic
pNS). Medical records review revealed that 41% of resected patients
received adjuvant chemotherapy. Only 8% of all responders participated in
clinical trials. In conclusion, our study utilizes novel methodology to provide
a prospective snapshot of PA across the province. Despite the use of PIMS
and e-Path, response rates remained low (B40%). Not surprisingly,
nonresponders were older, had more advanced disease, and more commonly
received care in non-academic centers. Responders, however, provide an
excellent resource to answer specific clinical research questions. In addition,
e-Path provides higher quality data for studies related to surgical manage-
ment since pathology reports are complete and available for all eligible
subjects. The use of adjuvant therapy and the rate of participation in clinical
trials seems disappointingly low.
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FREQUENCY WITH WHICH SURGEONS UNDERTAKE PAN-
CREATICODUODENECTOMY CONTINUES TO DETERMINE
LENGTH OF STAY, HOSPITAL CHARGES, AND IN-HOSPITAL
MORTALITY
Alexander Rosemurgy, MD, Sarah M Cowgill, MD, Brian Coe, Sam Al-
saadi, MD, Ashley Thomas, Jennifer Cooper, Sharona Ross, MD, Steven
Goldin, MD, PhD, Emmanuel Zervos, MD
University Of South Florida And Tampa General Hospital, Tampa, FL
Introduction. Numerous studies purport that complex operations are best
undertaken by ‘‘high volume’’ surgeons. It is unknown how these studies have
impacted delivery of care. This study was undertaken to determine changes
in the number of, frequency with which surgeons undertake, and outcomes
after pancreaticoduodenectomy (PD) in Florida 8 years after a study denoted
that in Florida the frequency with which surgeons undertake PD impacted
outcome.
Methods. Using the State of Florida Agency for Health Care Administration
database, we correlated the frequency with which surgeons undertake PD
with average length of hospital stay (ALOS), in-hospital mortality, and
hospital charges for identical 33 month periods in 19951997 and 2003
2005.
Results. Compared to 19951997, 88% more PD were undertaken in
20032005 by 6% fewer surgeons (Table). In 19951997 and 20032005,
the majority of PD were undertaken by surgeons doing less than one PD
every 2 months (76% of PD in 19951997 and 52% of PD in 20032005).
From 19951997 to 20032005 ALOS decreased. Conversely, from 1995
1997 to 20032005 in-hospital mortality rate did not decrease (Table); in-
hospital mortality rate significantly increased for surgeons undertaking less
than one PD every 2 months) (p0.03). For 20032005, frequency with
which PD was undertaken inversely correlated with ALOS (p0.01) (Table),
hospital charges (p0.003), and in-hospital mortality (pB0.0001) (Table).
Conclusions. More pancreaticoduodenectomies (PD) are now undertaken
in Florida by fewer surgeons with a shorter ALOS. In-hospital mortality
remains high due to surgeons infrequently undertaking PD. Lowest costs and
mortality with PD are seen with surgeons frequently undertaking PD. While
numerous studies purport that complex operations are best undertaken by
‘‘high volume’’ surgeons, most PD in Florida are still undertaken by surgeons
who undertake PD infrequently with ensuing greater lengths of stay, hospital
costs, and in-hospital mortality rates. Because of increased in-hospital
mortality from 19951997 to 20032005, patients needing PD, to an even
greater extent than previously demonstrated, are best served by surgeons
frequently undertaking the procedure.
Pancreaticoduodenectomies (PD) in Florida over 33 mo in 19951997 and
20032005 stratified by number of PD per surgeon.
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IMPORTANCE OF LYMPH NODE SAMPLING IN STAGING OF
PERIAMPULLARY MALIGNANCIES
Juan C Gutierrez, MD, Alan S Livingstone, MD, Leonidas G Koniaris, MD
University of Miami Miller School of Medicine, Miami, FL
Pancreaticoduodenectomies (PD) in Florida over 33 mo. in 19951997 and 20032005 stratified by no. of PD per surgeon
# PD per surgeon over 33 months Period # Surgeons
#PD over
33 months
ALOS
(days)
In-hospital
mortality (%)
13 19951997 251 365 23 5.5
(51 PD every 12 months) 20032005 192 284 18 12.3*
49 19951997 21 111 20 9.9
(51 PD every 4 months) 20032005 50 287 16 7.3
1016 19951997 4 52 18 0
(51 PD every 2 months) 20032005 9 113 15 7.1
]17 19951997 6 170 17 2.6
(]1 PD every 2 months) 20032005 15 630 15 2.2
TOTAL
19951997 282 698 21 5.1
20032005 266 1,314 16 5.9
*Significantly greater than in 1995 1997, pB0.01, chi-square test.
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Objective. To determine the impact of lymphadenectomy in prognosis and
staging in pancreaticoduodenectomy for pancreatic, distal bile duct, duode-
nal or ampullary malignancies.
Methods. All pancreaticoduodenectomies for periampullary carcinomas
from the SEER cancer registry were examined from 1993 through 2003.
Results. Overall, 6330 pancreaticoduodenectomies for non-metastatic
periampullary carcinomas were identified. The cohort was comprised of
60.6% pancreatic, 18.7% ampullary, 13.2% distal bile duct and 7.5%
duodenal cancers. A linear association between the number of lymph nodes
(LNs) examined and overall survival was observed overall and for pancreas
and distal bile duct cancers for node negative (N0) disease only. A trend
towards improved survival was observed for ampullary and duodenal lesions.
Median survival for all patients with localized, N0 disease improved from 30
months to 43 months with sampling of a minimum of 10 LNs, while two and
five-year survival improved from 54.5% and 36.5% withB10 nodes
examined to 61.0% and 45.0% with 10 nodes examined (P0.026; see
figure). Two and five-year survival in N0 pancreatic malignancies improved
from 43.1% and 20.4% withB10 nodes examined to 49.5% and 33.5% with
10 nodes examined (P0.037). A similar benefit was seen in N0 distal bile
duct lesions where two and five-year survival rose from 53.8% and 32.6%
withB10 nodes examined to 90.9% and 43.6% with 10 nodes examined
(P0.042). No significant improvement was observed in the setting of N1
disease.
Conclusions. Significantly better median survival and cure rates are
observed following pancreaticoduodenectomy for localized periampullary
adenocarcinoma when a minimum of 10 lymph nodes are examined. This
benefit likely represents more accurate staging. No benefit is observed with
increasing lymphadenectomy in the setting of node positive disease. In order
to optimize the prognostic accuracy for individual patients and prevent
staging errors in multicenter trials a minimum of 10 lymph nodes should be
obtained and examined in the setting of node negative periampullary cancers.
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THE IMPACT OF EXTENDED LYMPH NODE DISSECTION ON
THE SURGICAL RESECTION OF PANCREATIC HEAD ADENO-
CARCINOMA
Joseph A Greco III, MD, Eric T Castaldo, MD, Alexander A Parikh, MD,
Nipun B Merchant, MD
Vanderbilt University, Nashville, TN
Introduction. The extent of lymph node dissection (LND) associated with
resection of pancreas cancer is still largely debated. Adequately powered
randomized trials to address the potential benefit of extended LND in these
patients are unfeasible. Therefore, the primary aim of this study is to
determine if the number of lymph nodes (LN) excised during surgical
resection improves overall survival in patients with pancreatic head cancer by
analyzing a large population database.
Methods. Using the Surveillance, Epidemiology, and End Results (SEER)
registry, all patient records from 1988 2003 with surgically resected
pancreatic head adenocarcinoma were queried. Patients with Stage 3 or 4
disease, multiple primary malignancies, or incomplete tumor grading,
staging, radiation, demographic data, or number of LN examined were
excluded. Kaplan-Meier methods and the log-rank test were used for
survival. A Cox regression model was tested to determine the survival impact
of LND. The number of LN excised were categorized into groups 15, 6
10, and 10. Gender, race, tumor grade, age 60 years, T-stage, and
radiation were controlled co-variates in this model.
Results. Analyses were performed separately for patients with node negative
[N] (Stage IA/IB/IIA disease; 792 patients) and node positive [N] (Stage
IIB; 1243 patients) disease. Extent of LND was a statistically significant
variable in terms of overall survival in both cohorts. For the N cohort,
patients who had 610 LN resected (HR0.80; 95% CI 0.650.98; p
0.03) and 10 LN resected (HR0.79; 95% CI 0.64 0.97; p0.02) had a
significantly improved survival over patients who had 15 LN resected.
Similarly, in the N cohort, patients who had 610 LN resected (HR
0.83; 95% CI 0.700.99; p0.03) and 10 LN resected (HR0.73; 95%
CI 0.62 0.86; pB0.01) had a significantly improved survival over patients
who had 15 LN resected. Mean f/u time for all patients was 18.2 months
(mos). Median overall survival was significantly increased in both cohorts
with extended LND. N- survival was 16 mos for 15 LN, 20 mos for 610
LN, and 21 mos for 10 LN (p0.02). N survival was 10 mos for 15
LN, 13 mos for both 610 &10 LN (pB0.01). In these models, extent of
LND was an independent predictor of survival even after adjusting for the
effects of gender, race, age, tumor grade, T-stage, and adjuvant radiation
therapy.
Conclusion. These data suggest an overall survival benefit for extended
LND with surgical resection for pancreatic head adenocarcinoma regardless
of nodal status. Given the similar hazard ratios and survival outcomes for the
610 & 10 LND groups, these data appear to support the removal of at
least 6 lymph nodes to gain a survival benefit.
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BUDD-CHIARI SYNDROME REPORT OF 3 UNIQUE CASES AND
REVIEW OF THE LITERATURE
Juan M Palma-vargas, MD, Jorge A Ortiz, MD, Helen L Goldberg, MD,
Kenneth Lazarus, MD, Francis Wright, MD, Preston Foster, MD
Texas Transplant institute, San Antonio, TX
Background. Budd-Chiari syndrome (BCS) is a clinical condition char-
acterized by hepatic venous outflow obstruction due to a variety of underlying
etiologies. Therapeutic modalities range from transjugular intrahepatic
porto-systemic shunt (TIPS), to surgical shunt procedures and ultimately
liver transplantation.
Material and methods. Retrospective chart review of 3 patients diagnosed
with BCS at our institution from 2005 to 2006.
Results. All our cases involved female patients, age range from 10 to 50
years. Etiology of BCS included myelodisplastic syndrome, systemic lupus
erythematosus (SLE) and Trysomy 8. Clinical presentation included
symptomatic ascites (3/3), severe lower extremity edema (2/3) and liver
dysfunction in (3/3) patients. Anatomically, the first patient had occlusion
confined to the hepatic veins and the remaining two had additional occlusion
involving the inferior vena cava. Therapeutic modalities included porta-caval
shunt after failed TIPS for the first patient. The remaining 2 patients
underwent simultaneous porta-caval and cavo-atrial shunts. One developed
shunt dysfunction and despite repeated radiologic and surgical attempts of
revascularization, ultimately required a liver transplantation. The other
patient with dual shunting eventually underwent a kidney transplant for
treatment of ESRD due to SLE. To our knowledge this is the first patient
with BCS receiving initial surgical shunting and subsequent successful living
related kidney transplantation. All patients remain on anticoagulation after
surgical procedures. After a short term follow-up (7 to 9 months) no patients
have had a recurrence of BCS. Initial clinical ascites and lower extremity
edema have resolved and synthetic liver function remains normal. In the two
patients not receiving liver transplantation, surgical shunts are patent to date
corroborated by follow-up MRI.
Conclusion. Shunting and transplantation are satisfactory methods for
treatment of BCS. Anatomic, physiological and clinical conditions dictate
which one of the two procedures should be performed.
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LAPAROSCOPIC INCISIONAL HERNIA REPAIR AFTER LIVER
TRANSPLANTATION
Kristin L Mekeel, MD, Kunam S. Reddy, MD, Adyr H. Moss, MD, David
C. Mulligan, MD, Kristi L. Harold, MD
Mayo Clinic, Phoenix, AZ
Purpose. Incisional hernias occur in 4.6 to 17.2% of patients after liver
transplantation. Laparoscopic ventral hernia repair is associated with fewer
wound complications and a decreased incidence of recurrence when
compared to open hernia repair. This study is to evaluate the results of
laparoscopic incisional hernia repair after liver transplantation.
Methods. This is a retrospective review of 334 patients who underwent liver
transplantation at the Mayo Clinic Arizona between 6/99 and 10/06. 14 of
these patients subsequently had laparoscopic incisional hernia repair.
Results. Of the 14 patients, 86% (12) were male and 14% (2) were female.
Age ranged from 51 to 69 with a mean of 61. 57% (8) of the patients had end
stage liver disease secondary to hepatitis C. 14% (2) had primary sclerosing
cholangitis, and the remaining patients were diagnosed with alcoholism and
hemachromatosis. The time between transplant and hernia repair ranged
from 4.5 to 38 months, with a mean of 19.5 months. 86% (12) patients had
deceased donor transplantation, while 14%(2) had living donor liver
transplantation. 21% (3) patients had five prior open abdominal surgeries,
including umbilical hernia repair, cholecystectomy, appendectomy, and
nephrectomy. None had prior incisional hernia repair or required re-
operation following transplantation. Body mass index ranged from 21 to 37
with a mean of 27.8. Primary maintenance immunosupression at the time of
hernia repair was tacrolimus in 64% (9), sirolimus in 21% (3), and
cyclosporine in 14% (2). 71% (10) patients were also on mycophenolate
mofetil. All patients had been weaned off steroids by 4 months after
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transplant by protocol. The hernias ranged from 208 to 1485 cm2, with a
mean of 396 cm2. They were fixed with composite mesh ranging from 680 to
2365 cm2, with a mean of 873 cm2. All operations were completed with a
laparoscopic approach, there were no conversions to open. Length of stay was
2 to 11 days, with an average of 5.5 days. Complications occurred in 14% (2)
of patients. One patient developed infected seroma and mesh, requiring open
operation and mesh removal. One patient developed a recurrence (7%) that
required open operation and revision. This patient was on sirolimus. There
were no graft losses or patient deaths.
Conclusion. Laparoscopic incisional hernia repair is safe in patients after
liver transplantation, with a low risk of infection or recurrence.
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CHANGING CONTRAINDICATIONS TO LIVER TRANSPLANTA-
TION WITH IMPROVED SURVIVAL: OBESITY, AGE 65 AND
MALIGNANCY
Lynt B Johnson, MD, MBA, Kirti Shetty, MD, Amy D Lu
Georgetown Univ Hospital, Washington, DC
Historically absolute contraindications to transplantation included patients
who were older (65 years old), patients with severe obesity and patients
with primary malignancy of the liver. With improvements in perioperative
care and immunosuppressive strategies many centers began to liberalize the
criteria for selection of patients. The proportions of the waiting list and
survival across two eras was analyzed to determine the change and
characteristics of those patients awaiting transplantation in the United States,
as well as, any changes in survival across two distinct eras.
Methods. We compared patients in the UNOS database from two five year
periods, 1/1/199412/31/1998 and 1/1/1999 to 12/31/2003 using both
waiting list data and transplant data. The following variables were examined:
age 65, diagnosis of cholangiocarcinoma, obesity characterized by BMI
3040, BMI30 (all obesity) and BMI40 (morbid obesity) and diagnosis
of hepatocellular carcinoma (HCC). We tested for change in proportion
across eras. A survival analysis was done using the log rank test for equality
over strata.
Results. Change in proportions across eras were significant at pB0.0001 for
both waiting list data and transplant data; Age 65, BMI 3040, BMI 30
and diagnosis of HCC. Graft survival rates across era were significant for
patients with BMI 3040, BMI 30 and diagnosis of HCC (p0.001).
Patient survival rates were significantly improved only for the group with a
diagnosis of HCC across the two eras (p0.006).
Conclusion. The acceptance of candidates for liver transplantation who are
older, obese or with HCC has increased over the last decade. Improved graft
survival has been seen in obese patients and in those patients with HCC.
Additionally, patients with a diagnosis of HCC have also shown improved
patient survival.
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WILL LIVER TRANSPLANT FOR HEPATOCELLULAR CANCER
USING THE UCSF CRITERIA HELP?
Linda L Wong, MD
University of Hawaii School of Medicine, Honolulu, HI
Background. Liver transplant (LT) is currently done for hepatocellular
cancer (HCC) for patients that meet Milan criteria (single mass B5 cm or 3
tumors each less than 3 cm). There is controversy as to whether this should
be extended to the UCSF criteria (single mass B6.5 cm or 3 tumors, largest
of which is 4.5 cm and total diameter of B8.5 cm), but how this will impact
on overall HCC survival is unknown.
Methods. We retrospectively reviewed a prospectively-collected database on
HCC referred to our center from 19912006 for those who underwent LTor
met Milan vs UCSF criteria.
Results. In 409 HCC patients, 33 underwent LTand 7 patients are currently
on the LT waiting list. Of 114 patients who met Milan criteria, 21 underwent
liver resection (LR), 52 had non-surgical therapies due to age/comorbidities,
41 did not undergo/complete LT evaluation for various reasons. Of 27
additional patients who met UCSF criteria, 6 underwent LR, 8 had non-
surgical therapy due to age/comorbidities, and 5 did not undergo/complete
LT evaluation. Eight patients were reasonable candidates for LT had UCSF
criteria been used. Seven of these pts have died a mean 807 days and one is
alive at 714 days after ablative therapies (chemoembolization/radiofrequency
ablation). 1 and 3-yr survival were 67% and 43% in this group.
Conclusions. Using the UCSF criteria for LT for HCC may only affect
small numbers of HCC patients (B2% in this series). Survival may be better
than locally-ablative treatments but more data will be needed.
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MIDDLE HEPATIC VEIN OF THE RECIPIENT AS DRAINAGE
FOR ANTERIOR SECTOR VEINS (SEGMENTS V VIII) IN
ADULT-TO-ADULT LIVING DONOR LIVER TRANSPLANTA-
TION. (LDLT)
Manuel I Rodriguez-davalos, Juan Pablo Rocca, MD, Michael Marvin, MD,
Patricia A Sheiner, MD, Marcelo E Facciuto, MD
New York Medical College, Hawthorne, NY; New York Medical College,
Tarrytown, NY
Introduction. Controversy exists among the centers performing right lobe
adult to adult living donor liver transplantation in terms of the preservation of
the middle hepatic vein (MHV) in the donor. Some advocate that taking the
MHV with the graft prevents congestion of the anterior sector, therefore
decreasing the chances of a small-for-size syndrome. Others have described
interposition grafts to the main tributaries of the MHV to prevent this
congestion and improve graft function.
Aim. Describe a novel surgical technique in which the recipients MHV is
dissected and anastomosed to the donor MHV tributaries of the anterior
sector that are larger than 5 mm. Providing adequate functional mass without
compromising donor safety.
Methods. This surgical technique was utilized in two adult-to-adult LDLT
in both cases the MHV of the recipient was exposed approximately 5 cm from
junction to the cava, this was done by blunt dissection of the liver
parenchyma leaving a long trunk for the end-to-end anastomosis with the
MHV tributary. The donor right lobe was brought to the operative field after
back table flush, the recipient caval opening was anastomosed to the donor
right hepatic vein orifice using 4-0 polypropylene running fashion. Donor
segment 5 hepatic vein was anastomosed to the recipient middle hepatic vein
with 6-0 polypropylene running fashion. Small branches of the recipients
MHV were over sawn with 7-0 polypropylene; the left HV was closed with 4-
0 polypropylene running fashion. The portal vein anastomosis was completed
in standard fashion. Upon completion of the vascular anastomosis, portal
vein flow was released, all clamps were removed and the liver was reperfused,
no congestion of the right lobe graft was noted.
Results. Two female recipients (59 yo and 56 yo) with diagnosis of end stage
liver disease secondary PSC in one case and HCV in the second were
transplanted successfully with right lobe grafts from two male donors (26yo
and 34yo) Routine Doppler ultrasound (DUS) was done on postoperative
day #1, showing adequate outflow of the MHV to Segment V HV branch in
both cases, patients were discharged from the hospital on postoperative day
#9 and #12 respectively. There were no postoperative complications.
Conclusions. Donor safety and functional graft volume are the essence of
LDLT, by utilizing the recipient’s MHV for drainage of anterior sector veins
with the described technique, congestion of the graft is prevented and early
graft function optimized.
173
INTRAOPERATIVE PLACEMENT OF AN EXPANDABLE METAL-
LIC STENT FOR A PORTAL VEIN TROMBOSIS AFTER LIVING
DONOR LIVER TRANSPLANTATION
Diego Ferna´ndez, MD, Martı´n Palavecino, MD, Juan Salceda, MD, Juan
Mattera, MD, Juan Pekolj, MD, Miguel Ciardullo, MD, Eduardo De
Santiban˜es, MD, PhD
Hospital Italiano, Buenos Aires, Argentina
Background. Portal vein thrombosis, complicating living donor living
transplantation by occurring in the intraoperative period is often managed
with thrombectomy or splenorenal-shunt when is necessary.
Objetive. To show a case of intraoperative portal vein thrombosis managed
with an endovascular approach placing an expandable metallic stent.
Population and Methods. We report on an 8 month old female patient with
biliary atresia who received a LDLT, and the portal vein thrombosed at the
time of reperfusion, unsuccessfully managed with thromboendovenectomy.
Results. An angiography was performed through IMV to diagnose the
anatomy and also showed the steal phenomena. Another catheter was placed
in an ileal vein branch to access the SMV. With angiographic control it was
placed a stent 6 mm diameter and 40 mm long to resolve the problem (Cordis
PRECISE RX Nitinol Stent System†). The portal vein was patent on the
Doppler US and angiographic control, also the steal phenomena disappeared.
The postoperative follow up was done by Doppler US without stenosis or
thrombosis. The patient was discharged at day 34 postoperative.
Conclusions. Endovascular techniques during liver transplantation can
resolve some liver graft perfusion problems due to PVTand steal phenomena,
especially with an unsatisfactory thromboendovenectomy. Although primary
permeability of stents has been good, these results need to be confirmed in
the long term follow up.
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REASSESSING THE IMPACT OF PERIOPERATIVE BLOOD
TRANSFUSIONS ON OUTCOMES OF LIVER TRANSPLANTA-
TION
Markus Selzner, MD, Huang Zhang, MD, Nazia Selzner, MD, PhD, Paul
Greig, MD, Mark Cattral, MD, David Grant, MD, Stuart Mccluskey, MD,
Ian Mcgilvray, MD, PhD
Toronto General Hospital, Toronto, ON, Canada
In the early experience with liver transplantation, the number of perioperative
blood transfusions (PRBC) given was a strong predictor of poor patient
outcomes after transplantation. With improved anaesthesia and intensive
care, it is not clear whether the same negative implication of PRBC
transfusions persists today.
Methods. We performed a retrospective review of outcomes in 555 adult
patients who underwent orthotopic liver transplantation at our center
between January 1998 and October 2005. PRBC transfusions were recorded
as a continuous variable. Univariate and multivariate regression analyses were
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performed to investigate whether postoperative outcomes (length of hospital
stay, postoperative rise in transaminases, ALP, bilirubin, creatinine, graft
failure, patient death) were influenced by perioperative variables including
PRBC, year of transplantation, donor age, recipient gender, recipient age,
MELD score, UNOS status, cold and warm ischemia times, acute vs chronic
liver failure, and living vs cadaveric transplantation.
Results. Increased PRBC transfusions were associated with lower UNOS
status, prolonged cold ischemic times, increased recipient age, and cadaveric
liver transplantation, but not with higher MELD scores. In univariate
regression analysis RPBC transfusions were significantly correlated with
length of hospital stay, maximum postoperative creatinine, graft loss, and
patient death. MELD score was significant for maximum postoperative
creatinine, patient death and graft loss, while the UNOS status was associated
with the length of hospital stay and maximum creatinine. However, in
multivariate regression analysis the PRBC transfusion rate was an indepen-
dent predictive factor only of the length of hospital stay and the maximum
postoperative creatinine. MELD score was the only independent predictive
factor for patient death, while cold ischemia time was the only independent
predictive factor for postoperative max AST in our model.
Conclusions. In the modern era of transplantation, PRBC transfusion rates
are associated with prolonged hospital stay and postoperative kidney
dysfunction but not with graft failure or patient survival. These data highlight
the impact of improved peri-operative anaesthesia and intensive care.
175
CHOLEDOCHODUODENOSTOMY OFFERS AN ALTERNATIVE
BILIARY RECONSTRUCTION TO CHOLEDOCHOJEJUNOST-
OMY IN LIVER TRANSPLANTATION
William Bennet, MD, PhD, Michael Zimmermann, MD, Michael Wachs,
MD, Tom Bak, MD, Igal Kam, MD
University of Colorado Health and Science Center, Denver, CO
A standard Roux-en-Y choledochojejunostomy (CDJ) can be a difficult
biliary reconstruction to perform in patients who have had previous
abdominal surgery. A choledochoduodenostomy (CDD) can be an alter-
native procedure in these cases. However, the potential role of CDD in liver
transplantation as an alternative to CDJ remains controversial with only
limited reports in the literature. Here we report our experience using CDD
during liver transplantation.
Methods. Since 2000 eleven patients undergoing cadaveric orthotopic liver
transplantation (OLTx) at our center had a CDD performed instead of a
CDJ. The first patient had the CDD performed as a biliary reconstruction of
a duct-to-duct anastomotic stricture occurring 13 months after the OLTx.
The remaining ten cases all had the CDD performed at the time of OLTx. Six
patients were transplanted for primary sclerosing cholangitis, one for
autoimmune hepatitis, one for laennec’s cirrhosis, one for Wilsons disease,
one for primary biliary cirrhosis and one for biliary atresia (previous Kasai
procedure). The patients MELD scores at the time of OLTx ranged from 18
to 31. In all patients, a tension-free CDD anastomosis was performed over an
internal stent using interrupted, 50 resorbable monofilament sutures. All
patients received conventional immunosuppression.
Results. The median follow up time to date is 13.9 months with a mean of
17.997.11 months and a range of 2.084.3 months. No patient developed a
bile leak or bleeding from the CDD anastomosis in the post operative period.
One patient has had an episode of suspected cholangitis that resolved on a
short course of oral antibiotic treatment. No patient is on prophylactic
antibiotic treatment and no patient has developed signs of a biliary stricture.
All patients have normal liver function tests.
Conclusion. CDD can be performed as an alternative to CDJ during liver
transplantation with potential benefits over the CDJ including easier post-
OLTx endoscopic evaluation and absence of an entero-entero anastomosis.
Furthermore, CDD seems to be associated with a low risk for early and late
complications. Our experience warrants further investigation of the potential
benefits of CDD over CDJ in liver transplantation.
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OUTCOME OF BILIARY STRICTURE AFTER RIGHT LIVING
DONOR LIVER TRANSPLANT
A. Gangemi, MD, U. Bareato, MD, A. C. Owens, MD, J. Bui, MD, D. West,
MD, M. Porubsky, MD, J. Oberholzer, MD, Enrico Benedetti, MD, G.
Testa, MD
University of Illinois at Chicago, Chicago, IL; University of Chicago,
Chicago, IL
Introduction. The incidence of biliary complications (BC) ranges 20 40%
in living donor liver transplant (LDLT). Scant information is available on the
long-term outcome of BS after interventional or surgical treatment (TR) of
biliary stricture (BS) in LDLT.
Materials and methods. In a 4 year period, 46 patients (pts) underwent
right LDLT. Primary biliary anastomosis was either duct-to-duct (D-D) or
Roux-en-Y (R-Y). The long-term outcome of percutaneous transhepatic bile
duct dilatation/ stent placement (PTC) or R-Y anastomosis in pts with BS
was studied. BS resolution was defined as absence of both clinical/imaging
evidence and stents 1 year from TR.
Results. BS was diagnosed in 6 pts (13%), 5 after R-Y and 1 after D-D (see
Table). Two pts with D-D had conversion to R-Y 5 days post LDLT. Three
out of 6 pts were treated for biliary leak prior to BS. One pt with conversion
of D-D to R-Y had BS resolution, F/U 1095 days. Three pts underwent R-Y
redo and required additional PTC after surgery average 10.3 TR/pt (220).
Average time of TR was 27 months (1839). Of these pts, 2 are symptoms
free/no stent at F/U at 1 and 3 months from last TR and 1 had to be re-
transplanted after 2 R-Y redo. PTC was the only TR in 2/6 pts (see Figures
12), 1 pt is stent free 3 months after the last of 6 TR, 1 still has a stent after
12 TR. Pts and graft survival is 100% and 88.8% respectively. Pts without BS
resolution have normal bilirubin and mean alkaline phosphatase 462 IU/L
(206626).
Discussion. Complete resolution of BS in right LDLT is difficult to achieve
particularly after R-Y. Long term graft survival is achievable at the expenses
of frequent intervention. Re-transplantation must be considered as definitive
TR in many pts. D-D anastomosis, when technically feasible, seems to offer
more TR opportunities.
Pts
Primary
Anastomosis
First
Complication
# of
treatments
F/U
free
disease
days Outcome
1 R-Y POD 8: Leak 0 S 6 IR 75 ALK 622
2 D-D POD 7: Leak T-tube
obstruction, R-Y
conversion
2 S 2 IR 0 ALK 729
ReTx
3 D-D POD 5: HA
thrombosis, R-Y
conversion
1 S 20 IR 30 ALK 206
4 R-Y POD 25: leak 0 S 12 IR 0 ALK 626
5 D-D POD 150: stenosis 1 S 3 IR 1095 ALK 134
6 R-Y POD 180: stenosis 1 S 9 IR 120 ALK 396
Ssurgical treatment; IRinterventional radiology treatment; ALKalka-
line phosphatase; ReTxre-transplanted. Pts 2 and 3 had early conversion to
R-Y.
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PREDICTORS OF BILIARY COMPLICATIONS FOLLOWING LIV-
ING DONOR LIVER TRANSPLANTATION
Timothy Michael Schmitt, MD, David Kashmer, MD, Timothy L Pruett,
MD
University of Virginia, Charlottesville, VA
Introduction. Adult living donor liver transplantation (ALDLT) is most
frequently complicated by biliary related issues. The reported incidence of
bile leak is up to 30% in some series.
Methods. A retrospective review of a single center experience with ALDLT
was performed to evaluate possible mechanisms for bile leaks. Parenchymal
transection technique, biliary anatomy, type of reconstruction and timing of
leak were reviewed.
Results. We performed 44 ALDLT grafting segments VVIII without the
middle hepatic vein from May 1999 to August 2006. Biliary anatomy was
investigated using magnetic resonance cholagiography pre-operatively with
intra-operative cholangiography for confirmation. In 19 cases a single right
biliary duct (43.2%) was noted. In 25 cases multiple biliary ducts (56.8) were
present. A single biliary anastomosis was performed in 28 cases (63.6%) and
a double anastomosis was created in the remaining 16 (36.4%) cases. With a
mean follow up of 698 days (range 442700 days), patient and graft survivals
were 87.5% and 87.5% respectively. The incidence of biliary leak was 7/44
(15.9%). Biliary complications observed include: three instances of leak from
the cut surface, three cases of anastomotic leak, and one leak noted from a
transhepatic tube site. Two patients required operative interventions. All
other patients were managed by interventional and/or endoscopic means.
Conclusions. Biliary complications were infrequent in this series of ALDLT.
One leak contributed to a patient death early in the series secondary to sepsis
and multiorgan failure. No other grafts were lost directly to biliary
complications. Multiple biliary reconstructions were strongly related with
bile leak. Method of transaction did not have a significant effect on outcome.
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LONGITUDINAL DUODENOTOMY FOR EXCISION OF BENIGN
DUODENAL NEOPLASMS
B Dillard, J Hering, S Garrean, J Espat
UIC, Chicago, IL
Introduction. Given their rare occurrence and variable presentation, benign
duodenal neoplasms (BDNs) pose an interesting surgical challenge, as
optimal evidence-based treatment has yet to be defined. Though literature
on this subject is scant, some reports suggest that, for BDNs not amenable to
endoscopic polypectomy, choice of operation should be influenced by
location of the lesion. As such, the operation of choice would be transduo-
denal excision for lesions in poriton 1, pancreaticoduodenectomy for lesions
in portion 2, especially near the ampulla, and segmental resection for lesions
in portions 3 and 4.
Purpose. To present a recent experience with local transduodenal excision of
symptomatic BDNs in the 2nd4th portions of the duodenum.
Methods. Since 2001, 4 patients meeting these anatomic criteria with
symptomatic BDNs have undergone excision at our institution.
Results. The mean age of the 2 males and 2 females in this series was 64
years. Presenting symptoms were dyspepsia (1 patient), epigastric pain (1
patient), and upper GI hemorrhage (2 patients). All patients underwent EGD
with consequent localization of their duodenal tumors and further character-
ization via EUS. The characteristics of the BDNs are as follows: one 2 cm
hamartomatous polyp on the antimesenteric wall of D2; one well differ-
entiated 3 cm neuroendocrine tumor at D3; one 4 cm pedunculated GISTon
the antimesenteric wall of D4, and one 3 cm ampullary tubulovillous
adenoma. All operations were performed via a right subcostal incision. All
non-ampullary BDNs were excised via logitudinal duodenotomy with
transverse 2 layer closure. The single ampullary tubulovillous adenoma was
excised via ampullectomy with subsequent septoplasty between the common
bile duct and pancreatic duct, circumferential sphincteroplasty, and trans-
verse 2 layer closure. In all cases, periduodenal JP drains were placed
intraoperatively. Postoperatively, patients underwent a gastrograffin upper GI
study with no evidence of leaks or luminal narrowing. There were no
postoperative complications and there was no mortality.
Discussion. This modest series supports that anatomic location is not a
limitation for proceeding with local excision of BDNs via longitudinal
duodenotomy with transverse closure. When necessary, ampullectomy with
reconstruction is technically feasible. This procedure can be performed with
minimal morbidity and, when possible, is preferable to the alternatives of
pancreaticoduodenectomy or segmental resection.
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DIC-CT AND INTRA-OPERATIVE CHOLANGIOGRAPHY FOR
LAPAROSCOPIC CHOLECYSTECTOMY
Jun-Ichi Tanaka, MD, PhD, Yoshio Deguchi, MD, PhD, Shin-Ei Kudo, MD,
PhD
Showa University Northern Yokohama Hospital, Yokohama, Japan
In case of laparoscopic cholecystectomy (LC), we routinely examine
preoperative DIC-CT to evaluate an anatomy of biliary tract, and also
perform intra-operative cholangiography (IOC) to avoid intra-operative bile
duct injury (IBDI). We investigated feasibility of DIC-CT and IOC for IBDI.
During resent five years, we have experienced LC for 509 patients in our
hospital.
Results. DIC-CT revealed anatomical anomaly on 30 patients out of 509
patients. IOC was performed completely on 96% of the patients. Four
patients out of 509 patients who underwent LC encountered IBDI due to
marked inflammation around the cystic duct, and two patients were treated
surgically with T-tube drainage or direct repair of injured cystic duct under
laparoscopic guidance, and these postoperative courses were uneventful.
Four patients were successfully treated with ENBD or just intra-abdominal
drainage which was placed intra-operatively. Summary: IOC is still con-
troversially, however it is reported to be useful for intra-operative examination
of CBD stones, and also to be useful to avoid injury of bile duct. Routine IOC
during LC including dissection of cystic duct and catheterization into the
cystic duct could improve skill of surgical procedures such as laparoscopic
CBD exploration or laparoscopic gastrointestinal surgery.
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LAPAROSCOPIC CHOLECYSTECTOMY IN PROGRESSIVE SYS-
TEMIC SCLEROSIS
Nihar R Dash, Devendra Gupta, MD, Rajan Saxena, MS
AIIMS, New Delhi, India, New Delhi, India; SGPGIMs, Lucknow,
Lucknow, India
Aim. To discuss the challenges of laparoscopic cholecystectomy that can be
posed in a patient with systemic sclerosing disease.
Background. Progressive systemic sclerosis or Scleroderma is a not so
uncommon disease which is characterised by inflammation, vascular sclerosis
and fibrosis of skin, viscera and other organs of the body. Laparoscopic
cholecystectomy in these cases can be troublesome and challenging for the
surgeon as well as the anaesthetist. Here in we, for the first time, report a case
which addresses the issue. The Case: A 42 year old lady presented to us with
symptomatic uncomplicated cholelithiasis .She was a diagnosed case ofFigure 1. Excision of BDN via longitudinal duodenotomy.
Figure 2. Reconstruction of common bile duct and pancreatic duct
after ampullectomy.
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scleroderma since last 22 years and was on steroid and penicillamine.In her
case the manifestations were raynaud’s phenomena, hardening of skin of
upper half of the body associated with skeletal,pulmonary,endocrine,vascu-
lar,ocular and other connective tissue manifestations. High risk consent for
general anaesthesia and high chance for conversion to open were taken. In the
operation theatre exposure to cold was avoided.Intra venous cannulation,
intubation, blood pressure recording and anaesthesia required skill and
special measures. Pneumoperitoneum was created with veress needle.
Because of circumferential hardening of the abdominal wall the inflation
was restricted and coupled with the fatty mesentery, thickened bowel and
unyielding liver, the working space was very limited. Two fan retractors were
used for retraction of the bowel. The calot dissection and gall bladder
removal were not problematic especially in the hand of an experienced
surgeon of the department. Extra attention was given to hemostasis.Wounds
closed with subcutaneous sutures only. The patient had a smooth post
operative course.
Conclusion. Laparoscopic cholecystectomy in patients with scleroderma is
of immense benefit to the patient if precautions are taken; as described in our
case; according to the pathological changes, with the availability of advanced
anaesthetic facilities and experienced surgeon.
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NEW APPROACHES FOR BLOODLESS LAPAROSCOPIC CHO-
LECYSTECTOMY IN THE CIRRHOTIC PATIENT
Geetha Jeyabalan, MD, T. Clark Gamblin, MD, Fady Balaa, MD, David A
Geller, MD
UPMC Liver Cancer Center, University of Pittsburgh, Pittsburgh, PA
Introduction. The prevalence of cholelithasis in cirrhotic patients is
reported to be twice that of the general population. Cirrhosis has represented
a relative contraindication to laparoscopic cholecystectomy, however, tech-
nological advances in minimally invasive surgery and haemostatic devices
have allowed advances in the field of high risk biliary surgery. A review of
peri-operative outcomes in a series of high risk cirrhotic patients undergoing
laparoscopic cholecystectomy was undertaken.
Methods. Records of cirrhotic patients undergoing laparoscopic cholecys-
tectomy at a single institution performed by two surgeons were reviewed
(199906). Demographic data, conversion to open surgery, haemostatic
techniques, operative times, blood loss, length of stay, and 30-day mortality
were assessed.
Results. 47 patients (25 males, 22 females) underwent an attempted
laparoscopic cholecystectomy of which 4 cases were converted to laparotomy.
Symptomatic cholelithiasis was the indication for operation in the majority of
cases with acute cholecystitis representing only 2 of cases. All patients were
Child’s class A or B cirrhotics (42 A and 5 B). Median age was 55 and median
length of stay was 1 day (113). Mean estimated blood loss was 115 (50
600cc ). Blood products were required in a only 4 patients: one patient
required transfusion of packed red blood cells, two required platelet
transfusions, and one fresh frozen plasma. Tissuelink electrocautery and
argon beam coagulation were utilized in all cases. There were no reoperative
cases for bleeding in the series. Intraperitoneal drains were left primarily for
ascites in 14 cases and most were removed by the first post-operative day.
Mean operative time was 126 minutes. There was no acute on chronic
hepatic decompensation in the immediate post-operative period. Addition-
ally, there was no 30-day mortality in these patients.
Conclusion. This series represents the second largest review of laparoscopic
cholecystectomies in cirrhotic patients in the United States. Although
operative interventions in the setting of cirrhosis may represent more
challenging cases with respect to blood loss and other morbidity, laparoscopic
cholecystectomy is feasible and safe with acceptable conversion rates and
length of stay. Furthermore, utilizing advanced laparoscopic hemostatic
devices can minimize both blood loss and transfusion rates. A representative
video demonstration of the laparoscopic hemostatic techniques described
above will also be included.
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HEMOCONCENTRATION AS AN EARLY MARKER OF SEVERITY
IN THE ACUTE BILIARY PANCREATITIS
Alberto Fersini, MD, Tiziano Pio Valentino, MD, Caterina Santacroce, MD,
Nicola Tartaglia, MD, Antonio Ambrosi, MD, Vincenzo Neri, MD
University of Foggia, Foggia, Italy
Purpose of the Study. Studies that associate the hemoconcentration with
the development of necrotizing acute pancreatitis, are present in literature.
The aim of this study was to evaluate if the hemoconcentration can be an
early marker of necrotizing pancreatitis.
Methods. In the period January 1998June 2005, 60 patients admitted with
diagnosis of acute biliary pancreatitis; 24 had a CT-scan within 3672 hours;
Ranson’s criteria were applied in all patients. Seven of the 24 patients had a
necrotizing pancreatitis (Balthazar’s score). The hematocrit (Hct) was
retrospectively evaluated and associated with the CT-scan morphological
data.
Results. The regression analysis showed an association between pancreatic
necrosis, by means of CT evaluation, and the hemoconcentration. Hemato-
crit more than 43% in the males and more than 39% in the females within the
first 24 hours from the admission, was a marker of severity and pancreatic
necrosis. In 6 of the 7 patients with necrotizing pancreatitis there was critical
value of Hct and only in 4 of the 17 patients with edematous pancreatitis
there was a high value of Hct, showing the statistical significativity of the
proposed criteria (pB0.01). The negative predictive value of the hemocon-
centration was 94.7% for the evolution in pancreatic necrosis.
Conclusions. The prognostic value of the hemoconcentration is comparable
with the score of Ranson. So, it is an early and simple marker of the
necrotizing evolution of the acute pancreatitis, because of its high negative
predictive value: the patients with acute pancreatitis without hemoconcentra-
tion will rarely develop a necrotizing pancreatitis.
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REFRACTOMERY ROLE FOR DIAGNOSIS OF PATHOLOGIC
PROCESS IN ACUTE PANCREATITIS
Valentina Lisienko, Edvard Mikaelyan
Urals State Medical Academy, Ekaterinburg, Russian Federation
Acute pancreatitis (AP) is a disease characterized by unpredictable outcomes.
In most AP cases the process is controlled at the phase of the gland edema. In
a number of cases the disease develops into the phase of pancreanecrosis
(PN). The 3rd phase is that of suppurative complications (SC). These phases
make up a single whole the manifestations of which as well as transitions of
one phase into another are, at first, caused by enzymatic autoagression degree
and, then, by an infection. It’s known that the 1st phase is from 1 to 3 days
long, and the 2nd one is up to 7 days long. Later, there can appear resorption
of necrotic infiltration  from 2 to 8 weeks long, aseptic sequestration or
necrosis foci infection, i.e. transition into the 3rd phase. The SC phase is
usually evident on the 15th day or later. The time of transition of one phase
into another is relative. Its diagnosis is especially difficult. The main
difficulties appear during diagnosis of infiltrate infection and SC course.
This is followed by delayed intervention. To make the transition of 1 phase
into another more exact, to determine suppurative process and its course in
pancreas, to perform a surgical intervention in time we propose to evaluate
the index of blood serum refraction (IBSR) by refractometry method. We
examined 30 patients having various AP forms using this method and made
up the following groups of patients: 1st gr.- patients with pancreas edema.
2nd gr- patients with ‘‘aseptic’’ pancreanecrosis. 3rd gr- patients at the phase
of SC.The following results were obtained: On admission mean IBSR of the
patients in the 1st gr was 1.3472. While the patients were improving IBSR
was decreasing and to the time of their discharge from the hospital it was
1.3454. In the 2nd gr mean IBSR on admission was higher than in the 1st gr
and made up 1.3500; on discharge it became 1.3475 that also demonstrated
their clinical improvement. All the patients from this group recovered. In the
3rd gr mean IBSR on admission was 1.3490, in the course of treatment it was
lowering. And on discharge mean IBSR of the three recovered patients was
1.3448 that showed a clinical course of improvement as well. Three patients
died during SC phase. Mean IBSR of these patients on admission was
1.3497.One should pay attention to IBSR decrease, the patients’ state
becoming worse and the treatment being unsuccessful. Thus, preliminary
study of IBSR importance for the changes taking place in pancreas, for the
course of pathologic process demonstrates IBSR diagnostic value. While AP
is progressing the IBSR figures have a tendency to go up and the process of
recovery is accompanied by a decrease in these figures.
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MINIMALLY INVASIVE PROCEDURES FOR THE TREATMENT
OF ACUTE PANCREATIC PSEUDOCYSTS
Oscar Mazza, MD, Martı´n Palavecino, MD, Diego Ferna´ndez, MD, Ricardo
Mentz, MD, Juan Pekolj, MD, Eduardo De Santiban˜es
Hospital Italiano, Buenos Aires, Argentina
Background. The treatment of acute pancreatic pseudocyst has been open
surgery for a long time. However, in the last years, minimally invasive
techniques have been performed more frequently, with less morbidity and
mortality rates.
Objetive. To show the experience at a single Center with laparoscopic,
endoscopic and percutaneous approach for the treatment of acute pancreatic
pseudocysts, and to define the use of the ‘‘open’’ surgery nowadays.
Population and Methods. We performed a retrospective analysis of the last
10 years. We analyzed patients with acute pancreatic pseudocyst. We
reviewed procedures, morbidity, mortality and effectiveness rates.
Results. Between 19962006, we treated 39 patients with 43 acute
pancreatic pseudoscysts. We performed 7 open surgeries (2 because surgeon
preference and 5 because diagnostic doubts). In 19 patients we performed
laparsocopic surgery; 12 cystojejunostomies, 1 double cystojejunostomy, 2
cystogastrostomies, 1 external drainage and 1 splenopancreatectomy. We
converted 2 laparoscopic surgery to open fashion because of a technique
problem. Only one patient had recurrent pseudocyst. In 5 patients we
performed endoscopic approach, 2 transgastric drainage, 2 transpapillar
drainage and one transduodenal drainage with excellent results. In 9 patients
who were approached percutaneusly, 3 failed and required surgery.
Conclusions. The ‘‘open’’ surgery should be indicated only when the
percutaneous approach fails and/or exists diagnostic doubts. The minimally
invasive surgery should be taken as the first option because of its excellent
successful rate.
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ADULT CONGENITAL CHOLEDOCHAL CYST
Ricardo Joaquin Mondrago´n-sa´nchez, MD, FRCP, Elizabeth Aguilar-alaniz
2003, MD, Alejandro Mondrago´n-sa´nchez 80, MD, Yisvanth Pe´rez-ponce
80, MD
Issemym, Toluca, Mexico
Background. There are five types of choledochal cyst, which are anomalies
that involve intrahepatic or extrahepatic bile ducts, or both. These lesions are
found most frequently in patients who are Asian, female, infants but are
recognized with increasing frequency in adults. It has been estimated that the
actual clinical incidence of choledochal cyst ranges from 1 in 13,000 to 1 in 2
million patients. Biliary cyst account for approximately 1% of all benign
biliary disease. The frequency of bile duct cyst in decreasing order is type I
choledochal cyst (80%); followed by type IV, 13%; type III, 4%; and type II,
2.6%. Multiple intrahepatic bile duct cyst without an extrahepatic compo-
nent occurs in less than 1% of the patients.
Patients and Methods. A Retrospective review of clinical files of all patients
with choledochal cysts diagnosed between 2003 and 2006 was performed.
Results. We have managed 7 patients with this anomaly. All were female.
The mean age was 44 years (range 3260 years) and there were 7 type I cysts.
Procedure used to diagnose cyst included Computed Tomography (CT) in
combination with retrograde cholangiopancreatography (ERCP) in three
patients, CT/magnetic resonance cholangiopancreatography (MRCP) three
patients, ultrasonography/ERCP one patient. Presenting complaints included
abdominal pain in three patients, pancreatitis in two patients, and jaundice in
two patients. Our operative treatment included choledochal cystectomy,
cholecystectomy, and Roux-Y hepaticoyeyunostomy. There was no mortality.
Surgical morbidity was limited to two patients with pneumonia and empyema
(20%), respectively. Hospital stay range was nine to 42 days with an average
of 20 days. Operative time range 210360 minutes with a mean time of 275
minutes. Surgical bleeding range was 2501110ml, mean bleeding was
535 ml. Median follow-up was 21 months. All patients are symptom free.
Conclusions. MRCP provides essential information of the duct anatomy
without the risk of pancreatitis. Management of choledochal cysts is
successful after their complete removal. Biliary continuity after cyst resection
is best established by Roux-Y hepaticoyeyunostomy.
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TREATMENT OF BENIGN BILIARY STENOSIS WITH TEMPOR-
ARY SELF-EXPANDABLE METALLIC STENT
Maryla˜n¨e Plasse, MD, Franck Vandenbroucke, Richard La˜#tourneau, MD,
Michel Dagenais, MD, Ra˜#al Lapointe, MD, Andra˜# Roy, MD
Hopital Saint Luc  CHUM, Montra˜#al, PQ, Canada
Introduction. Metallic self-expandable stent (MSES) are commonly use for
treatment of neoplasic biliary stenosis. Recently MSES for treatment of
benign biliary stenosis (bile duct injury, chronic pancreatitis, post-tranplan-
tation stenosis) have been reported with good results. Thus, the aim of our
study is to evaluate the safety and feasibility of temporary MSES in different
type of benign stenosis.
Patients and Methods. Between November 2004 and Mars 2006, 8
patients (1 woman and 7 men with a mean age of 55 y.o.) underwent
MSES insertion to treat a benign stenosis. The origin of benign stenosis was:
post-liver transplant (n4), chronic pancreatitis (n3), choledochocele
(n1). All, but one, patients were treated with multiple dilatations and
plastic prothesis insertion before the use of MSES. The indication of MSES
was a persistent stricture despite optimal endoscopic treatment, poor surgical
candidate, poor tolerance of the procedure, adverse local conditions. For one
patient with a very poor general condition, MSES was use immediately to
avoid multiple endoscopic procedures.
Results. The mean interval between first dilatation and the MSES insertion
was 126 days (range: 0 to 338). The average number of endoscopic
procedures before insertion of MSES was 1.6 (range: 0 to 4). There were 2
complications after MSES insertion: 1 pancreatitis and 1 cholangitis. MSES
retrieval was performed without difficulties and complications (mean: 288
days after insertion; range: 100 to 453) in 7 patients. The follow-up is 141
days.
Conclusions. The treatment of benign biliary stenosis with MSES is safe
and feasible. Moreover, MSES can be removed without complications after a
few months, used as a temporary method for dilatation. It is also an
alternative for selected patients in poor medical condition or in whom the
local duodenal conditions make repeted ERCP hazardous. A longer follow-
up will be necessary to evaluate the long term efficacy of this method of
dilatation for resolution of benign strictures.
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LIVER RESECTION COMBINED TO BILE DUCT REPAIR AFTER
A BILE DUCT INJURY DURING LAPAROSCOPIC CHOLECYS-
TECTOMY
Franck Vandenbroucke, Maryle`ne Plasse, MD, Richard Le´tourneau, MD,
Michel Dagenais, MD, Andre´ Roy, MD, Koen Vermeiren, MD, Re´al
Lapointe, MD
Hopital Saint Luc  CHUM, Montre´al, PQ, Canada
Introduction. Laparoscopic cholecystectomy increases the risk of major
bile duct injuries. The aim of this study was to define the place of liver
resection combined to bile duct repair in the treatment of major bile duct
injuries.
Methods. A retrospective study of 23 patients (16 women and 7 men with a
mean age of 51.4 y.o.). We analyze the following criteria: gallbladder disease,
injuries diagnosis time, Strasberg classification of injuries, type of bile duct
repair and long-term results.
Results. Between 1991 and 2005, 123 patients were referred for a biliary
tract injury; 23 patients (28.3%) required a liver resection combined to bile
duct repair. The bile duct injury was recognized during the surgery for 7
patients or following the surgery in 16 patients. The Strasberg classification
was: 3 type E3, 16 type E4 and 4 type E5. Before the 23 patients were
referred, 12 have had hepaticojejunostomies, 5 primary closures, 3 drainage
of bilioma (2 percutaneous and 1 open approaches) and 3 conservative
treatments. After referral, we have had to perform an intrahepatic hepatico-
jejunostomy combined to 9 central hepatectomies and 14 right hepatec-
tomies. There is one postop mortality (4,3%), and 17 patients (74%) had ]1
postop complications. The mean follow-up was 88 months. During the long-
term follow-up, 2 patients developed a secondary biliary cirrhosis and 1 an
anicteric cholestasis.
Conclusions. Liver resection combined to bile duct repair may be necessary
in the treatment of bile duct injury in order to obtain the best results,
especially in patients with Strasberg E4 bile duct trauma.
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PARENCHYMAL SPARING CENTRAL HEPATECTOMY FOR HI-
LAR STRICTURE
John Stauffer, MD, Marjorie Dougherty, PA-C, MPH, Denise Harnois, MD,
Nguyen Justin, MD
Mayo Clinic, Jacksonville, FL
Introduction. The role of parenchymal sparing central hepatectomy
(PSCH) for hilar biliary stricture is not well established. In this study, we
report 4 cases of hilar strictures which were treated with PSCH.
Methods. Liver resections performed at our center from 1/98 to 8/06 were
retrospectively reviewed.
Results. A typical preoperative hilar stricture is shown in Fig 1. Among 221
cases, 4 required the partial resection of segments V and IV with multi-
segmental biliary reconstruction via RNY hepaticojejunostomy, Fig 2. A
typical postoperative cholangiogram is seen in Fig 3. Case 1 involved a
gallbladder cancer which invaded the hilum. PSCH was performed with en-
bloc extended cholecystectomy and biliary reconstruction as shown. The
hospital course was uncomplicated. Patient received adjuvant chemoradia-
tion and survived 7 months. Case 2 involved a benign hilar stricture
consistent with sclerosing cholangitis which presented as painless jaundice.
He is doing well at 13 months after PSCH. Case 3 involved a cholangio-
carcinoma found in 83 y.o. woman treated with PSCH. Her recovery was
complicated by pulmonary embolus but she is doing well at 1 year without
undergoing adjuvant therapy and has no evidence of recurrence. The 4th
PSCH case involved 2.5 cm cholangiocarcinoma in the setting of micro-
nodular cirrhosis which was found intraoperatively. His postoperative course
was complicated by a late onset of ascites and sepsis resulted in multiorgan
failure and death in 5 months. Postoperative cholangiograms obtained in all
patients demonstrated no biliary leaks.
Conclusion. In selected cases of hilar strictures, parenchymal-sparing
central hepatectomy can be useful. It is particularly attractive for benign
lesions and for lesions in the presence of limited hepatic reserve. Although
complex, multisegmental biliary reconstruction can be safely performed.
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AGE INCREASES MURINE RESTING GALLBLADDER VOLUME
Abhishek Mathur, MD, Kyle Yancey, MD, Julia J. Walker, MS, Debao Lu,
MD, Deborah A. Swartz-basile, PhD, Attila Nakeeb, MD, Henry A. Pitt,
MD
Indiana University, Indianapolis, IN
Introduction. Age, obesity and diabetes are known risk factors for
cholesterol gallstone formation. We have previously demonstrated that
young, obese, diabetic mice have increased resting gallbladder volume and
decreased in vitro gallbladder emptying compared to young lean mice.
However, the influence of ageing on gallbladder volume and response are
unknown. Therefore, we tested the hypothesis that old mice would have
increased resting gallbladder volume and impaired gallbladder emptying
compared to young mice.
Methods. Thirteen lean, nondiabetic (C57BL/6J) and 12 obese, diabetic,
leptin-deficient (Lepob) female mice were fed a nonlithogenic diet for three
weeks. Fourteen mice (7 lean, 7 obese) were young (3 months) while 11 mice
(6 lean, 5 obese) were old (12 months). After an overnight fast, in vivo
gallbladder volume was measured by ultrasound before and after an injection
of cholecystokinin 1 nmol/kg. Gallbladder ejection fraction was calculated.
Serum was drawn for glucose and insulin levels, and HOMA (an index of
insulin resistance) was calculated. Data were analyzed by ANOVA and
Student’s t test.
Results. Gallbladder resting volume, residual volume, ejection fraction (EF)
and serum data are presented in the table.
Group
Resting
Vol (ml)
Residual
Vol (ml)
EF
(%)
Glucose
(mg/dl)
Insulin
(mIU/L)
HOMA
Index
Lean-Young 1592 391 8099 134919 191 0.290.1
Lean-Old 2392 592 8197 215911* 793 3.391.3
Obese-
Young
2895* 492 8794 290921* 29911* 20.398.1*
Table (Continued )
Group
Resting
Vol (ml)
Residual
Vol (ml)
EF
(%)
Glucose
(mg/dl)
Insulin
(mIU/L)
HOMA
Index
Obese-Old 6295$ 1797$ 73911 180941§ 53911D 24.8910D
*pB0.05 vs Lean-Young, $pB0.01 vs Others, §pB0.05 vs Obese-Young,
DpB0.06 vs Lean-Old.
Conclusions. These data suggest that age, obesity and diabetes all 1)
increase resting gallbladder volume but 2) do not alter in vivo gallbladder
response to cholecystokinin and that 3) age increases residual gallbladder
volume in obese mice. Therefore, we conclude that age contributes to
gallstone pathogenesis by enhancing gallbladder stasis.
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DEVELOPMENT OF A REVERSIBLE SURGICAL MODEL OF
GALLBLADDER INFLAMMATION AND CHOLESTASIS
Carlos U Corvera, Jacob G Kirkland, Sanjay Kakar, Lygia Stewart
University of California, San Francisco, San Francisco, CA
Introduction. Previous mouse models of gallbladder inflammation used
ligation of the cystic duct alone that resulted in inflammation that is
histologically different from that seen in human cholecystitis. Ligation of
the common bile duct (CBD) is popular method used to induce biliary
inflammation because it induces histological changes identical to acute
cholecystitis. In mice, however, CBD ligation results in a high early post-
operative mortality rate, which may be due to post-operative traumatic
pancreatitis. To overcome this problem, we developed a simplified model of
gallbladder inflammation in mice, which minimizes post-operative death,
maintains an effective inflammatory response, and is easily reversible.
Methods. Mice were anesthetized. At laparotomy, without tissue dissection,
a 1 mm titanium clip is applied across the distal CBD. To reverse the
obstruction, a fine silk suture was incorporated into the clip during initial
placement and secured to the abdominal wall. The suture was removed on
postoperative day 5, thereby reversing CBD obstruction without repeat
surgery. Mice were allowed to recover for 10 days after relief of obstruction.
Results. Obstruction for 5 days caused distension of the gallbladder and
CBD. The gallbladder showed marked hypertrophy (8-fold increase in wall
thickness) and inflammation (17-fold increase in tissue myeloperoxidase
activity) compared to sham controls. Serum levels of alkaline phosphatase
and bilirubin were markedly elevated, indicating injury to the biliary
epithelium. Early (day 02) survival was 100% and later (day 35) survival
was 85% (n54 mice). We successfully reversed biliary obstruction (n10
mice), with one death from infection 2 days after clip removal. Of the
surviving animals, gross examination showed complete biliary decompres-
sion, reduced inflammation and resolution of jaundice. Histological findings
confirmed reduced epithelial damage, edema and neutrophil infiltration.
Serum alkaline phosphatase and bilirubin levels also returned to within
normal levels.
Conclusion. We have developed a new and reversible technique to induce
bile duct obstruction in mice. Obstruction of the CBD causes injury and
inflammation in the gallbladder, which resolves after reversal. This reversible
model of cholestasis can be applied to genetically altered mice to further
define molecular mechanisms of biliary inflammation.
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CHALLENGES IN PRIMARY STEATOTIC HEPATOCYTE ISOLA-
TION PROCEDURES
Justin D Ellett, John W Turner, MD, Eric Hall, Zachary P Evans, Kenneth D
Chavin, MD, PhD
Medical University of South Carolina, Charleston, SC; Duke University,
Durham, NC; CellzDirect, Inc., Pittsboro, NC
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The use of primary human hepatocytes is essential for basic research and
pharmaceutical arenas. To meet this demand, viable hepatocytes are being
procured from residual tissues of hepatic resections. The tissue is preserved
with a standard cold-storage solution. Hepatocytes are then isolated using a
collagenase solution to dissolve the extracellular matrix and purified via a
density gradient separation. The increasing prevalence of human liver
steatosis offers a technical hurdle for the isolation of viable hepatocytes due
to differences in cell density compared to normal hepatocytes. In order to
determine the significance of liver steatosis in hepatocellular yield, we
conducted a retrospective analysis of 75 samples. Steatosis was broken into
the following groups: none/minimal, mild/moderate, and severe using
conventional analysis of H&E stained slides. Initial cell yields (after
collagenase digestion) showed no difference in average cells/gram tissue
between the none/minimal and mild/moderate steatosis groups (21.6Aˆ915.5
cells/gm tissue vs 20.9Aˆ913.6, respectively), but severe steatosis significantly
decreased initial yield versus both groups (8.60Aˆ92.4, pB0.001). This trend
was similar to the results for a final cell yield (after density gradient
purification), however the differences were not stastically significant (none/
minimal: 9.1Aˆ99.9, mild/moderate: 9.9Aˆ97.5, severe: 3.8Aˆ95.1). Inter-
estingly, there were no significant differences in the percentage yield (final
yield/initial yield) within the groups, indicating high variability in yield after
purification. Steatosis of increasing severity decreases the cell yield after
whole tissue perfusion for isolation of human hepatocytes. The problems
appear to lie with the collagenase perfusion and not with the density gradient
purification. Our data shows a significant difference in initial yield immedi-
ately after the tissue digestion and not in the final yield. Most surprising was
that when the final yield was divided by the initial yield, no differences in
ratios were observed between groups. This indicates that our methods for
compensating for hepatocellular steatosis are adequate during the density
separation. However, because so much variability in yield exists in all groups,
other factors should be evaluated, including ischemia times, degree of
necrosis/fibrosis, etc, which may affect the hepatocyte purification. Because
steatosis clearly affects the initial yield, these results implicate either the
quality of perfusion or enzymatic digestion. Further analysis will be necessary
to determine which step is responsible.
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HEPATIC FIBROSIS INDUCED BY XENOSERA IS FEATURED
BY INCONSPICUOUS INFLAMMATION BUT ROBUST ECM
REMODELING
Gordon D Wu, Yao He, MD, PhD, Tomohito Sadahiro, MD, Jan Li, PhD,
Hui Zhu, MD, PhD, Sangik Noh, MD, Andrew S Klein, MD
Cedars-Sinai Medical Center, Los Angeles, CA
Objective. Hepatic cirrhosis in rats induced by injection of pig sera (IPS)
represents a model of fibrogenesis caused by immunological injury. However,
the underlining pathogenesis is not well characterized. This study was carried
out to determine the interrelation between hepatic inflammation and fibrous
proliferation.
Methods. A chronic model of liver cirrhosis introduced by IPS in rats was
studied. An acute model of cholestatic cirrhosis induced by common bile
duct ligation (BDL) served as comparison. Liver tissue was collected for
histology, histochemistry and quantitative real time PCR (qPCR) analysis to
quantify the mRNA expression of genes relating to inflammation (IL-1, IL-6,
MCP-1, MIP-1, TNF-a, RANTES, TGF-b, PDGF and CD44) and
fibrogenesis (collagen 1, aSMA, MMP-9 and TIMP-1).
Results. IPS resulted in an insidious development of liver fibrosis character-
ized by intensive septum formation, collagen I deposition and aSMA
myofibroblast proliferation, without prominent hepatic parenchymal changes
and limited inflammation. Immunohistochemistry showed limited number of
T cells (CD3), macrophages (CD68) and total leukocytes (CD45) in
the cirrhotic livers. qPCR demonstrated that mRNA coding for genes relating
to ECM remodeling such as collagen 1, aSMA, MMP-9 and TIMP-1 were
significantly up-regulated in the IPS livers when compared with normal
control. However, mRNA transcripts coding for inflammation-related
cytokines TGF-b, PDGF, IL-1, IL-6, TNFa, CD44, MIP-1 and MCP-1
were at levels comparable with normal control. Only RANTES was mildly
up-regulated. In contrast, the BDL livers exhibited histological changes with
hepatocyte degeneration/necrosis, bile duct proliferation and portal inflam-
mation. BDL liver gene expression was remarkable for up-regulation of all
the pro-inflammation genes examined in association with increased expres-
sion of collagen-1, aMSA, MMP9 and TIMP-1, indicating that in BDL livers
robust inflammation coincides with fibrous proliferation.
Conclusion. Unlike BDL livers which exhibited remarkable up-regulation of
various pro-inflammation cytokine genes, cirrhotic livers induced by IPS
exhibit robust extracellular matrix remodeling in the absence of notable
hepatic inflammation. The insidious nature of cirrhosis development seen in
this IPS model mimics certain types of liver cirrhosis in the humans.
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LIVER SINUSOIDAL ENDOTHELIAL CELLS: PHENOTYPIC
CHARACTERIZATION BY ELECTRON MICROSCOPY
Luis J Garcia, MD, Olivier Rolin, Diego Avella, Eric Kimchi, MD, Kevin
Staveley-O’carroll, MD, PhD
Penn State University, Hershey, PA
Introduction. The liver possesses several unique immunological functions,
including the induction and maintenance of peripheral tolerance. Thus, the
immune functions of cells within the sinusoids are of particular interest. Liver
sinusoidal endothelial cells (LSECs) comprise the major cell type within the
hepatic sinusoids and interact directly with the portal and systemic circula-
tions. Therefore, LSECs are strategically placed to play a critical role in the
immune functions of the liver. LSECs have been shown to have high antigen
uptake and processing capacity, similar to other antigen presenting cells.
Some studies have shown that LSECs express surface molecules such as CD-
80, CD-86, and MHC class II allowing LSECs to stimulate T-cells; in
contrast, other studies show data indicating that LSECs do not express these
surface molecules and are thus unable to stimulate T-cells. These previous
studies used flow cytometric analysis after LSEC isolation to study the
phenotypic characteristics of LSECs. In our study, we use electron micro-
scopy as a novel technique to analyze LSECs directly and further elucidate
their phenotypic characteristic.
Methods. Adult C57BL/6 mice were anesthetized per standard
protocol. The left ventricle was cannulated and the animal perfused with
PBS followed with 5 ml of 4% paraformaldehyde and 0.1% glutaraldehyde.
The liver was extirpated, cryoprotected and frozen. Liver sections were
placed on glass super frost slides and kept at 80C. Liver sections were
stained with anti-CD45 and anti-MHC II primary antibodies. Goat anti-
mouse Alexa Fluoro nanogold antibody was used as the secondary antibody.
Slides were then prepared for analysis with electron microscopy using
standard protocols.
Results. High resolution electron microscopy images at magnifications
ranging between 6,000 and 12,000 allowed LSECs to be identified by
morphology. These cells expressed neither MHC class II nor CD45. In
contrast, macrophages and dendritic cells, which were identified by mor-
phology, clearly demonstrated the positive staining for MHC class II and
CD45 that is characteristic of professional antigen presenting cells.
Conclusions. Electron microscopy is an effective method to further
elucidate the phenotypic characteristics of liver sinusoidal endothelial cells.
Using this technique, we have phenotypically characterized LSECs and
demonstrated that they lack the phenotypic characteristics usually associated
with antigen presenting cells. This may represent a powerful tool to further
characterize LSECs in terms of molecules such as CD-80, CD-86, and MHC
I, and hopefully further our understanding of the immunological role of these
cells.
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CELLULAR HETEROGENEITY OF HEPATIC MACROPHAGES:
ISOLATION AND CHARACTERIZATION OF TWO SUBSETS OF
ED2 (CD163) POSITIVE CELLS IN THE RAT LIVER
Gordon D Wu, MD, Yao He, MD, PhD, Tomohito Sadahiro, MD, PhD, Jan
Li, PhD, Sang-ik Noh, MD, Hui Zhu, MD, PhD, Andrew S Klein, MD
Cedars-Sinai Medical Center, Los Angeles, CA
Objective. ED2 is a mouse monoclonal antibody which is widely used for
recognizing rat CD163, a cell surface marker for tissue macrophages. Using
flow cytometry we have recently identified two distinct subsets of ED2 cells
from the rat liver. The current study was conducted to isolate and
characterize these ED2 liver cells subsets.
Methods. Adult F344, ACI or LEW rats were used in this study. Total liver
cells were obtained by in vivo perfusion /digestion of the livers with
collagenase solution, followed by gradient centrifugation. ED2 liver cells
were isolated by FACS. Phenotypes of the sorted cells were determined by
quantitative PCR for gene expression of selected lineage differentiation
markers. Primary cultures were established for studies of cell growth and
phagocytosis. Transmission electron microscopy was used to define the ultra-
microstructures of the cells.
Results. Flow cytometry detected 2 subsets of hepatic macrophages positive
for ED2. The first subset exhibited an ED2high/AFhigh (autofluorescence)
phenotype while the second subset was ED2dim/AFdim. The ED2high/AFhigh
cells in culture exhibited morphology, growth pattern and phagocytic
activity consistent with the general description of Kupffer cells. On the
other hand, the ED2dim/AFdim cells were smaller in size, monocyte-like in
cellular appearance and weak in phagocytosis. In addition to expression
of low levels of macrophage-related surface markers such as ED1 (CD68),
ED8 (CD18), and CD172a, the ED2dim/AFdim cells expressed moderate
levels of mRNA encoding for myeloid lineage differentiation markers
c-fms, ERMP12 (PECAM) and ERMP20 (Ly-6C). Transmission elec-
tron microscopy demonstrated that these two subsets of ED2 cells
were characteristic of myeloid cells. Gadolinium treatment effectively
eliminated the ED2high/AFhigh population but had no effect on the ED2dim/
AFdim cells.
Conclusion The data suggest that the ED2high/AFhigh population of non-
parenchymal liver cells represent the conventional Kupffer cells. The ED2dim/
AFdim cells, however, belong to a subset of non-Kupffer cell hepatic
macrophages with functions and origin yet to be defined.
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LEUKOCYTE-ENDOTHELIUM INTERACTIONS IN ACUTE PAN-
CREATITIS AFTER TNF-ALPHA MODULATION: AN INTRAVI-
TAL MICROSCOPIC STUDY
Andre S Matheus, MD, PhD, Jose Jukemura, MD, Ana Maria M. Coelho,
Paulina Sannomiya, PharmD, PhD, Naomi C. Nakagawa, Jose Eduardo M.
Da Cunha, MD, PhD, Marcel C. C. Machado, MD, PhD
Dept. of Gastroenterology University of Sao Paulo, Sao Paulo, Brazil;
Research Division  Heart Institute (InCor) University of Sao Paulo, Sao
Paulo, Brazil
Background. Leukocyte-endothelium interaction is known to be a remark-
able event at the beginning of systemic inflammatory response syndrome.
Leukocyte activation and infiltration are believed to be critical steps in the
progression from mild to severe pancreatitis and responsible for many of its
systemic complications. The aim of this study was to evaluate leukocyte-
endothelium interactions in mesenteric postcapillary venules and cytokines
serum levels in experimental acute pancreatitis followed by inhibition of
TNF-alpha prodution.
Methods. Severe pancreatitis was induced in Wistar rats with a injection of
0.5ml of 2.5% sodium taurocholate into the pancreatic duct. Eighteen rats
were divided in 3 groups: Sham (surgical procedure without AP induction),
Pancreatitis (AP Induction), and Pentoxifylline (AP induction plus admin-
istration of 25 mg/kg pentoxifylline). Intravital microscopy was used to
observe inflammatory leukocyte rolling, adhesion, and transendothelial
migration in small venules in vivo (venule diameter, 1525 mm). TNF-
alpha, IL-6, and IL-10 levels were measured by ELISA.
Results. Modulation of TNF-alpha by pentoxifylline shows beneficial effects
in this experimental model. The Pentoxifylline group had a statistically
significant reduction of leukocyte rolling, adhesion, and transendothelial
migration in vivo and a statistically significant reduction of inflammatory
cytokines levels (IL-6, IL-10, and TNF-alpha).
Conclusion. Modulation of TNF-alpha reduced systemic inflammatory
response in this experimental model. Moreover, our data suggest that TNF-a
induce accumulation (adhesion, and transendothelial migration) of leuko-
cytes in acute pancreatitis.
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THE EFFECT OF ISCHAEMIC PRECONDITIONING IN HUMAN
LIVER SINUSOIDAL ENDOTHELIAL CELLS FOLLOWING HY-
POXIA-REOXYGENATION
Dhanwant Gomez, Ann Graham, Nicholas Orsi, Uma Ekbote, Lance Burns,
Shervanthi Homer-vanniasinkam, K. Rajendra Prasad
Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom; University
of Bradford, Bradford, United Kingdom; Leeds Institution of Molecular
Biology, Leeds, United Kingdom; Department of Clinical Sciences, Shef-
field, United Kingdom
Background. Ischaemic preconditioning (IPC) is known to have protective
effects against ischaemic-reperfusion injury following major liver resection
and transplantation. However, its effect on liver regeneration is still
undetermined. We aimed to assess the cytokine and growth factor production
by human liver sinusoidal endothelial cells (HLSEC) and evaluate the effect
of IPC on these mediators in an in vitro hypoxia-reoxygenation (H-R) model
mimicking ischaemic-reperfusion injury.
Methods. Confluent culture flasks of HLSEC were subjected to H-R (1 hour
hypoxia1 hour reoxygenation), IPC with H-R (10 minutes hypoxia10
minutes reoxygenation1 hour hypoxia1 hour reoxygenation) and com-
pared to untreated Controls. Production of interleukin (IL)-1b, IL-1 receptor
antagonist (IL-1ra), IL-6, IL-8, transforming growth factors (TGF)-a,
granulocyte-colony stimulating factor (G-CSF) and tumour necrosis factor
(TNF)-a were determined over a 48 hour period.
Results. IL-6, IL-8 and G-CSF were produced by HLSEC, while IL-1b, IL-
1ra, TGF-a and TNF-a were not. IPC prior to H-R increased IL-6 (36% and
38%) and G-CSF (31% and 85%) production compared to H-R alone after
36 and 48 hour respectively. IPC prior to H-R decreased IL-8 output by 9%
and 7% compared to H-R alone after 36 and 48 hours respectively. Although
there was a trend in increased IL-6 and G-CSF production, there was no
significant difference in IL-6, IL-8 and G-CSF production between the IPC-
treated group and non-IPC-treated groups.
Conclusion. HL-SEC produces pro-regenerative mediators such as IL-6,
IL-8 and G-CSF. Although IPC affects IL-6, IL-8 and G-CSF release in
HLSEC between 24 to 48 hours following H-R, this was statistically not
significant. The final effect on liver regeneration would depend on the
interaction of various liver cells and studies on co-culture models are
required.
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ISCHEMIC PRECONDITIONING AND INTERMITTENT CLAMP-
ING INCREASE THE TOLERANCE OF FATTY LIVER TO HEPA-
TIC ISCHEMIA-REPERFUSION INJURY IN THE RAT
Reza F Saidi, MD, Jennifer Chang, MD, Steven Verb, MD, Steven Brooks,
MD, I Nalbantoglu, MD, Volkan Adsay, MD, Michael J Jacobs, MD
Providence Hospital and Medical Centers, Southfield, MI; Detroit Medical
Center, Detroit, MI
Introduction. Liver ischemia-reperfusion (I/R) injury is a well-known cause
of morbidity and mortality following liver surgery and transplantation.
Hepatic steatosis increases the extent of cellular injury incurred during I/R
injury. Further investigation is warranted to identify measures that reduce the
untoward sequellae of liver I/R injury.
Methods. Male Zucker rats were subjected to 75-minutes of 70% hepatic
ischemia and three hours of reperfusion. The ischemic periods were based on
following protocols: Continuous clamping (CC) for 75-minutes; Intermittent
clamping (IC) with 5 cycles of 15-minutes clamp on and 5-minutes clamp
off; or Ischemic preconditioning (IP) with 10-minutes clamp on, 15-minutes
off, and 60-minutes on. Each group was further subdivided (7 rats in each
subgroup) into control and treatment (methylprednisolone- MP) arms. The
rats were pretreated with intravenous methylprednisolone (2 mg/kg) or
normal saline (NS) prior to the induction of ischemia. Warm I/R injury
was evaluated using serum levels of aspartate aminotransferase (AST), serum
IL-6, hematoxylin and eosin staining, and a specific marker of apoptosis
(TUNEL staining).
Results. Hepatocellular injury was significantly reduced with IP and IC
compared with CC (AST- 32859122.3 and 28759285.4 compared with
5436.39984.7 units/L, respectively (PB0.01). Serum IL-6 level was also
significantly reduced with IP and IC compared CC (7098.8 and 7696.2
compared with 14798.5 ng/l respectively (PB0.01). Histologic analysis also
revealed that IC and IP provided significant protection as compared with CC
group. TUNEL-positive cells were clearly reduced in hepatic tissue of IC and
IP groups compared to CC. Interestingly, pretreatment with MP was
associated with an increase in serum AST, IL-6, and worsening histologic
features in all groups compared to the NS arm.
Conclusions. IC and IP increase the tolerance of fatty liver to hepatic
ischemia-reperfusion injury in the steatotic liver. MP is associated with
increased hepatic I/R injury in the fatty liver.
199
ISCHAEMIC PRECONDITIONING VERSUS INTERMITTENT
CLAMPING ON HUMAN LIVER SINUSOIDAL ENDOTHELIAL
CELLS: EFFECTS ON CYTOKINES AND GROWTH FACTORS
Dhanwant Gomez, Ann Graham, Nicholas Orsi, Uma Ekbote, Lance Burns,
Shervanthi Homer-vanniasinkam, K. Rajendra Prasad
Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom; University
of Bradford, Bradford, United Kingdom; Leeds Institution of Molecular
Biology, Leeds, United Kingdom; University of Sheffield, Sheffield, United
Kingdom
Background. Ischaemic preconditioning (IP) with continuous clamping and
intermittent clamping (IC) of the portal triad are distinct protective strategies
against ischaemic-reperfusion injury (IRI) following liver surgery but their
effect on liver regeneration is still undetermined. Therefore, we aimed to
evaluate the effect of IP and IC on cytokine and growth factor production by
human liver sinusoidal endothelial cells (HLSEC) in an in vitro hypoxia-
reoxygenation (H-R) model to mimic IRI.
Methods. Confluent culture flasks of HLSEC were subjected to H-R
(1 hour hypoxia1 hour reoxygenation), IP with H-R (10 minutes
hypoxia10 minutes reoxygenation1 hour hypoxia1 hour reoxygena-
tion), IC (15 minutes hypoxia5 minutes reoxygenation x31 hour
reoxygenation) and compared to untreated Controls. Differences in produc-
tion of interleukin (IL)-1b, IL-1 receptor antagonist (IL-1ra), IL-6, IL-8,
transforming growth factors (TGF)-a, granulocyte-colony stimulating factor
(G-CSF) and tumour necrosis factor (TNF)-a were determined over a 48
hour period.
Results. The production of IL-1b, IL-1ra, TGF-a and TNF-a was
undetectable in all groups. IP prior to H-R featured increased levels of IL-
6 (36% and 38%) and G-CSF (31% and 85%) compared to H-R alone after
36 and 48 hours, respectively. IP prior to H-R exhibited a decrease in IL-8
profile by 9% and 7% compared to H-R alone after 36 and 48 hours,
respectively. By contrast, IC increased IL-6 production (22% and 42%) and
G-CSF (57% and 107%) compared to H-R alone after 36 and 48 hours,
respectively. IC decreased IL-8 production by 8% and 1% compared to H-R
alone after 36 and 48 hours, respectively. There was no significant difference
in IL-6, IL-8 and G-CSF production between IP-treated and IC-treated
groups.
Conclusion. Both IP and IC appear to equally influence the expression of
pro-regenerative mediators such as IL-6, IL-8 and G-CSF in HLSEC. Both
IP and IC seem to influence the release of IL-6, IL-8 and G-CSF between 24
to 48 hours following H-R. These results suggest that both IP and IC could
potentially affect the liver regeneration signaling cascade. Hence, both
strategies require further evaluation using co-culture models to determine
their final effect on these mediators of liver regeneration.
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A SINGLE-INSTITUTION RETROSPECTIVE REVIEW OF LA-
PAROSCOPIC AND OPEN DISTAL PANCREATECTOMIES
Beth Schrope, MD, PhD, John Allendorf, MD, Joseph Dinorcia, MD, Aliye
Bill, None, Mary Digiorgi, MS, John Chabot, MD
Columbia University, New York, NY
Laparoscopic surgical techniques are being used more frequently in the
treatment of pancreatic disease with minimal morbidity and mortality. In this
retrospective review, we compare multiple variables and outcomes in the
laparoscopic and open distal pancreatectomies performed at our institution
over a four-year period. We reviewed the medical records of 116 patients
undergoing distal pancreatic resection from 2002 to 2006. Data gathered
included demographics, pancreatic pathology, operative time, estimated
blood loss, control of pancreas stump, pancreatic leak and other post-
operative complications, and length of stay. Student t-test, median test, and
chi-square analyses were used to determine significant differences between
laparoscopic and open groups. A p-value of less than 0.05 was considered
significant. Of 116 distal pancreatectomies, 26 were performed laparoscopi-
cally and 90 open (including 9 laparoscopic cases converted to open).
Difficult dissection due to adherent tumor (5), bleeding (2), and technical
limitations (2) were reasons for conversion. There were no significant
differences in demographics, median operative time, pancreatic leak rate
(7.7% versus 8.2%) or overall complication rate (22.7% versus 25.6%).
Twenty-five laparoscopic cases were performed for benign disease and one for
malignant disease versus 36 for benign and 49 for malignant disease in the
open group (pB0.0001). Median EBL was 250 mL in the laparoscopic
group versus 750 mL in the open group (pB0.0001). A stapling device was
used in 92.3% of the laparoscopic cases to control the pancreatic stump
whereas sutures were used in 61.9% of the open cases (pB0.001).
Laparoscopic patients had a median length of stay of 5 days versus 7 days
in the open group (pB0.006) with 34.8% of the laparoscopic group staying
more than 5 days versus 67.1% of the open group staying more than 5 days
(pB0.005). Laparoscopic distal pancreatectomy yields comparable surgical
results with significantly shorter hospital stays than open pancreatectomy.
Pancreatic leak and overall complication rates appear similar. Laparoscopic
distal pancreatectomy is a safe, effective treatment option for select cases of
pancreatic disease.
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OPEN AND LAPAROSCOPIC SPLEEN-PRESERVING, SPLENIC
VESSEL-PRESERVING DISTAL PANCREATECTOMY: INDICA-
TIONS AND OUTCOMES
Matias Bruzoni, MD, Aaron R Sasson, MD
University of Nebraska Medical Center, Omaha, NE
Background. Historically, distal pancreatectomy included removing the
spleen because of the relations of the splenic artery and vein with the tail of
the pancreas. Spleen preserving distal pancreatectomy has been described
lately in order to reduce the risk associated with splenectomy. The aim of this
study is to report a series of open and laparoscopic distal pancreatectomies
with spleen and splenic vessel preservation.
Methods. From June 2001 to June 2006, a total of 29 distal pancreatec-
tomies were performed. Spleen and splenic vessel preservation was possible
in 10 patients (35%). Both open and laparoscopic approaches were
performed. The main variables recorded were demographic data, intra and
postoperative complications, length of stay, final pathology results, and
incidence of pancreatic leak. A closed suction drain close to the pancreatic
stump was placed in every patient. Amylase levels on the drain output were
checked on postoperative day two and five.
Results. All ten spleen-preserving pancreatectomies were performed succes-
fully. Laparoscopic resection was possible in six patients. Only one patient
suffered an intraoperative splenic artery injury, which was repaired without
consequence. Postoperative morbidity consisted of one pancreatic fluid
collection, which was drained succesfully by interventional radiology. Ninety
percent of the patients presented high amylase levels on postoperative day
two. However, all drains were removed on the first outpatient clinic visit, once
the patients were tolerating a regular oral diet. The median length of stay for
the open and laparoscopic approach was 4.5 and 7.5 days, respectively.
Overall, median length of stay was 5.5 days. Final pathology results revealed
serous cystadenoma in 40% of the cases, neuroendocrine tumor of the
pancreas in two cases, two mucinous cystadenomas, one carcinoid tumor and
one intrapancreatic spleen. With an average follow-up of 18.6 months, no
splenic vein thrombosis was detected.
Conclusions. Open or laparoscopic spleen-preserving distal pancreatectomy
(with splenic vessel preservation) appears to be a feasible and safe procedure.
The laparoscopic approach resulted in shorter length of hospital stay and
was associated with minimal morbidity. In selected cases of cystic lesions
and low grade neoplasms, distal pancreatectomy with splenic preservation
is possible.
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CYSTIC PANCREATIC NEUROENDOCRINE TUMORS: A RARE
ENTITY?
Marshall S Baker, MD, MBA, John M Dewitt, MD, Pradermchai Kognkam,
MD, Julia K Leblanc, MD, Harvey M Cramer, MD, Thomas J Howard,
MD, C Max Schmidt, MD, PhD, Keith D Lillemoe, MD, Henry A Pitt, MD
Indiana University Medical Center, Indianapolis, IN
Introduction. Pancreatic incidentalomas including non-functioning cystic
neuroendocrine tumors (CNETs) are being detected with increasing
frequency. CNETs are rare premalignant conditions with fewer than 60
cases reported and the largest published series comprised of only 4 patients.
Computed tomography (CT) has been the diagnostic study of choice but
only occasionally demonstrates the hypervascular border characterisitic of
NETs. Endoscopic ultrasound (EUS) with fine needle aspiration (FNA) and
immuno-histochemistry may be a more consistent means to establish the
diagnosis, but no data on the role of EUS is available. The current review
aims to report the largest series of CNETs treated to date, to describe the
management of CNETs in that series and document the role of EUS in the
diagnosis of CNETs.
Methods. Our experience with CNETs treated at an academic medical
center between 1995 and 2006 was reviewed with regard to patient
demographics, preoperative radiologic/endoscopic evaluation, operative ap-
proach, pathology, and perioperative/long-term outcomes.
Results. Ten CNETs were treated. The mean age at diagnosis was 55.99
10.8 years. Nine patients were male, one female. One patient had symptoms
consistent with a functional tumor (hypoglycemia). The others were non-
functional and either aymptomatic (2) or presented with epigastric pain (4) or
pancreatitis (3). Nine tumors were detected by CT, but only two demon-
strated peripheral hypervascularity. Nine lesions were studied with preopera-
tive EUS and FNA, and all nine demonstrated strong staining for
synaptophysin and chromogranin. Tumors were evenly distributed through-
out the pancreas with four in the pancreatic head and 6 in the body or tail. All
were resected: 1 by enucleation, 3 by pancreaticoduodenectomy, and 6 by
distal pancreatectomy. Average tumor size was 2.390.9 cm. Perioperative
morbidity occurred in 30% (2 intra-abdominal abscesses, one pancreatic
fistula). All patients survived surgery. The average length of follow-up was
2.791.7 years. One patient had evidence of lymph node involvement at the
time of resection and had late hepatic recurrence treated with hepatic artery
emoblization. The remaining nine have had no evidence of recurrence. All
ten are alive presently.
Conclusions. Cystic neuroendocrine tumors are rare pancreatic neoplasms
which are being detected with increasing frequency as diagnostic CT
becomes ever more prevalent. Endoscopic ultrasound with aspiration is an
accurate method to establish the diagnosis preoperatively. Surgical resection
is safe. Long term outcomes following resection are excellent.
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CYSTIC PANCREATIC NEOPLAMS: AN EMERGING PROBLEM
Kamran M. H. Karimi, MD, Irfan A. Rizvi, MD, Magesh Sundaram, MD,
Harold J. Williams, MD, David W. Mcfadden, MD
West Virginia University, Morgantown, WV
Background. Widespread usage of advanced abdominal imaging has
resulted in an increased finding of cystic lesions in the pancreas. Greater
than 90% of cystic pancreatic lesions are of inflammatory origin. The critical
issue confronting the specialists managing these patients is differentiating
these inflammatory lesions from neoplastic ones.
Materials and methods. Encompassing the duration from June 2001 to
June 2006, we performed 121 pancreatic resections. Herein, we report their
preoperative workup, operative management, pathologic findings, complica-
tions and follow-up.
Results. 121 pancreatic resections were performed with 16 (13.2%) patients
having cystic pancreatic neoplasms. Our series comprised mostly females (13/
16, 81%), with a mean age of 56 (range 2290). The most commonly
utilized preoperative imaging modalities were contrast enhanced computed
tomography and gadolinium enhanced magnetic resonance imaging. The
lesions were fairly evenly distributed through the pancreas with 5 (5/16, 31%)
in the head, 6 (6/16, 38%) in the body and 5 (5/16, 31%) in the tail. Based on
pathologic findings 6 (6/16, 38%) tumors were mucinous cystic neoplasms, 1
of which was borderline malignant, 6 (6/16, 38%) were serous cystadenomas,
2 were intraductal papillary mucinous neoplasm, also known as IPMNs (2/
16, 12%) and 1 each (1/16, 6%) of neuroendocrine (non-functioning islet
cell) and pseudo-papillary types. Operative procedures tailored to location
consisted of distal pancreatectomy and splenectomy, pancreatico-duodenect-
omy (Whipple’s procedure) and isolated head resection. Ileus, (5 days) or
poor tolerance of oral diet (7 days), including delayed gastric emptying,
was the most common complication and noted in 6 (6/16, 38%) of patients.
This was followed closely by pancreatic leak in 4 patients (25%). Pancreatic
leaks were divided equally between proximal and distal pancreatic resections.
Three patients were managed with closed suction drains; either by main-
taining operatively placed drains or additional drains placed by interventional
radiology. Other complications were deep venous thrombosis (1), fascial
dehiscence (1), pneumothorax (1), psoas abscess (1) and new onset
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pancreatic insufficiency. We had no in-hospital or 30 day mortality. Our
follow-up radiographic data (range 448 months, mean follow-up duration
21 months) does not show any recurrences at this time.
Conclusions. Our results are comparable to other high volume centers.
Complications, if and when they arise need prompt diagnosis and quick
resolution the availability of specialists, intensive care facilities, interventional
radiology services and expert anesthesiologists cannot be overemphasized.
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CURRENT DIAGNOSIS AND MANAGEMENT OF SOLID PSEU-
DOPAPILLARY TUMORS OF THE PANCREAS
Gregory Watson, MD, Kevin Mcgrath, MD, Niraj Jani, MD, Kenneth Lee,
MD
University of Pittsburgh, Pittsburgh, PA
We reviewed our recent institutional experience with solid pseudopapillary
(papillary cystic-solid) tumors in order to characterize the presentation and
current methods of diagnosis and surgical management of these uncommon
tumors of the pancreas. Through an electronic search of patients treated from
2003 until the present, patients with the pathologic diagnosis of a solid
pseudopapillary tumor of the pancreas were identified, and their medical
records were reviewed. A total of 10 patients (nine females, one male) ranging
in age from 14 to 53 (median 33) were identified. In eight patients the
tumor was asymptomatic and was found incidentally on abdominal imaging
studies; in two patients the tumor was found during evaluation of related
symptoms. Radiologic diagnoses included neuroendocrine tumor, mucinous
cystic neoplasm, and an unspecified solid mass of the pancreas. The
preoperative diagnosis of a solid pseudopapillary tumor was established in
7 patients by means of an EUS-guided biopsy and in one patient by means of
a CT-guided biopsy. EUS-guided biopsy was non-diagnostic in one patient,
and preoperative biopsy was not performed in 1 patient. In two patients
the tumor was located in the head of the pancreas and was treated by means
of a Whipple procedure. In eight patients, the tumor was located in the
body or tail of the pancreas. Six of these patients underwent a laparoscopic
distal pancreatectomy. An open distal pancreatectomy was instead performed
in two patients because of the size of the tumor (11 cm) or the patient’s
body habitus. In all patients negative margins of resection were achieved. In
one patient malignant features (capsular invasion, perineural and vascular
invasion) were found, but to date (followup 236 months, median 21
months) there have been no recurrences. Solid pseudopapillary tumors are
considered rare tumors of the pancreas. Our recent institutional experience
suggests, however, that they have been underdiagnosed because they
frequently remain asymptomatic despite reaching large size. EUS-guided
biopsy should be performed as it provides an accurate means of establish-
ing the diagnosis of a solid pseudopapillary tumor. While confirmation
of this diagnosis is not necessary to determine the need for surgical resec-
tion, establishing the diagnosis of a solid pseudopapillary tumor avoids
inappropriate enucleation of such tumors and permits consideration
of laparoscopic resection for tumors located in the body or tail of the
pancreas.
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INCIDENCE, PREVALENCE AND MANAGEMENT OF INTRA-
DUCTAL PAPILLARY MUCINOUS NEOPLASM IN OLMSTED
COUNTY, MINNESOTA, 19762005: A POPULATION STUDY
Kaye M Reid Lombardo, MD, Jennifer St. Sauver, PhD, Zhou Li, MS,
William A Ahrens, MD, K. Krishnan Unni, Florencia G. Que, MD
Mayo Clinic, Rochester, MN
Background. IPMN is being recognized with increasing frequency around
the world but the true incidence of Intraductal Papillary Mucinous Neoplasm
remains unknown.
Methods. We used the records-linkage system of the Rochester Epidemiol-
ogy Project to ascertain incident cases of Intraductal Papillary Mucinous
Neoplasm in Olmsted County, Minnesota from January 1, 1976December
31, 2005. We also evaluated the number of prevalent cases as of December
31, 2005. Age and sex-adjusted incidence rates for IPMN in residents aged
20 or older were estimated for the period, 19762005.
Results. We identified 28 incident cases of IPMN. The age- and sex-adjusted
cumulative incidence for IPMN Olmsted County MN is 1.63 cases per
100,000 persons (95% CI 1.02, 2.23) from 19762005. Point prevalence on
December 31, 2005 was 25.96 cases per 100,000 persons (95% CI 14.53) or
one per 3,852. Restricting to County residents aged 60 and older the point
prevalence is 101.86 cases per 100,000 persons (95 CI 57.22, 146.50) or one
per 981 persons. Thirty-two percent of patients were treated surgical while
the remainder was followed annually with imaging studies, primarily
abdominal CT and EUS. The five year survival rate after diagnosis was
59.6%. The cause of death was pancreatic cancer in four of the eight patients
that died.
Conclusion. The incidence of IPMN in Olmsted County is low but appears
to be increasing. Most patients with this disease were followed annually with
imaging studies while about a third of the patients required surgical resection.
While our data does not depict an epidemic more epidemiologic studies from
other populations are required.
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IS SURGERY NECESSARY FOR THE TREATMENT OF PREO-
PERATIVE DIAGNOSED AMPULLA OF VATER ADENOMA?
Dong-Sup Yoon, Joon Seong Park, MD, Kyung-Sik Kim, MD, PhD, Jin Sub
Choi, MD, Woo-Jung Lee, MD, PhD, Hoon-Sang Chi, MD, PhD, Byung-Ro
Kim, MD, PhD
Yonsei University Medical College, Seoul, Republic of Korea
Background. Ampullary adenoma is very rare and is truly premalignant
neoplasm. Current methods of endoscopic biopsy and even intraoperative
frozen sections are limited in their ability to rule out co-existing foci of
carcinoma. Recently therapeutic endoscopic physician preferred endoscopic
snare excision (ESE) even in case of relatively large adenoma. In this study we
evaluate diagnostic accuracy of ampullary adenoma and when we should do
perform transduodenal local resection (TDLR) or pancreaticoduodenectomy
(PD).
Methods. The records of 37 patients who admitted at Yonsei Medical Center
from January 1986 to December 2005 and with a endoscopic biopsy result
was ampullary adenoma were retrospectively reviewed. Final pathologic
result, recurrence and re-treatment result in case of margin positive after
endoscopic snare excision or TDLR or PD were analyzed and long-term
follow-up was ascertained.
Results. Among 37 patients, 32 were treated by ESE, TDLR or PD, but 5
were observed without further treatment or follow-up loss. Among these 32
patients, 13(40.6%) were pathologically confirmed adenoma with adenocar-
cinoma. In these 32 patients, ESE, ESEPD(PPPD), TDLR and
PD(PPPD) were performed for 2, 3, 2 and 6 patients respectively. All
patients were alive from 2 to 115 months after treatment except one
operation mortality, one recurrence 2months after ESE and one follow-up
loss. For 24 patients with adenoma, ESE, TDLR and PD(PPPD) were
performed in 14, 1 and 4 patients respectively. Among 14 ESE patients,
seven(50.0%) were lateral or base margin positive. In these seven patients, six
patients were treated by re-ESE and two patients had recurrence 18 and 19
months after re-ESE.
Conclusions. For the management of ampullary tumor, complete removal
of tumor should be obtained. For adenoma with adenocarcinoma, we
recommened TDLR of PD(PPPD) and for adenoma ESE is one of
acceptable treatment modality and margin negative resection is important
for long-term good result.
Key Words. ampullary adenoma, endoscopic snare excision, surgery.
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SOMATOSTATINOMA: A 20-YEAR SURGICAL EXPERIENCE
Gerard Abood, MD, Asghar Rizvi, None, Gerard Aranha, MD, Sherri Yong,
MD, Margo Shoup, MD
Loyola University Medical Center, Maywood, IL
Objective. The objective of this study was to identify and describe the
characteristics of patients diagnosed and treated for somatostatinomas at a
single institution.
Methods. The pathology and operative databases were queried to identify
patients with the histologically confirmed diagnosis of somatostatinoma from
the time period of 1986 until 2006. Following patient identification, inpatient
charts were reviewed and clinicopathologic data were analyzed. All tumors
were re-examined and were confirmed to be somatostatinomas.
Results. The results of the search identified six patients with histologically
confirmed somatostatinomas. Of the six patients, four presented with
significant weight loss (15 lbs) and abdominal pain, while two patients
presented as an incidental finding. All of the patients identified underwent
pancreaticoduodenectomy, where four patients had tumor located in the
pancreas, while two patients had tumor located in the duodenum. One
patient underwent liver resection for metastatic disease. The average size of
the primary tumor was 1.090.5 centimeters (0.31.5 cm). While all tumors
were described as strongly positive for somatostatin, immunohistologic
staining also demonstrated three of six tumors to be positive for chromo-
granin. At a median follow up of 4 years (range 4 months to 17 years), five
patients were alive without evidence of recurrent disease and one patient, who
presented with weight loss and liver metastasis, was alive with recurrent
disease.
Conclusions. Although rare, six cases of somatostatinoma were identified
and treated at a single institution in a 20-year period. Weight loss was the
presenting symptom in four patients and two patients were asymptomatic.
Long term survival can be expected following surgical resection regardless of
symptoms.
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IS THERE AN INDICATION FOR INITIAL CONSERVATIVE MAN-
AGEMENT OF CYSTIC LESIONS OF THE PANCREAS?
Stephen R Grobmyer, MD, Steven N. Hochwald, MD, William G. Cance,
MD, Stephen B. Vogel, MD
University of Florida, Gainesville, FL
92 Abstracts
Background. The evaluation and surgical recommendation for small
pancreatic and peri-pancreatic cystic lesions presents a clinical challenge.
Our traditional bias has been an aggressive surgical approach based on the
‘‘malignant potential’’ of even small cystic lesions.
Methods. We reviewed our experience with patients (n78) who presented
with a presumed cystic pancreatic lesion and who underwent operative
management between 1995 and 2005.
Results. There were 55 (71%) females; median age 63 years. Patients
presented with an incidental finding (48%), pain (40%), acute pancreatitis
(4%), other (8%). The median lesion size was 4 cm (range 1 30 cm).
Operations were distal pancreatectomy (n48), pancreaticoduodenec-
tomy (n14), other (n26). Most patients had a non-malignant lesion
(n65, 83%) (mucinous cystadenoma (n29), serous cystadenoma (n
15), IPMN without invasion (n8), pseudocyst, other benign). Malignant
lesions (adenocarcinoma, neuroendocrine tumor, and other) were found
in 13 patients (17%). The risk of malignancy increased with size:B3 cm
(n25), 4%; 35 cm (n23), 13%; and5 cm (n30), 30%. The median
size (range) of tumors was: adenocarcinoma (n7) 8 cm (315 cm);
neuroendocrine (n2) 2.7 cm (2.43 cm); and other (n4) 8 cm (5
30 cm). Pre-operative cyst fluid cytology was performed in 41 patients.
The negative predictive value (NPV) of cytology for malignancy was 88% and
the positive predictive value (PPV) was 100%. Pre-operative serum CA 19-9
was measured in 40 patients (normalB37). The NPV of CA 19-9 for
malignancy was 90%; the PPV was 50%.
Conclusion. These data support a role for initial conservative management
of small cystic pancreatic lesions as the risk of associated malignancy is very
low. Cyst fluid cytology and a serum CA19-9 may help select patients with
cystic lesions for conservative management. The role of CT and PET for
monitoring small cystic lesions is currently being evaluated.
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FRANTZ-GRUBER TUMOR  A SPECTRUM OF DISEASES AND
SURGICAL TREATMENT OPTIONS: PANCREATICODUODE-
NECTOMY TO LAPAROSCOPIC DISTAL PANCREATECTOMY
Sean Garrean, MD, Justin Hering, MD, Barney Dillard, MD, Abdul Saied,
MD, William Scott Helton, MD, Nocif Joseph Espat, MD
University of Illinois at Chicago, Chicago, IL
Frantz-Gruber tumor, also known as solid and cystic pseudopapillary tumor
of the pancreas, is an uncommon disease that occurs predominantly in young
females. Surgical resection remains the treatment of choice as it offers
excellent prognosis. Herein, we present three cases of Frantz-Gruber tumor,
highlighting the varied presentation and spectrum of surgical options for this
disease.
Methods. A review of the HPB database was conducted to identify patients
who underwent resection for Frantz-Gruber tumor.
Results. Three patients were identified; all young females presenting with a
variety of clinical features, including upper abdominal pain, mass, and
obstructive jaundice. Based on tumor location, the surgical approach
consisted of either pancreaticoduodenectomy or laparoscopic distal pancrea-
tectomy. Two patients underwent a Whipple procedure for tumors in the
head of the pancreas, while one patient had a laparoscopic distal pancrea-
tectomy and splenectomy for a pancreatic tail tumor. In all cases, disease was
confined to the pancreas with no vascular involvement or distant metastases.
All three patients underwent a successful, margin-negative resection of their
tumor and are alive and disease-free today. Patient #1: A 22 y/o female was
referred for evaluation of a periampullary mass detected on physical exam
and CT scan. Staging laparoscopy revealed an 8.5 cm resectable mass in the
head of the pancreas. Pancreaticoduodenectomy was performed. Final
pathology showed a pT2N0M0 pseudopapillary tumor. The patient remains
alive and disease-free four years later. Patient #2: A 26 y/o female presented
with epigastric pain of several months duration. CT of the abdomen revealed
a 5 cm mass in the pancreatic tail; endoscopic ultrasound-guided biopsy
showed pseudopapillary cells. She underwent resection of her tumor via a
laparoscopic approach. Patient #3: A 22 y/o female with history of
obstructive jaundice presented to the surgical clinic for evaluation of a
pancreatic head mass. She had undergone a biliary/duodenal bypass and
failed resection attempt at an outside institution. CT of the abdomen showed
a resectable 8 cm pancreatic head mass, diagnosed as pseudopapillary tumor
by biopsy. The patient underwent a Whipple procedure and remains disease-
free nearly 3 years later.
Conclusion. Frantz-Gruber tumors may vary considerably in their pre-
sentation and location in the pancreas. While surgical resection offers a
uniformly excellent prognosis and is the treatment of choice, the approaches
to resection are diverse and must be tailored to the tumor’s location within
the pancreas.
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OUTCOMES FOLLOWING AGGRESSIVE SURGERY FOR MA-
LIGNANT NEUROENDOCRINE TUMOURS OF THE PANCREAS
Glenn K Bonney, MBBS, Dhanwant Gomez, Caroline Verbeke, Sakhawat
Rahman, Michael Mcmahon, Giles Toogood, K. Rajendra Prasad, J. Peter
Lodge, Krishna Menon
St James’ University Hospital, Leeds, United Kingdom; St James’ University
Hospital, Leeds LS9 7TF, United Kingdom
Background. Pancreatic neuroendocrine tumours (PNET) often present a
diagnostic and therapeutic challenge. Besides the morbidity and mortality
associated with surgery, recurrence of disease has hampered its wider
application. This study evaluates the outcome of patients following aggressive
surgery.
Methods. From 19992005, records of patients undergoing surgical
resection were reviewed. Patients with benign PNETs were excluded.
Outcomes studied were patient demographics, radiological investigations,
surgical procedures, pathologic characteristics, complications, mortality and
disease free survival.
Results. Twelve patients were identified with a median age at diagnosis of 54
years (Range: 2279 years) and a male to female ratio of 7:5. The most
common presenting symptoms were abdominal pain (n7). Two patients
presented with synchronous liver metastasis. Surgical procedures included
total pancreatectomy (n3), pancreaticoduodenectomy (n4) and distal
pancreatectomy and splenectomy (n5, 2 were laparoscopic). Additional
procedures included hepatic resection (n2), adrenalectomy (n1) and
portal vein reconstruction (n2). Histological diagnosis was non-function-
ing PNET (n9), Multiple Endocrine Neoplasia (MEN)-1 (n2) and
malignant insulinoma (n1). The median tumour size was 3 cm (Range: 1
14 cm). Eight (66%) had lymph node metastasis and 7 had evidence of
angioinvasion (58%). Overall morbidity was 33% with one post-operative
death. The median follow-up was 27 months (Range: 272). Completeness
of resection (p0.015), nodal involvement (p0.008), and vascular inva-
sion (p0.002) were independent predictors of disease recurrence on
multivariate analysis. The overall actuarial survival rate at 2-years was 91%
and the disease free survival was 69%.
Conclusion. In selected patients, aggressive surgery for malignant PNET
may improve survival rates with low morbidity. Tumour vascular invasion and
nodal involvement are associated with early disease recurrence and poor
survival.
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IS RESECTION OF PERIAMPULLARY OR PANCREATIC ADE-
NOCARCINOMA WITH SYNCHRONOUS HEPATIC METAS-
TASES JUSTIFIED?
Timothy M Pawlik, MD, MPH, Ana Gleisner, MD, Jordan Winter, MD,
Michael Choti, MD, MBA, Richard Schulick, MD, John Cameron, MD,
Johns Hopkins
Baltimore, MD
Introduction. There is no consensus regarding what tumors are appro-
priately managed with hepatic metastectomy. Specifically, the role of hepatic
resection for metastatic periampullary or pancreatic adenocarincoma remains
controversial. We report the morbidity and survival of patients (pts) with
periampullary or pancreatic adenocarcinoma who underwent simultaneous
hepatic resection for synchronous liver metastasis.
Methods. Between 1995 and 2005, 1563 pts underwent surgery for
periamullary (n608) or pancreatic adenocarcinoma (n955). A matched
1:3 paired analysis was used to compare pts with synchronous metastatic
disease who underwent primary tumor resectionsimultaneous hepatic
metasectomy (Group A) to pts without evident metastatic disease who
underwent primary tumor resection alone (Group B).
Results. Of 1563 pts undergoing resection of periampullary or pancreatic
adenocarcinoma, 22 (1.4%) underwent hepatic resection for synchronous
liver metastasis. The primary tumor site was ampullary (n1), duodenal
(n2), distal bile duct (n2), or pancreas (head, n10; tail, n7). The
majority of pts (86.4%) had a solitary hepatic metastasis; median size of
the lesion was 0.6 cm. Hepatic metastectomy included wedge resection
(n20), segmentectomy (n1), and hemi-hepatectomy (n1). Group A
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pts were matched to Group B pts based on primary tumor histology,
location, and size, as well as nodal and surgical margin status. On matched
analysis, perioperative complications were similar (Group A, 45.5% vs.
Group B, 48.4%; p.99), but post-operative mortality (Group A, 18.2%
vs. Group B, 4.5%; p.06) was increased in pts undergoing hepatic
resection. Median survival of Group A pts was 5.9 mon compared to 14.2
mon for Group B (p.004) (Fig). In pts undergoing resection of
synchronous liver metastasis, pancreatic (median, 6.2 mon) vs. non-
pancreatic (median, 7.1 mon) primary tumor histology was not associated
with survival (p.09).
Conclusion. Resection of periampullary or pancreatic adenocarcioma with
resection of synchronous metastastic liver disease was associated with higher
perioperative mortality. Long-term survival for even well-selected pts with
low volume metastatic liver disease was uncommon. Simultaneous resection
of periampullary or pancreatic carcinoma with synchronous liver metastasis
may not be justified.
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THE ROLE OF PANCREATICODUODENECTOMY IN THE
TREATMENT OF COMPLEX PANCREATIC TRAUMA
Alexander R Karamarkovic, MD, PhD
University Center for Emergency Surgery, School of Medicine University of
Belgrade, Belgrade, Serbia and Montenegro
Objectives/background. This study evaluated the role of pancreaticoduo-
denectomy in the management of complex proximal pancreatic injuries.
Patients and Methods. Demographic data, mechanism and extent of
injury, Abdominal Trauma Index, operative procedure, postoperative course,
complications and outcome were analyzed in 64 patients who had pancreatic
injuries between January 2001 and December 2005.
Results. 8 patients (median age 27 years; 4 gunshot, 3 blunt trauma, 1 stab)
had cephalic pancreaticoduodenectomy for complex duodeno-pancreatic
injury. 2 had IVC and 1 portal vein injuries. Three patients had a pylorus-
preserving PD and five patients had a standard Kausch-Whipple resection.
The mean ATI was 47 (range 3476). The median intraoperative blood
replacement was 1200 ml (range 6006300 ml). The median duration of
surgery was 5 h 25 min (range 4 h 10 min to 6 h 50 min). One patient died
postoperatively of multi-organ failure. Complications included anastomotic
leaks due to pancreatic (1) and biliary (1) fistulae, delayed gastric emptying
(2). Factors complicating surgery were shock on admission, the number of
associated injuries, coagulopathy, hypothermia and gross bowel oedema.
Conclusions. Pancreaticoduodenectomy is a life-saving procedure applic-
able to a small cohort of patients with complex unreconstructable or
devitalized injuries to the pancreatic head. ATI score accurately predicted
severity and mortality.
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ANTHROPOMETRIC ASSESSMENT OF THE ‘‘STAGING WIN-
DOW’’ PRIOR TO PANCREATICODUODENECTOMY
Kolitha S Goonetilleke, MBBS, Sorrel Burden, PhD, Ajith K Siriwardena
HPB Unit, Dept of Surgery, Manchester Royal Infirmary, Manchester,
United Kingdom; Dept of Nutrition and Dietetics, Manchester Royal
Infirmary, United Kingdom
Introduction. Although several studies have examined peri-operative nutri-
tional supplementation in patients undergoing pancreaticoduodenec-
tomy (PD) all provided support at various timepoints. In theory, the pre-
operative period offers a therapeutic ‘‘window’’ for nutritional support.
This study undertakes a detailed nutritional assessment in the pre-operative
work-up period to identify whether there is a window for nutritional
supplementation.
Methods. Data were collected prospectively on 25 patients undergoing PD
under the care of an individual hepatobiliary surgeon in a regional HPB
service from January 2005 through September 2006. Data were collected
from index admission to discharge on: demography, clinical course, tumour-
related data, anthropometric measurements, calorie intake, operative detail
and outcome. All data refer to time from admission to HPB unit. The median
age was 58 (range 3275) yrs and 14 were female. 13 were in-patients at
admitting hospitals prior to referral with a-pre HPB unit median hospital stay
of 10 (131) days. Seven were jaundiced on arrival. Median delay from
admission to surgery in the jaundiced group after stenting was 30 (346
days). Median delay from admission to surgery in the non-jaundiced group
was 32 (165 days). Measured end-points were: body mass index (BMI),
mid-arm circumference (MAC in cms), triceps skinfold thickness (TST in
mms), Grip strength in kilopascals (kPa). Data were compared from
admission to pre-op and from surgery to discharge with analyses being
undertaken by non-parametric tests (Mann-Whitney U).
Results. Median in-patient stay was 33 (1147) days. Twelve (48%)
experienced some form of complication. There were no in-hospital deaths.
There was a significant fall in BMI from base to discharge (P0.02) which
was associated with a fall in MAC (P0.005) indicative of loss of lean body
muscle mass. However, there was no significant difference from admission to
pre-op in any parameter, even in the jaundiced subgroup.
Conclusions. Although PD can be accomplished safely, it results in a drastic
peri-opertive fall in BMI. Even with a prolonged pre-operative staging period,
there does not appear to be a likely benefit from pre-operative supplemental
nutrition in excess of a normal diet.
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CHARACTERIZATION OF PERI-OPERATIVE BLEEDING AND
TRANSFUSION UTILIZATION IN A MODERN SERIES OF PAN-
CREATICODUODENECTOMIES
Matthew J. Delano, MD, Steven N. Hochwald, MD, Chris A. Garces, MD,
William G. Cance, MD, Stephen R. Grobmyer, MD
University of Florida, Gainesville, FL
Background. Peri-operative bleeding requiring transfusion and/or re-opera-
tion has historically been a common complication following pancreaticoduo-
denectomy (PD). High cost and low supply of red blood cells, as well as short
and long complications associated with transfusion warrant a critical analysis
of bleeding and transfusion utilization.
Methods. We reviewed 50 PDs performed by 3 surgeons (20002005). Peri-
operative bleeding and red blood cell transfusion utilization was analyzed in
the context of patient’s presentation and operative findings.
Results. Median patient age in this series was 64 years (2383 years);
50% male. Median pre-operative hematocrit was 37.3% (range 24.7
50.1%). Median intra-operative blood loss was 800 mL (range 2003500
mL). Overall, 56% of patients received a red cell transfusion in this series;
46% of patients received an intra-operative transfusion. Among patients who
received a transfusion, the median number of units transfused was 1.5 units
(range 18 units). No patient in the series required re-operation for bleeding.
Median post-operative day #1 hematocrit in patients not receiving an intra-
operative transfusion was 33.5% (range 28.7 37) while median hematocrit
in patients receiving a transfusion was 31.8% (range 24.242.1). Estimated
blood loss was significantly higher in patients receiving perioperative
transfusions (1311 mL) than those who received no transfusion (569.2
mL) (pB0.001). Age60 (pB0.05) and pre-operative hematocritB35%
(p0.05) were significantly associated with transfusion utilization. Peri-
operative mortality was 2/50 (4%); causes of mortality were sepsis (POD 37)
and aspiration (POD 10).
Conclusions. Transfusion utilization with PD remains high although
bleeding requiring re-operation and bleeding associated mortality in this
modern series is low. More selective intra-operative transfusion utilization
may be indicated. Patients undergoing PD who are60 years of age and
those who have pre-operative hematocrit B35% would good candidates for
aggressive transfusion prevention strategies.
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MODIFIED CATELL’S PANCREATICO-JEJUNOSTOMY, BUT-
TRESSING AND ISOLATED BILIO-PANCREATIC LOOP RE-
SULTS IN BETTER OUTCOMES FOLLOWING
PANCREATICODUODENECTOMY
Mohammad Abu-Hilal, Hamilton-Burke Wurbena, Glenn K Bonney,
Krishna V Menon
St James’ University Hospital, Leeds LS9 7TF, United Kingdom
Aim. Pancreaticoduodenectomy (PD) is considered as one of the most
challenging and complex intra-abdominal procedures, with different techni-
cal variations having been described. We assessed outcomes following PD
using the modified Catell’s method, with buttressing of soft pancreas and
using an isolated bilio-pancreatic loop.
Patients and Methods. Over a 4 year period, between May 2002 and June
2006, 50 PDs were performed by a single surgeon using the modified Catell’s
method. Post-operative morbidity, mortality, details of pancreatic texture,
PD size were recorder prospectively.
Results. Median pancreatic duct size 4 mm (0.210 mm) respectively. The
pancreas was found to be firm in 18 patients (36%), intermediate in 13
patients (26%) and soft in the remaining 19 patients (38%). Buttressing was
performed in 21 (42%) of patients. Additional procedures included portal
vein reconstruction (n5) and metastectomies (n2). Median intra-
operative blood loss was 300 mls. There were no intra-operative and
in-hospital mortalities in this cohort. Major complications occurred in 7
patients (5 requiring relaparotomy and 2 managed conservatively). The re-
operated group included bleeding from the stapled jejuno-jejunal anastamosis
(n4), bowel obstruction from internal herniation (n1). Two patients with
a biliary and pancreatic leak respectively were successfully managed
conservatively.
Conclusion. Our early results suggest, the Modified Catell’s Pancreatico-
jejunostomy with buttressing for soft pancreas using an isolated bilio-
pancreatic loop are safety measures for better outcomes following Pancrea-
ticoduodenectomy.
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SURGICAL ASPECTS OF LIVER ARTERIALIZATION AFTER
PANCREATECTOMY WITH CELIAC AXIS RESECTION FOR
LOCALLY ADVANCED CANCER OF THE PANCREATIC BODY
Emilio Vicente, MD, PhD, Yolanda Quijano, MD, PhD, Carmelo Loinaz,
MD, PhD, Ramon D Conradi, MD, Fabiola Maches, MD, Luis Cordoba,
MD, Elena Ayerbe, MD, Enrique Niembro, MD
Hospital Madrid-Monteprincipe, Boadilla Del Monte, Madrid, Spain
The main reason for unresectability in locally advanced cancer of the
pancreatic body (ACPB) is the invasion of major vessels such as the common
hepatic artery and celiac axis.
Aim. To present different surgical techniques and results of liver arterializa-
tion after radical pancreatectomy with en bloc resection of the celiac axis in
patients with ACPB.
Methods. Between May 2004 and October 2006, 4 patients with carcinoma
of the body (3) and head-body (1) of the pancreas underwent radical
resection. Vascular invasion was observed on preoperative three-dimensional
CT angiographic scan. Encasement of the celiac axis (CA) (4), common
hepatic artery (CHA) (4) and splenic artery (SA) (4) were noted, as
well as infiltration of superior mesenteric vein (SMV) (1). No regional o
general dissemination was demonstrated. In all 4 patients, complete macro-
scopic tumor removal (R0) was achieved by body and tail pancreatectomy (3)
and total pancreatoduodenectomy (1) with en bloc resection of the CA, CHA,
SA and left gastric artery. Combined resection of SMV vein was required (1).
The adequacy of liver blood supply was assessed by manual palpation and
Doppler study. Appleby operation was performed with intraoperative radia-
tion in 1 patient with hepatic arterial flow through the pancreatoduodenal
arcade from the superior mesenteric artery. 3 patients underwent arterial
reconstruction: Direct end to end anastomosis (CHA-stump CA) was feasible
in 2 patients. An interposition of a PTFEt prosthesis of 6 mm in diameter was
required in 1 patient.
Results. Operative time ranged from 350 to 820 minutes. Red blood
transfusions of 3, 5, 6 and 8 Units were administered during the surgery,
respectively. The serum concentrations of ASTand ALTon postoperative day
1 were 210620 and 130590 in the three patients who underwent arterial
reconstruction. The patient with Appleby operation had significantly higher
values; 1200 and 1080, respectively. AST and ALT recovered to the
preoperative level within 11 days. Postoperative mortality (30 days) was 1/
4. The patient, with radiotherapy and chemotherapy previous treatment died
as a result of sepsis fifteen days after the operation. No vascular or digestive
complications could be demonstrated.
Conclusions. Pancreatectomy with CA resection to treat locally advanced
ACPB is feasible. The surgical procedure offers a high resectabilty and
radicality. Late outcome should be further studied.
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NODAL SAMPLING IN PERIAMPULLARY CANCER: DOES IT
CHANGE YOUR APPROACH?
Roozbeh Rassadi, MD, Dhiresh Rohan Jeyarajah, MD
Dallas Methodist Medical Center, Dallas, TX
Objective. To evaluate the predictive value of regional pancreatic nodal
sampling in periampullary tumors.
Background. Lymph node status in periampullary cancers has been
discussed as a way to avoid proceeding with pancreaticodudenectomy at an
early stage in exploration. Common hepatic artery and common bile duct
nodal groups (lymph node groups of 8 and 12 respectively according to Japan
Pancreas Society Classification) are among the first nodal groups that are
exposed during initial exploration for pancreaticodudenectomy. Although
lymph node sampling and the idea of sentinel lymph node biopsy have been
proposed as a guide for treatment selection, the predictive value of lymph
node sampling has not been addressed.
Study design. 45 patients underwent pancreaticoduodenectomy in a single
institution and by a single surgeon between September 2005 and September
2006. 36 patients had a diagnosis of periampullary tumor and had regional
node sampling at the beginning of the procedure. In a retrospective analysis,
we evaluated the predictive value of regional nodal sampling on overall nodal
status.
Results. Of the 36 patients with diagnosis of periampullary tumor, 23 had
both negative nodal sampling and final regional nodal involvement for
metastatic tumor; 9 patients had a negative nodal sampling but positive final
nodal involvement; 4 patients had both positive nodal sampling and final
nodal involvement for metastatic tumor (see table).
Conclusion. Sampling of common hepatic artery and common bile
duct nodal groups has a negative predictive value of (0.718) and positive
predictive value of (1) in evaluating regional pancreatic nodal status.
Therefore, decision regarding performing a pancreaticodudenectomy
and prediction of final nodal status can not be based on initial nodal
sampling.
Patients (n) Sentinel Node $ Regional Nodal Status
23 Negative Negative
9 Negative Positive
4 Positive Positive
$ Hepatic artery and common bile duct nodal groups.
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LYMPH NODE RATIO AS A PREDICTIVE FACTOR IN PANCREA-
TIC ADENOCARCINOMA
Mohamed Alassas, J Wang, S Agrawal, J Parsons, K Stephen, J Wrozek, I
Fung, J.F. Gibbs
Roswellpark Cancer Institute, Buffalo, NY; SUNY, Buffalo, NY
Background. Survival after curative resection for pancreatic adenocarci-
noma remains poor. Lymph node status has been reported as an important
prognostic factor. This study evaluates the impact of lymph node ratio
(positive lymph nodes to total number of lymph nodes removed) on the
survival of patients who underwent a curative resection for pancreatic
adenocacinoma.
Methods. A review of the institutional pancreatic cancer database
identified 408 patients diagnosed with pancreatic ductal adenocarci-
noma between 19712005. Demographic data and clinico-pathologic
information for patients who underwent a curative resection was reviewed.
Prognostic variables for the patients who underwent a curative resection were
analyzed.
Results. Of the 395 patients, 67 (17%) were resectable and 328 (83%) were
inoperable. Of these 328 patients, 239(58.5%) had distant metastatic disease
at presentation. The 67 resectable patients underwent a curative pancrea-
tectomy with regional lymphadenectomy. Of these 67 patients, 10 patients
died within 12 months and were excluded from the study. Median follow up
for the remaining 57 patients was 26.8 months. Median number of lymph
nodes removed was 14 (range: 147). Of the 57 patients, 33 patients had
positive and 24 had negative lymph nodes. Median survival for all patients
was 42 months. Number of harvested lymph nodes had no impact on overall
survival in the node- negative or node-positive patient populations. When
lymph node ratio was examined as a continuous variable a Relative Risk ratio
of 3.115 (p value0.0947) was noted (Table).
Conclusion. The data suggests that lymph node ratio may be predictive of
survival in patients with resected pancreatic adenocarcinoma. A lager sample
size will be required to fully evaluate its role.
Variable P-Value Relative Risk 95% RR confidence limits
Total nodes 0.7576 0.994 0.956 1.033
Positive nodes 0.4285 1.027 0.962 1.095
Node ratio 0.0974 3.115 0.822 11.812
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ROLE OF PREOPERATIVE 18-FDG-PET IN PANCREATIC
MASSES
Marjorie K Dougherty, PA-C, MPH, Justin Nguyen, MD
Mayo Clinic Jacksonville, Jacksonville, FL
Background. Pancreatic cancer is a lethal disease. The role of 18-
fluorodexoxyglucose positron emission tomography (18-FDG-PET) in the
preoperative evaluation of pancreatic masses is incompletely understood.
Aim. To determine a role of preoperative 18-FDG-PET in the clinical
evaluation and management of a pancreatic mass.
Methods. During January 2004December 2005, 54 patients who were
evaluated for pancreatic mass subsequently underwent surgical resections.
Final pathology reports were available for all 54 patients. Twenty-nine
patients had 18-FDG-PET in addition to the standard preoperative workup.
These 29 cases formed the basis of this retrospective report.
Results. Among the 29 cases with preoperative 18-FDG-PET, the pathology
of the malignant tumors included 20 ductal adenocarcinoma (DA), 1
metastatic renal cell (RCC) carcinoma, 1 gastrointestinal stromal neoplasm
(GIST), and 2 intraductal papillary mucinous neoplasms with dysplasia
(IPMN), and 2 neuroendocrine neoplasms (Neu.) The benign pathology
included 1 chronic pancreatitis (CP), and 2 cystadenoma. The preoperative
18-FDG-PET was positive showing the hypermetabolic foci in the pancreas
in 18 of DA, 1 Neu, and 1 GIST. The 18-FDG-PET was negative in 2 DA, 1
RCC, 1 Neu, 2 IPMN, 1 CP, and 2 cystadenomas.
Conclusion. Preoperative 18-FDG-PET correlates well with pancreatic
adenocarcinoma. However, 18-FDG-PET did not change the clinical
decision and management of the primary pancreatic cancer. The role
of 18-FDG-PET in IPMN, nonpancreatic malignancies, and recurrent
pancreatic cancer remains to be determined.
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PANCREATIC RESECTION FOR METASTATIC RENAL CELL
CARCINOMA TO THE PANCREAS
Kamran M. H. Karimi, MD, David W. Mcfadden, MD
West Virginia University, Morgantown, WV
Background. Although extremely rare for most primary malignancies, the
presence of metastases to the pancreas is usually a harbinger of diffuse
systemic involvement. Clear cell renal cell carcinoma (RCC) of the kidney
differs in that respect. Metastatic deposits tend to be isolated and diffuse
systemic involvement may be absent.
Materials and methods. An IRB approved retrospective review of 3 cases of
histologically confirmed RCC metastases to the pancreas was performed. We
present their pre-operative workup, surgical treatment, histopathological
findings and postoperative course.
Results. Three out of 121 pancreatic resections performed in the last
five years at the our institution have been for the indication of RCC
metastasis to the pancreas. All 3 of our patients were female. Their ages
ranged from 56 to 70 years (mean age63 years). The time interval between
nephrectomy and detection of the pancreatic recurrence ranged from 5 to 15
years (mean11.6 years). Two of our patients had Stage I disease at the time
of initial diagnosis of primary RCC and one had Stage III. Only one out of
three patients was symptomatic with fatigue, for the other two the lesions
were detected either during surveillance or during workup of an unrelated
illness. Surgical procedures were performed at a mean interval of 3.6 months
(range 34 months) from the time of diagnosis and referral. Multimodal
preoperative imaging with magnetic resonance (MR) scan and combined
computed tomography with positron emission tomography (CT-PET) was
utilized in all cases. None of our patients underwent any preoperative tissue
diagnosis. The surgical procedure in all cases was distal/subtotal pancrea-
tectomy and splenectomy. Solitary metastases were found in two and multiple
in one of our patients. We had one complication in the form of a pancreatic
leak, which required a combined surgical and interventional approach to
effect a resolution. We did not encounter any in-hospital or 30-day mortality.
Conclusions. Three patients, all women, underwent distal pancreatectomy
and splenectomy. Mean time period between nephrectomy and findings of
pancreatic metastasis was 11.6 years. One patient had a major complication
with a pancreatic fistula. Two patients have developed extrapancreatic
recurrences. Resection of RCC metastases to the pancreas may offer a
survival advantage in select group of patients. Development of metastatic
deposits after a prolonged disease-free period may actually be a negative
prognostic indicator, implying a rapid and uncontrollable change in tumor
biology.
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UNUSUAL EARLY AND LATE COMPLICATIONS OF PANCREA-
TICODUODENECTOMY: RECOGNITION IS PARAMOUNT TO
DIAGNOSIS
Nicholas J Zyromski, MD, Attila Nakeeb, C. Max Schmidt, MD, PhD,
Henry A Pitt, MD, Keith D Lillemoe, MD, Thomas J Howard, MD
Indiana University, Indianapolis, IN
Background. Pancreaticoduodenectomy (PD) is being performed more
frequently; common complications are well described. A number of unusual
complications are less well characterized.
Methods. Review of a prospectively collected database.
Results. Superior mesenteric vein/portal vein (SMV/PV) thrombosis may
occur early or late after PD. Unusually large fluid requirements (early) or
sudden appearance of ascites (late) should prompt SMV/PV ultrasound to
confirm the diagnosis. Anticoagulation should be instituted immediately;
immediate re-operation is appropriate in select patients. Chylous fistula
presents with high-volume, milky drain effluent. This diagnosis is confirmed
by elevated triglyceride level in drain fluid. Institution of total parenteral
nutrition (TPN) and sandostatin is effective therapy in most patients. Colicky
post-prandial epigastric pain and diaphoresis suggests afferent limb obstruc-
tion. Abdominal computed tomography (CT) may demonstrate a dilated
afferent limb; treatment is by endoscopy (early) and operative revision
(definitive). Hepatic abscess may present with low-grade fever, chills,
diaphoresis, or subtle mental status alteration. Abdominal CT proves the
diagnosis. Antibiotic therapy alone may successfully treat small abscesses;
percutaneous drainage is optimal for large abscesses. The appearance of
blood in a surgical drain or the gastrointestinal (GI) tract following PD
suggests arterial pseudoaneurysm. Angiography proves the diagnosis, and
angiographic embolization generally provides definitive therapy. Control of
concomitant pancreatic fistula is mandantory. Pancreaticojejunostomy stric-
ture is a late complication after PD, presenting with post-prandial pain, and/
or diarrhea. Magnetic resonance cholangiopancreatography (MRCP) with
secretin stimulation proves the diagnosis; treatment is by surgical revision.
Hepaticojejunostomy stricture is also a late complication after PD, usually
presenting with post-prandial right upper quadrant pain. MRCP proves the
diagnosis; percutaneous transhepatic cholangiography (PTC) allows treat-
ment by stenting.
Conclusions. With increased performance of PD, ‘‘unusual’’ complications
will be seen more frequently. Early recognition and treatment of these
complications will contribute to optimal patient outcome.
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LIFE-THREATENING BLEEDING FROM DUODENUM DUE TO
PANCREATIC DISEASES
Yuki Sakuraoka, MD, Mitsugi Shimoda, MD, PhD, Masato Katoh, MD,
PhD, Kyu Rokkaku, MD, PhD, Tokihiko Sawada, MD, PhD, Keiichi
Kubota, MD, PhD
Dokkyo Univ, School of Med., Mibu, Tochigi, Japan
Introduction. Although some bleeding from the duodenum is frequently
observed in patients with pancreatic head tumors, life-threatening bleeding
from the duodenum due to pancreatic diseases is an extremely rare condition.
Here we report two such rare cases treated by pancreatoduodenectomy (PD).
[Case 1] A 60-year-old man was admitted to our department with upper
abdominal pain and tarry stool. Abdominal CT and angiography showed
arterio-venous malformation (AVM) of the pancreas head. Endoscopy
revealed bleeding from the duodenal varices caused by portal hypertension
induced by AVM. After placement of embolization coil in the gastro-
duodenal artery, PD was performed. Histological examination showed
AVM of the pancreas head. Postoperatively, the bleeding was stopped.
[Case 2] A 63-year-old man was admitted to our department with jaundice
and tarry stool. CT demonstrated no definite tumor. Endoscopy revealed
severe bleeding from a duodenal ulcer of the second portion. Under a
tentative diagnosis of post-bulbar ulcer, PD was performed immediately.
Histological examination revealed pancreatic cancer invading the duodenal
wall, causing a huge ulcer.
Conclusion. Only PD can cure the rare conditions of life-threatening
bleeding from the duodenum due to pancreatic diseases.
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SURGICAL INTERVENTIONS FOR METASTATIC LESIONS TO
THE LIVER: A NATIONAL PERSPECTIVE
James T Mcphee, MD, Joshua S Hill, MD, Zachary Hurwitz, MS, Giles F
Whalen, MD, Mary E Sullivan, RN, Jennifer F Tseng, MD
University of Massachusetts Medical School, Worcester, MA
Background. Metastatic lesions to the liver are associated with an exceed-
ingly poor prognosis. Complete surgical resection, when feasible, remains the
gold standard and has been shown to improve five-year survival for primary
colon lesions. Optimizing outcomes for the peri-operative period are
imperative to improve one’s chance of long-term survival. The purpose of
this study was to evaluate operative outcomes for hepatic resections for
metastatic disease at the national level.
Methods. The Nationwide Inpatient Sample was queried to identify all
patient discharges that occurred for hepatic resection of metastatic lesions
from the years 19982004. Patients were identified by appropriate
ICD9-CM diagnostic and procedural codes. Inpatient mortality was the
primary measured outcome. Categorical variables were analyzed by chi
square. A multivariate logistic regression was performed with mortality as the
Complication Timing Symptoms Diagnosis Treatment
SMV/PV Thrombosis Early Increased fluid sequestration Ultrasound Anticoagulation, surgical revision
Chylous fistula Early Chyle in drain  triglyceride in drain fluid TPN, sandostatin
Afferent limb obstruction Early/Late Postprandial pain, diaphoresis Abdominal CT Endoscopy, Surgical revision
Hepatic abscess Early Fever, mental status change Abdominal CT Antibiotic, drainage
Pseudoaneurysm Late Blood in drain, GI bleed Angiography Embolization, control fistula
Pancreaticojejunostomy stricture Late Postprandial pain MRCP (secretin) Surgical revision
Hepaticojejunostomy stricture Late Right upper quadrant pain MRCP/PTC Stent
See text for abbreviations
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dependent variable. The regression was adjusted for patient age, sex, race,
and selected co-morbidities. In addition adjustments were made for certain
hospital level characteristics including geographic location, teaching status,
and annual surgical volume.
Results. Over the seven-year period of the study, an estimated 42,000
patient-discharges occurred for the surgical treatment of a metastatic liver
lesion. 50% of patients were women; 82% were white. Overall, 23% of
patients undergoing resection underwent a hepatic lobectomy, 44% under-
went a wedge resection and 33% underwent enucleation/local destruction of
their lesion, with respective mortality rates of 4.3%, 2.7%, and 1.5%. By
univariate analysis, in aggregate form, procedures performed at teaching
hospitals had a lower mortality (3.3 vs. 2.5%, pB0.05). Teaching hospitals
also performed a higher percentage of hepatic lobectomies compared to non-
teaching hospitals (26% vs. 11%, pB0.05). There was no correlation
between annual hospital surgical volume and operative mortality on
univariate or multivariate analysis (p0.05).
Conclusions. Based on a large retrospective administrative survey, patients
with metastatic lesions to the liver have acceptable operative mortality rates
when they undergo resection. While teaching and non-teaching hospitals
have similar mortality rates, teaching hospitals perform higher-mortality
procedures such as hepatic lobectomy more frequently than non-teaching
hospitals. These data suggest that heterogeneous procedures such as liver
resection for metastatic disease may require more complex analyses to
ascertain the true effects of factors such as hospital procedure volume and
academic status on mortality.
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MULTIMODAL TREATMENT OF LIVER METASTASIS FROM
GASTROINTESTINAL STROMAL TUMOURS
Osama M Damrah, Peter Sipos, Long Jiao, Nagy Habib, Hapreet Wasan,
Ruben Canelo
Hammersmith Hospital, London, United Kingdom
Introduction. Gastrointestinal Stromal Tumours (GIST) clinical behaviour
is unpredictable and surgery alone does not cure recurrent GIST. Metastatic
liver disease is a major determinant of patient’s survival.
Methods. Database and records of patients with liver metastasis from GIST
(n13) treated at our unit between January 2002 and June 2006 were
reviewed.Treatment modalities included surgical resection, radio frequency
ablation, hepatic artery chemoembilisation, imatinib mesylate, and selective
internal radiation therapy using Yttrium microsphres (SIRTEX) .Patient
demographics, clinicopathological characteristics of the primary tumour and
the extent of intrahepatic and extrahepatic metastatic disease were recorded.
Results. There were 6 (46%) males and 7 (54%) females. The mean age at
time of diagnosis of the primary tumour was 65.599.7 years (range 4580).
Five patients (38%) had synchronous metastasis at presentation.The primary
tumour site was the stomach in six patients (46%), terminal ileum three
patients (23%), duodenum two patients (15%) and the pelvis in two patients
(15%). The mean size of the metastatic liver lesions was 8.03 cm94.33(SD).
In 7 patients liver resections were performed (in 3 patients repeatedly). RFAs
were performed in 4 patients, in two patients repeatedly. In two patients
trans-arterial chemoembolisation (TACE) was performed and one patients
was treated with SIRTEX treatment. 5 patients were treated with imatinib,
two patient received repeated series. One patient received 8 therapeutic
modalities, 2 patients 7 modalities and another patient received 4 treatment
modalities.The more modalities were given the longer survival time was
observed. Resection and imatinib treatment significantly improved the
survival time in comparison with imatinib treatment alone (p0.031). Of
all patients who underwent hepatectomy, three patients survived more than 5
years (23%) after the initial hepatectomy. The average survival was 35.14
month.
Conclusion. Multimodal approach for patients having liver metastasis from
GIST provides better survival rates.Well-conducted prospective studies are
needed to further evaluate the different treatment options.
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HEPATIC RESECTION FOR METASTATIC GASTRO-INTEST-
INAL AND PANCREATIC NEUROENDOCRINE TUMOURS: OUT-
COME AND PROGNOSTIC PREDICTORS
Dhanwant Gomez, Karim Halazun, Ahmed Al-mukthar, Krishna V Menon,
Giles J Toogood, J. Peter A Lodge, K. Rajendra Prasad
Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, United Kingdom
Background. Treatment modalities of hepatic metastases from neuroendo-
crine tumours (NET) include surgery, somatostatin analogues or chemoem-
bolization. The aims of this study were to evaluate the outcome of patients
following surgery and identify prognostic predictors of recurrent disease.
Methods. Retrospective clinico-pathological analysis of patients managed
with hepatic NET metastases over a 13-year (January 1993December
2005) period.
Results. 18 patients with hepatic metastases from NET were identified with
a median age of 53 (3175) years. The localization of the primary tumour
was the terminal ileum (n8), pancreas (n7), appendix (n2) and
duodenum (n1). 12 patients had synchronous hepatic metastases and 6
patients developed metachronous hepatic tumours over a median period of
20 (6144) months. Presenting symptoms included abdominal pain (n13),
recurrent diarrhoea (n7) and flushing (n7). 15 patients underwent
surgery with curative intent and 3 patients had palliative resection. The
overall 2- and 5-year actuarial survival rates were 94% and 86%, respectively.
The 2- and 5-year disease-free rates following hepatic resection with curative
intent were both 66%. Partial or complete control of endocrine-related
symptoms was achieved in all patients following surgery. Recurrent disease
occurred in 4 patients. Resection margin involvement was associated with
developing recurrent disease. The overall morbidity was 22% with one post-
operative death. The overall follow-up period was 45 (993) months.
Conclusion. Surgical resection for hepatic NET metastases may improve
survival in selected patients and a clear resection margin predicts disease-free
interval.
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PARTIAL HEPATECTOMY FOR HEPATIC NEUROENDOCRINE
MALIGNANCY: WHO BENEFITS?
Clifford S Cho, MD, Daniel M Labow, MD, Jinru Shia, MD, David S.
Klimstra, MD, Mithat Gonen, PhD, William R. Jarnagin, MD, Michael I.
D’angelica, MD, Leslie H. Blumgart, MD, Ronald P. Dematteo, MD
University of Wisconsin School of Medicine and Public Health, Madison,
WI; Memorial Sloan-Kettering Cancer Center, New York, NY
Introduction. Controversy persists regarding the indications for and timing
of surgical resection of hepatic neuroendocrine (NE) tumors. Aggressive
strategies of resection or debulking have often been adopted. However,
guidelines for patient selection are lacking, and long-term outcomes of
resection in the setting of multimodal therapies remain unclear.
Method. We reviewed a prospectively maintained database of patients
undergoing resection of hepatic NE tumors between 1992 and 2004.
Clinicopathological variables were analyzed to identify factors associated
with overall survival (OS), progression-free survival (PFS) and symptom
control.
Results. Sixty patients were identified. Two-thirds underwent prior or
concomitant resection of primary tumor. One-third presented with hormonal
symptoms. Median extent of liver involvement by disease was 40%. Sixty
percent underwent at least a hemihepatectomy; complete resection was
performed in 63%. After a median follow-up of 52 months, median OS was
61 months. Recurrent or progressive disease was observed in 88%; the liver
was the site of initial recurrence or progression in 83%, and median PFS was
12 months. All patients with hormonal symptoms experienced complete relief
for a median of 27 months. Eighty percent received additional therapy after
resection, including 53% who underwent hepatic arterial embolization.
Absence of extrahepatic disease and prior or concomitant resection of
primary tumor were associated with improved OS on multivariate analysis;
ability to perform a complete resection was associated with improved PFS.
Conclusion. Partial hepatectomy can be performed safely with effective
control of hormonal symptoms. Long-term survival outcomes appear reason-
able, but recurrence or progression is usually observed. Extrahepatic disease
and the absence of primary tumor resection are associated with significantly
poorer survival; inability to perform a complete resection is associated with
faster time to disease progression. These findings suggest that certain
oncological characteristics can identify those patients who may not expect
to benefit from surgical intervention.
median survival (months) multivariate p
extrahepatic disease (OS) 91 vs 34 0.04
primary tumor resection (OS) 91 vs 48 0.04
complete resection (PFS) 18 vs 6 0.01
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SIMULTANEOUS RESECTION OF COLORECTAL TUMORS AND
LIVER METASTASES
Juan Francisco Guerra Castro, MD, Enrique Norero, MD, Jorge Martı´nez,
MD, George Pinedo, MD, Michel Butte, MD, Luis Iban˜ez, MD, Nicola´s
Jarufe, MD
Universidad Cato´lica de Chile, Santiago De Chile, Chile
Introduction. Recent advances in hepatobiliary and colorectal surgery had
permitted to do simultaneous resection of a primary colorectal tumor and
liver metastases. The aim of this study is to compare our surgical results in
colorectal synchronous liver metastases resection versus staged liver metas-
tases resection from a previously treated colorectal cancer.
Methods. A retrospective database of patients who underwent liver
metastases resection from a colorectal primary tumor from 1990 to August
2006 was reviewed. From 2003 up to now, data were obtained from a specific
prospective designed protocol. Non anatomical resections were excluded.
Two groups were defined: Group I: Patients with a simultaneous colorectal
and liver metastases resection, Group II: Patients with staged colorectal and
hepatic resection. Demographic characteristics, technical aspects, postopera-
tive liver function, morbidity and mortality were reviewed. Statistical
significance was obtained by t test.
Abstracts 97
Results In this period, 67 patients underwent a hepatic resection from
colorectal liver metastases, of which 48 fulfilled the inclusion criteria.
Group I; n13, Group II n35. Both groups were comparable in
demographic variables. Mean number of resected Couinaud’s Segments
was 2.5 in Group I and 3.5 in Group II. The most frequent hepatic resec-
tion was a left lateral segmentectomy in the synchronous group and a
right hepatectomy in the metachronous group. There were no statistical
differences in mean intraoperative blood loss (838 ml in Group I, 1116 ml
in Group II), mean red blood cell units transfused (0,6 versus 1) and
mean operative time (268 and 244 minutes, respectively). Mean post-
operative stay was 11,1 days for the first group and 11,3 days for the
second.) In Group I, 5 of 13 patients developed a postoperative complication,
and 17 of 35 in Group II. In each group, 2 patients had a postoperative liver
failure, with good response to medical support. There was no perioperative
mortality.
Conclusion. Simultaneous resection of large bowel and liver parenchyma is
a feasible and safe alternative in patients with a primary colorectal tumor and
liver metastases.
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SURVIVAL AFTER RESECTION OF HEPATIC AND PULMONARY
COLORECTAL METASTASES
Srinevas K Reddy, Andrew S. Barbas, MD, Thomas A. D’amico, MD, David
H. Harpole Jr., MD, William R. Burfeind Jr., MD, Bryan M. Clary, MD
Duke University Medical Center, Durham, NC
Introduction. While benefits from resection of isolated pulmonary and
hepatic colorectal metastases (CRM) are well recognized, outcomes after
resection at both sites are not established. The objective of this retrospective
study is to determine long-term survival in patients who undergo resection of
hepatic and pulmonary CRM.
Methods. Clinicopathologic, operative, and long-term survival data were
reviewed from patients identified from a hepatectomy database who under-
went resection of pulmonary and hepatic CRM. Survival was calculated with
Kaplan-Meier analysis and compared with the log-rank test.
Results. From 19972006, 27 patients underwent resection of hepatic and
pulmonary CRM. 13/27 (48%) presented with synchronous disease at both
sites; 5/13 (38%) underwent simultaneous pulmonary and hepatic resections.
No patient presented with CRM outside the lung or liver at the time of
resections. Median patient age was 52 years, 14/27 (52%) patients had
multiple hepatic CRM, 11/27 (41%) patients had multiple pulmonary CRM,
4/27 (15%) patients had bilateral pulmonary CRM, 7/27 (26%) patients
underwent anatomic pulmonary resection, and 22/27 (81%) patients under-
went major hepatectomy (]3 segments). 26/27 (96%) patients were treated
with chemotherapy before or after resection of initial metastases. There were
no cases of post-operative mortality. After a median patient follow-up of 45
months, actuarial 3-year and 5-year survival after resection of initial
metastases was 72% and 64%. 3-year and 5-year survival after resection of
primary tumor was 96% and 64%. The only factor associated with survival
was timing of hepatic and pulmonary CRM (Figure). Patients with
synchronous metastases at both sites had shorter overall survival after
resection of initial metastases than metachronously presenting patients (5-
year 46% vs. 80%, pB0.05).
Conclusion. Excellent long-term survival and low post-operative mortality
can be achieved after resection of hepatic and pulmonary colorectal
metastases in selected patients presenting without extra-pulmonary or
extra-hepatic disease and who are heavily treated with chemotherapy. The
favorable survival demonstrated in this series in comparison to older reports
may reflect better lesion identification with current imaging techniques in
addition to more effective chemotherapeutic regimens.
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OUTCOMES AFTER HEPATIC RESECTION IN THE PATIENTS
WITH COLORECTAL CANCER LIVER METASTASES: A RETRO-
SPECTIVE COMPARISON WITH NON-RESECTION CASES
Hyung-Chul Kim, MD, PhD, Jong Woo Joo, MD, Chun Jun Cho, MD, Nam
Kyu Choi, Hee Jae Lee
SoonChunHyang University Hospital, Bucheon,gyeonggi Do, Republic Of
Korea, Republic of Korea; Ansan Jungang WAM Hospital, Ansan, Gyeonggi
Do, Republic Of Korea, Republic of Korea
Background. The survival benefit in patients with colorectal cancer liver
metastases (CLM) underwent the curative surgical resection has been
demonstrated. However, the resectability may be determined differently at
the discretion of each departments.
Patients and Methods. From Feb 2001 through Feb 2006, 140 patients
were diagnosed with CLM. 27 patients with CLM were treated with hepatic
resection (Group A, n27). Palliative managed patients were 113. Among
them, 21 patients who had resectability at initial diagnosis or after
chemotherpay were selected. (Group B, n21). For this assessment, two
expert surgeons and two radiologists conducted the re-evaluation for
resectability. The authors compared outcomes between Group A and
Group B.
Results. In total 48 patients, the median age was 61 years (3286) and mean
size of the masses was 4.3 cm (0.814), which were not different significantly
among two groups, including performance status, liver function, CEA level,
stage, and hepatic lesion numbers. The median number of mass was 4 (1
14) in group A and 3 (19) in group B (P0.123). After a median follow up
duration of 31.3 months, estimated 3-year overall survival (OS) rates was
71.1916.9% in group A and 14.2997.0% in group B (P.0001). The
median OS in group A was 23.6 months, while it was 14.8 months in
group B.
Conclusion. Accurate lesion detection, aggressive surgical resection, and
optimal adjuvant/neo-adjuvant chemotherapy should be performed for long
term survival in the patients with CLM. Therefore, expert surgeons,
gastroenterologists, oncologists, and radiologists might be cooperated to
decide the adequate treatment plan the optimal time of surgery in the CLM
patients.
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PROGNOSTIC FACTORS IN HEPATIC RESECTIONS FOR THE
COLORECTAL CANCER METASTASES
Alexander R Karamarkovic, MD, PhD
University Center for Emergency Surgery, Belgrade, Serbia and Montenegro
Background. Liver resection currently serves as the only one curative
therapy for liver metastases from colorectal carcinoma. Appropriate criteria
for surgical resection are controversial.
Aim. The aim of this study was to determine the caracteristics of the disease
which affected prognosis.
Methodology. Between March 1999 and December 2005, 135 patients with
hepatic metastases from colorectal carcinoma underwent anatomical liver
resection at our institution. There were 77 men and 58 women, with a mean
age of 56.9 years (range 2274). The follow-up period ranged from 2 to 69
months. The survival rate was estimated by the Kaplan-Meier method and
compared by log-rank test.
Results. 76 of the primary lesions were located in the colon and 59 in the
rectum. There were 42 Dukes B, 54 Dukes C and 39 Dukes D. Liver
metastases were detected synchronously in 45 and metachronously in 90
patients at the time of diagnosis. The operative mortality rate within 30
postoperative days was 3.1%. During the follow-up period we registered
tumor recurrence rate of 14.1%. The overall 5-year survival rate was 31.8%.
Multivariate analysis shows a significant correlation between 5-year survival
and solitary (pB0.05) and unilobar (pB0.01) metastases. The survival rate
did not significantly correlate with gender, age, location of primary tumor,
Dukes classification, time of diagnosis or CEA level.
Conclusions. According to our results, number and localization of meta-
static liver lesions represents the prognostic factors of significant importance.
Without an effective therapeutic alternative, liver resection is still recom-
mended and represent a ‘‘gold’’ standard in the treatment of colorectal liver
metastases.
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PREDICTORS OF EARLY DISEASE RECURRENCE FOLLOWING
HEPATIC RESECTION FOR COLORECTAL CANCER METASTA-
SIS
Hassan Z Malik, Dhanwant Gomez, Giles J Toogood, J. Peter A Lodge, K.
Rajendra Prasad
Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, United Kingdom
Background. With the broadening indications of hepatic resection for
colorectal liver metastases (CRLM), the exact group of patients who would
benefit from surgery is still debatable. The aim of this study was to identify
predictors for early recurrence, defined as recurrence within 6 months of
CRLM resection, in order to identify those patients that may require further
pre-operative radiological staging of the disease prior to surgical resection.
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Methods. Prospectively collected dataset of 430 patients undergoing curative
resection for CRLM. Exclusion criteria were patients who had a previous liver
resection and those who received neo-adjuvant chemotherapy.
Results. Eighty-six (20%) patients developed early recurrence. Early
recurrence was associated with poorer outcome when compared to late
recurrences, pB0.001. The predictor of early recurrence on multivariable
analysis was the presence of numerous (8 or more) metastases, p0.036.
Numerous metastases also predicted for extra-hepatic recurrent disease.
Conclusion. We have identified a group of patients with numerous
metastases who recur early following resection of CRLM. We suggest that
these patients should be considered for additional pre-operative radiological
workup in the form of PET scanning to identify those patients that would be
deemed suitable for resection.
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THE PATHOLOGY OF LIVER NODULES AFTER NEOADJUVANT
CHEMOTHERAPY IS ASSOCIATED WITH OUTCOME FOR
COLORECTAL CANCER METASTASES
Gabriel Chan, MD, Mazen Hassanain, MBBS, Prosanto Chaudhury, MD,
Tamara Znajda, MD, Ryan Coughlin, B.Sc., Peter Metrakos, MD
Royal Victoria Hospital, McGill University Health Centre, Montreal, PQ,
Canada
Background. Colorectal cancer (CRC) is the second leading cause
of cancer-related deaths in Western countries. Due to the improved
response rates achieved by irinotecan and oxaliplatin-based chemo-
therapeutic regimens, and the introduction of biological therapies, an
increasing number of patients can be treated with intent to cure. Neo-
adjuvant chemotherapy offers several advantages: 1) downsizing of tumors,
making unresectable lesions resectable; 2) gauge the effectiveness of the
regimen to tailor post-operative therapy; 3) allow treatment of occult systemic
disease and control of synchronous lung metastases for subsequent resection.
Aim. To determine if the use of a neoadjuvant treatment strategy is
associated with increased rate of R0 resection, systemic disease control and
to correlate this with pathologic findings.
Methods. We conducted a retrospective chart review of patients who
underwent resection for CRC metastases between March 2003 and June
2004.
Results. 26 patients with liver metastases from CRC were treated with
either irinotecan-based or oxaliplatin-based therapy prior to hepatectomy.
Seventeen patients presented with synchronous liver metastases, while two
also had concurrent lung involvement. The median clinical risk score (1)
was 3. Nineteen patients (73%) achieved complete resection of all nodules.
Six patients had a complete pathological response to neoadjuvant treatment.
Mild to moderate steatosis of the background liver was found in 52%.
There was no grade 3 or 4 complications or mortality related to liver
insufficiency. A survival at two years and a status of disease-free at last
follow-up were associated with a significantly increased amount of fibrosis
and a decreased percentage of viable tumour cells in their liver nodules on
pathologic analysis (pB0.05). The amount of necrosis and mucin were not
significantly associated. The median follow-up was 30 months. Twenty
(77%) patients were alive at two years and thirteen (50%) are currently
without disease.
Conclusion. The use of neoadjuvant chemotherapy may provide early
systemic disease control allowing for complete resection of involved liver and
long-term disease-free survival. The percentage of fibrosis and tumour
viability after neoadjuvant chemotherapy correlates with the success of
metastectomy.
Reference.1. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH.
Clinical score for predicting recurrence after hepatic resection for metastatic
colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;
230(3):309 18; discussion 1821.
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RESECTION FOR COLORECTAL AND NON-COLORECTAL LI-
VER METASTASES: A COMPARATIVE STUDY
Ricardo Joaquin Mondragon-Sanchez 80, MD, PhD, Rodrigo Jasso-Barranco
2006, MD, Elvira Gomez-Gomez 2003, MD, Alejandro Mondragon-
Sanchez 80, MD, Ofelia Arias-Arias 2005, MD, Brenda Elena Aguilar-
Alvarez 2005, MD, Alicia Ivette Lopez-Estrada 2006, MD
Issemym, Toluca, Mexico
Background. Surgical treatments results in patients with colorectal (CR)
liver metastases have been analyzed in different series in the world. However
for non-colorectal liver metastases this matter has not been perfectly studied.
Therefore, it has been observed that surgical treatment increase free time of
disease and survival in both cases.
Aim. To compare long term results in patients with metastases treated with
liver resection.
Patients and Methods. A retrospective study in 81 patients with liver
metastases from CR and NCR cancer, treated with liver resection in the
Instituto Nacional de Cancerologia de Me´xico and Centro Me´dico ISSE-
MyM from August 1995 to September 2006 was performed. Data were
analyzed from the clinical records and included epidemiological data and
survival.
Results. Of a whole of 81 patients with liver metastases surgically treated
with a mean age of 41 years old (range 15 to 71), 45 (55%) were female and
36 (45%) were male. Thirty three patients (40.74%) had metastasis from CR
and 48 (59.3%) from NCR. The primary tumor in nine (18.75%) of them
was from breast cancer, nine (18.75%) from carcinoid tumors, six (12.5%)
from testicle cancer, five (10.41%) from ovarian cancer and 17 (35.42%)
from other places. The mean time of follow up was 14 months, the status
from the patients treated with metastases from CR is as follows: 60.6% alive
without tumoral activity, 18.18% died without tumoral activity and 21.22%
died with tumoral activity. The mean survival was 23.53 months for this
group, and only eight (24.24%) patients had tumor recurrence. Comparing
to the patients treated with metastases from NCR, 50% are alive without
tumoral activity, 10.4% are alive with tumoral activity, 8.3% died without
tumoral activity and 31.3% died with tumoral activity. This group presented
a mean survival of 28.46 months, and sixteen (33.33%) patients had tumor
recurrence.
Conclusions. Surgical resection of liver metastases from NCR is an effective
treatment in a well selected group of patients. Our results in these group of
patients are similar to those resected with CR. However, it is necessary to
increase the number of patients to confirm these results.
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AN EXPERIMENTAL STUDY OF THE TREATMENT OF LIVER
INJURY WITH INLINE RFA
Peng Yao, Steve Daniel, Aravin Gunasegaram, David L Morris
The University of New South Wales, Sydney, Australia
Background. The liver is the most frequently injured abdominal organ after
trauma. Hemorrhage is often the major cause of death after liver injury.
Hemostasis however sometimes may be very difficult to achieve, liver
resection is occasionally required in the trauma setting.
Aim. In this study we examined the use of InLine RFA device (ILRFA,
Resect Medical Inc, Fremont CA) designed for liver resection, in the entirely
different setting of simulated liver trauma where the injury is actively bleeding
prior to an attempt at surgical control.
Materials and methods. Six pigs were tested in this study. We created two
types of grade III to IV liver injury: peripheral (cut off the edge of one lobe)
and central (cut an incision on the central part). Then treatment with InLine
RFA was compared to conventional diathermy and suture, totally 32
surgeries were performed: peripheral injury (12 InLine versus 6 dia-
thermysuture); central injury (8 InLine versus 6 diathermysuture).
Blood loss was measured by determining the difference in the weights of
dry sponges and blood stained sponges after resection. The weight difference
was expressed as the blood loss in grams.
Results. Six pigs were used to simulate a total of 32 liver trauma injuries.
This resulted in 20 simulated liver injuries which were then treated with the
InLine and 12 controls which were treated with conventional diathermy and
suture. No massive bleeding occurred, and no animal died during the
experiment. After surgery, pigs were euthanized. The reduction of blood loss
was 63.88% in peripheral injury and 53.57% in central injury respectively.
There were highly significant differences in both two types of injuries: blood
loss (pB0.001), blood loss per cm2 (pB0.001).
Conclusions. In this study we examined the use of ILRFA for the
coagulation and hemostasis of simulated liver trauma. After the InLine
RFA device is deployed into the liver parenchyma, it seals small arterial and
venous vessels; therefore hemostasis was achieved with a significant reduction
of blood loss (63.88% in peripheral injury and 53.57% in central injury)
compares to conventional diathermy plus suture. We believe that ILRFA will
be an interesting device to evaluate in certain liver injuries in man.
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BENIGN LIVER TUMORS: ROLE FOR LAPAROSCOPIC ULTRA-
SOUND-GUIDED RADIOFREQUENCY ABLATION
Dmitri Alden, MD
Vassar Brothers Medical Center, Poughkeepsie, NY
Introduction. The treatment decision for benign liver lesions must be
individualized and based upon risk of treatment versus the risks of
observation. The role of laparoscopic RFA is studied.
Methods. The records of all patients who presented with initial diagnosis of
benign liver mass between 06/03 10/06 were reviewed, and those who
underwent laparoscopic ultrasound guided RFA were identified. Indications
included hepatocellular adenoma, indeterminate lesion by 3 imaging studies
(ultrasound, three-phase computed tomography (CT scan) and gadolinium
magnetic resonance imaging (MRI)), growth of the lesion, and clear tumor
related symptoms during follow-up. Demographics, underlying liver disease
(if present), history of estrogen use, tumor size, location, and number were
noted. Results of intra-operative core needle biopsy were noted. Initial results
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of ablation were assessed with postoperative CT scan one month after the
procedure. Follow-up data including survival, complications, and quality of
life were gathered.
Results. Sixty-nine patients with initial diagnosis of benign liver mass
were evaluated; 25 (36.2%) were symptoms free, had clear radiological
findings of hemangioma or focal nodular hyperplasia (FNH), and were
not considered surgical candidates. Seventeen (24.6%) were observed
with follow-up imaging every 36 months; 27 (39.1%) patients had
surgical intervention. 14 of them had history of long term use of
estrogens. Nine (13.0%) had symptomatic lesions 5 cm, and underwent
open surgical enucleation or resection. Eighteen (26.1%) met the criteria
for laparoscopic surgical intervention. The mean age was 47.2913.6; all
patients were females. Two patients had 4 lesions, one had 3 lesions, 4 had 2
lesions, and 11 patients had one lesion. Two patients had underlying liver
disease (1 hepatitis C, 1 alcoholic liver disease). Procedures included
laparoscopic intra-operative ultrasound of the liver, RFA, and 4 patients
had additional cholecystectomy. Mean length of stay was 1.891.2 days.
Mean tumor diameter was 2.691.1 cm (range 25 cm). Pathology demon-
strated 10 cases of FNH, 6 hepatocellular adenomas, 1 macroregenerative
nodule, and 1 fatty infiltration. Mean follow-up was 17.6913 months (range
139). There were no deaths. Three patients developed postoperative right
side pleural effusion. Two resolved with diuretic therapy, and one required
one time thoracentesis. All patients were symptoms free 3 months after the
procedure.
Conclusions. Laparoscopic ultrasound guided RFA is a safe modality that
achieves excellent local control of liver tumors. When combined with intra-
operative core needle biopsy it offers excellent diagnostic and therapeutic
solution for patients with benign liver tumors.
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THE HEAT SINK EFFECT MAY LEAD TO LOCAL RECUR-
RENCE: A COMPARATIVE STUDY OF RADIOFREQUENCY,
CRYOTHERAPY AND MICROWAVE IN THE LIVER
Neil Bhardwaj, Andrew D Strickland, MBBS, Lilit Atanesyan, MBBS, Fateh
Ahmad, MBBS, Kevin West, David M Lloyd, MBBS
Leicester Royal Infirmary, Leicester, United Kingdom
Background. The majority of primary and secondary liver tumours are
unresectable. Ablative modalities such as microwave (MTA), radiofrequency
(RF) and cryotherapy are alternative treatment modalities in current use.
Blood flow adjacent to ablation zones may cause inconsistencies in ablation
morphology and impair the cytotoxic abilities of these modalities. This is
known as the heat sink effect.
Aims/Objectives. To assess the ability of the heat sink phenomenon to alter
the ablation morphologies of MTA, RF and cryotherapy.
Methods. Twenty-one rats received microwave, 21 RF and 21 cryotherapy
ablations to their liver at laparotomy. Twenty-one rats were used as a control
arm. Livers were analysed 48 hours after ablation by H&E staining.
Results. All livers showed sharp macroscopic demarcation between treated
and unablated tissue. Histological analysis showed MTA to have the clearest
ablated/unablated boundary with little inflammatory reaction and no
perivascular hepatocyte survival. Coagulative necrosis of all portal structures
in the ablation zone was noted. Cryotherapy showed evidence of an increased
inflammatory reaction with perivascular cell survival within the ablation zone.
An irregular burn edge was seen with RF with evidence of perivascular and
intra-lesional hepatocyte survival.
Conclusion. A relatively higher proportion of tumour recurrences, with
cryotherapy and radiofrequency, occur at sites ablated in proximity to
vascular structures; this may be due to the heat sink effect. Cryotherapy
and radiofrequency rely on conduction to induce their cytotoxic effects and
hence due to the increased treatment time required, are more prone to loss of
thermal energy to blood flow. MTA on the other hand creates a field effect
and causes uniform tissue destruction within a radiated field, thereby
markedly reducing treatment times and subsequent corruption of the
ablation morphology.
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LIVER RESECTION USING A FOUR-PRONG RADIOFRE-
QUENCY COAGULATION DEVICE (HABIB 4X, RITA MEDICAL)
Byrne Lee, MD, Lawrence D. Wagman, MD
City of Hope National Medical Center, Duarte, CA
Objective. To assess the efficacy of liver resection using a four-prong
radiofrequency coagulation device.
Background. Advances in surgical technique and perioperative care have
reduced mortality from liver resection over recent years. A significant focus
has been on the reduction of blood loss during parenchymal division.
Intraoperative hemorrhage during parenchymal transection and need for
transfusion remain a predictor of perioperative morbidity.
Methods. From August 2005 to October 2006, 29 patients with hepatic
lesions underwent resection using a four-prong radiofrequency (RF)
device. The use of bipolar RF energy and multiple prongs rapidly creates a
zone of necrosis within the liver substance approximately 1 cm wide and
nearly as deep as the needles are placed. Intraoperative ultrasound was
performed to delineate the tumor location and assess for other lesions. The
selected line of transection is thermoablated using the device. The parench-
yma is then cut using a scalpel or parenchymal fracture (clamp or finger
fracture). Surgical clips are selectively used to ensure vessel and bile duct
ligation. The patients charts were reviewed for estimated operative blood loss,
procedure time, need for transfusion, length of stay, and perioperative
mortality and morbidity.
Results. No drains were used. There were 5 right hepatic lobectomies, 4 left
hepatic lobectomies, and 20 segmental resections. A synchronous colonic
resection was performed on three patients having segmentectomies. Mean
operative blood loss was 354 ml (range1001500). Mean procedural time
was 244 minutes (range97557). There were no intraoperative deaths.
Average LOS was 8 days (range418). There were 6 perioperative
complications: 4 hepatic abscesses, one pulmonary embolus, and one upper
GI bleed from a peptic ulcer. Two of the patients who had hepatic abscesses
had a synchronous colon resection. There was one perioperative mortality,
which was secondary to a cardiac arrhythmia. Two patients required
transfusions. One of these patients was transfused for a bleeding peptic ulcer.
Conclusions. Use of the four-prong radiofrequency dissecting device for
liver resection is safe. This novel device offers a new tool for near bloodless
hepatic parenchymal transection.
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A MULTICENTRE CONTROL STUDY OF INLINE RADIOFRE-
QUENCY ABLATION DEVICE FOR LIVER TRANSECTION
David L Morris, Frank Chu, Peng Yao, Steve Daniel, Aravin Gunasegaram,
Tristan Yan, Werner Lindemann, Georg Pistorius, Martin Schilling, Junji
Machi, Randall Zuckerman
The University of New South Wales, Sydney, Australia; Saarland University
Hospital, Saarbru¨cken, Germany; University of Hawaii, Hawaii, HI; Bassett
Health Care, Cooperstown, NY
Background. Surgical resection is the best established treatment known to
provide long-term survival for liver malignancy. Intraoperative blood loss has
been the major concern during major liver resections, and mortality and
morbidity of surgery is clearly associated with the amount of blood loss. We
have previously demonstrated that the use of InLine Radiofrequency
Ablation Device (Resect Medical Inc†, Fremont CA) to precoagulate the
liver transection plane prior to resection is safe and effective in significantly
reducing intraoperative blood loss and transection time in both animal
experiments and human trials.
Aims. To study blood loss, transection time and postoperative complications
in patients in a multicentre using ILRFA precoagulation and conventional
CUSA in liver resection.
Materials and methods. 102 liver resections were performed in 4
institutions from Nov 2003 to Oct 2006: 51 (29 men and 22 women) were
ILRFA precoagulation followed by CUSA transection and 51 (28 men and
22 women) were performed only by CUSA transaction as control, these were
prospective sequential series. The average age were 62.9 (3085) in the
ILRFA and 61.9 (2879) in the control group. group had cirrhotic liver.
Pringle manoeuvre was applied only when required. Blood loss was measured
from sponge weights and suction bottle contents.
Results. The type of liver resection was very similar in both groups, included
14 non-anatomic and 37 anatomic resections (formal lobectomies or
extended resections) in the ILRFA, 19 non-anatomic and 32 anatomic
resections in controls. Median number of RFA deployments was 3 (range 1
12) with a median coagulation time of 9 (range 336) minutes. Median
operation blood loss was 165.33920.38 ml (range 5675 ml) in the
ILRFA and 598.53979.36 ml (range 803600 ml) in the control, a
72.4% reduction and PB0.05. The median transection surface area
was not different in the ILRFA and control groups. The median transection
blood loss per unit resection area was 3.3590.42 (0.1412.33) ml/cm2 in
the ILRFA patients compared with 6.0990.72 (0.9236) ml/cm2 in
controls, the reduction was 45.0% and PB0.05. The median transection
time was 27 (2219) minutes in the ILRFA and 35 (562) minutes in
controls.
Conclusions. ILRFA precoagulation is a safe, effective technique for liver
resections which significantly reduces blood loss.
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RADIOFREQUENCY ABLATION OF SMALL HEPATIC MALIG-
NANCIES PROVIDES EQUAL LOCAL CONTROL TO RESEC-
TION
Eric C Feliberti, MD, Rebecca A. Nelson, PhD, Alicia Holt, MD, Jonathan
Roybal, Layla Rouse, MS, Lawrence D Wagman, MD
Eastern Virginia Medical School, Norfolk, VA; City of Hope National
Medical Center, Duarte, CA
Background. The efficacy of ablative techniques in the treatment of hepatic
malignancies is limited by the size of the tumor. We hypothesize that ablation
of appropriately sized lesions can produce local control similar to resection.
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Methods. A retrospective analysis of a single-surgeon consecutive series was
performed on patients with metastatic colorectal carcinoma (mCRC) or
hepatocellular carcinoma (HCC) who underwent operative ablation (radio-
frequency (RFA), cryosurgery or fulguration) and/or resection at a single
institution from 19982005. Local recurrence (LR), defined as lesion
enlargement or satellite lesion on imaging, and adverse prognostic factors
were analyzed by operative technique.
Results. One hundred nineteen patients (97 mCRC, 22 HCC) received
surgical treatment for 241 hepatic lesions (90 ablations and 151 resections).
Lesion size (median, range) was significantly larger in resected lesions
(3.0 cm, 0.426.0) than lesions treated by RFA (2.5 cm, 0.3 8.0), cryosur-
gery (2.5 cm, 0.910.8) or fulguration (1.0 cm, 0.52.7) (p0.02). With a
median 16-month follow-up, LR did not differ significantly across procedure
type with rates of 13.5%, 16.7%, 20% and 8.7% for RFA, cryosurgery,
fulguration and resection, respectively. LR of lesions greater than 3 cm
treated with RFA was significantly greater than for similarly treated lesions
3 cm or less (36.4% vs. 7.3%, p0.007). LR of lesions 3 cm or less treated
by RFA was comparable to similarly sized lesions treated by resection (7.3%
vs. 8.1%, p value0.88). Using a Cox proportional hazard model, factors
that significantly decreased survival included cryosurgery, lesion size of 
3 cm, extra-hepatic recurrence, and absence of LSLR, while adjuvant
chemotherapy significantly increased survival. Factors that did not affect
survival included RFA, primary histology, and presence of more than 4
hepatic lesions.
Conclusion. RFA of small (3 cm or less) hepatic lesions is as effective as
resection in preventing LR from mCRC and HCC and is not associated with
an adverse outcome. This confirms that multiple operative techniques may be
considered for this patient population.
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IS RADIOFREQUENCY-ASSISTED LIVER RESECTION SAFE
AND ONCOLOGICALLY-SOUND?
Giles Smith, MBBS, Marco Bertucci, MD, Duncan Spalding, MD, MBBS,
Robert Hutchins, MD, MBBS
Royal London Hospital, London, United Kingdom; Hammersmith Hospital,
London, United Kingdom
Data was prospectively collected on consecutive liver resections with the
TissueLinkTM device. Morbidity, blood loss, transfusion, inflow occlusion,
failures, haemoglobin, mortality and resection margin was collated. 153
patients were opened for hepatic resection over 3 years by one surgeon
(RH). 10 (6.5%) had no treatment. 11 (7.2%) had open radiofrequency
ablation. 132 (86.3%) patients had hepatic resection. 18 of those resected
(13.6%) did not undergo radiofrequency-assisted technique  8 Kelly
clysis, 3 laparoscopic, 2 total vascular exclusion and 5 CUSA. Of these
resections, only 4 were converted from tissuelinkTM to another method. The
failure rate was 3.4%. 114 patients underwent radiofrequency-assisted
resection. 61 males. Mean age 58.5 (3284). Pre-operative chemotherapy
was given to 51.5% of patients. Pre-operative portal vein embolisation was
used in 16 (14%). Significant co-morbidity was present in 18.4%. There
were 10 bowel resections, 2 pancreatic, 1 portal vein resection, 1 reversal
Hartmans and 1 gastrectomy. 11 patients had 2 stage hepatectomy and 6
patients had re-hepatectomy. There were 68 colorectal metastasis resec-
tions, 5 breast, 12 other primary sites, 2 unknown primaries, 7 neuroendo-
crine, 6 hepatomas, 4 biliary malignancies and 10 benign. Median operating
time3.5 hours. 78.1% of patients had no inflow occlusion. Central venous
pressure was not controlled. Median blood loss was 300 mls. Mean in-
hospital transfusion requirement was 0.9 units with median transfusion 0
units. 4.3% of patients had fresh frozen plasma in hospital. 7.8% had
vitamin K for elevated INR. There was no significant difference between
admission/discharge haemoglobin. Median hospital stay was 10 days (5
60). 60 day mortality was 0.87%. Morbidity was 27% including that from
associated procedures and hepatic failure. There was one biliary stricture
due to thermal damage early in the series (0.87%). Hilar dissection has
since not been carried out with the device. Bile leaks occurred in 5 cases
(4.3%), 3 being stented. Median margin of clearance for colorectal liver
metastases was 4 mm, for hepatoma 2 mm, biliary malignancy 15 mm and
other malignancies 5.5 mm.
Conclusion. Radiofrequency-assisted resection using an anatomically-based
method is a safe method of parenchymal transection. It appears to allow for
appropriate resection margins.
Hepatic resections
Resection type Number
3 or more Couinaud segments 55
2 or more Couinaud segments 25
Other 34
Total 114
Formal right hepatectomy 20
Formal left hepatectomy 7
Trisectionectomy 17
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THE EVOLUTION AND PERIOPERATIVE COURSE OF PA-
TIENTS UNDERGOING RADIOFREQUENCY ABLATION OF LI-
VER TUMORS BETWEEN 1996 AND 2006
Paul Hansen, Y Khajanchee, M Cassera, W Alexander, C Wilson
Legacy Health System, Portland, OR
Purpose. Radiofrequency ablation (RFA) is widely touted as a safe and
effective means of liver tumor destruction. More data is required before this
technique can be accepted as an appropriate part of the standard manage-
ment algorithm. The purpose of this study is to examine the perioperative
course and complications following RFA of liver tumors at a single high
volume institution over a 10-year period.
Methods. Between September 1996 and June 2006, data was collected
prospectively on ablations in 192 patients. All procedures were performed
under the direction of a single surgeon. Substantial changes occurred in
ablation technology during this period, including increases in maximum
power generation and alterations in tip design.
Results. Patients included 80 women and 112 men, with an average age of
63 years (SD923). A total of 464 tumors were ablated for an average of 2.4
tumors per patient. Mean tumor size was 2.4 cm (SD91.70, range 0.7 to
13 cm). Average operative time was 172 minutes and blood loss for all
ablations averaged 116 ml with a mean EBL for the 15 open procedures of
832 ml. Laparoscopic ablations were used in 147 patients, 15 patients had
open treatments, 26 were CT guided and 4 thoracoscopic (transdiaphrag-
matic). Major intraoperative complication occurred in 7 patients including 1
tumor rupture during ablation, 1 thermal bowel injury, 1 gallbladder thermal
injury, 3 enterotomies, and 1 bowel trocar injury. Major post-operative
complications occurred in 17 patients and included 1 cardiac death, 6 RFA
site abscesses, 5 PE/pneumonia, and 5 patients had significant hepatic
dysfunction. Overall, major complications occurred in 24/192 (12.5%) of
patients.
Conclusions. Radiofrequency ablation has rapidly become a popular
treatment modality for hepatic tumors, especially in patients who are poor
operative candidates. Although overall morbidity is reduced compared to
open surgical resection, major complications do occur. We have reviewed our
short-term outcomes with the intention of better understanding how to
incorporate RFA into our management algorithm.
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RESECTION OF HEPATIC RECURRENCE FOLLOWING RADIO-
FREQUENCY ABLATION FOR LIVER METASTASES
Brian Badgwell, MD, Jean Nicolas Vauthey, MD, Dario Ribero, MD, Steven
A Curley, MD, Eddie K Abdalla, MD
M.D. Anderson Cancer Center, Houston, TX
Background. Advances in surgical technique have enabled selected
patients with recurrent liver metastases (LM) to undergo repeat hepatic
surgery with curative intent. The utility of hepatic resection after radio-
frequency ablation (RFA) of LM has not been studied. The purpose of this
study was to examine early outcomes following hepatic resection for
recurrence at any site in the liver in patients who previously underwent
RFA of LM.
Materials and Methods. Using a prospective hepatobiliary database, 45
patients were identified with LM treated by RFA who subsequently under-
went hepatic resection of recurrence between 1998 and 2006. Safety and
early outcomes of hepatic resection were analyzed.
Results. Indications for RFA were inadequate liver remnant (n22, 49%),
liver disease (n5, 11%), prohibitive comorbidities (n1, 2%), and referral
following RFA (n17, 38%). Thirty-five patients had colorectal LM; 10
patients had LM of other origins (4 sarcoma, 4 pancreatic, 1 breast, and 1
carcinoid). Recurrence occurred at a median of 12 months (range 164) after
index RFA. Chemotherapy was administered before or after hepatic resection
in 38 patients (84%). Preoperative portal vein embolization was performed in
4 patients. Resections included 13 hemihepatectomies, 8 extended hepatec-
tomies, 9 mono- or bisegmentectomies, 4 wedge resections, and 11 resections
combined with RFA. Seventeen patients (38%) required additional resection
(10 diaphragm alone, 5 diaphragm combined with adjacent structures, and 2
other). Median operating time, median blood loss, and transfusion rate were
186 minutes (range 71516), 425 ml (range 5010,000), and 18%. Most
patients had a single recurrent tumor (n29, 64%); median tumor size was
4 cm. Ninety-day morbidity and mortality rates were 49% (n22) and 4%
(n2), respectively. At median follow-up of 25 months, median overall
survival was 47 months for all patients and also 47 months for the subgroup
with colorectal metastases. Median disease-free survival was 10 months for
both groups.
Conclusion. Although morbidity and extent of resection are
significant, resection in patients with hepatic recurrence after RFA is safe.
In this selected group of patients, median and overall survival rates at
early follow-up are similar to previously published rates for up-front
resection.
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SURVIVAL RESULTS OF NON-SURGICAL TREATMENT MOD-
ALITIES FOR MALIGNANT LIVER TUMOURS
Hassan Garba, Osama M Damrah, Paul Tait, Hapreet Wasan, Long Jiao,
Nagy Habib, Ruben Canelo
Hammersmith Hospital, London, United Kingdom
Introduction. Surgical resection provides the best survival for patients with
primary and secondary liver cancer. It is only possible in 15%20% of
patients. Non-surgical treatment modalities remain the only option.
Material and methods. From November 2004, patients whose liver
tumours were not amenable for surgery were considered for chemotherapy,
radiofrequency ablation, trans-arterial chemoembolization and yttrium-90
microspheres treatment after discussion at our multidisciplinary meeting.
None of the patients had extrahepatic disease.
Results. A total of 123 patients were considered for chemotherapy (n27),
radiofrequency ablation (RFA) (n41) trans-arterial chemoembolization
(TACE) (n20) and yttrium-90 microspheres treatment (n14). They
were 71 men and 52 women with a mean age of 57. Among them 58 had
colorectal liver metastases (CLM), 27 had Hepatocellular carcinoma (HCC)
and the remaining 38 were grouped as others. The mean survival time for
each treatment group was 18.8 months, 18.1 months, 18.7months and 15.1
months for RFA, yttrium-90 microspheres treatment, chemotherapy and
TACE respectively. As for type of diseases, patients with colorectal liver
metastases had 75%, 56% and 24% survival rates at 1-, 2-, and 3 years
respectively, compared with 60%, 43% and 13% for the noncolorectal group.
The HCC group had 43%, 18% and 10% survival rates over the same period.
Conclusion. Patients survival is more correlated to the tumour histopato-
logic type than the non-surgical treatment modality used. Younger patients
survived longer and this we attribute to co-morbidities in the elderly.
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MICROWAVE ABLATION IS AN EFFECTIVE TOOL TO TREAT
UNRESECTABLE PRIMARY AND SECONDARY LIVER TU-
MOURS
Neil Bhardwaj, MBBS, Andrew D Strickland, MBBS, Ahmad Fateh, MBBS,
Moshier El-abassy, MBBS, Lloyd M David, MBBS
Leicester Royal Infirmary, Leicester, United Kingdom
Background. Microwave tumour ablation (MTA) is one of 3 thermal
ablative modalities available to treat unresectable liver tumours. Radio-
frequency and cryotherapy have poor local control rates and have been
associated with high recurrence rates. We have successfully used microwave
ablation to treat liver tumours since 2001.
Aims. To assess the safety and efficacy of MTA to treat patients with less
than 5 unresectable liver tumours.
Methods. Thirty-six patients with unresectable liver metastases received
MTA between 2001 and 2006. A total of 84 tumours (mean 23 mm; range
470 mm) were ablated. Tumour types included colorectal carcinoma
secondaries (28), Parathyroid metastases (PTH) (1), HCC (6) and carcinoid
(1). All patients underwent pre- and post-operative cross sectional imaging.
Most tumours were treated between 23 minutes at 150 W. Seven patients
had a left hemi-hepatectomy and MTA, 10 right hemi-hepatectomy and
MTA and 19 had MTA alone.
Results. No bleeding, abscess formation, bile duct injury or microwave
related complications were observed. Fifteen patients are alive post ablation
of whom 8 are disease free (mean f/u 19 months; range 635), 7 are alive
with tumour recurrence (mean f/u 24 months; range 12 42), of whom 2
patients have developed local recurrence, probably due to tumour proximity
to major hilar vessels. Of those with recurrence, 72% of patients are alive
more than 2 years post ablation. There were 3 deaths in the immediate 30 day
post-operative period, all unrelated to MTA, and at post-mortem were
confirmed to be secondary to significant co-morbidities of the patients. The
other 18 patients survived an average of 18 months (range 242 months).
Discussion. MTA is a safe treatment option and is related to a low
recurrence rate compared to radiofrequency and cryotherapy. As with all
surgical techniques a learning curve is often evident and the 3 post-op deaths
were between 2001 and 2002. Stringent patient selection has reduced our 30
day patient mortality and the local recurrence rates compare favourably to
other ablative treatment options.
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NOVEL HIGH SPEED RADIO FREQUENCY (HSRF) TISSUE
ABLATION SYSTEM-INITIAL CLIICAL EXPERIENCE
David L Morris, MD, PhD, Steve Daniel, PhD, Frank K Chu, MBBS, Kee
Lee, None
The University of New South Wales, Sydney, Australia
We report an evaluation of a new and novel High Speed Radio Frequency
(HSRF) tissue ablation system (RFA Medical, Inc., Fremont California).
This system is unique in both it’s speed and ability to use a variety of existing
RFA generators currently available in many hospitals around the world as the
energy source. Our experience included various generators such as the Radio
Therapeutics Corporation (Boston Scientific, Boston MA), Celon LabPower
(Celon  Olympus, Teltow  Berlin Germany), and the Rita 1500 and
1500X (Rita Medical Systems, Fremont CA). We evaluated use of the device
in-vitro (explanted bovine liver), in-vivo (ovine liver), and clinically in a ten
patient prospective study. In this study patients which were scheduled for
resection of their liver tumors underwent tumor ablation followed by the
planned resection. Following the liver resection the ablated tissue was bread
loafed and the ablation size was noted. The total ablation time was also
recorded. Patient and procedure details for this study included gender, age,
tumor type, the use of any inflow occlusion, and operative or postoperative
complications. There was no significant difference within the demographics
between patients. The amount of time required to achieve the target ablation
size was significantly less than any RFA device currently available. Although
operation of each generator varies slightly, there was no significant effect
noted between uses of the different generators. In each case the desired
ablation was achieved at a significantly reduced ablation time as compared to
the experience of either our institution or in published literature with
standard RFA devices. The target ablation size, achieved ablation size, and
ablation time was noted and recorded.
Ablation Sizes with Ablation Times
Target Ablation
Size (cm)
Ablation Size
Mean / SD (cm)
Ablation Time
(min)
5 5.0 / 0.3 5
7 6.9 / 0.4 12
Based on our results we have concluded that this HSRF (High Speed Radio
Frequency) tissue ablation system is safe, effective, and requires only a small
fraction of the time that current ablation devices require.
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A STANDARDIZED APPROACH TO TEACHING LAPAROSCOPIC
CHOLECYSTECTOMY ELIMINATES COMMON BILE DUCT IN-
JURY IN AN INNER CITY UNIVERSITY TEACHING HOSPITAL
Marco Fisichella, MD, N. Joseph Espat, MD, Subashini Ayloo, MD, Phillip
Donahue, MD, Joseph Vitello, MD, Robert Berger, MD, W. Scott Helton,
MD
University of Illinois at Chicago, Chicago, IL; University of Illinois at
Chicago, Chicago, IL; Flagstaff Hospital, Flagstaff, AZ; Hospital of Saint
Raphael, New Haven, CT
The purpose of this study was to evaluate if teaching laparoscopic
cholecystectomy (LC) in a University Hospital using an approach focused
on obtaining ‘‘the critical view of safety ’’ while avoiding dissection in an
inflamed triangle of Calot would prevent common bile duct injury.
Methods. We retrospectively reviewed 601 consecutive patients undergoing
attempted laparoscopic cholecystectomy (LC) for cholecystitis and/or
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cholelithiasis between 1999 and 2005. If the critical view of safety could not
be achieved by a retrograde approach, alternative measures were employed
including fundus-first LC (FFLC); partial cholecystectomy (PC); cholecys-
tostomy tube; or conversion to open cholecystectomy (COC). Main out-
comes were death, common or segmental bile duct injury, cystic duct leak,
conversion to OC, and length of stay.
Results. 30-day mortality was zero and there were no common bile duct
injuries. There were 5 bile leaks (0.8%), and 89 conversions to OC (15%).
Average length of stay was 1 day for patients having successful LC, and 5 days
for patients who were converted to open cholecystectomy. PC was performed
in 19 patients (3%) and cholecystostomy tube was placed in 9 (1%).
Intraoperative cholangiography was performed selectively in 344 patients
(57%). There were 2 right posterior sector duct injuries caused by a single
surgeon and both occurred in patients who had dissection performed within
an inflamed triangle of Calot during RLC prior to obtaining the critical view.
There were 3 post operative cystic duct leaks; 2 occurred from necrosis of the
gallbladder neck and/or cystic duct and one occurred in a patient whose
inflamed gallbladder neck was stapled close.
Conclusions. Obtaining the ‘‘critical view of safety ’’ by dissection that begins
lateral and high on the gallbladder wall is a good technique to avoid common
bile duct injury during RLC. When the critical view cannot be achieved in
this manner, especially in the presence of inflammation, alternative measures
are indicated which include: FFLC, PC; or cholecystostomy tube while
avoiding dissection below the gallbladder neck. If FFLC or PC cannot be
safely accomplished, conversion to OC combined with IOC are indicated.
This step-wise approach to teaching cholecystectomy to residents dealing
with a high acuity patient population substantially reduces the risk of bile
duct injury during laparoscopic cholecystectomy.
248
MICROWAVE ABLATION IS EXTREMELY EFFECTIVE AT GAIN-
ING LOCAL CONTROL OF LARGE LIVER TUMOURS
Neil Bhardwaj, Andrew D Strickland, MBBS, Fateh Ahmad, MBBS,
Moshier Elabassy, MBBS, David M Lloyd, MBBS
Leicester Royal Infirmary, Leicester, United Kingdom
Background. Large primary or secondary unresectable liver tumours have
always been a challenge to treat. Several ablative modalities such as
radiofrequency and cryotherapy have been tried but often failed to gain local
control over tumours greater than 35 mm. Microwave tumour ablation
(MTA), has been successfully used in our centre since 2001.
Aims. To assess the efficacy of MTA to gain local control over tumours
greater than 35 mm.
Methods. We have treated over 60 patients and performed 208 microwave
ablations since 2001. Fourteen patients with either single or multiple
tumours had 1 or more tumour measuring 35 mm or larger. All patients
underwent pre-operative cross-sectional imaging. A total of 34 tumours were
treated, 17 of which were 35 mm (mean 47 mm; range 3570 mm) or
greater. Ten patients had colorectal liver metastases, 3 patients had HCC and
1 a parathyroid carcinoma metastasis. All patients with colorectal secondaries
were treated at laparotomy under ultra-sound guidance. The parathyroid
metastases (4 cm) and 1 patient with HCC (7 cm), were treated laparasco-
pically at 100 watts for 4 mins and 6 mins respectively. Most tumours were
treated with 150 Watts of power for 23 minutes only by a single insertion of
the applicator. Ten patients underwent MTA alone, 1 a formal right hemi-
hepatectomy and 3 a left hemi-hepatectomy along with MTA. All patients
had 3 monthly cross-sectional imaging post-operatively.
Results. There were no ablation related complications, such as bile leaks,
abscess formation or bleeding. Six patients are alive of whom 3 are disease
free (mean 25 months; range 635). Three have recurrence of disease (mean
29 months; range 1642) of whom one has local recurrence of a tumour
impinging on the hilar vessels. Seven evaluable patients died (mean 19
months; range 242) of either hepatic or extra-hepatic disease progression,
none had evidence of local recurrence on their latest scan. One patient died
day 1 post-procedure of an MI, a post-mortem report did not site microwave
ablation as a cause of death.
Discussion. Microwave is capable of effectively treating tumours greater
than 35 mm. Of those patients initially declared in-operable, 50% were alive
more than 2 years post-ablation and of those surviving more than 1 year post-
ablation (10/14), 90% had no evidence of local recurrence on cross-sectional
imaging. MTA is capable of producing complete tumour ablation of large
(3570 mm in diameter) liver tumours without the need for multiple
insertions of the applicator. Other alternative ablation modalities such as
radiofrequency have a poor local control rate and a high local recurrence rate,
particularly with large tumours.
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PREOPERATIVE STAGING FOR EXTRAHEPATIC CHOLANGIO-
CARCINOMA USING MDCT PRIOR TO BILIARY DRAINAGE
Katsuhiko Uesaka, MD, PhD, Atsuyuki Maeda, MD, PhD, Kazuya
Matsunaga, MD, Hideyuki Kanemoto, MD, Hiroyoshi Furukawa, MD, PhD
Shizuoka Cancer Center, Shizuoka, Japan
Preoperative staging and management of extrahepatic cholangiocarcinoma
(CC) had been very complicated.
Aim. To clarify the efficacy of our new strategy using multidetector row CT
(MDCT) prior to biliary drainage for preoperative staging and management
of extrahepatic CC.
Patients and Methods. Sixty-six consecutive patients with extrahepatic
CC, who underwent resection with curative intent between September 2002
and August 2006, were enrolled in this study. Among 66 patients, 36 had
upper or hilar CC and 30 had middle or lower CC. In principle, MDCT
study was performed before biliary drainage with a plain scan followed by a
four-phasic contrast-enhanced CT at 20sec, 40sec, 70sec, and 120sec after
an injection of 150ml of non-ionic contrast medium. Axial images, coronal
images, and CT angiography of the hepatic artery and portal venous system
were routinely obtained. Diagnostic criteria of longitudinal cancerous
extension along the biliary system were 1) caliber change of the dilated
proximal ducts and 2) thickened bile duct wall with contrast enhancement.
After assessment of cancer extent by MDCT, the operative procedure was
decided. Biliary drainage was performed only for the future remnant hepatic
segments in cases with upper or hilar CC. Preoperative portal vein
embolization was performed if necessary and angiography was not done
as a general rule.
Results. MDCT study prior to biliary drainage was carried out in 25
patients (69%) with upper or hilar CC and 14 patients (47%) with middle
or lower CC. Major hepatic resection with caudate lobectomy was performed
for all patients with upper or hilar CC. Pancreaticoduodenectomy was carried
out in 29 patients with middle or lower CC and extrahepatic bile
duct resection was done in one patient. Curative resection with negative
surgical margins was achieved in 31 patients (86%) with upper or hilar
CC and 27 patients (90%) with middle or lower CC. A cumulative 3-year
survival rate for upper or hilar CC was 72.4% and for middle or lower CC
70.4%.
Conclusions. MDCT prior to biliary drainage provides us with reliable
information for tumor staging and decision making of the operative
procedure of extrahepatic CC.
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CT VS. MRCP: OPTIMAL CLASSIFICATION OF IPMN
Joshua A Waters, Jason W Pinchot, MD, Patrick B White, Henry A Pitt, MD,
Kumar Sandrasegaran, MD, Fatih M Akisik, MD, Thomas J Howard, MD,
Atilla Nakeeb, MD, Nicholas J Zyromski, MD, Keith D. Lillemoe, MD, C
Max Schmidt, MD, PhD
Indiana University, Indianapolis, IN
Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas are being
diagnosed with increased frequency. Utilizing CT scanning as the sole source
of imaging prior to definitive surgical management is not uncommon. We
hypothesize MRI/MRCP may provide greater accuracy in identification of
IPMN type and extent.
Methods. From 1991 to 2006, 214 patients with IPMN were treated at our
tertiary care center; of these, 150 underwent 157 operations. Preoperatively,
30 patients had both CT and MRCP. Of these, 18 met criteria of high quality
and close proximity to operation. Two independent readers performed
retrospective blinded analysis using standardized criteria for IPMN type,
focality, distribution (diffuse1 surgical site), number, size of the index
lesion and main duct dilation.
Results. The mean time from MRCP and CT to operation was 76 and
78 days respectively (p0.96). A lesion characteristic of IPMN was
identified on CT and MRCP in all patients. MRCP showed 13 (72%)
branch, 4 (22%) mixed, and 1(6%) main duct type IPMN, whereas CT
showed 9 (50%) branch, 6 (33%) mixed, and 3 (17%) main duct type
IPMNs. IPMN type was different in 7 (39%); 4 (22%) of these were read
on CT as having main duct involvement, but no main duct disease was
seen on MRCP or identified on surgical pathology. MRCP showed
multifocal disease in 13 (72%) versus only 9 (50%) on CT. A different
distribution was seen in 9 (50%). MRCP showed non-diffuse disease in 6
(33%) where CT indicated diffuse disease; conversely, MRCP showed
diffuse disease in 3 (17%) where CT indicated non-diffuse disease.
Finally, there were 101 branch lesions identified on MRCP compared to
46 on CT.
Conclusions. While CT is cost-effective, it should not be the only test to
classify IPMN. CT overestimates main duct involvement, a significant
predictor of malignancy. This is due to the inability to consistently
differentiate main duct dilation from multifocal branch duct dilations. Small
branch duct cysts are more often identified on MRCP, decreasing the chance
they will go undetected preoperatively. Based on this study, CT is not
adequate as the sole method of evaluating IPMN type and extent. MRCP
should be employed for optimal management of these patients.
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ANTRAL PRESERVING PANCREATODUODENECTOMY:
IMPACT ON EARLY POST-OPERATIVE DELAYED GASTRIC
EMPTYING
Paul D Renfrew, MD, Francis R Sutherland, MD
Tom Baker Cancer Center, Calgary, AB, Canada
In an effort to diminish the occurrence of early post-operative delayed gastric
emptying following pancreatoduodenectomy one of the authors (FRS)
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changed the type of gastroduodenal resection utilized in his performance
of pancreatoduodenectomy from pylorus preserving to an ‘‘antral preser-
ving’’ resection. This variant of gastroduodenal resection is characterized
by the margin of gastric resection being located immediately proximal to
the pylorus. To determine if this change in practice has produced the
desired effect we compared proxy indicators for the occurrence of
delayed gastric emptying, duration of nasogastric intubation and length
of hospital stay, between patients that underwent pylorus preserving
pancreatoduodenectomy (PPPD) and antral preserving pancreatoduode-
nectomy (APPD). The study series was comprised of 99 consecutive
patients that underwent pancreatoduodenectomy between January 1998
and August 2006. Data was accrued from a prospective data base and
supplemented with retrospective review of medical records. In the series
29 patients had a PPPD and 70 had undergone APPD. There was no
evidence that these two groups differed in age, pre-operative co-
morbidities or proportion of malignant diagnosis. There was no in-
hospital mortality for the series. The incidence of morbidity was 48%
and the incidence of ‘‘major’’ morbidity (]Clavien grade III) was 34%.
Eight of the 99 patients (8.1%) had their post-operative course
complicated by pancreatic fistula, there was one biliary leak and six
patients in the series (6.1%) required a second operation to deal with
post-operative complications. Included in this group was one patient
whom had undergone APPD that required a remedial operation nine
months later for stenosis at the gastrojejunostomy due to marginal
ulceration. Of note, following APPD patients were not routinely
maintained on acid suppressive therapy. Median duration of nasogastric
intubation was significantly less for APPD than for PPPD, 3 vs. 7 days
(pB0.001). Median length of hospital stay was shorter following APPD
than for PPPD, 12 vs. 14 days, however this difference did not reach
statistical significance (p0.063). APPD is an attempt to draw upon
the strengths of both ‘‘classical’’ pancreatoduodenectomy and PPPD
by, respectively, minimizing early delayed gastric emptying and long-
term post gastrectomy sequelae. Based on these results it appears that
the adoption of APPD has had a favourable influence on early post-
operative delayed gastric emptying. Future work will aim to study
long-term sequelae and evaluate gastrointestinal quality of life in patients
undergoing this variant of gastroduodenal resection in pancreatoduode-
nectomy.
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DOES PANCREATIC DUCT SIZE PREDICT THE RISK OF FIS-
TULA AFTER PANCREATICODUODENECTOMY?
Lynt B Johnson, Reena Jha, MD, Naddim Haddad, MD, Firas Al-kawas,
MD, John Carroll, MD, Thomas Fishbein, MD
Georgetown Univ Hospital, Washington, DC
Postoperative pancreatic fistula (POPF) is the most common complication
following pancreaticoduodenectomy (Whipple Procedure). The reported
incidence ranges from 1% to 30%. The large range of this complication is
due to varying definitions of POPF along with the patient profile of those
undergoing surgery. We and others have hypothesized that in pancreatic
adenocarcinoma and chronic pancreatitis the pancreas has a more fibrotic
consistency and is more likely to maintain anastamotic integrity of the
pancreatojejunostomy than those with soft normal gland consistency.
Thus we hypothesized that pancreatic duct size could be used as a
surrogate for pancreas gland fibrosis and may predict the risk of
POPF.
Methods. 126 patients underwent a Whipple procedure by the Transplant
and Hepatobiliary Surgical Unit between January 2000 and July 2006.
Information on Pancreatic duct size was available for 106 patients. Drain data
was available for sixteen of the remaining 20 patients and only 1 had evidence
of POPF. Pancreatic duct measurements were available through computed
tomography, ERCP, endoscopic ultrasound, and/or direct operative calibra-
tion. Two groups were identified; those patients with ducts less than or
equal to 3 mm (small duct) and those with duct size greater than 3 mm
(large duct). POPF was defined as drain fluid amylase greater than 5 times
normal on or after day 4 with a 24 hour volume greater than 30 ml.
Patient demographic and clinical outcome data was analyzed to correlate
with the duct size. Histologic examination for fibrosis was also reviewed. Data
was evaluated by chi square, student’s T test and Cox proportional hazards
ratio.
Results. Overall postoperative fistula formation was 13 of 122 (10.6%). Nine
of 44 (20.4%) patients in the small duct group developed POPF, while only 3
of 62 (4.8%) patients in the large duct group developed a fistula post-
operatively (PB0.0001). Age, sex, post op length of stay, and estimated
blood loss was no different between the two groups. Overall 30 day mortality
was 2 of 126 (1.5%).
Conclusions. Large (3 mm) pancreatic duct size predicts a lower risk
for pancreatic fistula formation after Whipple procedure. A large
pancreatic duct is an indicator of obstruction and often results in
increased fibrosis in the pancreatic parenchyma. Preoperative measure-
ment of duct size may allow for a more accurate prediction of post-
operative pancreatic fistula and may allow for improved individual patient
risk assessment.
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SELF-EXPANDABLE ENTERAL METALLIC STENTS FOR
TREATMENT OF GASTRIC OUTLET OBSTRUCTION: A SINGLE
CENTRE EXPERIENCE IN 67 PATIENTS
Franck Vandenbroucke, MD, Maryle`ne Plasse Plasse, Richard Le´tourneau,
MD, Michel Dagenais, MD, Re´al Lapointe, MD, Andre´ Roy, MD
Hopital Saint Luc  CHUM, Montre´al, PQ, Canada
Introduction. Gastric outlet obstruction (GOO) is a late stage complication
of a variety of malignancies of the biliopancreatic area. Palliative treatment
through self-expendable metallic stent (SEMS) insertion is an option. It is a
minimally invasive alternative with a lower morbidity and mortality than
surgical bypass. The aims of this study were to assess the feasibility, efficacy
and complications associated with enteral SEMS insertion.
Patients and Methods. Between February 2002 and September 2006, 67
patients (33 women, 34 men; mean age 66 years) were referred for
endoscopic enteral stenting for GOO caused by various malignancies of the
biliopancreatic area.
Results. The causes of obstruction were pancreatic neoplasm (n42),
gallbladder and bile duct neoplasm (n16), gastric neoplasm (n7) and
others (n2). Forty-eight patients had a biliary tract obstruction and
underwent biliary stenting. Enteral stenting was successful in 63 patients
(94%) and failed in 4 patients (1 severe gastroparesis without mechanical
obstruction and 3 major duodenal strictures). Nine patients required a
second stent for various reasons: inadequate length (n3), tumour progres-
sion (n5) and stent migration (n1). The morbidity rate was 24%. The
complications were as followed: duodenal perforation (n2), acute chole-
cystitis or cholangitis (n2), food impaction (n1), inadequate stent length
(n3), stent migration (n1) and stent obstruction secondary to tumour
progression (n6). Two patients died from complications related to the stent
insertion. The median hospital stay was 8 days. Four patients were lost at
follow-up. Food tolerance was analyzed in 57 patients: excellent (normal
diet) (n42), average (soft or liquid) (n7) and poor (frequent vomiting)
(n8). Median survival post stent insertion was 75 days.
Conclusion. Endoscopically inserted enteral SEMS for malignant gastric
outlet obstruction was successful in 63 of 67 patients. Palliation of symptoms
was satisfactory in 86% of patients with an acceptable morbidity and
mortality.
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LAPAROSCOPIC DISTAL PANCREATECTOMY: COMPARISON
WITH OPEN SURGERY
Attila Nakeeb, MD, C. Max Schmidt, MD, PhD, Thomas J. Howard, MD,
Nicholas J Zyromski, MD, Keith D Lillemoe, MD, Henry A Pitt, MD
Indiana University School of Medicine, Indianapolis, IN
Laparoscopic surgery has become the standard technique for the manage-
ment of gallstones, gastroesophageal reflux disease and achalasia. The
laparoscopic approach also has become the preferred technique for the
majority of patients requiring adrenalectomy and splenectomy. In recent
years, laparoscopic surgery of the colon, liver and pancreas also have been
introduced. However, the least experience has been gained with the pancreas,
and no concurrent comparative data are available. Therefore, the aim of this
analysis is to compare the results of laparoscopic and open distal pancrea-
tectomy.
Methods. From April, 2004 through September, 2006, 47 laparoscopic
distal pancreatectomies were undertaken at our institution. From a 10-year
database of open distal pancreatectomies, 40 patients who were age-, gender-
and disease-matched were chosen for comparison. Thirty of the 40 open
control patients (75%) underwent surgery during the past three years.
Records were reviewed for splenic preservation, operative time, blood loss,
complications and length of hospital stay (LOS).
Results. The mean age of the laparoscopic and open patients was 57 and 55
years, respectively, and 60% versus 65% were female. Three of the
laparoscopic patients (7%) were converted to an open procedure. The
most common diagnoses for the laparoscopic and open patients was benign
mucinous tumor (43 vs 56%), chronic pancreatitis (13 vs 16%), and islet cell
tumor (13 vs 11%). Four patients with malignant lesions (2 adenoCA and 2
malignant neuroendocrine tumors) underwent laparoscopic resection. Op-
erative and postoperative results are shown in the table.
Conclusions. These data suggest that laparoscopic distal pancreatectomy is
associated with a) a higher rate of splenic preservation, b) increased operative
time, c) decreased blood loss and d) decreased length of stay. We conclude
that laparoscopic distal pancreatectomy can be performed safely and can be
undertaken by surgeons experienced in both laparoscopic and pancreatic
surgery.
Distal
Pancreatectomy N
Spleen
Preservation
Op
time
(min)
Blood
loss
(ml)
Pancreatic
fistula
LOS
(days)
Laparoscopic 47 60% 270 587 8% 5.5
Open 40 6%* 230* 1200* 20% 7.7*
* pB0.05 vs laparoscopic
104 Abstracts
Free Papers
Liver II
FP-09
4/22/07 7:30 to 9:30 am
Abstract Numbers 255262
255
CLINICOGENOMIC CHARACTERIZATION OF PRIMARY COL-
ORECTAL CARCINOMA ASSOCIATED WITH LIVER METAS-
TASES
K Meredith, MD, E Siegel, J Mcloughlin, MD, R Nair, MD, J Lewis, MD, S
Eschrich, PhD, G Bloom, PhD, Q Ly, MD, E Jensen, MD, M Alvarado, MD,
T Yeatman, MD, D Shibata, MD
H. Lee Moffitt Cancer Center, Tampa, FL
Purpose. Approximately 20% of patients with colorectal carcinoma (CRC)
present with hepatic metastases. Genome-wide alterations that occur during
the metastatic progression of CRC remain poorly understood. Using a
clinicogenomic CRC database, we have sought to compare clinical variables
as well as microarray gene expression profiles between metastastic and non-
metastatic primary CRCs.
Methods. From 1993 to 2003, primary CRC specimens were collected from
patients consenting to our tissue bank protocol. RNA was extracted from
tissue collected at surgery. All specimens underwent gene profiling using the
Affymetrix 133 Plus 2.0 Gene chip. We identified a total of 96 analyzable
cases. Clinical data were collected by chart review, and statistical compar-
isons performed using the Fisher Exact Test. Gene expression data were
normalized and compared using the Mann-Whitney non-parametric test. A
Q-value analysis was used to estimate the false discovery rate (FDR).
MetaCore software was used to identify potential pathways and interactions
between differentially expressed genes.
Results. We identified 66 patients without evidence of nodal or distant
metastases. An additional 30 patients were noted to have either synchronous
or metachronous hepatic metastases. The study population was comprised of
58 males and 38 females with a median age of 72 years (range 3990).
Patients with metastatic disease were more likely to present with weight loss
(44% vs. 16% p0.006) and higher T (3 or 4) stage (72% vs. 100%; p
0.004). There were no significant differences between the 2 groups with
respect to grade and perineural or lymphovascular invasion. At a FDR of 1%,
metastatic tumors displayed a total 234 upregulated genes (0 downregulated)
as compared to non-metastatic CRCs. Amongst the most upregulated genes
were EGF Receptor (1.7 fold change) and genes associated with the
ubiquitin proteolytic pathway (UMF11.5, EDD11.4, UBE2W1.3,
UBE2E31.3). By MetaCore analysis, 15 pathways were significantly
altered, of which 11 were associated with cell adhesion functions (Cytoske-
leton remodeling; p0.0005, TGF/Wnt p0.0007; Integrin mediated cell
adhesion p0.001).
Conclusions. CRCs with metastatic potential display a dramatically altered
panel of differentially expressed genes that are associated with upregulation of
EGFR, ubiquitin proteolysis and various aspects of cell adhesion. Our data
add to the understanding of the biologic processes involved in tumor
metastasis and have the potential to contribute to the development of novel
modalities for CRC diagnosis, prognosis and targeted therapies.
256
NEOADJUVANT CHEMOTHERAPY PRIOR TO MAJOR HEPATIC
RESECTION OF COLORECTAL METASTASES IS ASSOCIATED
WITH INCREASED MORTALITY AND HIGHER COMPLICA-
TIONS RATE
Ory Weisel, Nir Lubezky, Ravit Geva, Einat Shmueli, Arie Figer, Richard
Nakache, Menahem Ben-haim
Tel Aviv medical center, Tel-aviv, Israel
Introduction. Although Neoadjuvant approach to treat hepatic colo-rectal
metastases is widely accepted, there is insufficient data regarding its impacts
on postoperative morbidity and mortality.
Methods. Patients with resectable colo-rectal hepatic metastases were
assigned to either an immediate surgery (group 1) or to neoadjuvant
treatment with Irinotecan or Oxaliplatin together with Bevacizumab (Avas-
tin) followed by surgery (group 2). Selection was based on the oncologist’s
and patient’s preference and was guided by the estimated risk of recurrence.
A multivariate analysis was conducted to identify risk factors for various
postoperative complications.
Results. Of 106 included patients, 54 were operated immediately and 52
following neoadjuvant treatment. Overall mortality rates were 1.9% (1/54) in
group 1 and 9.6% (5/52) in group 2 (p0.07). Mortality rates following
extended lobar resections (]5 segments) were 8% (1/12) within group 1,
and 41% (5/12) in group 2. The only other outcome measure that was
different significantly is wound complications (infection, dehiscence and
hernia; 7.4% vs. 23% respectively, p0.03). The rates of other infectious
complications (pulmonary, line, UTI, intraabdominal collection) and the
mean length of stay were also higher in the group 2, but these did not reach
statistical significance. Interestingly, synchronous GI surgery was not an
independent risk factor of post-operative complications.
Conclusions. Neoadjuvant chemotherapy is associated with increased
mortality and morbidity following major hepatic resections. The oncological
justification of neoadjuvant approach should be balanced accordingly.
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TOTAL LOSS OF FDG AVIDITY IN COLORECTAL CANCER
LIVER METASTASES AFTER CHEMOTHERAPY IS INFRE-
QUENTLY ASSOCIATED WITH A COMPLETE PATHOLOGICAL
RESPONSE
Marcus C Tan, MBBS, David C Linehan, MD, William G Hawkins, MD,
Steven M Strasberg, MD
Barnes-Jewish Hospital / Washington University School of Medicine, St.
Louis, MO
Introduction. Newer chemotherapeutic regimens, especially those includ-
ing biologic agents such as bevacizumab, have improved outcomes in
patients with metastatic colorectal cancer. In some cases, dramatic res-
ponses have been associated with loss of FDG uptake on follow-up PET
scans. It is unclear how often loss of FDG avidity in the face of continuing
presence of a lesion on CT or MRI scan is associated with complete tumor
destruction. This information is of importance in determining further
management.
Methods. This is an analysis of a specific subset of patients undergoing
neoadjuvant chemotherapy for hepatic metastases from colorectal adenocar-
cinoma. The inclusion criteria were: 1) whole body PET scan demonstrating
FDG-avid hepatic lesions prior to initiation of neoadjuvant therapy; 2) whole
body PET scan demonstrating loss of FDG-avidity of the same hepatic
lesions after completion of neoadjuvant therapy; and 3) histopathological
sampling of hepatic lesions by biopsy or resection to document extent of
response to treatment.
Results. 16 patients treated from 6/2002 to 6/2006 fit inclusion criteria,
including 12 since 1/2005. Median age was 58.5 years (range: 3284 years),
twelve were male, and fifteen had either stage 3 or 4 disease at the time of
resection of the primary colorectal cancer. The chemotherapeutic regimen
used in 13/16 patients was 5-fluorouracil-based (either FOLFOX or
FOLFORI) combined with bevacizumab. No patient had focal FDG uptake
in the liver after chemotherapy  12/16 had uniform uptake of FDG in the
liver, and 4/16 had heterogeneous uptake. On microscopic examination of
resected tumors (15 patients) or biopsies (1 patient), viable tumor was
present in 13 patients (81%). Complete response (only necrotic tumor
identifiable) was declared when no viable tumor was present in a completely
resected tumor. This was found in only 3 cases (19%).
Conclusion. Most patients with colorectal cancer whose hepatic metastases
become FDG-PET negative after newer neoadjuvant chemotherapy regimens
still have active residual tumor in the liver. Curative resection of liver
metastases in these patients should not be deferred on the basis of FDG-PET
negativity.
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RIGHT HEPATIC LOBECTOMY USING THE STAPLE TECHNI-
QUE IN 101 PATIENTS
Fady K Balaa, MD, Allan Tsung, MD, T. Clark Gamblin, MD, J. Wallis
Marsh, MD, David A Geller, MD
UPMC Liver Cancer Center, University of Pittsburgh, Pittsburgh, PA
Background. Application of linear stapling devices for extra-hepatic
vascular control in liver surgery has been well-established. However, the
technique for use of stapling devices in hepatic parenchymal transection is
not well defined.
Purpose. To describe the safety and efficacy of our technique for use of
endo-vascular stapling devices in hepatic parenchymal transection during
open right hepatic lobectomy (Right Hemihepatectomy).
Methodology. We reviewed our experience with 101 consecutive open right
hepatic lobectomies performed by a single surgeon between January 2003
and July 2006, in which endovascular staplers were utilized for the
parenchymal transection phase.
Results. Of the 101 patients who underwent resection, 53 (52%) were
female. The mean age was 58 years. Malignant disease was the indication for
resection in the majority of patients (88%). Of those with cancer, 78% (69 of
89) had metastatic colorectal cancer, 6% (5 of 89) had metastatic
neuroendocrine tumor, 4% (4 of 89) had hepatocellular carcinoma, 4% (4
of 89) had cholangiocarcinoma, and the remaining 8% were other metastatic
cancers. 12 patients (12%) underwent resection for hepatic adenoma or
symptomatic benign disease (FNH or hemangioma). 48 patients (48%)
underwent a major ancillary procedure at the time of hepatic resection. 39
patients (39%) had a non-anatomic wedge resection of a left lobe lesion, 27
patients (27%) had one or more lesions treated with radiofrequency ablation
(RFA), and 6 patients (6%) were treated with a synchronous bowel resection.
The median total operative time was 336 minutes (range 155620 minutes).
A Pringle maneuver for temporary vascular inflow occlusion was utilized in
all cases, with a median time of 9 minutes (range 417 minutes). 10 patients
(10%) required blood transfusion during surgery or in the post-operative
period. The maximum transfusion was 2 units of pRBC in 7 patients, and 1
unit of pRBC in 3 patients. The mean nadir post-operative hematocrit was
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28.2%. All patients with malignant disease had tumor free margins at the
completion of the procedure. The average hospital length of stay was 6.0
days. One patient (1%) developed a clinically significant bile leak requiring a
post-operative ERCP. No patient required re-operation. Thirty and ninety
day survival was 100%.
Conclusion. These findings indicate that application of endovascular
stapling devices for parenchymal transection in major hepatic resection is a
safe technique, with low transfusion requirements and minimal post-
operative bile leak. The technique allows for rapid transection of the entire
right hepatic lobe in under 10 minutes.
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HEPATECTOMY FOLLOWING COLORECTAL CANCER RESEC-
TION IN THE ELDERLY IN THE UNITED STATES
Jensen C. C. Tan, MD, Natalie G. Coburn, MD, Calvin H. L. Law, MD
University of Toronto, Toronto, ON, Canada
Introduction. After colectomy for colorectal cancer (CRC), patients have a
50% lifetime risk of developing metastases, with the liver as the most
common site. It is estimated that approximately 20% of CRC liver metastases
are resectable. Despite the proven benefit of liver resection for metastatic
disease for long term survival, it is not known whether elderly metastatic
CRC patients are appropriately offered liver resection for metastatic disease.
Methods. Patients with resected CRC aged between 65 and 75 years
at the time of diagnosis were identified from the linked Surveillance,
Epidemiology and End Results (SEER)  Medicare program from 1991
through 2003. Patients without continuous part A and B Medicare coverage,
or had HMO coverage at any time from diagnosis of CRC to date of death
were excluded. Patients with any cancers other than CRC were also excluded.
Medicare claims data was used to determine whether resected CRC patients
received a hepatectomy at any time following their colorectal resection.
Overall survival (OS) was analyzed using the Kaplan Meier method and log-
rank test.
Results. A total of 32652 patients were identified. The mean age at CRC
diagnosis was 70.5, with 50% males. Of these patients, 596 (1.8%) received a
subsequent liver resection. For patients who received a liver resection, mean
age was 69.9 years at CRC diagnosis and 71.0 years at liver resection. The
extent of hepatectomy was as follows: 131 (22%) formal right hepatectomy;
41 (7%) formal left; 35 (6%) trisegmentectomy; and 389 (65%) lobectomy
not otherwise specified. There were 368 (62%) and 228 (38%) patients who
received a hepatectomy for synchronous (within 6 months of the CRC
resection) and metachronous metastases, respectively with no clinical
difference in median survival for either group (24 and 25 months,
respectively). One, three and five year OS for resected patients was 76%,
27% and 7.3%, respectively. Age and sex adjusted rates of liver resection by
SEER region varied from 1.0% to 2.5%.
Conclusions. A lower than expected rate (2%) of hepatic metastatectomy
was found among patients with previously resected colorectal cancer in the
SEER-Medicare program. No difference in mortality was found between
patients with synchronous or metachronous disease. Not unexpectedly, the
long term overall survival rates among this older group were lower than that
from literature series of younger patients. Further study is warranted to
examine both access to and selection for hepatic resection for metastatic
CRC in this population.
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RECURRENCE AND SURVIVAL OUTCOMES AFTER HEPATIC
RESECTION WITH AND WITHOUT CRYOTHERAPY FOR COL-
ORECTAL LIVER METASTASES
Rui Niu, Tristan D Yan, MBBS, Jacqui C Zhu, Francis Chu, MBBS, David L
Morris, MD, PhD
St George Hospital, Sydney, Australia
Introduction. Only 10% of patients with colorectal liver metastases
(CRLM) are amenable to resection. Ablative techniques have increased the
proportion of patients that can undergo potentially curative treatment. Some
reports support resection combined with cryotherapy for multiple bilateral
liver diseases that would otherwise be ineligible for curative treatment. This
series demonstrated long-term results of 415 patients with CRLM who
underwent resection with or without cryotherapy.
Method. From January 1990 to December 2005, 291 patients were treated
with resection only, 124 were treated with combined resection and
cryotherapy. Resection was performed where technically possible,
while cryotherapy was used to complement resection in bilobar disease.
Hepatic arterial chemotherapy was used in patients who had more than 2
lesions. Recurrence and survival outcomes were analyzed. Kaplan-Meier
and Cox-regression analyses were used to identify significant prognostic
indicators.
Result. Median length of follow-up was 25 months (1 to 124). The 30-day
perioperative mortality rate was 3.1%. Overall median survival was 32
months (1 to 124), with 1-, 3- and 5-year survival of 85%, 45% and
29% respectively. The overall recurrence rates were 66% and 78% for
resection and resection/cryotherapy groups, respectively. Median lengths of
disease-free intervals were 13 months and 8 months for resection and
resection/cryotherapy groups, respectively. For the resection group, the
median survival was 34 months, with 1-, 3- and 5- year survival of 88%,
47% and 32%, respectively. For the resection/cryotherapy group, the median
survival was 29 months, with 1-, 3- and 5-year survival of 84%, 43% and
24%, respectively (p0.206) (Figure 1). Three factors were independently
associated with an improved survival in multivariate analysis: absence of
extrahepatic disease at diagnosis (p0.026; HR1.490; 95% CI1.049
2.116), largest lesion size 54 cm (p0.012; HR0.271; 95% CI0.098
0.752) and a low postoperative CEA (pB0.001; HR1.887; 95% CI
1.369 2.6).
Conclusions. Long-term survival results of resection combined with
cryotherapy for multiple bilobar CRLM are comparable to that of resection
alone. An presence of extrahepatic disease at diagnosis,6 lesions with
largest lesion size ]4 cm and a postoperative CEA5 ng/ml are associated
with a reduced survival outcome.
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COLORECTAL LIVER METASTASES: RECURRENCE AND SUR-
VIVAL FOLLOWING HEPATIC RESECTION, RADIOFRE-
QUENCY ABLATION, AND COMBINED RESECTION/ABLATION
Timothy M Pawlik, MD, MPH, Lia R Assumpcao, MD, Ana Gleisner, MD,
Michael Choti, MD, MBA, Johns Hopkins
Baltimore, MD
Introduction. Radiofrequency ablation (RFA) is increasingly accepted as an
option for patients (pts) with colorectal liver metastases (CRLM). Long-term
data following treatment of CRLM using RFA with or without hepatic
resection are limited.
Methods. Between 1984 and 2006, 383 pts with CLRM were treated
surgically at a single institution. Data were analyzed using univariate and
multivariate analyses. To account for clinical differences between the RFA
and resection group, a matched case control analysis was performed.
Results. Median number of treated hepatic lesions was 2 (range, 115);
median size of the largest lesion was 3.5 cm (range, 0.215 cm). 310
(80.9%) pts underwent resection only, 61 (15.9%) resectionRFA, and
12 (3.2%) RFA only. The perioperative complication rate was 19.3% and
90-day mortality rate was 1.4%. At a median follow-up of 20.5 months,
184 (48.0%) pts had recurred. Factors associated with overall recurrence
included primary tumor nodal status, tumor number, and history of RFA
(all PB.05). On multivariate analysis, pts who had undergone RFA
remained over twice as likely to recur (HR2.81, PB.001). Pts who
underwent either ablation alone (35.2%) or RFAresection (40.0%) also
had a higher rate of local recurrence within the liver compared with pts
who underwent resection alone (9.8%) (PB.001). The median actuarial
survival for the entire cohort was 49.6 months and the 5-year survival
rate was 42.6%. Patients who underwent resection only (61.4 months)
had a longer median survival compared with pts who had either RFA
alone (45.2 months) or RFAresection (29.0 months ) (both PB.001).
For pts treated with RFA, as tumor number increased so did the risk of
disease-specific death (one lesion, HR2.24; 23 lesions, HR3.28;3,
HR3.73) (all PB.001). Pts who underwent RFA9resection were
matched to pts who underwent resection only based on metastatic lesion
size and number, as well as primary tumor T- and N-stage. On matched
analysis, pts who underwent RFA9resection still had a higher risk of
recurrence and disease-specific death vs. pts who underwent resection
alone (Table).
Conclusion. Pts with CRLM who were treated with RFA alone or in
combination with resection had a higher risk of hepatic recurrence and
disease-specific death. When feasible, hepatic resection should remain the
treatment of choice for pts with CRLM.
106 Abstracts
Risk of Recurrence and Disease-Specific Death Stratified
by Surgical Procedure
Hepatic
Recurrence
(Percent, %)
Any
Recurrence
(Percent, %)
5-year
Disease-Specific
Death
(Percent, %)
Unmatched Analysis
Resection Only 9.8 55.8 49.7
ResectionRFA 40.0 92.8 93.7
RFA Only 35.2 75.0 76.9
Matched Analysis
Resection Only 16.6 58.7 52.6
RFA9Resection 69.9 91.2 91.3
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MICROWAVE HEPATIC TUMOR ABLATION RESULTS OF ON-
GOING PHASE 2 TRIAL
Robert Cg Martin, MD, Kelly M Mcmasters, MD, PhD, David A. Iannitti,
MD, Damian E. Dupuy, MD
University of Louisville, Louisville, KY; Carolinas Medical Center, Char-
lotte, NC; Brown Medical School, Providence, RI
Background. Microwave hepatic tumor ablation represents a new and
expanding technology in hepatic tumor ablation techniques. A majority of the
initial experience had been in Asia and the United Kingdom. Microwave
ablation has been demonstrated to be effective in the treatment of hepatic
tumors in multiple treat and resect studies. This study represents our ongoing
phase 2 evaluation of microwave ablation as the primary therapy in patients
with hepatic malignancies.
Method. A prospective multi-institutional study of microwave ablation of
hepatic tumors from 3/2004 until 5/2006 is presented. A standard bracketed
technique of placing multiple (maximum 3) probes around the periphery of
the tumor was utilized. In all cases multiple ablations of hepatic lesions was
performed simultaneously.
Results. Two hundred and fifty-four hepatic tumors were ablated in 107
patients (45 colorectal, 28 hepatocellular, 13 breast, 21 other), in 108
ablation sessions. The median tumor number was 3 (range 113) with a
median size of 3 cm (range 1.5 to 5.0 cm). Multiple types of microwave
probes were utilized depending on location and size, with 56 open, 7
laparoscopic, and 45 percutaneous. 18 patients underwent additional
procedures including partial hepatectomies, colectomy, and gastrectomy.
Total median ablation time was 10 minutes (range 5 to 22.5), with median
ablation volume 50.5cc (range 21 to 147). There were two peri-operative
mortalities, with peri-operative morbidity occurring in 22 patients. After a
median follow up of 22 months there have been 7 (2.8%) ablation
recurrences and 46 (43%) regional recurrences.
Conclusion. Microwave hepatic tumor ablation is a safe and effective
technique for tumor ablation. The ability to perform multiple ablations
simultaneously allows for a more efficient surgical procedure, especially in
patients with multiple lesions. The ability to perform bracketed ablations in
tumors that are not perfectly spherical may result in more complete initial
ablations and fewer ablation recurrences. Continued evaluation in ongoing
trials in specific malignant histology’s and specific hepatic parenchyma is
needed to optimize this and other ablation technologies.
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GALLBLADDER BILE CHANGES IN PATIENTS TREATED WITH
PREOPERATIVE TOTAL PARENTERAL NUTRITION
Lillian G. Dawes, MD, Steven J. Stryker, MD
University of Michigan, Ann Arbor, MI; Northwestern University Feinberg
School of Medicine, Chicago, IL
Total parenteral nutrition increases the risk of gallbladder sludge and
gallstones. Although the cause of this association has been studied in animal
models, little data on bile composition with TPN exists in humans. In animal
models, changes in bile salt secretion, bile salt profiles, gallbladder bile
calcium, bilirubin, and biliary phospholipids have been reported with TPN.
Whether any of these gallbladder bile changes occur in patients on TPN is
unknown. We investigated gallbladder bile composition and bile salt profiles
in 16 surgical patients on preoperative TPN (7days to 4 weeks) and
compared this to gallbladder bile from 17 patients with normal oral intake
undergoing operation for elective surgery (12 colectomy, 1wedge liver
resection, 2 gastric resection, 1 Nissen, 1distal pancreatectomy). None of
the patients had gallstones. Bile was analyzed for Ca, total Ca,
electrolytes, cholesterol and phospholipids (Wako and Boehring-Mannheim
kits). Bilirubin profiles and bile salt profiles were analyzed with respective
hplc assays.
Results. Gallbladder bile calcium (both ionized and total), bilirubin and bile
salt concentrations, sodium, potassium, and bile acidification were similar in
patients on preoperative TPN and patients with normal oral intake
preoperatively. Similar to findings in animal models, TPN was associated
with decreased phospholipids concentrations in gallbladder bile. Neither the
concentration, nor the profile of bile acids changed, yet the percent of bile
acids conjugated with taurine as compare to glycine was decreased in patients
on TPN.
Gallbladder Bile values Oral intake TPN
Calcium (mM) 6.490.7 6.591.4
Bilirubin (mg%) 295952 204955
Bile salt (mM) 138913 148924
Cholesterol (mM) 7.791.7 8.091.9
Phospholipids (mM) 46.495.9 31.494.6*
%Taurine conjugated bile salts 3694 1994*
* Significant difference, pB0.05, t-test.
Conclusion. Gallbladder bile from patients on preoperative TPN did not
show changes in calcium, bilirubin nor bile salt concentration as seen in
animal models on TPN. Whereas the bile composition of cholic acid,
chenodeoxycholate and deoxycholate conjugates did not change, the percent
of bile salts conjugated with taurine decreased. Biliary phospholipid
concentrations decreased similar to that seen in several animal models. A
reduction in biliary phospholipids may alter the solubility of cholesterol in
bile and predispose to gallstones in patients fed intravenously.
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UNCONSCIOUS BIAS INFLUENCES THE DIAGNOSIS OF LA-
PAROSCOPIC BILE DUCT INJURIES
Lygia Stewart, MD, Lawrence W. Way, MD
UCSF, San Francisco, CA
Purpose. Framing (assumptions about context, that leads to assigning
meaning to certain observations and discounting others deemed irrelevant)
channels all types of human decision-making, including the diagnosis
of bile duct injuries. The clinician’s ability to frame data using well-developed
pattern-matching confers expertise. But, this can sometimes lead to
diagnostic errors (eg. if the clinician frames symptoms of bile ascites as
ileus rather than bile duct injury). Another common diagnostic error
(premature closure) occurs when an initial diagnosis is given more credence
than the evidence supports and subsequent disconfirmatory findings
are discounted. In 74% of injuries resulting from a laparoscopic cholecys-
tectomy, the complication is undetected until sometime later in the post-
operative period. We analyzed the thinking patterns that eventually led to the
diagnosis.
Methods. Of 303 bile duct injuries, the 224 (74%) that were detected
postoperatively were grouped by presentation: bile ascites (Fist) or biliary
obstruction (Obst), and whether jaundice (bili]3) was present. Time to
diagnoses, number of encounters (clinic/ER visit, hospitalization, etc.) before
diagnosis, and the effect of prior diagnostic hypotheses on final diagnosis was
tabulated.
Results. 53% of these injuries were diagnosed at first presentation (Rec),
70% presented with Fist and 30% with Obst. Among those with Fist, only
45% were Rec (45% vs 71%, Fist vs Obst, P0.003). When accompanied by
jaundice, Fist cases were Rec more often (60% vs 40%, with vs without
jaundice, PB0.05). 43% of cases with persistent bilious drainage were
observed for 2 weeks (range 1140 days) before obtaining diagnostic
studies. Injuries initially missed were more likely to be missed on subsequent
encounters: 58% were missed on the 2nd encounter, 24% were missed again
on the 3rd-5th encounters (PB0.0001); and recognition time was longer (7
vs 27 days, Rec vs missed, PB0.0001). This pattern was repeated at each
point of missed injury (opened without recognition, missed during hospita-
lization, clinic, etc).
Conclusions. Inadequate framing (failure to appreciate the significance of
bile leaks) and premature closure (giving excessive credence to the initial
hypothesis) accounted for most diagnostic delays. Increasing awareness that
most laparoscopic bile duct injuries present with bile ascites rather than
obstructive jaundice (better framing), and a more balanced weighting of the
diagnostic findings would lead to earlier diagnosis, earlier treatment, and less
morbidity. Understanding the innate idiosyncrasies of human decision-
making is critical for improving outcomes.
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EVOLUTION OF THE SURGICAL REPAIR OF BILE DUCT
INJURIES: THE TRANSITION TO INTRAHEPATIC REPAIR
Miguel Angel Mercado, MD
Instituto Nacional de la Nutricio´n Salvador Zubira´n, Mexico City, Mexico
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The most frequent technique used for reconstruction is a Roux en Y
hepatojejunostomy. Long-term results of reconstruction are related to several
technical and anatomic factors, but an ischemic duct play a mayor role. We
report the results seen during the transition of low extrahepatic repair to high
intrahepatic repair.
Methods. In 15 years a total of 355 patients have been referred to our
hospital for bile duct repair. Thirty two cases have been repaired minutes to
hours after the injury occurred. The remaining 323 patients arrived weeks
after the injury with heterogeneous symptoms related to intrabdominal
collections, external fistulae and occluded ducts. Surgical treatment was done
when either the radiological or endoscopic approach were ruled out and when
the general conditions of the patient allowed the surgical intervention for
reconstruction. In all cases, a Roux en Y hepatojejunostomy was done. Partial
resection of segment IV was performed in order to obtain non-inflamed, non-
scarred, non-ischemic biliary ducts with the purpose of achieving a high
quality bilioenteric anastomosis. This technique was done in 101 patients. In
a total of 243 cases an anastomosis at the level of the confluence was
attempted (in 163 we found the confluence preserved and in 80, the
confluence was lost). In the remaining 80 patients, a low bilioenteric
anastomosis was done at the level of the common hepatic duct. We compared
the cases in which an intrahepatic repair was done (163) with those who had
an extrahepatic one (80).
Results. All of the injuries were classified as Strasberg E. In all cases the
confluence was preserved (N243). In 163 a high intrahepatic repair was
done, including the 101 patients in which resection of segment IV and V was
part of the surgery. The anastomosis was made with 50 absorbable
monofilament sutures, opening the anterior aspect of the left duct in order
to obtain a wide, tension free anastomosis. In the remaining 80 cases
(operated between 19901997) an anastomosis was done at the level of the
common hepatic duct were the surgeon seemed to find a healthy duct. Twelve
(15%) of the 80 cases with low extrahepatic anastomosis required a new
intervention (surgical or radiological), compared to the 5 cases of the 163
(3%) that had a high intrahepatic anastomosis (P0.00062). Good results
were obtained in 85% and 97% of the cases with low extrahepatic
anastomosis and high intrahepatic anastomosis respectively.
Conclusions. A high intrahepatic anastomosis warrants the finding of non-
scarred, non-ischemic ducts, allowing a safe and high quality anastomosis
with significant results compared to the low level anastomosis group.
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TREATMENT OF MAJOR BILE DUCT INJURIES AFTER LA-
PAROSCOPIC CHOLECYSTECTOMY  FIFTEEN YEAR EX-
PERIENCE IN A REFERENCE CENTER
Franck Vandenbroucke, Koen Vermeiren, Maryle`ne Plasse, MD, Richard
Le´tourneau, MD, Michel Dagenais, MD, Andre´ Roy, MD, Re´al Lapointe,
MD
Hopital Saint Luc  CHUM, Montre´al, PQ, Canada
Introduction. Laparoscopic cholecystectomy increases the risk of major bile
duct injuries. We report our fifteen year experience of treatment of these
injuries in a referral center.
Methods. A retrospective study of 123 patients (93 women and 30 men;
mean age: 49917 years) referred between 1991 and 2005 in our tertiary
center. We analyze: gallbladder disease, injuries diagnosis time, Strasberg
classification of injuries, type of reparation procedures and long terms results
of follow-up.
Results. Cholecystectomy was performed for 77 symptomatic chronic
calculous cholecystitis and 46 acute calculous cholecystitis. The injury was
diagnosed during the surgical procedure for 60 patients and in the post-
operative time for 63 patients. The Strasberg classification of injuries was: 5
type A, 8 type E1, 28 type E2, 34 type E3, 36 type E4, 12 type E5. Before the
transfer of patients, primary reparation procedure was: 39 primary closures,
23 hepaticojejunostomies, 13 exploratory laparotomies, 17 percutaneous
drainage of bilioma, 7 ERCP or transhepatic procedures and 24 medical
treatments. In our center, 104 patients needed 1 to 4 surgical corrections
with: 72 hepaticojejunostomies, 12 surgical drainages, 23 hepatectomies and
1 liver transplantation. Forty-six ERCP or percutaneous therapeutic proce-
dures and 16 percutaneous drainages were done. The median follow-up was
78 months. The mortality was 2.5%. Seven patients were lost during the
follow-up. Long-term results were: 102 patients with normal hepatic blood
tests and 88 with normal liver ultrasound examination.
Conclusions. Roux-en-y hepaticojejunostomy is the best procedure for the
repair of bile duct injuries and allows very good long-term results.
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MANAGEMENT OF BENIGN BILIARY STRICTURES: ANALYSIS
OF MINIMALLY INVASIVE TECHNIQUES VERSUS SURGICAL
TREATMENT
Osama M Damrah, Andrea Lauretta, Long R Jiao, Nagy A Habib, Ruben
Canelo
Hammersmith Hospital, London, United Kingdom
Introduction. The effectiveness of various benign biliary stricture treat-
ments has not been evaluated systemically. The authors reviewed the
treatment and outcome of patients with benign biliary stricture who under-
went surgical treatment, minimally invasive treatment (ERCP, PTCD) or
both.
Methods. Between 2002 and 2006 Patients(n49) referred for treatment of
benign bile duct strictures due to chronic pancreatitis (17), sclerosing
cholangitis (12), bile ducts injuries (11), choledochal cystS (3), pancreatic
pseudocystS (3), crohn’s disease of the duodenum (2), Aberrant anatomy
(1). Surgery and/or endoscopic treatment were performed according to the
degree, the level (Bismuth-Collins classication) and the etiology of the
stricture. Multivariate and univariate analysis of clinical and pathologic
factors in relations to patient’s outcome, hospitals stay and survival were
performed.
Results. 28 patients had only endoscopic intervention (stenting, balloon
dilatation). 16 patients were managed with both surgical and minimally
invasive procedure. 5 patients underwent only surgical treatment. Repeated
minimally invasive treatments gave less complications (4/28) than surgery
alone (4/5) or surgery and endoscopy (15/16); as well as were correlated to a
less initial hospital stay (PB0.01) and total hospital stay (PB0.01).There
was no difference in the outcome according to the etiology and the level of the
stricture.Recurrence rate was less in patients treated by surgery and
endoscopy (PB0.01).
Conclusion. Successful management of benign biliary stricture requires a
multidisciplinary approach. Initial endoscopic treatment should be attempted
and repeated minimally invasive procedures are a real option.Combination of
surgery and endoscpic intervention provides the best outcome.
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RECURRENT PYOGENIC CHOLANGITIS  THE ROLE OF SUR-
GICAL INTERVENTION
Wigdan R Al-Sukhni, MD, Steven Gallinger, MD, FRCP, Alice C Wei, MD,
FRCP, Chia Sing Ho, MD, FRCP, Paul Kortan, MD, FRCP, Paul D Greig,
MD, FRCP
Toronto General Hospital  University of Toronto, Toronto, ON, Canada;
Mount Sinai Hospital  University of Toronto, Toronto, ON, Canada; St.
Michael’s Hospital  University of Toronto, Toronto, ON, Canada
Purpose. To assess the outcomes of surgical management of Recurrent
Pyogenic Cholangitis (RPC) at a North American tertiary care centre.
Methods. Retrospective analysis of 42 RPC patients, presenting between
19862005. Patients were identified through a search of hospital and
hepatobiliary surgeons’ clinical records.
Results. Mean age is 54 years (2487), and 23 patients were female (55%).
All subjects had recurrent episodes of bacterial cholangitis; sixteen patients
(38%) had predominantly left-lobe disease, while 19/42 (45%) had bilateral
disease. Twenty-seven patients (64%) underwent surgery, after failed attempt
at stone removal by ERCP in 11 and by interventional radiology in 9. The
principles of surgical management were: intraoperative stone extraction and
provision of a Hutson choledochojejunal access loop when necessary.
Surgical procedures were: 10 CBD explorations with Hutson loop; 17
hepatectomies, 10 with, and 7 without Hutson loop. Liver resection was
used in patients whose stone disease was dominant in one lobe. In the non-
resection group, 7/10 had CBD dominant or bilobar stones; 2 had
parenchymal atrophy but no significant intra-hepatic stones; and one had
right-sided stones considered to be extractable. Operative mortality was zero;
complication rate for hepatectomy (35%) was similar to that of CBD
exploration (30%). Median follow-up was 24 months (3228). Of 21
Hutson loops constructed, only 7 (33%) were subsequently used for
percutaneous removal of stones, with three failures. Post-op need for
interventional radiology (excluding Hutson access) occurred in 4 other
patients. At completion of surgical therapy (i.e. operation9use of Hutson
loop), 21/27 (78%) patients were free of stones. At last follow-up, no surgical
patients had recurrent symptoms due to stones, while in the non-operated
group 4/15 were symptomatic from stones (27%). Cholangiocarcinoma was
identified in 6/42 (14%) patients; 5 were unresectable and one was an
incidental in-situ carcinoma in the resected specimen.
Conclusion. Surgery appears to be a safe and effective treatment option for
RPC, and hepatectomy is a valuable option for lobe-dominant disease with
no apparent increased morbidity. Though Hutson loop has not been used
frequently, it has low morbidity and provides for direct percutaneous removal
of stones. The risk of cholangiocarcinoma is increased in RPC and often
presents as advanced disease. Hepatectomy should be considered in patients
with lobe-dominant RPC.
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COMPARISON OF TWO METHODS OF FUTURE LIVER REM-
NANT VOLUME MEASUREMENT
Yun Shin Chun, MD, Dario Ribero, MD, Eddie K. Abdalla, MD, David C.
Madoff, MD, Melinda M. Mortenson, MD, Jean Nicolas Vauthey, MD
MD Anderson Cancer Center, Houston, TX
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Background. In liver transplantation, a minimal graft to patient body weight
(BW) ratio is required for graft survival; in liver resection, total liver volume
(TLV) calculated from body surface area (BSA) is used to determine the
future liver remnant (FLR) volume needed for safe hepatic resection. These
two methods of estimating liver volume have not previously been compared.
The purpose of this study was to compare FLR volumes standardized to BW
versus BSA and to assess their utility in predicting postoperative hepatic
dysfunction following hepatic resection.
Methods. Records were reviewed of 68 consecutive noncirrhotic patients
who underwent major hepatectomy after portal vein embolization between
1998 and 2006. FLR (cm3) was measured preoperatively with three-
dimensional helical computed tomography; TLV (cm3) was calculated from
patients’ BSA. The relationship between FLR/TLV and FLR/BW (cm3/kg)
was examined using linear regression analysis. Receiver operating character-
istic (ROC) curve analysis was used to determine FLR/TLV and FLR/BW
cutoff values for predicting postoperative hepatic dysfunction (defined as
peak bilirubin level 3 mg/dl or prothrombin time 18 seconds).
Results. Regression analysis revealed that the FLR/TLV and FLR/BW ratios
were highly correlated (Pearson correlation coefficient, 0.98; figure 1). The
area under the ROC curve was 0.85 for FLR/TLV and 0.84 for FLR/BW
(95% confidence interval, 0.71 0.97). Sixteen of the 68 patients developed
postoperative hepatic dysfunction. ROC curve analysis yielded a cutoff FLR/
BW value of 50.4, which had a positive predictive value (PPV) of 78% and a
negative predictive value (NPV) of 85%. The corresponding FLR/TLV cutoff
value of 520% had a PPV of 80% and a NPV of 86%.
Conclusions. Based on the strong correlation between the FLR measure-
ments standardized to BW and BSA and their similar ability to predict
postoperative hepatic dysfunction, both methods are appropriate for asses-
sing liver volume. In noncirrhotic patients, a FLR/BW ratio of 50.4 and
FLR/TLV520% provide equivalent thresholds for performing safe hepatic
resection.
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STEATOSIS IS AN INDEPENDENT PREDICTOR OF POST-OP-
ERATIVE MORBIDITY FOLLOWING HEPATIC RESECTION FOR
COLORECTAL METASTASIS
Dhanwant Gomez, Hassan Z Malik, Glenn K Bonney, Vincent Wong, Giles J
Toogood, J. Peter A Lodge, K. Rajendra Prasad
Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, United Kingdom
Background. Hepatic resection is commonly performed for colorectal liver
metastasis (CRLM). To date, few studies are available on the effect of
steatosis on morbidity and mortality.
Methods. Patients undergoing hepatic resection for CRLM from January
2000 to September 2005 were identified from the Hepatobiliary database.
Data analyzed included demographics, laboratory analyses, extent of hepatic
resection, blood transfusion requirements and steatosis.
Results. 386 patients were identified with a median age of 66 (3287) years.
201 (52%) patients had at least one co-morbid condition and 192 (50%)
patients had an ASA score of 1. 279 patients (72%) underwent anatomical
resections and the remaining 107 (28%) had non-anatomical resections. 165
(43%) patients underwent additional procedures. 194 patients (50%) had
steatosis and were classified on severity: mild (n122), moderate and severe
(n72). Overall morbidity was 49% (n139) and mortality was 2% (n7).
The presence of co-morbid conditions, higher ASA grade, major hepatic
resection, additional procedures, steatosis and blood transfusion were
associated with increased morbidity. ITU admission, morbidity, infective
complications and changes in biochemical profile were associated with a
greater severity of steatosis. Independent predictors of morbidity were
steatosis, extent of hepatic resection and blood transfusion.
Conclusion. Steatosis is associated with an increase in morbidity following
hepatic resection for CRLM. Other predictors of outcome were extent of
hepatic resection and blood transfusion. Patients with steatosis, undergoing
major hepatic resection and require blood transfusion should be considered
high-risk and managed aggressively post-surgery.
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INCREASED USE OF PARENCHYMAL-SPARING SURGERY FOR
BILOBAR COLORECTAL LIVER METASTASES IS ASSOCIATED
WITH REDUCED MORTALITY WITHOUT CHANGE IN ONCO-
LOGIC OUTCOME
Jason S. Gold, Chandrakanth Are, Peter Kornprat, William R. Jarnagin,
Mithat Go¨nen, Yuman Fong, Ronald P. Dematteo, Leslie H. Blumgart,
Michael D’angelica
Memorial Sloan-Kettering Cancer Center, New York, NY
Introduction. Resection of bilobar colorectal liver metastases has unique
technical concerns and has been associated with worse oncologic
outcome. We aimed to determine the association of operative variables with
morbidity, mortality, and oncologic results for resection of bilobar liver
metastases.
Methods. Patients were identified from a prospectively maintained database.
The log-rank test was used to assess differences in survival, and the Pearson’s
chi-square test was used for morbidity. Cox regression was used for
multivariate analysis. The Cochran-Armitage, Jonckhree-Terpstra, and log-
rank trend tests were used to assess trends in categorical variables, continuous
variables, and survival.
Results. From 7/1/19922/13/2003, 443 operations for bilobar colorectal
metastases were performed in 440 patients. The complication rate was
51% with a liver-related complications rate of 24% and a major complications
rate of 29%. The 30-day and 90-day mortality was 2.9% and 5.4%. Kaplan-
Meier predicted 5-year survival was 30%, although 5-year recurrence
was 82%. The 5-year hepatic disease-free survival was 39%. Positive
resection margin independently correlated with worse disease-specific
survival, and the use of wedge resection independently correlated with
shorter liver recurrence-free survival. The number of liver segments resected
was independently associated with liver-related complications. Vascular or
biliary resection as well as intra-abdominal, extra-hepatic resections other
than of the primary tumor was independently associated with major
complications. There were too few deaths for multivariate analysis of
operative mortality. Operative approach changed over time (Table) with
greater use of multiple simultaneous liver resections, wedge resections, and
ablations, as well as less use of major hepatectomies. This correlated with
decreased mortality without change in disease-specific survival or liver
recurrence.
Conclusions. Resection of bilobar colorectal liver metastases can be
accomplished with acceptable morbidity, mortality, and oncologic results.
Increased use of a parenchymal-sparing approach is associated with
decreased mortality without compromise in cancer-related outcome.
Trends in Procedures and Outcome over Time
19921994
(n96)
19951997
(n122)
19982000
(n144)
20012003
(n81) p-value
Major procedure lobectomy or trisectionectomy 89 (93%) 106 (87%) 119 (83%) 60 (74%) B0.001
Four or more segments resected 88 (92%) 98 (80%) 111 (77%) 57 (70%) B0.001
Number of segments resected (median/mean) 5/4.7 5/4.4 4.5/4.2 4/3.9 B0.001
More than 2 simultaneous liver resections 2 (2.1%) 9 (7.4%) 17 (12%) 13 (16%) B0.001
Wedge resection used 15 (16%) 28 (22%) 51 (36%) 31 (38%) B0.001
Ablation used 1 (1.0%) 0 (0%) 4 (2.8%) 7 (8.6%) 0.001
Ninety day mortality 6 (6.3%) 13 (11%) 4 (2.8%) 1 (1.2%) 0.02
Median disease-specific survival (months) 45 34 34 NR 0.52
Median liver recurrence-free time (months) 22 20 20 15 0.43
NRnot reached.
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RESECTABLE EXTRAHEPATIC DISEASE IS NO LONGER A
CONTRAINDICATION TO HEPATECTOMY FOR COLORECTAL
METASTASES
Ryan L Neff, MD, Osama Al-Saif, MD, Colin Brady, MD, Edward Martin,
MD, Mark Bloomston, MD
Ohio State University, Columbus, OH
Introduction. The presence of extrahepatic disease, bilobar disease, and
greater than three hepatic lesions have traditionally been considered contra-
indications to hepatectomy for colorectal metastases because of the perceived
increased perioperative risk without improved long-term survival. Resectable
extrahepatic disease (EHD) at the time of hepatic resection was considered to
expand criteria for further treatment of colorectal metastases.
Methods. The charts of 328 patients who underwent hepatectomy for
colorectal cancer metastasis from 1988 to 2005 were reviewed. Prior
chemotherapy, if received, in these patients consisted of bolus 5-FU. Data
were compared by Student’s T-test and Fisher’s Exact Test, where appro-
priate. Overall survival curves were constructed using the Kaplan-Meier
method and compared by log-rank analysis. Multivariate analysis was
undertaken to determine predictors of decreased survival and perioperative
mortality.
Results. Fifty (15%) patients presented with EHD at the time of
hepatectomy. There were no significant differences between patients with
and without EHD with regard to age, gender, disease free interval, and the
number and distribution of hepatic metastases. Patients with EHD were as
likely to undergo complete (i.e. R0) resection as those with isolated liver
metastases (58% vs. 72%, p0.05). Perioperative mortality was 5.8% and
was not affected by concomitant resection of EHD (p0.471). Only
increasing number of segments resected was predictive of perioperative
mortality by multivariate analysis. Median overall survival was 19.7 months
in patients with EHD compared to 34.0 months in patients without EHD
(pB0.001). Only age and EHD remained significant predictors of decreased
survival by multivariate analysis.
Conclusion. Despite similar populations, extrahepatic disease remains a
poor prognostic indicator for survival after hepatectomy for colorectal
metastasis. However, low perioperative mortality coupled with median
survival of nearly 20 months emphasizes the potential of a curative approach
to patients with traditionally incurable disease. The presence of resectable
extrahepatic disease should no longer be a contraindication to hepatectomy
for colorectal metastases, particularly when coupled with modern chemo-
therapy.
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SURVIVAL FOLLOWING RADIOFREQUENCY ABLATION OF
COLORECTAL LIVER METASTASES: A TEN YEAR EXPERI-
ENCE
Peter Denk, MD, Yashodhan S Khajanchee, MD, Whitney Alexander, Paul
Daniel Hansen, MD, M Cassera, C Wilson
Lagacy Health System, Portland, OR; Oregon Clinic, Portland, OR
Purpose. The purpose of this study is to examine the outcomes and survival
of patients who had radiofrequency thermal ablation (RFA) of colorectal liver
metastases.
Methods. Between September of 1996 and Jun of 2006, perioperative and
follow-up data were collected prospectively on 110 patients with isolated
colorectal liver metastases who underwent 128 RFA procedures.
Results. The average patient age was 54 (SD924). Cardiopulmonary co-
morbidities were present in 65 (59%) patients. Out of 128 procedures, there
were 107 laparoscopic, 12 open, 7 CT guided, 1 thoracoscopic, and 1 US
guided. 13 patients had two procedures and 6 patients had three procedures.
The average number of tumors ablated per patient was 2.3, the average size of
tumor was 2.63 cm (SD91.5).
RFA only RFA/Resection RFA/HAI RFA/Resection/HAI
Laparoscopic 74 8 23 2
Open 3 4 1 4
There were 5 intraoperative complications (3 enterotomies, 1 minor skin
burn, 1 GB burn) and 9 minor and two 2 major postoperative complications.
One patient with a concomitant colostomy takedown had an anastamotic
leak. One patient with a severe aortic valve gradient died three weeks
postoperatively of pneumonia and an MI. Two patients with concomitant
liver resections needed blood transfusions. The median follow-up is 20
months (range3 to 120). 78 (71%) patients have recurred, with a median of
9 months to first recurrence. Overall distant failure rate was 42 (38%).
Overall RFA site failure was 22/110 (20%). Kaplan-Meier survival analysis
was done and showed a mean and median survival was 38 and 32
respectively. Overall 5-year survival was 25%. A Cox regression analysis for
overall survival showed the likelihood of death was 3.88 (p0.003)for
tumors 5 cm in diameter and 2.41 (p0.043) for patients with more than
1 tumor.
Site of 1st Recurrence 78/110
RFA site only 16 (14.5%)
New liver site only 14 (12.7%)
RFA and new liver only 6 (5.4%)
Extrahepatic only 22 (20%)
Extrahepatic and liver 20 (18.2%)
Discussion. We have shown that RFA is an effective means of tumor
destruction with a low perioperative morbidity. RFA may have a role in the
treatment of selected in patients with colorectal liver metastases.
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HEPATECTOMY AND LUNG RADIOFREQUENCY ABLATION
FOR HEPATIC AND SUBSEQUENT PULMONARY METASTASES
FROM COLORECTAL CARCINOMA
Sivapirabu Sathasivam, MD, Tristan D. Yan, MD, Julie King, MPH, Derek
Glenn, MD, David L Morris, MD, PhD
Department of Surgery and Radiology, St George Hospital, Sydney, New
South Wales, Australia
Background. Liver and lung are the two most involved organs in colorectal
carcinoma metastases. This reflects the porto-systemic spread of the disease.
In selected groups of patients, hepatic resection has been regarded as the only
curative treatment of colorectal liver metastases, achieving a median survival
of 20 to 40 months and a 5-year survival of 3050%. Despite hepatectomy
with curative intent, many patients develop pulmonary metastases after initial
hepatectomy. Resection of colorectal pulmonary metastases can achieve a
2040% 5-year survival, but only in a small group of patients. Lung
radiofrequency ablation (RFA) is a relatively safe procedure and may have
a useful role in the management of non-surgical candidates with colorectal
pulmonary metastases.
Methods. This study consists of 30 patients, who had previously undergone
hepatectomy for colorectal liver metastases and subsequently developed
pulmonary metastases, which were then treated with lung RFA. The primary
aim of this presentation is to demonstrate survival in patients with two organ
metastases, who are not candidates for surgical resection of colorectal
pulmonary metastases. The secondary aim is to assess the prognostic
indicators for survival after lung RFA. Lung RFA was performed percuta-
neously under local anaesthesia and conscious sedation, with fluoro-CT
guided imaging, using the RITA 1500 generator. All patients were reviewed
at one week, one month and every three months with repeat CEA and chest
CT scans. The follow-up was complete.
Results. In the 30 patients involved in this study, there was no lung RFA
related mortality. The periprocedural morbidity rate was 37%. The median
survival after initial liver surgery was 64 months (range 15 118 months).
The 1-, 3-, and 5-year survival rates were 100%, 77% and 53%, respectively.
The median survival after lung RFA was 32 months (range 5 to 50 months).
The 1-, 2-, and 3-year survival rates were 75%, 63% and 45%, respectively.
The following 4 factors were found to significantly affect survival in the
univariant analysis: the size of the largest pulmonary metastasis (p0.032),
the proximity of metastases to major pulmonary vessels (p0.003), pre-lung
RFA CEA levels (p0.013) and post-lung RFA CEA levels (p0.022).
Conclusions. Lung RFA is a relatively safe procedure in the management of
non-surgical candidates with colorectal pulmonary metastases.
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